Fernández-Penny, F. E., Jolkovsky, E. L., Shofer, F. S., Hemmert, K. C., Valiuddin, H., Uspal, J. E., Sands, N. A., & Abella, B. S. (2021). COVID-19 vaccine hesitancy among patients in two urban emergency departments. Academic Emergency Medicine, 28(10), 1100–1107. https://doi.org/10.1111/acem.14376
- Apr 2022
-
onlinelibrary.wiley.com onlinelibrary.wiley.com
- Mar 2022
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.26.485922: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Human subject study and biosafety approvals for blood draws: All research activities with human blood specimens of pre-COVID-19, sero-negative (healthy) donors and convalescent COVID-19 patients were implemented under NIH guidelines for human subject studies and the protocols approved by the Northwestern University Institutional Review Board (STU00205299) as well as the Institutional Biosafety Committee for COVID-19 research.<br>IRB: Human subject study and biosafety approvals for blood draws: All research activities with human blood specimens of pre-COVID-19, sero-negative (healthy) donors and convalescent COVID-19 patients were implemented under NIH guidelines for human subject studies and the protocols approved by the Northwestern University Institutional Review Board (STU00205299) as well as the Institutional Biosafety Committee for COVID-19 research.<br>Consent: For collecting human blood specimens, patients and donors were recruited at Northwestern Memorial Hospital based on their availability and willingness to consent and participate in the research.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results were normalized to the CR3022 antibody with known affinity to the receptor binding domain of SARS-CoV2 (Creative Biolabs, MRO-1214LC)(29, 52).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CR3022</div><div>suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were stained for surface antigens using fluorescence-conjugated monoclonal Abs specific to human CD45, CD3, CD4, CD127 and CD25 antibodies for Treg identification and sorting as well as CD45, CD3, CD64, CD14 and CD16 for monocyte characterization and sorting.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD45</div><div>suggested: (RayBiotech Cat# CS-11-0019, RRID:AB_1227882)</div></div><div style="margin-bottom:8px"><div>CD4</div><div>suggested: (BD Biosciences Cat# 560249, RRID:AB_1645496)</div></div><div style="margin-bottom:8px"><div>CD127</div><div>suggested: (BD Biosciences Cat# 560249, RRID:AB_1645496)</div></div><div style="margin-bottom:8px"><div>CD25</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD64</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD14</div><div>suggested: (BioLegend Cat# 348805, RRID:AB_2889063)</div></div><div style="margin-bottom:8px"><div>CD16</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization assays with 10 μL or 80 μL of plasma were performed using HEK293 cells with stable expression of human ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">0.5 μL RBD-647 was then pre-incubated with PBS as a control or 80 μL patient-derived plasma for 45 minutes on ice, after which it was combined with 106 HEK/ACE2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK/ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The levels of RBD-647 binding to HEK293/ACE2 cells were then assessed BD FACSAria Cell Sorter and analyzed using FlowJo v10software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293/ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The levels of RBD-647 binding to HEK293/ACE2 cells were then assessed BD FACSAria Cell Sorter and analyzed using FlowJo v10software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quality control of the libraries was performed using an Invitrogen Qubit DNA high sensitivity kit (ThermoFisher Scientific, Q32851) and Agilent Bioanalyzer high sensitivity DNA kit (Agilent, 5067-4626).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Agilent Bioanalyzer</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">scRNA-seq data acquisition and analysis: Data from scRNA-seq was demultiplexed and mapped to hg38 (refdata-gex-GRCh38-2020-A) using Cell Ranger software version 4.0.0 (10x genomics).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cell Ranger</div><div>suggested: (Cell Ranger , RRID:SCR_017344)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.25.485875: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.<br>IACUC: K18-hACE2 mice: The Institutional Animal Care and Use Committee at Rocky Mountain Laboratories provided animal study approvals, which were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility, following the basic principles and guidelines in the Guide for the Care and Use of Laboratory Animals eighth edition, the Animal Welfare Act, U.S. Department of Agriculture, and the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Male and female macaques per group were balanced.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">All slides were examined by a board-certified veterinary anatomic pathologist who was blinded to study group allocations.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Mycoplasma testing is performed at monthly intervals, and no mycoplasma was detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw Illumina sequencing data for the antibody-escape mapping experiments are available on the NCBI Short Read Archive (SRA) at BioProject PRJNA770094, BioSample SAMN26315988.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-escape</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Half-maximal inhibitory dilutions (ID50 values) were derived using 4-parameter nonlinear regression in AntibodyDatabase (87).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AntibodyDatabase ( 87</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The libraries were washed and secondarily labeled for 1 hour with 1:100 fluorescein isothiocyanate-conjugated anti-MYC antibody (Immunology Consultants Lab, CYMC-45F) to label for RBD expression and 1:200 Alexa Fluor-647-conjugated goat anti-human-IgG Fc-gamma (Jackson ImmunoResearch 109-135-098) to label for bound NHP antibodies or Alexa Fluor-647-conjugated goat anti-mouse-IgG Fc-gamma (Jackson ImmunoResearch 115-605-008) to label for bound mouse antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-MYC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human-IgG Fc-gamma</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse-IgG Fc-gamma</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">/, version 0.8.10) to process Illumina sequences into counts of each barcoded RBD variant in each pre-selection and antibody-escape population.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-escape population.</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and virus for K18-hACE2 mouse studies: Virus propagation was performed in VeroE6 cells in DMEM containing 2% FBS, 1 mM L-glutamine, penicillin (50 U/mL), and streptomycin (50 μg/mL (DMEM2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The TCID50 assay was conducted by addition of 10-fold graded dilutions of samples to Vero/TMPRSS2 cell monolayers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero/TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mosaic-8b RBD-mi3 and homotypic SARS-2 RBD-mi3 were compared by negative-stain EM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Mosaic-8b RBD-mi3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">K18-hACE2 mice: The Institutional Animal Care and Use Committee at Rocky Mountain Laboratories provided animal study approvals, which were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility, following the basic principles and guidelines in the Guide for the Care and Use of Laboratory Animals eighth edition, the Animal Welfare Act, U.S. Department of Agriculture, and the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunizations of mosaic-8b or homotypic SARS-2 Beta (5 µg each based on RBD content, 11.4 µg of total RBD-mi3) in 100 µL of 50% v/v AddaVaxTM adjuvant (InvivoGen) were done using intramuscular (IM) injections of 7-8-week-old female BALB/c mice (Envigo) (8 animals per cohort).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Preparation of RBD-mi3 nanoparticles: SpyCatcher003-mi3 nanoparticles (78) were expressed in BL21 (DE3)-RIPL E coli (Agilent) transformed with the pET28a His6-SpyCatcher003-mi3 gene (Addgene) as described (34, 84).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET28a</div><div>suggested: RRID:Addgene_139598)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw Illumina sequencing data for the antibody-escape mapping experiments are available on the NCBI Short Read Archive (SRA) at BioProject PRJNA770094, BioSample SAMN26315988.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI Short Read Archive</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Curves were plotted and analyzed to obtain midpoint titers (EC50 values) using Graphpad Prism 9.3.1 (Graphpad Softwatre, San Diego, CA) assuming a one-site binding model with a Hill coefficient.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw sequencing data are available on the NCBI SRA under BioProject PRJNA770094, BioSample SAMN26315988.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioProject</div><div>suggested: (NCBI BioProject, RRID:SCR_004801)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.28.486075: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals with sex- and age-matched littermates were randomly included in experiments.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal experiments were carried out in a blinded fashion whenever feasible.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">For the number of animals needed to achieve statistically significant results, we conducted an a priori power analysis.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For assays examining the avid binding of dimeric sACE22-IgG1 and monoclonal antibodies, cells were resuspended in PBS-BSA containing 1:150 polyclonal chicken anti-MYC-FITC (Immunology Consultants Laboratory) and 1:300 anti-human IgG-APC (clone HP6017, BioLegend).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-MYC-FITC (Immunology Consultants Laboratory)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgG-APC</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HeLa-hACE2-11 (a stable human ACE2 HeLa clone) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (4500 mg/l) with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin at 37 °C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa clone</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 (ATCC HTB-55) cells were grown in Modified Eagle’s Medium high glucose (4500 mg/l) with 10% FBS, 4 mM L-Glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin at 37 °C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal antibodies, sACE2-8his proteins, and RBD-8his were expressed in Expi293F cells transfected using Expifectamine (Thermo Fisher) according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus titers were quantitated by a plaque forming assay using Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions were created following a polyethylenimine (PEI)-based transient co-transfection on 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus Inhibition Assay: HeLa-hACE2-11 cells were seeded (5×103 cells/well) onto white-bottomed 96-well tissue culture plates (100 μL/well) and incubated for 16 h, 37 °C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa-hACE2-11</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HeLa-hACE2-11 (a stable human ACE2 HeLa clone) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (4500 mg/l) with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin at 37 °C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa-hACE2-11</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hemizygous K18-hACE2 mice (strain 034860: B6.Cg-Tg(K18-ACE2)2Prlmn/J) were purchased from The Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids for sACE22-IgG1 (Addgene #154104), sACE22.v2.4-IgG1 (#154106), sACE2(18-615)-8his (#149268), sACE2(18-615).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>sACE22-IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutations for the CDY14 decoy receptor were introduced into the wild type sACE2 plasmids using extension overlap PCR and confirmed by Sanger sequencing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>sACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">S Binding Assay: Human codon-optimized genes encoding N-terminal myc-tagged S proteins of BA.1 and BA.2 omicron were synthesized (Integrated DNA Technologies) and cloned into the NheI-XhoI sites of pcDNA3.1(+) (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1(+)</div><div>suggested: RRID:Addgene_129020)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirion Production: Pseudoviruses were created using plasmids for SARS-CoV-2 Omicron B.1.1.529 (BA.1) S and HIV-1 proviral vector pNL4-3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were taken by Aperio ImageScope 12.4.3 and analyzed by Zen software (Zeiss).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageScope</div><div>suggested: (ImageScope, RRID:SCR_014311)</div></div><div style="margin-bottom:8px"><div>Zen</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 values were determined by fitting dose-response curves with four-parameter logistic regression in GraphPad Prism 8 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04335136</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) a…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.25.485832: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Animals: Animal research was conducted at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).<br>IACUC: Ethics statement: These experiments and procedures were reviewed and approved by the United States Army Medical Research Institute for Infectious Diseases Institutional Animal Care and Use Committee (IACUC).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Genders were mixed male and female, and all animals were SARS-CoV-2 naïve at the outset of the study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: R4719 was determined to have no detectable mycoplasma, endotoxin or adventitious agents based on the assays and techniques used.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum binding and ACE-2 inhibitory antibody assessment: SARS-CoV-2-specific binding IgG antibody responses were measured using MULTI-SPOT® 96-well plates, V-PLEX SARS-CoV-2 Panel 7 Kit (Meso Scale Discovery (MSD), Rockville, MD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2-specific binding IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MSD SULFO-TAG™ conjugated anti-IgG antibody was added to each well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Stimulations consisted of two pools of peptides spanning the S protein of SARS-CoV-2 or SARS-CoV-1 (1 µg/mL, JPT, PM-WCPV-S and PM-CVHSA-S respectively) in the presence of Brefeldin A (0.65 µL/mL, GolgiPlug™, BD Cytofix/Cytoperm Kit, Cat. 555028), co-stimulatory antibodies anti-CD28 (BD Biosciences Cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-1 (1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following stimulation, cells were stained serially with LIVE/DEAD Fixable Blue Dead Cell Stain (ThermoFisher #L23105) and a cocktail of fluorescent-labeled antibodies (BD Biosciences unless otherwise indicated) to cell surface markers CD4-PE-Cy5.5 (S3.5, ThermoFisher #MHCD0418, Lot 2118390 and 2247858), CD8-BV570 (RPA-T8, BioLegend #301038, Lot B281322), CD45RA BUV395 (5H9, #552888, Lot 154382 and 259854), CD28 BUV737 (CD28.2, #612815, Lot 0113886), CCR7-BV650 (GO43H7, # 353234, Lot B297645 and B316676) and HLA-DR-BV480 (G46-6, # 566113, Lot 0055314).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD8-BV570</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RPA-T8</div><div>suggested: (BD Biosciences Cat# 563795, RRID:AB_2722501)</div></div><div style="margin-bottom:8px"><div>CD45RA</div><div>suggested: (BD Biosciences Cat# 552888, RRID:AB_394517)</div></div><div style="margin-bottom:8px"><div>CD28</div><div>suggested: (BD Biosciences Cat# 612815, RRID:AB_2870140)</div></div><div style="margin-bottom:8px"><div>CCR7-BV650</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>B316676</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>G46-6</div><div>suggested: (BD Biosciences Cat# 566113, RRID:AB_2739515)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infectivity and neutralization titers were determined using ACE2-expressing HEK293 target cells (Integral Molecular, Philadelphia, PA) in a semi-automated assay format using robotic liquid handling (Biomek NXp Beckman Coulter, Brea, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, biotinylated SARS-CoV-2 Spike trimer (Hexapro) was incubated with red streptavidin-fluorescent beads (Molecular Probes, Eugene, OR) for 2h at 37°C. 10 μl of a 100-fold dilution of beads–protein was incubated 2h at 37°C with 100μl 900-fold diluted plasma samples before addition of THP-1 cells (25,000 cells per well; Millipore Sigma, Burlington, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293F-Spike-S2-WT cells were incubated with 10-fold diluted heat-inactivated (56°C for 30 min) plasma samples for 30 min at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F-Spike-S2-WT</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 pseudovirions (PSV) were produced by co-transfection of HEK293T/17 cells with a SARS-CoV-2 S plasmid (pcDNA3.4), derived from the Wuhan-Hu-1 genome sequence (GenBank accession number: MN908947.3) and an HIV-1 (pNL4-3.Luc.R-E-, NIH HIV Reagent Program, Catalog number 3418).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pNL4-3.Luc.R-E-</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, SARS-CoV-2 Spike-expressing 293 FreeStyle (293F) cells were generated by transfection with linearized plasmid (pcDNA3.1) encoding codon-optimized full-length SARS-CoV-2 Spike protein matching the amino acid sequence of the IL-CDC-IL1/2020 isolate (GenBank ACC# MN988713).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reduced data in the NSS files was extracted into Microsoft Excel workbooks using Notocord-derived formula add-ins, and the 30-minute (min) averages were calculated for each parameter for each subject.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Assay equivalency was established by participation in the SARS-CoV-2 Neutralizing Assay Concordance Survey (SNACS) run by the Virology Quality Assurance Program and External Quality Assurance Program Oversite Laboratory (EQAPOL) at the Duke Human Vaccine Institute, sponsored through programs supported by the National Institute of Allergy and Infectious Diseases, Division of AIDS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Quality Assurance Program</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Quality Assurance Program Oversite Laboratory</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sample staining was measured on a FACSymphony(tm) A5 SORP (Becton Dickenson) and data was analyzed using FlowJo v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Display of multicomponent distributions were performed with SPICE v6.0 (NIH, Bethesda, MD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPICE</div><div>suggested: (SPICE, RRID:SCR_016603)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04784767</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With A…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
drive.google.com drive.google.comview2
-
They are to b e found not onl y be-tween thos e organize d sound s whic h ar e conventionall y though t o f a sbeing th e stuf f o f musica l meaning but als o between th e peopl e who ar etaking part, i n whatever capacity, i n the performance; and they model, o rstand as metaphor for, ideal relationships as the participants in the perfor -mance imagine them to be : relationships between person an d person, be -tween individual and society, between humanity and the natural world andeven perhaps th e supernatural world . These are importan t matters , perhap sthe most importan t i n human life , an d how we learn about them throughmusicking is wha t this book is about
I don't think I totally understand what he is saying here...I kind of got lost in this long sentence and had to reread it several times...
-
as can be seen from th e fac t tha t a classical training i s thought to b e a fitpreparation for any other kind of musica l performance
So not true...I often am frustrated working with "classically trained" musicians in my church jobs who struggle working off of lead sheets, chord charts, improvising, understanding "groove" and the performance practices of more contemporary and popular musical styles.
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.24.22272871: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Ethics: Samples used in this study were collected as part of an approved ongoing surveillance conducted by the NRC of HCL.<br>IRB: This study was approved by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N°41).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sample selection: The samples sequenced at the National Reference Center (NRC) of Respiratory Viruses of Hospices Civils de Lyon (HCL) selected for this study were i) samples from systematic sequencing of hospitalized patients in the Lyon area (university hospital of Lyon, HCL) and from HCL health care workers; ii) samples from random sequencing performed during the weekly Flash survey conducted by the EMERGEN consortium (French consortium for the genomic surveillance of emerging pathogens).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following interim biosafety guidelines established by WHO, NPS were inoculated on confluent Vero E6 TMPRSS2 cells with DMEM supplemented with 2% penicillin– streptomycin, 1% L-glutamine, 2% G418 and 2% inactivated fetal bovine serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6 TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mapped reads were processed to remove duplicates tagged by picard, then realigned by abra2 to improve indel detection sensitivity and finally clipped with samtools ampliconclip to remove read ends containing primer sequences.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>samtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
This study has several limitations. First, the follow-up duration for the assessment of BA.1 /BA.2 co-infection is short, and as BA.2 detection is still increasing in France, the prevalence of BA.1 /BA.2 co-infection may be underestimated. In addition, ICU admission and vaccination status information was lacking for some Flash cases, limiting the clinical characterization of co-infected patients. Finally, additional sequencing methods were not tested, such as metagenomics or hybrid capture which are less prone to amplification-bias toward specific lineages 7. However, these techniques have lower sensitivity and lower throughput and were therefore not suitable as first-line sequencing methods in our laboratory 20. In conclusion, our findings emphasize the importance of using appropriate experimental and bioinformatic methods for the comprehensive identification of SARS-CoV-2 co-infections. Although these events are rare, SARS-CoV-2 co-infections need to be properly identified as they can lead to the emergence of new variants after a recombination event.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.23.485570: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enteroids were incubated with primary antibodies (Table 4) overnight at 4°C with agitation, then washed three times with PBS and incubated with secondary antibodies (Table 4) and phalloidin (F-actin detection) (1:100) (Invitrogen) for 1 hr at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>F-actin detection</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 24 hr incubation at 37°C 5% CO2, MA104 cells (1 x 105 cells/well) were added to transfected BSR-T7 cells and co-cultured for 4 days in FBS-free DMEM supplemented with 0.5μg/mL porcine pancreatic trypsin type IX (Sigma-Aldrich)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BSR-T7</div><div>suggested: CCLV Cat# CCLV-RIE 0583, RRID:CVCL_RW96)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid construction: pT7 plasmids used for reverse genetics of SA11 RV were kindly provided by Takeshi Kobayashi [42] through the Addgene plasmid repository against IDs #89162-72.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pT7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The constructs were synthesised by Invitrogen GeneArt on either pMK-RQ (kanamycin resistance), pMA-RQ or pMA-T (ampicillin resistance) vectors.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMK-RQ</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pMA-RQ</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pMA-T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RF strain NSP3 constructs RBM, T2A-RBM, RBD and T2A-RBD were ordered as gene blocks from Invitrogen GeneArt and cloned into pT7-NSP2SA11 expression plasmid (Addgene #89169) after the NSP2 ORF was removed using SmaI and SalI restriction enzymes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pT7-NSP2SA11</div><div>suggested: RRID:Addgene_89169)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 70% confluency, monolayers of BSR-T7 cells in 6-well plates were co-transfected with 11 plasmids corresponding to each RV genome segment (2.5μg for plasmids encoding NSP2 and NSP5; 0.8μg for the remaining plasmids) and plasmids encoding two vaccinia virus capping enzyme subunits (pCAG-D1R and pCAG-D12L −0.8μg each) using 16μL Lipofectamine 2000 (Invitrogen) per transfection reaction in a total volume of 200μL of Opti-MEM (Gibco).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAG-D1R</div><div>suggested: RRID:Addgene_89160)</div></div><div style="margin-bottom:8px"><div>pCAG-D12L</div><div>suggested: RRID:Addgene_89161)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The panels of viruses were titred by plaque assays, and the presence of mutations in the target gene segments was confirmed by RT-PCR and Sanger sequencing (GATC Biotech or Genewiz, Germany) as described below.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Genewiz</div><div>suggested: (GENEWIZ, RRID:SCR_003177)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification was performed by densitometry of scanned gel images using Image J.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Image J</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The optical density (OD) was measured at 405nm using Cytation™ 3 Cell Imaging Multi-Mode Reader (Agilent) and data was analysed using BioTek Gen5 software (Agilent).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gen5</div><div>suggested: (Gen5, RRID:SCR_017317)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were analysed using the Zen Black software and processed using Photoshop v23.1.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zen Black</div><div>suggested: (Black Zen software, RRID:SCR_018163)</div></div><div style="margin-bottom:8px"><div>Photoshop</div><div>suggested: (Adobe Photoshop, RRID:SCR_014199)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: GraphPad Prism v9 was used for all statistical analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.scienceintheclassroom.org www.scienceintheclassroom.org
-
5. J. Aguilar, T. Zhang, F. Qian, M. Kingsbury, B. Mclnroe, N. Mazouchova, C. Li, R. Maladen, C. Gong, M. Travers, R. L. Hatton, H. Choset, P. B. Umbanhowar, D. I. Goldman, A review on locomotion robophysics: The study of movement at the intersection of robotics, soft matter and dynamical systems. Rep. Prog. Phys. 79, 110001 (2016).
Aguilar et. al define "robophysics" as the pursuit of principles of self-generated motion.
-
-
www.biorxiv.org www.biorxiv.org
-
Reviewer #1 (Public Review):
Overview
This is a well-conducted study and speaks to an interesting finding in an important topic, whether ethological validity causes co-variation in gamma above and beyond the already present ethological differences present in systemic stimulus sensitivity.
I like the fact that while this finding (seeing red = ethnologically valid = more gamma) seems to favor views the PI has argued for, the paper comes to a much simpler and more mechanistic conclusion. In short, it's good science.
I think they missed a key logical point of analysis, in failing to dive into ERF <----> gamma relationships. In contrast to the modeled assumption that they have succeeded in color matching to create matched LGN output, the ERF and its distinct features are metrics of afferent drive in their own data. And, their data seem to suggest these two variables are not tightly correlated, so at very least it is a topic that needs treatment and clarity as discussed below.
Minor concerns
In generally, very well motived and described, a few terms need more precision (speedily and staircased are too inaccurate given their precise psychophysical goals)
I got confused some about the across-group gamma analysis:
"The induced change spectra were fit per participant and stimulus with the sum of a linear slope and up to two Gaussians." What is the linear slope?
To me, a few other analyses approaches would have been intuitive. First, before averaging peak-aligned data, might consider transforming into log, and might consider making average data with measures that don't confound peak height and frequency spread (e.g., using the FWHM/peak power as your shape for each, then averaging).
Moderate
I. I would like to see a more precise treatment of ERF and gamma power. The initial slope of the ERF should, by typical convention, correlate strongly with input strength, and the peak should similarly be a predictor of such drive, albeit a weaker one. Figure 4C looks good, but I'm totally confused about what this is showing. If drive = gamma in color space, then these ERF features and gamma power should (by Occham's sledgehammer...) be correlated. I invoke the sledgehammer not the razor because I could easily be wrong, but if you could unpack this relationship convincingly, this would be a far stronger foundation for the 'equalized for drive, gamma doesn't change across colors' argument...(see also IIB below)...
...and, in my own squinting, there is a difference (~25%) in the evoked dipole amplitudes for the vertically aligned opponent pairs of red- and green (along the L-M axis Fig 2C) on which much hinges in this paper, but no difference in gamma power for these pairs. How is that possible? This logic doesn't support the main prediction that drive matched differences = matched gamma...Again, I'm happy to be wrong, but I would to see this analyzed and explained intuitively.
II. As indicated above, the paper rests on accurate modeling of human LGN recruitment, based in fact on human cone recruitment. However, the exact details of how such matching was obtained were rapidly discussed-this technical detail is much more than just a detail in a study on color matching: I am not against the logic nor do I know of a flaw, but it's the hinge of the paper and is dealt with glancingly.
A. Some discussion of model limitations
B. Why it's valid to assume LGN matching has been achieved using data from the periphery: To buy knowledge, nobody has ever recorded single units in human LGN with these color stimuli...in contrast, the ERF is 'in their hands' and could be directly related (or not) to gamma and to the color matching predictions of their model.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.21.485247: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal experiments: All the animal experiments were performed in accordance with protocols approved by the Icahn School of Medicine at Mount Sinai (ISMMS) Institutional Animal Care and Use Committee (IACUC).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mouse immunization and challenge studies: Female BALB/c mice were used in all studies.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">All samples were analyzed in a blinded manner.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The HN protein was detected by a mouse monoclonal antibody 8H2 (MCA2822, Bio-Rad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MCA2822</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA plates were afterwards washed 3 times with PBST and 50 μL of anti-mouse IgG-horseradish peroxidase (HRP) conjugated antibody (Cytiva, GE Healthcare) was added at a dilution of 1:3,000 in blocking solution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG-horseradish</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">During this time the primary antibody was biotinylated according to manufacturer protocol (Thermo Scientific EZ-Link NHS-PEG4-Biotin)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NHS-PEG4-Biotin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blocking solution was removed and 100 μl/well of biotinylated mAb 1C7C7, a mouse anti-SARS nucleoprotein monoclonal antibody generated at the Center for Therapeutic Antibody Development at The Icahn School of Medicine at Mount Sinai ISMMS</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plaques were immuno-stained with an anti-SARS-CoV-2 NP primary mouse monoclonal antibody 1C7C7 kindly provided by Dr. Thomas Moran at ISMMS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 NP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An HRP-conjugated goat anti-mouse secondary antibody was used at 1:2000 and the plaques were visualized using TrueBlue™ Peroxidase Substrate (SeraCare Life Sciences Inc.)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VERO-TMPRSS2 cells (BPS Biosciences, #78081) were maintained in DMEM (Gibco) containing 10% (vol/vol)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VERO-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Specifically, transfected BSRT7 and DF-1 cells were washed with warm PBS and trypsinized.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DF-1</div><div>suggested: RRID:CVCL_XF08)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BSRT7 cells were mixed with DF-1 cells (~1: 2.5) in a 10-cm dish.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BSRT7</div><div>suggested: CCLV Cat# CCLV-RIE 0583, RRID:CVCL_RW96)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-E6 cells or Vero-TMPRSS2 were seeded onto 12-well plates in growth media at 1:5 and cultured for two days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse immunization and challenge studies: Female BALB/c mice were used in all studies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the variant HXP-S were inserted into the pNDV_LS/L289A rescue plasmid (between P and M genes) by in-Fusion cloning (Clontech, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNDV_LS/L289A</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The recombinant product was transformed into MAX Efficiency™ Stbl2™ Competent Cells (Thermo Fisher Scientific, MA, USA) to generate the pNDV-HXP-S rescue plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNDV-HXP-S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, cells were transfected with 2 μg of pNDV-HXP-S, 1 μg of pTM1-NP, 0.5 μg of pTM1-P, 0.5 μg of pTM1-L and 1 μg of pCI-T7opt and were re-suspended in 250 μl of a modified Eagle’s Minimum Essential Medium (Opti-MEM; Gibco).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pTM1-NP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pTM1-P</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pTM1-L</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCI-T7opt</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the mammalian-cell codon-optimized nucleotide sequence of a soluble spike protein (amino acids 1-1,213) lacking the polybasic cleavage site, carrying two stabilizing mutations (K986P and V987P), a signal peptide, and at the C-terminus a thrombin cleavage site, a T4 fold-on trimerization domain, and a hexahistidine tag was cloned into the mammalian expression vector pCAGGS. https://www.beiresources.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS.</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the mammalian-cell codon-optimized nucleotide sequence of a soluble spike protein (amino acids 1-1,213) lacking the polybasic cleavage site, carrying two stabilizing mutations (K986P and V987P), a signal peptide, and at the C-terminus a thrombin cleavage site, a T4 fold-on trimerization domain, and a hexahistidine tag was cloned into the mammalian expression vector pCAGGS. https://www.beiresources.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>https://www.beiresources.org/</div><div>suggested: (BEI Resource Repository, RRID:SCR_013698)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis was performed using GraphPad Prism 7 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed using Prism software (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04871737</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Study of a Live rNDV Based Vaccine Against COVID-19</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT05181709</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Live Recombinant Newcastle Disease Virus-vectored COVID-19…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04830800</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vacc…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04764422</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04993209</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactiv…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.22.485425: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: The study proposal was evaluated and approved by the Animal Welfare Body of Poonawalla Science Park – Animal Research Center (Bilthoven, The Netherlands) under permit number AVD32600 2018 4765 of the Dutch Central Committee for Animal experiments.<br>IACUC: The study proposal was evaluated and approved by the Animal Welfare Body of Poonawalla Science Park – Animal Research Center (Bilthoven, The Netherlands) under permit number AVD32600 2018 4765 of the Dutch Central Committee for Animal experiments.<br>Euthanasia Agents: Euthanasia was performed by exsanguination via heart puncture under anesthesia with ketamine and medetomidine.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Ferrets: Twenty outbred male ferrets (Mustela putorius furo), aged 8 months, were obtained from the colony of Euroferret (Denmark).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Histopathology was scored blindly by a veterinary pathologist.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All ferrets tested negative for antibody responses measured against SARS-CoV-2 spike protein (S), its receptor binding domain (RBD), and the nuclear protein of influenza virus by ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein (S), its receptor binding domain (RBD)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fixation of the cells occurred with incubation of Fixation/Permeabilization buffer for 20 min/4°C, followed by two washing steps with 1x permbuffer, prior to incubation for 30 min/RT with the antibodies: FITC-conjugated anti-CD3e (MCA1477A647, clone CD3-12, BioRad) and PE- conjugated anti-IFNγ (MCA1783PE, clone CC302, Bio-rad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD3e</div><div>suggested: (Creative Diagnostics Cat# CABT-48633RH, RRID:AB_2528922)</div></div><div style="margin-bottom:8px"><div>anti-IFNγ</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>MCA1783PE</div><div>suggested: (Bio-Rad Cat# MCA1783PE, RRID:AB_324003)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 virus culture was performed in VERO E6 cells (Vero C1008, ATCC CRL-1586), first grown in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 10% of fetal bovine serum (FBS) + 1x penicillin, streptomycin and glutamine (PSG) at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)</div></div><div style="margin-bottom:8px"><div>C1008</div><div>suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MDCK cells were washed twice with PBS, and H1N1 virus suspension was added to the cells in MEM + 1x PSG + 2 µg/ml L-</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MDCK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">TCID50 determination: SARS-CoV-2 virus stock, swab material and tissue samples were 1:10 serial diluted in DMEM medium containing 2% FBS and 1x PSG and added on VERO E6 cells in 96-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VERO E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell acquisition was performed on the BD LSRFortessa™ Cell Analyzer (BD Biosciences) and analyzed using FlowJo V10.6.2 (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All data were analyzed with GraphPad Prism 9.1.0 software (GraphPad Software, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.22.22272773: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Study design: After written informed consent, two combined nasopharyngeal and oropharyngeal swabs were collected from each patient.<br>IRB: Legal and ethical considerations: The study was conducted according to the revised principles of the Declaration of Helsinki and was approved by the ethics committee of the Ruhr-University Bochum (registration number 20-7065) in November 2020.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sample size calculation was performed using G*Power Version 3.1.9.6 for windows [12].</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Total RNA was purified from VeroE6 cells using the RNeasy Mini Kit (QIAGEN®, www.qiagen.com).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis was performed using GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sample size calculation was performed using G*Power Version 3.1.9.6 for windows [12].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>G*Power</div><div>suggested: (G*Power, RRID:SCR_013726)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequencing libraries were prepared from 4·5μl cDNA using NEBNext® ARTIC SARS-CoV-2 Library Prep Kit for Illumina sequencing platforms (New England BioLabs® Inc., neb.com, catalog #E7650).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>New England BioLabs®</div><div>suggested: (New England Biolabs, RRID:SCR_013517)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, variants in spike domains were identified and annotated using Geneious prime 2021.2.2 (https://www.geneious.com).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>https://www.geneious.com</div><div>suggested: (Geneious, RRID:SCR_010519)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our study encompasses several limitations. Patients were encouraged to forcefully cough twice to contaminate surfaces. However, we cannot exclude that potentially repeated coughing over a prolonged time results in a more effective virus transfer compared to our controlled conditions. Moreover, sneezing can produce significantly more infectious droplets potentially containing infectious particles, therefore, we cannot exclude potential transmissions via other this route. Furthermore, a selection bias cannot be excluded, and the included patients are not demographically representative. Strengths of the present study include the high viral load of the patients included, a standardized protocol for sample acquisition, laboratory procedures and the inclusion of VoC.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.22.22271707: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">RANDOMIZATION AND INTERVENTION: A randomly-selected subset of 6200 cohort participants who were assessed as eligible on the basis of data from their enrolment questionnaire, and who reported no supplemental vitamin D intake at baseline, were individually randomized by the trial statistician using a computer program (Stata v14.2) to receive an offer of a postal vitamin D test with supply of 3200 IU vitamin D/day if their blood 25(OH)D concentration was found to be less than 75 nmol/L (‘higher-dose offer group’) vs. the same testing offer with supply of 800 IU vitamin D/day if 25(OH)D was less than 75 nmol/L (‘lower-dose offer group’) vs. no offer of vitamin D testing or supplementation (‘no offer group’), with a 1:1:2 allocation ratio.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our study also has limitations. Provision of supplements to participants randomized to intervention was contingent on demonstrating inadequate vitamin D status: thus, a subset (13.7%) of participants randomized to intervention did not receive study supplements. On the other hand, another subset (49.9%) of participants randomized to no offer took a vitamin D supplement on one or more occasions during follow-up. This may have led to increases in 25(OH)D concentrations in the no offer arm over the course of the study, although seasonal effects (sampling in June vs. December) will also have contributed. Together, these factors could have diluted any effect of vitamin D in the primary intention-to-treat analysis. We sought to overcome this by conducting a sensitivity analysis, which included only those randomized to offer vs. no offer who did vs. did not take supplemental vitamin D, respectively. The fact that this analysis showed no effect of vitamin D supplementation on all outcomes investigated, despite the larger differences in end-study 25(OH)D concentrations between intervention vs. no-offer arms seen for this analysis vs. the intention-to-treat analysis (Fig. 2), provides some reassurance that the null result yielded by the intention-to-treat analysis is valid. Ultimately, however, this trial was designed to investigate the effectiveness of a pragmatic ‘test-and-treat’ approach to boosting population vitamin D status, rather than biologic efficacy of vitamin D to prevent AR...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04579640</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Trial of Vitamin D to Reduce Risk and Severity of COVID-19 a…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.22.485230: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mouse studies: All animal work was done under the oversight of the Bloodworks Northwest Research Institute’s Institutional Animal Care and Use Committee (Seattle, WA).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum IgG, IgG1, and IgG2a titers by ELISA: SARS CoV-2 spike protein-binding IgG antibodies in mouse serum were measured by ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were then washed, and spike protein-bound antibodies were detected using an Anti-Mouse IgG (Fc Specific)-Alkaline Phosphatase antibody (Sigma-Aldrich, #A2429) at a 1:4000 dilution in blocking buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Mouse IgG</div><div>suggested: (Innovative Research Cat# HM4000, RRID:AB_1482268)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Splenocytes were stained for viability with Zombie Green (BioLegend, San Diego, CA) in 50 μL of PBS, and then Fc receptors were blocked with CD16/CD32 antibody (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD16/CD32</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IL-17A (Invitrogen, #88-7371-88), or IL-5 (BD Biosciences, #51-1805KZ) capture antibodies at a 1:200 dilution in ELISpot coating buffer (eBioscience, Waltham, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IL-17A</div><div>suggested: (Thermo Fisher Scientific Cat# 88-7371-88, RRID:AB_2575104)</div></div><div style="margin-bottom:8px"><div>IL-5</div><div>suggested: (Novus Cat# NB 200-515, RRID:AB_535720)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After a 3-hour incubation, plates were washed with PBS with 0.1% Tween 20, and secondary antibody (Goat Anti-Mouse IgG-HRP or IgA-HRP [SouthernBiotech, Birmingham, AL; #1030-05 and #1040-05]) was added at a 1:1000 dilution in PBS with 0.1% Tween and 5% FBS overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Mouse IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After complexing, vaccine was lyophilized using a VirTis AdVantage 2.0 EL-85 (SP Industries, Warminster, PA) benchtop freeze dryer controlled by the microprocessor-based Wizard 2.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EL-85</div><div>suggested: RRID:CVCL_EL85)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK-293 cells (American Type Culture Collection, Manassas, VA; #CRL-3216) were plated at 4 x 105 cells/mL in 6-well plates 18-24 hours before the assay to achieve 50-70% confluency at assay start.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All animal work was in compliance with all applicable sections of the Final Rules of the Animal Welfare Act regulations (9 CFR Parts 1, 2, and 3) and the Guide for the Care and Use of Laboratory Animals, Eighth Edition.69 C57BL/6J mice obtained from The Jackson Laboratory (Harbor, ME) were used for all animal studies in this work.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:IMSR_JAX:000664)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These sequences were then codon-optimized for mammalian (human) expression by Codex DNA (San Diego, CA) using a proprietary algorithm, synthesized by BioXp (Codex DNA), and inserted into AAHI’s backbone saRNA expression vector by Gibson cloning.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioXp</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All RNA samples were mixed with glyoxal loading dye (Invitrogen, Waltham, MA) 1:1 by volume, incubated at 50°C for 20 minutes, loaded on a denatured 1% agarose gel in NorthernMax-Gly running buffer (Invitrogen) alongside Millennium RNA Markers (Thermo Fisher Scientific), and run at 120 V for 45 minutes before imaging on a ChemiDoc MP Imaging System (Bio-Rad Laboratories, Hercules, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spots were counted and data were analyzed using ImmunoSpot software (Cellular Technology Limited, Cleveland, OH)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImmunoSpot</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analyses were conducted using Prism 9 (GraphPad Software, San Diego, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.21.22272672: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We identified studies from published search strategies conducted by the Cochrane Haematology living systematic review teams which searched the following databases - MEDLINE, Embase, the Cochrane COVID-19 Study Register, Pubmed, Epistemonikos</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Embase</div><div>suggested: (EMBASE, RRID:SCR_001650)</div></div><div style="margin-bottom:8px"><div>Pubmed</div><div>suggested: (PubMed, RRID:SCR_004846)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">L*OVE List Coronavirus disease, World Health Organization COVID-19 Global literature on coronavirus disease and trial registry platforms, including ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) and medRxiv (see references8,10).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ClinicalTrials</div><div>suggested: (ClinicalTrials.gov, RRID:SCR_002309)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
This study has a number of limitations. Firstly, it aggregates studies using different therapeutics and with different enrolment and outcome criteria. Secondly, it tries to equate administered doses of convalescent plasma and monoclonal antibodies based on a single study comparing in vitro neutralisation of pseudovirus32. In the case of convalescent plasma, we consider mean titre of donor plasma and mean plasma volume for dilution, which does not reflect the considerable variability that exists between individual donor plasma neutralisation titres and individual recipients’ plasma volumes. In addition, we consider only the ‘administered dose’, as the studies did not directly measure plasma neutralisation titres in recipients after administration. Gordon et al33 studied the pharmacokinetics of convalescent plasma after administration of a volume of 5 ml/kg to infants (leading to an estimated dilution of approximately 10-fold34). Direct measurement of recipient titres 30 minutes after infusion found a mean of 6.2% of donor titres, suggesting a decrease in titre of around 40% compared to what would be predicted by dilution alone. Thus, there may be a tendency for the ‘administered dose’ to be higher than a serum neutralisation level that might be directly measured in vivo after treatment. Despite these limitations, a major strength of our approach is to apply a rigorous quantitative analysis to the available data on passive antibody treatment for SARS-CoV-2. A major factor that ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
ecampusontario.pressbooks.pub ecampusontario.pressbooks.pub
-
6.2 – Types of Locomotion
2c) The Pedagogical Science in Science Communication – Applications of a BIO202 Undergraduate Scientific Journal
When it comes to scientific communication, I am most passionate about pedagogy and how teaching can be altered to better reach students. In other words, the way in which our studies are taught can be better tailored towards our learning capabilities, allowing for clearer understanding of course content. More effectively comprehending material is imperative to the success of students alike, and I am interested in devising a fresh pedagogical approach to allow for this success to be sparked at the University of Toronto.
In classes, such as BI0202, which are tailored towards the potential training of novice scientists and professionals, it is imperative that the study design is optimized so that the future remains bright and innovative. Research is therefore aided by the facilitation of proper teaching facilitated by post-secondary programs. Optimizing learning will therefore optimize research, contributing to the development of science and other related fields.
Junior scientists often learn to communicate their research during coursework. They become socialized into their disciplines as they adjudicate the teachings from their courses into future applications (Lea, 2004; Street et al., 2015). The problem is that, in university, there is little opportunity to fully expand your learning through active learning and external assignments that help to apply your knowledge. Completing specialized assignments, alike this one, is important to aid in the facilitation of knowledge acquisition among undergraduates, but it leaves students to collaborate within their own disciplinary bubble. Classroom projects rarely get adapted for a context beyond that space, which means that they do not learn how to translate their work for wider audiences, a key component in research.
A combination of specialization and lack of formal and external training and projects (Brownell et al., 2013) has contributed to the problem. Bankston and McDowell (2018) highlighted that this lack is at the core of challenges when students bring their knowledge into the working world, where knowledge is not effectively applied to real-word contexts. The solution, for many sources (e.g., Brownell et al., 2013; Norris et al., 2019), is increased communication training in scientific programs to resolve the “deficit” (Bubela et al., 2009) in scientific communication pedagogy. The idea is that emphasizing communication skills in the scientific classroom will better prepare junior scientists to engage with wider audiences.
For this reason, I find great importance in allowing students the ability to branch out of their disciplinary bubble and seek opportunities to interact with different avenues with their newfound knowledge.
An assignment to devise an essay on a related BIO202 topic could mean greater understanding of the topic for later students. Posting essays and reviews of BIO202 topics done by previous students in the class will allow for a greater transmission of thought and knowledge. Acting as a BIO202 scientific journal, active learning done by previous students, and continued by current students, will allow for active learning to be instilled within BIO202’s teaching paradigms. I find great value in undergraduate scientific journals as they help to highlight the learning by other students, while increasing your comprehension of the course content. In essence, the pedagogical initiative enables students to become what Caprio (2014) called “change agents” through their scholarship and dissemination.
Essay topics can be derived from any chapter, giving BIO202 students an expanse of research avenues to pursue and continue their learning and comprehension with. Narrowing specifically to “6.2 – Types of Locomotion”, a potential research topic could be regarding swimming locomotion in extinct animals, such as the Hesperornithiformes (as mentioned in the video at the end of the chapter). This furthers understanding since students are able to learn more about the limitations of locomotion by focusing their research on a specific subsection of locomotion that will benefit current and future students in BIO202. Active learning through innovative thoughts and analyses has been a proven method to facilitate comprehension, and I wholeheartedly believe that the addition of this assignment will assist students looking to apply their learning through an undergraduate journal, a method of disseminating their knowledge in an academic environment. Furthermore, publishing through undergraduate journals enhances their prospects as future graduate students, meaning the benefits surrounding the addition of a journal dedicated to BIO202 is twofold. This assignment will follow the teaching paradigm of Learning, Studying, and then Application of content, as demonstrated in my figure below.
Visual Aid Below
https://docs.google.com/document/d/1IOxnWPzPtVEtp0vwED-wlFuCr4Np4aF54Oi8i06Z4P4/edit?usp=sharing
Reforming scientific curricula to emphasize communication is useful, but it is important to also consider what happens beyond formal classroom curricula. Asking how scientists learn communication skills is a good start, but it is equally important to ask how they apply these skills to an authentic, non-expert audience while they complete their education.
References
Bankston, A., & McDowell, G.S. (2018). Changing the culture of science communicatin training of junior scientists. Journal of Microbiology & Biology Education, 19(1), 1-6. https://doi.org/10.1128/jmbe.v19i1.1413
Brownell, S.E., Price, J.V., & Steinman, L. (2013). Science communication to the general public: Why we need to teach undergraduate and graduate students this skill as part of their formal scientific training. The Journal of Undergraduate Neuroscience Education, 12(1), E6-E10.
Bubela, T., Nisbet, M., Borchelt, R., Brunger, F., Critchley, C., Einsiedel, E., Geller, G., Gupta, A., Hampel, J., Hyde-Lay, R., Jandciu, E., Jones, S.A., Kolopack, P., Lane, S., Lougheed, T., Nerlich, B., Ogbogu, U., O’Riordan, K., Oulette, C…Caulfield, T. (2009). Science communication reconsidered. Nature Biotechnology, 27, 514-518.
Caprio, M.J. (2014). Student publishing: Future scholars as change agents. OCLC Systems & Services, 30(3), 144-157. http://dx.doi.org/10.1108/OCLC-01-2014-0003
Lea, M. (2004). Academic literacies: A pedagogy for course design. Studies in Higher<br /> Education, 29(6), 739–756.
Norris, S.L., Murphrey, T.P., & Legette, H.R. (2019). Do they believe they can communicate? Assessing college students’ perceived ability to communicate about agricultural sciences. Journal of Agricultural Education, 60(4), 53-70. https://doi.org/10.5032/jae.2019.04053
Street, B., Lea, M. R., & Lillis, T. (2015). Revisiting the question of transformation in academic<br /> literacies: The ethnographic imperative. In T. Lillis, K. Harrington, M. R. Lea, & S. Mitchell (Eds.), Working with academic literacies: Case studies towards transformative practice (pp. 383-391). Fort Collins, CO: WAC Clearinghouse.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.21.485224: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The studies design and animal usage were reviewed and approved by the Institutional Animal Care and Use Committee under numbers 20-024, 21-006, 21-020 and 21-029 for compliance with regulations prior to study initiation.<br>Field Sample Permit: Experimental protocols were approved by the Institut Pasteur Ethics Committee under number dap210050 and authorized by the French Ministry of Research under number 31816.<br>IRB: Experimental protocols were approved by the Institut Pasteur Ethics Committee under number dap210050 and authorized by the French Ministry of Research under number 31816.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membrane was incubated with a polyclonal anti-RBD antibody (Sino Biological: 40592-T62) at 1:2000 dilution followed by incubation with HRP conjugated anti-rabbit polyclonal antibody and reaction was detected by chemiluminescence and revealed the expressed protein at the estimated size of the RBD-NP.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The absorbance of the sample was inversely dependent on the titer of the anti-SARS-CoV-2 neutralizing antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 neutralizing antibodies .</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transcribed capped mRNA was electroporated into baby hamster kidney (BHK-21) cells expressing SARS-CoV-2 N protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21</div><div>suggested: ATCC Cat# CRL-6281, RRID:CVCL_1914)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently, progeny virus was used to infect fresh VeroE6-TMPRSS2 cells to generate P.1 stocks for downstream experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 delta neutralization assay: Vero-E6 cells were seeded at a density of 1.5x104 cells/100μl per well (in DMEM supplemented with 10% FBS, 1% non-essential amino acids (NEAA) and 1% Penicillin-Streptomycin) in 96-well cell culture plates one day before and incubated over night at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently 100 μl of serum and virus mixtures were added on confluent Vero E6 cells and 96-well plates were incubated for 72 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: CB6F1/J mice and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice were purchased from The Jackson Laboratory (SN 100007 and 034860, respectively) under a license agreement.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CB6F1/J</div><div>suggested: RRID:IMSR_JAX:100007)</div></div><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transient expression of RBD-NP protein: FreeStyle 293 cells (2.106) in 500 ml of SFM media were transfected using 600 μg of pHL-sec plasmid DNA containing RBD-NP cDNA for transient expression of glycosylated RBD-NP according to the manufacturer’s protocol (Life Technology).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHL-sec</div><div>suggested: RRID:Addgene_99845)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The supercoiled pUC19 DNA was upscaled, linearized with BsmBI, and purified.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pUC19</div><div>suggested: RRID:Addgene_50005)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analyses were performed using Prism v9.3.1 (GraphPad Software) (Fig. 2-3, 5, 10-11) or using R Statistical Software v4.1.2</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>R Statistical</div><div>suggested: (R Project for Statistical Computing, RRID:SCR_001905)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04742738</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle V…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04750343</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle V…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT05175950</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Not yet recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety, Reactogenicity, and Immunogenicity Study of Heterolo…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04523571</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.22.485248: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Studies using primary human cells were approved by the University of Queensland Human Medical Research Ethics Committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">THP-1 cells (TIB-202; ATCC) were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated foetal bovine serum (FBS), 2 mM GlutaMAX (Life Technologies) and 50 U/ml penicillin–streptomycin (Life Technologies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 cells purchased from ATCC (HTB-55) were maintained in Minimal Essential Media (Invitrogen), containing 10% heat-inactivated foetal bovine serum (Cytiva), 50 U/ml penicillin and streptomycin (Life Technologies Australia), and were seeded at 300 000 cells per well in a 12-well plate 48 h prior to experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293T cells were transfected with the expression vectors according to the manufacturer’s protocol with PEI 2500 (BioScientific) and transduced target THP-1 cells were selected with puromycin (1 μg/mL) after 24 h and used for assays after 72 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus was grown on Vero E6 TMPRSS2 cells for 48 h in DMEM with 2% FBS, and cell debris was cleared by centrifugation at 500G for 5 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6 TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For Calu3 cells, virus was added to cells to give a total volume of 500 μL of RPMI 1640 with 2% FBS (HMDM and THP-1) or MEM with 2% FBS (Calu3) per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For studies involving SARS-CoV-2 infection of BAL macrophages, the SARS-CoV-2 isolate hCoV-19/Australia/VIC01/2020 (kindly provided by the Victorian Infectious Diseases Reference Laboratory) was grown in Vero cells for 72 h in serum-free MEM with 1 μg/ml TPCK trypsin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral transduction: A lentiviral construct containing human ACE2 (Addgene 155295), or mScarlet (Addgene 85044) was cloned into pLV-CMV-MCS-IRES-Puro-Sin (48) and packaged into lentivirus in HEK-293T cells by means of third generation lentiviral packaging plasmids (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLV-CMV-MCS-IRES-Puro-Sin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Mpro expression vector was generated by cloning the Mpro PCR product into a modified pEF6 plasmid, with an HA-tag N-terminal of the multiple cloning site, by standard restriction digest cloning techniques.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pEF6</div><div>suggested: RRID:Addgene_70765)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: Statistics were calculated using GraphPad Prism using tests indicated in figure legends.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.22.485299: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293T cells (CRL-3216; ATCC, Manassas, VA, USA) were seeded onto 96-well plates at a density of 5×104 cells per well in 100 μL complete medium (DMEM supplemented with 10% fetal bovine serum).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-E6 cells (African Green Monkey renal epithelial cells; ATCC cat. no. CRL-1586) engineered to overexpress hACE2/Furin were seeded in 24-well plates to obtain a confluence of 80%.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Vero E6 cells (European Collection of Authenticated Cell Cultures) were seeded onto 96-well plates at a density of 3×104 cells per well in 100 μL cell culture media that consisted of DMEM (Lonza, Basel, Switzerland), 1% penicillin–streptomycin (Lonza, Basel, Switzerland) and 2% heat-inactivated fetal bovine serum (Gibco, Waltham, MA, USA) the day before the experiment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell fluorescence was detected using an EVOS FL microscope (Life Technologies, Carlsbad, CA, USA) and was quantified in ImageJ (US National Institutes of Health, Bethesda, MD, USA) [26] using the Analyze Particles tool after thresholding for the corresponding colors.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 values were determined using non-linear regression analysis (four-parameter logistic model; GraphPad Prism 8).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As before [12, 23], binding data were converted to percent inhibition and fitted with standard log inhibitor vs. normalized response models [30] using nonlinear regression in GraphPad Prism (GraphPad, La Jolla, CA, USA) to establish half-maximal inhibitory concentrations (IC50).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04619290</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Outpatient Treatment With CoVid-19 With Prexablu</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04635605</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Methylene Blue Treatment of COVID-19</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04370288</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Clinical Application of Methylene Blue for Treatment of Covi…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.20.485044: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: SARS-CoV-2 infection in Syrian Golden Hamsters: Ethics Statement and Animal Exposure: Animal research was conducted under BIOQUAL Institute Institutional Animal Care and Use Committee (IACUC)-approved protocols, 20-152 in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals.<br>Euthanasia Agents: Prior to all blood collections, animals were anesthetized using Ketamine/Xylazine.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">siRNA dosing and SARS-CoV-2 challenge: Syrian Golden hamsters approximately 6-8 weeks of age, male (N=5-6 per group) were dosed intranasal (IN) with a luciferase siRNA (Ctl-siRNA) or COV-siRNA1+2 at Day −7, Day-14, or Day −30 prior to SARS-CoV-2 infection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After blocking in 2% milk powder/PBS for 30 min, cells were incubated with a primary antibody targeting SARS-CoV-2 nucleocapsid protein (Sino Biological) at a 1:3000 dilution for 1h followerd by incubation with a secondary AlexaFluor647-labeled antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 nucleocapsid protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed three times with PBS and then incubated for 1 hour at RT with 50 μL/well of goat anti-rabbit-Alexa647 (Thermo Fisher Scientific) secondary antibody at 1:1,000 in blocking buffer along with 1 μg/ml Hoechst 33342 (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit-Alexa647</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Dual-luciferase assays: Cos7 cells were co-transfected with any of the reporter plasmids, and siRNAs in 384-well plates format at a density of 5×104 cells per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cos7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 in vitro infection assay: Vero E6 cells were reverse transfected with the corresponding concentration of siRNA in a 96-well plate format using RNAiMax.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 concatemeric sequences were synthesized and incorporated individually into the psiCHECK2 vector by Blue Heron Biotech [Bothell, WA].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psiCHECK2</div><div>suggested: RRID:Addgene_40763)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The final vectors are referred to as psiCHECK2-CoV-2A, psiCHECK2-CoV-2B, and psiCHECK-negCoV2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psiCHECK-negCoV2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The siRNAs with ≥80% target reduction relative to mock-transfected controls in both psiCHECK-CoV2 plasmids were selected for further evaluations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psiCHECK-CoV2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Illumina adapters were clipped using Trimmomatic.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Read alignment to SARS-CoV-2 Wuhan-Hu-1 reference (NCBI: NC_045512.2) was performed with Burrows-Wheeler Aligner (BWA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BWA</div><div>suggested: (BWA, RRID:SCR_010910)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nucleotide variants were annotated with SnpEff to generate amino acid variants.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SnpEff</div><div>suggested: (SnpEff, RRID:SCR_005191)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Extensive QCs were performed at read, alignment and variant level using FastQC, samtools, picard, mosdepth, bcftools and MultiQC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div><div style="margin-bottom:8px"><div>samtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div><div style="margin-bottom:8px"><div>MultiQC</div><div>suggested: (MultiQC, RRID:SCR_014982)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The siRNA sequences directly targeting the SARS-CoV-2 genomic RNA were generated from the exemplar sequence in NCBI Genbank®.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI Genbank®</div><div>suggested: (NCBI GenBank via FTP, RRID:SCR_010535)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The MAFFT application output is a multiple sequence alignment of the lineage sequences relative to the reference genome.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The multiple sequence alignment file was processed using a custom R script and the BioConductor Biostrings library to parse the FASTA alignment file and produce a table of insertions, deletions, and substitutions in the lineage sequences relative to the reference by simple pair-wise comparison of each aligned lineage sequence to the reference.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioConductor</div><div>suggested: (Bioconductor, RRID:SCR_006442)</div></div><div style="margin-bottom:8px"><div>Biostrings</div><div>suggested: (Biostrings, RRID:SCR_016949)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: Statistical analyses were performed where indicated using Prism v7.01 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
To address this limitation, we added a second siRNA (COV-siRNA2) as a two-siRNA combination and found this could prevent the emergence of escape mutants. This is consistent with prior results demonstrating that the use of multiple siRNAs to target other CoVs was more effective than a single siRNA (19). Using deep sequencing and a luciferase reporter assay, we confirmed that viral mutations observed with the single siRNA approach accumulated vRNA mismatches at key positions causing a reduction of siRNA efficacy. This finding highlighted the need to employ a multi-siRNA targeting distinct sites or combinations of orthogonal interventions to minimize the risk of viral resistance in any real-world therapeutic applications. Since late 2020, new SARS-CoV-2 variants have steadily replaced the spike D614G variant highly prevalent in the first wave of the pandemic. We performed an exhaustive in silico evaluation of current WHO VOI and VOC including those encoding the receptor binding motif N501Y spike mutation which emerged simultaneously in the variants Alpha, Beta, Gamma, Delta, and Omicron (20–22). While these variants encode substitutions across the viral genome, they possess similar mutation patterns associated with improved affinity for the ACE2, the known entry receptor for SARS-CoV-2. Favorably, the sequences targeted by COV-siRNA1+2 are located far away from the spike encoding region. Our in-silico analysis of public databases suggests no anticipated loss of activity (target ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.18.484814: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, all collected plasma and saliva samples were tested for SARS-CoV-2 specific antibodies by enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assay (Fig. 2 and Suppl.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 4X washing, 100 μL of 1:5000 diluted Goat anti-human secondary antibody was added into each well and incubated at 37°C for 1 hr (Goat Anti-Human IgG ɣ Chain Specific HRP conjugated, species Adsorbed (Human IgM, IgD and IgA) Polyclonal Antibody for IgG (Cat# AP504P, EMD Millipore, Burlington, MA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA</div><div>suggested: (Millipore Cat# AP504P, RRID:AB_805350)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Goat Anti-Human IgA, a-chain specific Peroxidase conjugate for IgA (Cat# 401132-2ML, Calbiochem, San Diego, CA) for IgA, and Goat Anti-Human IgM Fc5µ Fragment specific HRP conjugated secondary antibody for IgM (Cat# AP114P</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Goat Anti-Human IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-Human IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-Human IgM</div><div>suggested: (Millipore Cat# AP114P, RRID:AB_92449)</div></div><div style="margin-bottom:8px"><div>IgM</div><div>suggested: (Millipore Cat# AP114P, RRID:AB_92449)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pCAGGS.S (30 μg for a T75 flask) using Lipofectamine 3000 (Invitrogen, L3000015) following the manufacturer’s instruction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Vero cells were seeded at a density of 2.5 × 104/50 μL in a Greiner Bio-One™ CellStar™ μClear™ 96-Well, Cell Culture-Treated, Flat-Bottom, Half-Area Microplate (Thermo Fisher Scientific, Waltham, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: RRID:CVCL_ZW93)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of pseudo-virus (rVSV-GFPΔG*Spike): For pseudoviruses construction, spike genes from strain Wuhan-Hu-1 (GenBank: MN908947) were codon-optimized for human cells and cloned into eukaryotic expression plasmid pCAGGS to generate the envelope recombinant plasmids pCAGGS.S as described previously with slight modifications 73.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pCAGGS.S (30 μg for a T75 flask) using Lipofectamine 3000 (Invitrogen, L3000015) following the manufacturer’s instruction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS.S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Positive response was determined by the area under the curve (AUC) using GraphPad Prism version 8.3.1 (GraphPad Software, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The neutralizing activity of the plasma sample was determined as pNT50 calculated from a transformed non-linear regression curve generated by GraphPad Prism version 8.3.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Significantly enriched proteins in convalescent samples (p<0.05)(Table 2) were subjected to the network analysis by STRING enrichment analysis (Cytoscape software v</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STRING</div><div>suggested: (STRING, RRID:SCR_005223)</div></div><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The heatmap was created using the pheatmap package in R using hierarchical distance matrix and clustering option 80.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pheatmap</div><div>suggested: (pheatmap, RRID:SCR_016418)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Correlation among different parameters (antibody titers, proteomic marker expression levels, categorized demographic information, and salivary protein subgrouping) was evaluated by both Pearson’s R and simple linear regression analyses using Graphpad Prism-8 suites of software (GraphPad Software, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pearson’s</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Limitation of our study consists of selection bias of donors enrolled in our study with inclusion criteria that considered most donors that had SARS-CoV-2 RT-qPCR-positive results and not healthy donors. The control population came from a pre-COVID era, and did not include an RT-qPCR, but attempted to match most of the demographics. Since our analysis was based on convalescent samples passively collected from persons with COVID-19 in the recovery phase, our study result does not directly reflect responses during the active disease phase of the viral infection. Some parameters, such as RBD binding IgG responses, seem to be already waned and did not display significant differences from healthy. While we could detect unresolved inflammatory status lagged from the acute phase of COVID-19, our study setting was not optimal to elucidate innate immunopathogenesis. As our data set was missing critical information, such as viral load, we cannot fully exclude the confounding factors that could possibly impact the antibody and proteomic alterations. Also, the samples were collected at only a one-time point, and antibody levels or proteomic responses were not adjusted by the different baseline of each individual and it was not possible to draw predictive conclusions on our findings but instead correlations. Most importantly, this is our cross-sectional study investigating one time point comparing health vesus disease and saliva versus plasma.Future longitudinal studies should investigate...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.20.485050: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Five square fields with an area of 1×10−6 μm were randomly placed on each imaged.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The person performing the analysis were blinded to the experimental design and tracer used.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-ACE2 antibody (R&D Systems, Cat# AF933) was labeled with Alexa Fluor 488 by following the manufacturer instructions (Microscale protein labeling kit; ThermoFisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-ACE2</div><div>suggested: (Millipore Cat# AB9896, RRID:AB_805247)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These include, anti ACE2 antibody (R&D Systems, Cat# AF933) used at a low (10 μg/m)l and high (60 μg/ml) concentration; anti TMPRSSE2 antibody (Invitrogen, Cat# PA5-14264) used at 13 μg/ml; anti CD147 antibody (Invitrogen, Cat# 34-5600) used at 2.5 μg/ml; anti NP-1antibody (Invitrogen, Cat# PA5-47027) used at 2 μg/ml and anti GM1 antibody (Abcam, Cat# Ab23943) used at 5 μg/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti ACE2</div><div>suggested: (Acris Antibodies Cat# BP2275, RRID:AB_972872)</div></div><div style="margin-bottom:8px"><div>anti TMPRSSE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti CD147</div><div>suggested: (Acris Antibodies Cat# SM2094P, RRID:AB_975010)</div></div><div style="margin-bottom:8px"><div>anti NP-1antibody</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti GM1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibodies, which were conjugated to Alexa Fluor 488, were donkey anti-rabbit (Thermofisher Scientific #A32790), anti-goat (Thermofisher Scientific #A32814) and anti-mouse (Thermofisher Scientific #A32766), and used at 1:200 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Thermo Fisher Scientific Cat# A32790, RRID:AB_2762833)</div></div><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: (Thermo Fisher Scientific Cat# A32814, RRID:AB_2762838)</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: (Thermo Fisher Scientific Cat# A32766, RRID:AB_2762823)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 Spike proteins (recombinant SARS-CoV-2 Spike Protein (SP-RBD, Arg319-Phe 541; cat# RP-87678, HEK293 cell expressed and binds ACE2) was obtained from Life Technologies Corporation, Carlsbad CA, USA. Mutants SPs and its control wild type protein were obtained from RayBiotech Inc, Peachtree Corners, GA, USA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All SPs were labeled separately with Alexa Fluor 555, using a kit (Microscale protein labeling kit; ThermoFisher Scientific; Waltham, MA, USA) and by following the manufacturer instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher Scientific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistic: All analysis were performed using Graphpad Prims version 9.2.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Outliers were identified and removed using ROUT method with Q= 10% in GraphPad Prism version 9.2.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Limitations of the study: Since RBD of the SPs were used as a model of SARS-CoV-2, uptake of the actual virus might be different. However, the SP of SARS-CoV-2 is essential for viral entry into host cells. Thus, the attachment part of the viral life cycle can be explored with the SP. Also other cell types of the neurovascular unit, such as astrocytes, microglia and neurons need to be explored for SP uptake mechanisms. However, it is likely that there will be similar mechanisms since these cell types also express ACE2 and have glycans, including GM1.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.18.484178: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cells were maintained in a humidified incubator with 5% CO2 at 37°C and were tested negative for mycoplasma. 2.2. Compounds: The following reagents were used: (5Z)-7-oxozeaenol (Cayman Chemical), sunitinib malate, (Selleckchem), erlotinib (LC Laboratories), gefitinib (Selleckchem), baricitinib (a gift from Dr. Chris Liang), SGC-GAK-1 and STK16-IN-1 (MedChemExpress).</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293T (ATCC) cells were grown in DMEM supplemented with 10% FCS, 1%L-glutamine, and 1% Pen-strep.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Vero E6 cells were transfected using Lipofectamine 2000 (Thermo Fisher) with 4 mg/well of pBeloBAC11-SARS-CoV-2/WT or – Nluc-2A.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">P1 virus was passaged twice in Vero E6-TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Twenty-four hours later, culture supernatant was harvested, clarified by centrifugation, filtered (0.22 μm) and stored at −80°C. rVSV-SARS-CoV-2-S was titrated on Vero cells via luciferase assay, and TCID50 was determined.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Entry assays: Calu-3 cells were infected with WT rSARS-CoV-2/WT (MOI=1) or a high inoculum of rVSV-GP SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: KCLB Cat# 30055, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293 cells were transiently transfected with the NanoLuc® Fusion DNA and incubated at 37°C. 20 hours post-transfection, NanoBRET™ tracer reagent and RMC-242 were added to the cells and incubated at 37°C for 2 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Vero E6 cells were transfected using Lipofectamine 2000 (Thermo Fisher) with 4 mg/well of pBeloBAC11-SARS-CoV-2/WT or – Nluc-2A.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBeloBAC11-SARS-CoV-2/WT</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Kinase abundance was quantified label-free using MaxQuant software. 2.16.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MaxQuant</div><div>suggested: (MaxQuant, RRID:SCR_014485)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: All data were analyzed with GraphPad Prism software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our findings suggest that the benefit demonstrated with baricitinib clinically likely does not result from its predicted anti-NAK effect and point out a limitation of the artificial intelligence approach for drug discovery in predicting antiviral activity. Lastly, we show that combining compounds with anti-AAK1/BIKE and anti-GAK activities may provide a synergistic antiviral effect against SARS-CoV-2 in vitro. This finding is in agreement with our prior data with sunitinib/erlotinib combinations in HCV, DENV, and EBOV in vitro (Neveu et al., 2015; Bekerman et al., 2017) and the finding that their combination protected 85% and 50% of mice from DENV and EBOV challenges, respectively (Bekerman et al., 2017; Pu et al., 2018). AAK1/BIKE and GAK have partially overlapping functions (Zhang et al., 2005; Neveu et al., 2015; Pu et al., 2020), which may explain moderate or no antiviral effect with drug alone, yet synergistic activity upon treatment with sunitinib/erlotinib combinations. The observed synergistic effect may also result from inhibition of additional targets by these drugs. In summary, these findings validate NAKs as candidate druggable targets for antiviral therapy against SARS-CoV-2 infection and provide a proof of concept that anti-NAKs approaches may have a utility for treating SARS-CoV-2 and possibly other coronavirus infections.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.20.485024: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were successively stained for 30 minutes on ice with the cocktail of fluorescently conjugated antibodies in 200 μl staining buffer (1X PBS + 2% FBS): 2 μg/ml biotinylated-RBD-Streptavidin-PE and FITC-anti-human IgG antibody (Biolegend, clone: M1310G05) and DAPI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FITC-anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells were seeded in a T-75 flask at a density of 4.5×106 cells/flask/15ml media.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For pseudovirus-based neutralization assay, HEK293 cells stably expressing ACE-2 receptor (HEK293-ACE2) were plated into a tissue culture treated opaque white 96-well microplate in complete medium at a density of 5000 cells/well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody and pseudovirus suspension was then added to the HEK293-ACE2 cells and 10μl of 50μg/ml (10X) of polybrene to the cells (5μg/ml final concentration).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day plasmid DNA was diluted in 500μl OptiMEM at a ratio of Transfer vector (CMV-GFP-T2A-Luciferase, BLIV101PA-1, System-bio)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CMV-GFP-T2A-Luciferase</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples showing the correct size band for heavy and light chain amplification in the respective wells were subsequently cloned into pAb20-hCHIgG1 (Synbio; for heavy chain) and pAb20-hCK (Synbio; for light chains) through in-fusion cloning (Takara).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pAb20-hCHIgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">24 hours later, pAb20-hCHIgG1 and pAb20-hCK plasmids separately expressing heavy and light chain of antibodies were transiently cotransfected into Freestyle-293F cells (R79007; Thermo Fisher) using purefection reagent (LV750A-1; System Bio) followed by manufacturer protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pAb20-hCK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">viral packaging (psPAX2): viral envelope (pMD2G) or Sars-CoV-2 envelope (pMT1-SARS-CoV-2-S, custom gene synthesis; Synbio) at 4:2:1 ratio (6:3:1.5ug, respectively).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2G</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pMT1-SARS-CoV-2-S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lastly, the half-maximal inhibitory concentrations (IC50) were measured using the four-parameter logistic regression in GraphPad Prism 8.0. 2.7 Statistical analysis: All grouped data are expressed as the mean ± standard deviation (SD) of a demonstrative experiment executed at least in triplicate, and almost similar data were obtained in at least three independent experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.18.484956: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: All the studies involving live viruses were conducted in the Vitalant Research Institute BSL-3 under approved safety protocols.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Image Analysis: To measure the frequency of infected cells, randomly-selected areas were imaged.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cells had been previously tested for mycoplasma contamination and incubated at 37°C in a humidified atmosphere with 5% CO2.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then incubated with a primary antibody (monoclonal rabbit anti-SARS-CoV-2 nucleocapsid antibody (GeneTex, GTX135357)) in 1 X PBS (1:1,000) overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following day, cells were washed three times with 1 X PBS and incubated with a secondary antibody (Goat anti-Rabbit IgG (H+L) secondary antibody, FITC (Thermo Fisher, 65-6111)) in 1 X PBS (1:200) for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rabbit IgG</div><div>suggested: (Thermo Fisher Scientific Cat# 65-6111, RRID:AB_2533966)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An unrelated anti-goat IgG antibody was used as a control.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The amount of captured ACE2, which is proportional to ACE2 binding activity, is then recognized by an ACE2 detection antibody and measured by reading the absorbance at a wavelength of 450 nm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses were propagated in Vero E6-TMPRSS2 cells in DMEM with 2% FBS and 1% penicillin/streptomycin and viral stocks were stored at −80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus titer was measured in Vero E6 cells by TCID50 assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, Calu-3 cells cultured in 96-well cell culture plates were incubated with different concentrations of Gal-9 (0-5,000 nM).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus production: VSVΔG-luciferase-based viruses, in which the glycoprotein (G) gene has been replaced with luciferase, were produced by transient transfection of viral glycoprotein expression plasmids (pCG SARS-CoV-2 Spike and pCAGGS VSV-G) or no glycoprotein control into HEK293T cells by TransIT-2020 as previously described (Ng et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus production: VSVΔG-luciferase-based viruses, in which the glycoprotein (G) gene has been replaced with luciferase, were produced by transient transfection of viral glycoprotein expression plasmids (pCG SARS-CoV-2 Spike and pCAGGS VSV-G) or no glycoprotein control into HEK293T cells by TransIT-2020 as previously described (Ng et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCG</div><div>suggested: RRID:Addgene_51476)</div></div><div style="margin-bottom:8px"><div>pCAGGS VSV-G</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data from three independent experiments was used to calculate the CC50 by nonlinear regression using GraphPad Prism 8.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA-seq and Ingenuity Pathway Analysis (IPA): RNA concentration and quality was measured using High Sensitivity RNA ScreenTape Analysis (Agilent, 5067-1500). cDNA libraries were prepared using the Illumina TruSeq Stranded total RNA library prep kit (Illumina, 20020597) and sequencing was performed on the Illumina Nextseq 550 platform generating 75 bp paired-end reads.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The quality of raw sequencing reads was assessed using FastQC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differentially-expressed genes were identified by GSA or ANOVA in Partek® Flow® imported into the QIAGEN Ingenuity Pathway Analysis (IPA) software application.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>QIAGEN Ingenuity Pathway Analysis</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Ingenuity</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed using FlowJo.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analyses were performed using Bio-Plex Manager™ 6.1.1 (Bio-Rad Laboratories, Hercules, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Plex</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantitative analysis of synergy: The combinatorial effects of Gal-9 treatment and SARS-CoV-2 infection on pro-inflammatory cytokine expression were analyzed using the SynergyFinder web application, implementing the Bliss Independence model.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SynergyFinder</div><div>suggested: (SynergyFinder, RRID:SCR_019318)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our study has limitations that must be considered. Firstly, we focused exclusively on the airway epithelium, and it is now established that SARS-CoV-2 is capable of infecting other cell lineages including monocytes, monocyte-derived macrophages, and microglia (Boumaza et al., 2021; Jeong et al.; Liu et al., 2021). It is possible that Gal-9 does not exert similar effects on viral replication or immune signaling in other target cell types. Secondly, our studies were all performed in vitro or in transplant tissue-derived primary epithelial cells ex vivo. As it is well-established that Gal-9 exerts conditional, pleiotropic immunomodulatory effects, the net effect of Gal-9 signaling on SARS-CoV-2 pathogenesis cannot be fully appreciated outside of an animal model with a functional immune system. Validation and extension of our observations in murine, hamster or nonhuman primate models of SARS-CoV-2 infection will help in evaluating the clinical relevance of our reported findings. In relevance to the implementation of animal models, our study did not elucidate the principal cell or tissue sources responsible for secreting Gal-9 in the setting of SARS-CoV-2 infection. Leveraging an animal model to identify these source compartments will be critical in developing interventions to manipulate Gal-9 signaling as a therapeutic approach. To our knowledge, the data presented here are the first to show that Gal-9 is directly involved in enhancing SARS-CoV-2 infection and virus-induced pro-i...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1: General comments:
Fujimoto and collaborators use Nanopore-based cDNA sequencing for genome-wide transcriptome analysis of a collection of hepatocellular carcinomas (HCCs) and matched normal liver tissues. To improve detection of alternatively spliced isoforms and hybrid transcripts potentially deriving from genomic rearrangements, they develop a dedicated pipeline SPLICE, which they benchmark against available software used for the same analysis. Besides having dual functionality (calls both alternative transcripts and fused transcripts), SPLICE seems to outperform previous software in calling alternative/fused transcripts and accuracy. They use the SPLICE pipeline to call isoforms and gene fusions in normal liver cells and HCCs and perform basic functional validations on novel fusions identified. The manuscript is well written, and the analyses are well performed. Perhaps the benchmarking of the SPLICE pipeline could have been more extensive (i.e., performed on additional independent datasets).
Major points: 1. Line 149-150: "We compared the results of mapping to the reference genome and the reference transcriptome sequences, and removed candidates if both were inconsistent (removal of mapping errors). " Please specify what "both were inconsistent" means.
Our reply; Thank you for this comment. The accuracy of fusion gene detection is influenced by mapping errors. To remove possible mapping errors, SPLICE aligned reads to the reference genome and the reference transcriptome sequences and compared the results. If the results are inconsistent (for example, GeneA-GeneB in the reference genome and GeneA-GeneB in the transcriptome genome, or GeneA-GeneB in the reference genome and GeneA in the transcriptome genome), SPLICE considers the candidates as false positive and removes them from the analysis.
We changed the sentence “We compared the results of mapping to the reference genome and the reference transcriptome sequences, and removed candidates if both were inconsistent (removal of mapping errors).” to “we compared the results of mapping to the reference genome and the reference transcriptome sequences, and removed candidates if both results did not detect same fusion genes (removal of mapping errors).” (line 150-152).- Concerning TE-derived novel exons, in principle, this may lead to altered expression of the TE-transcript (as the Authors report for L1-MET) or to altered splicing of the transcript (i.e., other exon/introns could be retained or excluded). Can the Authors assess whether the inclusion of the TE in a transcript enhances its expression or affects the splicing of the "parental" transcript? If so, can they verify if the position of the insertion of the TE has any effect on expression and splicing?*
Our reply; Thank you very much for this important comment. As the reviewer mentioned, exonization of TE may affect the splicing patterns and gene expression levels of transcripts. To determine the effect of TE on expression levels, we compared the expression levels of transcripts with TE-derived novel exons with those of known transcripts of the gene. We found that the expression levels of transcripts with TE-derived novel exon were lower than those of known transcripts (Figure 1 in the reply). Since the same results were observed in all novel transcripts (Fig. 1E,F), most TE exonization would not affect the expression level of transcripts.
We then analyzed the effects of TE in the splicing change, we compared the numbers of novel splicing junctions between transcripts with TE-derived novel exons and other transcripts in each gene. The proportions of genes with novel splicing junctions were not significantly different between the transcripts with TE-derived novel exons and others (transcripts with TE-derived novel exons; 9.1% and others; 11.9%) (Figure 2 in the reply). As observed in L1-*MET* and L2-*RHR1*, transposons can affect expression levels and structures of transcripts, however, their effect would be limited to a part of genes.Figure 1
Comparison of expression levels of transcripts with TE-derived novel exon and known transcripts. Only transcripts derived from genes with TE-derived novel exons were compared. The total number of transcripts is shown below the plot. Transcript abundance was measured in reads per million reads (RPM), and log10 converted values for RPM were shown in the violinplot. P-values were calculated by Wilcoxon rank-sum test.
Figure 2
Comparison of the percentage of novel splicing junction in transcripts with novel TE-derived exon and other transcripts. The total number of genes are shown below the plot. Transcripts with TE-derived novel exons and other transcripts were compared. P-value was calculated by Fisher’s exact test.
- Can the Authors explain why the NBEAL1-RPL12 was not detected by SPLICE?*
Our reply; Thank you for this comment. Although NBEAL1-RPL12 fusion was detected by SPLICE, mapping results to the reference genome and the reference transcriptome were inconsistent and removed from the final result. AsNBEAL1-RPL12 was not validated by PCR (Supplemental Fig. S4B) (line 183-184), we consider that this fusion-gene is a false positive, and filtering of SPLICE successfully removed false-positive fusions.
- Line 332: Can the Authors explain how the total amount of HVB mRNA was determined in each sample? Is it a relative amount calculated from the sequencing data? If so, it should be made clear in the text that this is a fractional measure.*
Our reply; Thank you very much for this comment. Expression levels were calculated by log10 converted reads per million reads (log10(RPM)) for each sample. We added the following sentences to the "Expression from HBV" subsection in the Results (line 337-338); “Expression levels were estimated by log10 converted support reads per million reads (log10(RPM)) for each sample.”.
- Fig4a: please specify if the y-axis "number of support reads" reports library normalized values.*
Our reply; Thank you for this comment. The values of the y-axis are row read counts. We added the following sentences to the Figure legend (line 348); “Y-axis shows the total number of support reads (raw counts).”.
- HCCs have more HBV-human genome fusion transcripts than normal liver. Could the authors clarify if these HCC transcripts are selectively found in tumors? or whether they are also expressed in normal liver samples? The paragraph starting from line 356 is confusing, and it is difficult to retrieve the above information for both HBs and HBx fusions.*
Our reply; We apologize for the confusing description. All HBV-human genome fusion transcripts were selectively expressed in tumor or normal liver. We added the following sentence to the "Expression from HBV" subsection in the Results (line 365-366); “All of these HBV-human genome fusion transcripts were selectively expressed in the HCCs and the livers.”.
- Figure 4C: what was the control used to calculate the relative viability in these analyses?*
Our reply; Thank you for this comment. Fig. 4C shows the number of HBV-human fusion transcripts in the six categories. If this comment refers to Fig. 4H, cell lines transfected with the empty vector (pIRES2-AcGFP1-Nuc) was used as controls. This has been described in the "Gene overexpression" subsection of Methods (line 716-717).
- MYT1L: the Authors report the identification of a novel MYT1L transcript downregulated in HCC, and argue it may have a potential tumor-suppressive function. For the sake of clarity, it will be advisable to show also the differential expression (HCC vs. Liver) of the other transcripts expressed from the same locus.*
Our reply; Thank you for this important comment. In HCCs and normal livers, only the novel MYT1L transcript was expressed from this locus, and no known transcript of MYT1L was expressed. We changed the sentence “In the MYT1Lgene, a highly-conserved novel exon was detected (Fig. 2E), and this transcript was significantly down-regulated in the HCCs” to “In the MYT1L gene, a highly-conserved novel exon was detected (Fig. 2E), and only a transcript with the novel exon was expressed.” (line 471-472).
- *
Minor points: 1. Table S4: there is a typo, correct “secific” in “specific”
Our reply; Thank you very much for this comment. We corrected the typo of Table S4.
-
*
-
*
*Reviewer #2: General comments:
Summary: This is both a presentation of a pipeline for analysis of Nanopore RNA-seq data, as well as an analysis of a cohort of 44 hepatocellular carcinomas against matched-normal liver tissue. It presents a number of quite intriguing results from the long-read RNA analysis, and suggests potential new targets for study in HCC. It is also worth noting that the current version of guppy (6) has functionality to detect primer sequences in the middle of reads and split those reads, which may obviate one of the steps in SPLICE.*
*Major comments:
1) The work done in this study used data that was basecalled using guppy 3.0.3. Since that version, I am aware of at least two major upgrades to the base caller accuracy, which would likely also improve the accuracy of isoform resolution. Given that the data is relatively low-coverage and that you have an automated workflow for the analysis, I would recommend re-basecalling using an updated basecaller and re-running your analysis using that. This is especially important given your comments in the paper about splice site misalignment.*
Our reply; Thank you very much for this important comment. We performed basecalling of a sequence data of MCF7 using the latest guppy v6.0.6 and compared the result with that by guppy v3.0.3. We randomly extracted 1M reads from MCF-7 reads that passed qscore filtering in guppy basecaller. The same reads were extracted and basecalled by guppy v3.0.3. These two data were analyzed by SPLICE.
The average error rate was 4.6 % for v6.0.6 and 6.8 % for v3.0.3. The number of transcripts was 9,674 for v6.0.6 and 9,329 for v3.0.3. Of these, the number of novel transcripts was 446 and 410, respectively. The number of fusion genes was 2 (BCAS3-BCAS4, and BCAS3-ATXN7) by v6.0.6 and one (BCAS3-BCAS4) by v3.0.3. As the reviewer mentioned, we found that using the latest version of guppy improved the accuracy and detected a larger number of transcripts.
We added the results to Supplemental Table S12. We also changed the sentences from “Second, our analysis removed the change of splicing sites within 5 bp to remove alignment errors (Fig. 1B). We consider that this cutoff value is necessary due to currently available high-error reads (S____upplemental Data S____2). However, sequencing technologies and basecallers are improving, and in the near future, we should be able to use a smaller cutoff value and identify larger numbers of splicing changes.” to “Second, the accuracy of the analysis depends on the sequencing error rate. Although several filters are used for currently available high-error reads (Fig. 1B and ____Supplemental____ Fig. S1), sequencing errors would affect the accuracy of the result. Sequencing technologies and basecallers are improving, and in the near future, we should be able to identify larger numbers of splicing changes with high accuracy (Supplemental Table S10).” (line 538-542).
2) You have compared your software to another tool for isoform analysis on Nanopore sequencing data, TALON. But a number of other tools exist for this purpose, including stringtie2, flair and bambu. My own testing has shown that stringtie2 outperforms TALON in terms of concordance with Illumina RNA-seq. It is quite important that you perform a complete comparison of your software to the state of the art for this purpose.
Our reply; Thank you very much for this important comment. We compared our tool with four tools (TALON, FLAIR, StringTie, and bambu). For this comparison, we used sequence data of MCF-7 and HCC (RK107C). We randomly extracted 1 M reads from MCF-7 and HCC (RK107C) sequence data using Seqtk (v1.3) (params: sample -s1 1000000). Reads were mapped to the reference genome sequence (hg38) with minimap2 (v2.17) (params: -ax splice --MD), and the output SAM files were converted to BAM files and sorted with samtools (v1.7) (Li et al. 2009).
For benchmarking of TALON (v5.0), we corrected aligned reads with TranscriptClean (v2.0.3) (Wyman and Mortazavi 2018). Next, we ran the talon_label_reads module to flagging reads for internal priming (params: --ar 20). TALON database was initialized by running the talon_initialize_database module (params: --l o --5p 500 --3p 300). Then, we ran the talon module to annotate the reads (params: --cov 0.8 --identity 0.8). To output transcript abundance, we first obtained a whitelist using the talon_filter_transcripts module (params: --maxFracA 0.5 --minCount 5), and then quantified transcripts using the talon_abundance module based on the whitelist. For FLAIR (v1.5), the sorted BAM file was converted to BED12 using bin/bam2Bed12.py. We then corrected misaligned splice sites with the flair-correct module. High-confidence isoforms were defined from the corrected reads using the flair-collapse module (params: -s 3 --generate_map). For benchmarking of StringTie (v2.2.1), Stringtie was performed with input files consisting of long-read alignment and reference annotation (params: -L -c 3). For benchmarking of bambu (v2.0.0), Bambu was performed with input files consisting of long-read alignment, reference annotation and reference genome (hg38) (params: min.readCount = 3). Candidates with low expression levels (support reads As a result, SPLICE identified the third-highest number of transcripts followed by FLAIR and StringTie (Supplemental Fig. S3A). In MCF-7 the concordance rate with IsoSeq MCF-7 transcriptome data was the highest in SPLICE for known transcripts and the second highest in SPLICE for novel transcripts (Supplemental Fig. S3B). These results indicate that SPLICE has sufficient accuracy for analyzing transcript aberrations.
We added the text to the "Comparison of SPLICE method with other tools" subsection of the Results (line 165-177) and the "Benchmarking" subsection of the Methods (line 640-679). We added the results to Supplemental Fig. S3.
3) Likewise, for fusion detection, you compare to LongGF. You should also compare to (and cite) JAFFAL.
Our reply; Thank you very much for this important comment. We compared our tool with the two tools (LongGF and JAFFAL). We used 1 M reads randomly extracted from MCF-7 and HCC (RK107C) sequence data as described above.
For benchmarking of LongGF (v0.1.2), reads were mapped to the reference genome sequence (hg38) with minimap2 (v2.17) (params: -ax splice --MD), and the output SAM files were converted to BAM files and sorted with samtools (v1.7). We then ran the *longgf* module and obtained the list of fusion genes (params: min-overlap-len 100 bin_size 50 min-map-len 200 pseudogene 0 secondary_alignment 0 min_sup_read 3). For benchmarking of JAFFAL (v2.2), we ran the *JAFFAL.groovy* module with zipped fastq files. In this comparison, close gene pairs (We added the text to the "Comparison of SPLICE method with other tools" subsection in the Results (line 178-186) and the "Benchmarking" subsection in the Methods (line 667-679). We showed the results in Supplemental Fig. 4.4) In terms of the source code, I have questions. Why did you use BASH to run the Python code, instead of making this into a Python package? Why did you not use the functionality already available in BioPython for a number of basic sequence data handling tasks? Why is there not even a single function defined anywhere, let alone classes?
At some level, if it works, it works. But I have serious concerns about the long-term maintainability of the code in its current state.
Our reply; Thank you very much for this critical comment. As the reviewer mentioned, we think it is better to make a python package and use BioPython for maintenance and long-term maintainability of the code. We have been building our analysis pipeline by trial and error, and at this stage, the current scripts are convenient for us (our group may need to learn software development). We provided a Docker package (see the reply to comment 5)), and this would promote usability.
5) Also related to the code, it is generally the standard now to create a BioConda package or Docker container for a bioinformatics package. BioConda has the advantage that the BioContainers project automatically generate Docker and Singularity containers from it. Please provide one of these.
Our reply; Thank you very much for this critical comment. We made a Docker file and provided it from our github page. It is available from the "Installation and usage via Docker" section.
6) There is some quite nice functional validation work done on some of the DE transcripts that would have been hidden in a gene-level analysis. There is also some nice work on detecting HBV fusion genes. These both contain important results which are not mentioned at all in the abstract. I feel like the abstract as it stands is selling the paper short.
Our reply; Thank you very much for this important comment. We added the following sentences to the abstract; “Comparison of expression levels identified 9,933 differentially expressed transcripts (DETs) in 4,744 genes. Interestingly, 746 genes with DETs, including LINE1-MET transcript, were not found by the gene-level analysis. We also found that fusion transcripts of transposable elements and hepatitis B virus (HBV) were overexpressed in HCCs. In vitro experiments on DETs showed that LINE1-MET and HBV-human transposable elements promoted cell growth.”.
7) Fig 5C shows a Venn diagram of fusions detected by short-read vs long-read sequencing, in which there is quite low overlap between these. You make the statement in the paper that "a combination of short- and long-reads can detect more fusion genes". I find it more likely that the short-read ICGC data had much greater depth of coverage than the MinION data you produced, which allowed for the detection of fusions that were expressed at much lower levels. This could be easily tested by downsampling the ICGC data to the same amount of sequence data as was generated on the MinION, and re-creating the Venn diagram with the fusions detected that way.
Our reply; Thank you very much for this very important comment. We compared the amount of data between our long-reads and the previous short-reads. However, the amounts of data were not quite different (Supplemental Fig. S14A). Therefore, differences in depth are not likely to be the cause of the low overlap. We considered that two possibilities could explain the low overlap. First, most of the fusion genes missed by short-read were very low expression levels, less than 1 reads per million reads (RPM) (Supplemental Fig. S14B), therefore, there are many fusion-genes with low expression levels, and they are difficult to be detected. Second, 28.9 % of transcripts in long-reads lacked 5' region (Supplemental Fig. S5 and Supplemental Fig. S14C,D). Therefore fusion-genes whose breakpoints are located in the 5' region were difficult to detect by long-read.
We added the following sentences to the "Fusion genes" subsection in the Results (line 400-405); “We considered that two possibilities could explain the low overlap. Since the most of the fusion genes missed by short-reads had very low expression levels (Supplemental Fig. S14B), many fusion-genes with low expression levels would be missed by a single approach. In addition, 28.9 % of transcripts in long-reads lacked 5' region (Supplemental Fig. S5 and Supplemental Fig. S14C, D). Therefore fusion-genes whose breakpoints are located in the 5' region would be difficult to detect by long-read.”. We also added a figure on the amount of data to Supplemental Information (Supplemental Fig. S14A).
8) Figure 5D is very interesting. What do you conclude from that result? Please comment in the manuscript.
Our reply; Thank you very much for this important comment. We used samples that used for whole-genome sequencing in our previous study. Therefore, a list of SVs is available. We classified fusion-gene to these supported by SVs (SV detected fusion-genes) and others (no SV detected fusion-genes), and compared the expression levels of them (Figure 5D).
Whole-genome sequencing can accurately identify clonal (high frequency) SVs, however, would miss sub-clonal (low frequency) SVs. Therefore, we considered that no SV detected fusion-genes were generated by sub-clonal SVs. This result suggests that there are a lot of sub-clonal fusion genes, and their expression levels are lower than clonal fusion genes. Although the functional importance of sub-clonal fusion genes is currently unknown, deeper RNA sequencing would detect a larger number of fusion genes.
We added the following sentences to the “Fusion genes” subsection in the Results (line 410-412); “This result suggests that there are a lot of sub-clonal fusion genes, and their expression levels are lower than clonal fusion genes. Although the functional importance of sub-clonal fusion genes is currently unknown, deeper RNA sequencing would detect a larger number of fusion genes.”.*Minor comments:
1) The manuscript has many small errors in English grammar, spelling and style. I would strongly recommend sending it for copy editing before submitting it to a journal.*
Our reply; Thank you very much for this comment. Due to the limitation of time, the current version has not been proofread by a native-English speaker. We are planning to review English grammar by a native-English speaker.
2) Neither the results section nor the methods section describing the sequencing that was performed specify whether it was done on a MinION or PromethION (or flongle). While this is implied elsewhere in the paper, it should definitely be specified in the methods at a minimum.
Our reply; Thank you for this comment. We used a MinION for sequencing. We added the following sentences to the Method section (line 579-580); “Libraries were sequenced on a SpotON FlowCell MKⅠ(R9.4) (Oxford Nanopore), using the MinION sequencer (Oxford Nanopore)”.
3) You also write in the introduction that your method, SPLICE, was developed for the MinION specifically. Please comment on its applicability to data generated on the PromethION and flongle Nanopore sequencers.
Our reply; Thank you very much for this comment. We consider that our method is applicable to data from MinION, PromethION, and flongle. We added the following sentence to the Methods section (line 592-593); “In the present study, we analyzed sequence data from MinION. We consider that our method is applicable to data from MinION, PromethION, and flongle.”.
4) The volcano plot in Fig 3A is missing its dots.
Our reply; Thank you very much for this comment. We modified the Fig. 3A.
*Reviewer #3: General comments:
Summary: In this manuscript, Kiyose et al have developed and tested a novel methodology for identifying splicing alterations, and fusions, from full-length transcript or long read sequencing data. They apply this approach to liver cancer and paired, non-cancerous liver tissue from a prior publication, and use wet-lab/experimental methods to validate their in silico findings. They conclude that their new methodology, SPLICE, outperforms one existing method, and is uniquely suitable to identifying fusion genes.*
Major Comments: 1) Figure 1B shows a schematic of common error patterns from MinION cDNA sequencing, and the text of the manuscript describes how the authors' new approach (SPLICE), overcomes several of these, e.g. sequencing errors, artificial chimeras, and mapping errors of highly homologous genes. However, there is a fundamental disconnect between the text and the graphic in Figure 1B. This should either be revised for clarity, or an additional graphic or flowchart placed in the supplementary materials to clearly show *how* SPLICE overcomes each of these limitations.
Our reply; We apologize for the insufficient explanation in Figure 1. We showed a detailed explanation of the data analysis procedure in Supplemental Fig. S1.
2) Why was TALON the only alternative approach chosen for validation of SPLICE performance? There are a number of other, more advanced pipelines such as SUPPA2, and IsoformSwitchAnalyzeR. It would strengthen the manuscript, and its conclusions, to incorporate at least one of these methods as a second comparator. This is particularly true for IsoformSwitchAnalyzeR, since Kiyose et al identify a number of differentially expressed transcripts (DETs) for genes that are not differentially expressed.
Our reply; Thank you very much for this important comment. Another reviewer also requested additional benchmarking, therefore we performed an additional performance comparison for the revised manuscript. As SUPPA2 and IsoformSwichAnalyzeR are used to analyze the annotated output GTF files, and direct comparison with SPLICE is difficult. Since IsoformSwichAnalyzeR recommends StringTie as an annotation soft, we compared using StringTie instead.
We compared the performance of SPLICE with that of four other methods (TALON, FLAIR, StringTie and Bambu) for splicing variant detection. SPLICE identified the third-highest number of transcripts followed by FLAIR and StringTie (Supplemental Fig. S3A). In MCF-7 the concordance rate with IsoSeq MCF-7 transcriptome data was the highest in SPLICE for known transcripts and the second highest in SPLICE for novel transcripts (Supplemental Fig. S3B).
We added the text to the "Comparison of SPLICE method with other tools" subsection of the Results (line 165-177) and the "Benchmarking" subsection of the Methods (line 640-665). We added the results to Supplemental Fig. 3.
3) The Venn diagram in Figure 5C appears to show that conventional short read sequencing identifies 46 fusion genes that are not also detected by long read sequencing. However, this result, and its implications are never addressed in the text.
Our reply; Thank you very much for this important comment. We apologize for the insufficient explanation. We considered that two possibilities could explain the low overlap. First, most of the fusion genes missed by short-read were very low expression levels, less than 1 reads per million reads (RPM) (Supplemental Fig. S14B), therefore these are many fusion-gene with low expression level and they are difficult to be detected. Second, 28.9 % of transcripts in long-reads lacked 5' region (Supplemental Fig. S5 and Supplemental Fig. S14C,D). Therefore fusion-genes whose breakpoints are located in the 5' region were difficult to detect by long-read.
We added the following sentences to the "Fusion genes" subsection in the Results (line 400-405); “We considered that two possibilities could explain the low overlap. The most of the fusion genes missed by short-reads had very low expression levels (Supplemental Fig. S14B). This result suggests that there are many missed fusion-genes with low expression levels. In addition, 28.9 % of transcripts in long-reads lacked 5' region (Supplemental Fig. S5 and Supplemental Fig. S14C, D). Therefore fusion-genes whose breakpoints are located in the 5' region would be difficult to detect by long-read.”. We also added a figure on the amount of data to Supplemental Information (Supplemental Fig. S14A).Minor Comments: 1) On pages 20-21, the language used to describe the HBV and/or HCV postive vs negative materials is very confusing. Please clarify that by "HBV- and HCV-related tissues" you in fact mean "HBV-and HCV-infected samples."
Our reply; We apologize for the confusing wording. We converted "HBV and HCV-related tissues" to " HBV and HCV-infected samples" in the manuscript.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.18.484873: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Study design and use of subject samples were approved by the Institutional Review Board of the Lausanne University Hospital and the ‘Commission d’éthique du Canton de Vaud’ (CER-VD).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Four female cynomolgus macaques aged 3–6 years were randomly assigned between the control and treated groups to evaluate the efficacy of P2G3 LS in the prophylaxis challenge study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Four female cynomolgus macaques aged 3–6 years were randomly assigned between the control and treated groups to evaluate the efficacy of P2G3 LS in the prophylaxis challenge study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike and RBD tetramers were prepared fresh before use and formed by combining biotinylated proteins with PE-conjugated Streptavidin (BD Biosciences) at a molar ratio of 4:1. Binding and ACE2 blocking studies with SARS-CoV-2 Spike: Luminex beads used for the serological and purified antibody binding assays were prepared by covalent coupling of SARS-CoV-2 proteins with MagPlex beads using the manufacturer’s protocol with a Bio-Plex Amine Coupling Kit (Bio-Rad, France).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biotinylated P5C3, P2G3, REGN10933, REGN10987, AZD8895, AZD1061, ADG-2 or S309 antibodies (prepared as described above) were added to each well at 1 μg/ml followed by a further 20-minute incubation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AZD8895</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>S309</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Freshly isolated cells were stained with the cocktail of fluorescent conjugated antibodies containing anti-CD19 APC-Cy7, anti-CD3-BV510, anti-IgM-FITC, anti-IgD PE-CF594, anti-CD27-APC, anti-CD38-V450 (BD Biosciences) along with the pre-complexed Beta variant Spike tetramer (2 μg in 100μl) coupled to PE-streptavidin (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD19 APC-Cy7, anti-CD3-BV510, anti-IgM-FITC, anti-IgD PE-CF594</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD27-APC</div><div>suggested: (Sigma-Aldrich Cat# SAB4700132, RRID:AB_10896618)</div></div><div style="margin-bottom:8px"><div>anti-CD38-V450</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The treated group (n = 2 [MF1 and MF2]) received one dose at 10 mg/kg of P2G3 LS human IgG1 monoclonal antibody delivered by intravenous injection three day prior to challenge, while control animals (n = 2 in parallel [MF3 and MF4] and n=2 historical [MF5 and MF6]) received no treatment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>human IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>MF4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In the ADCC assay, CEM-NKR-Spike-Luc cells were incubations with anti-Spike antibody at 0.3 μg/ml, isotype control antibodies at 0.3 μg/ml or an anti-HLA class I (MHC) positive control antibody (Invivogen) at 0.005 μg/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Spike</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>I (MHC) positive control antibody (Invivogen) at 0.005</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To monitor cell killing, co-cultured cells were washed and stained with fluorescent conjugated antibodies, CD56-AF488 (BD Biosciences,), CD16-FITC (BD Biosciences), Aqua Live/Dead cell stain (Invitrogen), CD4-PECF594 (BD Biosciences) and Annexin V-APC (BD Biosciences), and then analysed using a FACS LSR II cytometer instrument.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Annexin V-APC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Positive control anti-MHC (anti-HLA class I) antibody gave strong antibody dependent cell killing of 60-80% and anti-Spike antibodies gave intermediate responses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-MHC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-HLA class I</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral stocks were prepared in EPISERF on VeroE6 or Calu-3 (for Omicron), aliquoted, frozen and titrated on VeroE6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rev and pUltra-Chili-Luc vectors (Addgene) into 293T cells in DMEM medium + 10% FCS using Fugene 6 (Promega) for pseudoviruses production.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All animals were then exposed to a total dose of 105 TCID50 of Omicron B.1.1.529 SARS-CoV-2 virus produced in Calu-3 cells (NIH/BEI reference: NR-56462) via the combination of intranasal and intratracheal routes (day 0) with sample collection and testing performed as previously described 36.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">U937 cells incubated with Spike beads in the absence of antibody generally showed <5% phagocytic activity while increased ADCP activity was observed with increasing concentration of anti-Spike antibody with a maximum of 100% of cells exhibiting fluorescence associated with Spike bead phagocytosis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>U937</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Omicron Spike ectodomain was amplified by PCR with primers (listed in Table 3) designed on consensus sequence from available Omicron sequences, and introduced by In-Fusion cloning into the nCoV-2P-F3CH2S plasmid, replacing the original wild-type Spike29.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>nCoV-2P-F3CH2S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudoviruses were alternatively produced with the original 2019-nCoV (Cat #100976), Alpha / B.1.1.7 (Cat #101023) and Beta/B.1.351 (Cat #101024) pCAGGS-SARS2-Spike vectors obtained from NIBSC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-SARS2-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These vectors were co-transfected with pMDL p.RRE, pRSV.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMDL p.RRE</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pRSV</div><div>suggested: RRID:Addgene_106453)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rev and pUltra-Chili-Luc vectors (Addgene) into 293T cells in DMEM medium + 10% FCS using Fugene 6 (Promega) for pseudoviruses production.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pUltra-Chili-Luc</div><div>suggested: RRID:Addgene_48688)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To monitor cell killing, co-cultured cells were washed and stained with fluorescent conjugated antibodies, CD56-AF488 (BD Biosciences,), CD16-FITC (BD Biosciences), Aqua Live/Dead cell stain (Invitrogen), CD4-PECF594 (BD Biosciences) and Annexin V-APC (BD Biosciences), and then analysed using a FACS LSR II cytometer instrument.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Biosciences</div><div>suggested: (BD Biosciences, RRID:SCR_013311)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The soft mask volume were generated manually in UCSF Chimera and cryoSPARC 40.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cryo-electron microscopy model building: A model of a Spike trimer (PDB ID 7QO7) or AlphaFold2 (ColabFold implementation) models of the P5C3 and P2G3 Fabs were fit into the cryo-EM maps with UCSF Chimera These docked models were extended and rebuilt manually with refinement, using Coot and Phenix41,42.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Buried surface area measurements and centroid measurements were calculated within ChimeraX.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ChimeraX</div><div>suggested: (UCSF ChimeraX, RRID:SCR_015872)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analyses were performed in GraphPad Prism (GraphPad Software, Inc.) and Microsoft Excel.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.17.484786: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody Assays: ELISA for anti-S1 and anti-S2 antibodies: Sera from individual hamsters were tested for S-specific antibodies by ELISA on plates coated overnight with 100 µl of a mixture of S1 and S2 (Native Antigen Company, Kidlington, UK) each diluted to 1 µg/ml in bicarbonate buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-S2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An anti-hamster IgG (H+L)-Alkaline Phosphatase antibody produced in goat (Sigma-Aldrich, St Louis, MO) diluted to 1:1000 in 3% BAS-PBS was added at 60 µl/well for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>An anti-hamster IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-hamster IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>H+L)-Alkaline Phosphatase</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA for RBD-binding antibodies: Sera were tested for inhibition of ACE binding to the RBD of the S protein by the Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit from Acro Biosystems (Newark, DE) following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A positive standard with a known concentration provided by the kit was used to extrapolated anti-S antibody concentrations into µg per ml of serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The VSV-S vector was diluted in medium containing 1 µg/ml of a mouse monoclonal antibody against VSV glycoprotein (sc-365019, Santa Crusz Biotechnology, Dallas, TX) and then incubated with the serum dilutions for 90 min at room temperature under gentle agitation starting with a serum dilution of 1 in 40.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody against VSV glycoprotein (sc-365019, Santa Crusz Biotechnology, Dallas, TX)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A monoclonal antibody to N protein (Abbexa, MCA6373, lot# 156962) served as a positive control (data not shown).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MCA6373</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then incubated with an anti-INF-γ-FITC antibody (clone XMG1.2 BioLegend, San Diego, CA) at 4°C for 30 min in the dark.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-INF-γ-FITC</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: HEK 293 cells were grown in Dulbecco’s Modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Challenge virus: Challenge was conducted with the WT WAS stock, which was generated from seed stock (2019-nCoV/USA-WA1/2020), obtained from Biodefense and Emerging Infections Research (BEI) resources (Cat # NR-52281, Lot # 70036318) and expanded in Calu-3 cells at 37°C for 3 days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The stock (Lot # 12152020-1235) titers in Vero TMPRSS2 cells are 2.34×109 Median Tissue Culture Infectious Dose (TCID50)/mL and 3.68 × 107 plaque forming units (PFU)/mL, and 6 × 105 PFU/mL in Vero76 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero TMPRSS2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Vero76</div><div>suggested: JCRB Cat# IFO50410, RRID:CVCL_0603)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of VSV-S vectors: VSV vectors pseudotyped with S of SARS-CoV-2 were generated in BHK-21/WI-2 cells using a the ΔG-GFP (G*ΔG-GFP) rVSV kit (Kerafast, Boston, MA, USA) and S sequences cloned into an expression plasmid under the control of the CMV promoter as described previously [51].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549A/T cells were plated into Terasaki plate wells as described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549A/T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549-hACE-TMPRSS2 (A549A/T) cells (InvivoGen, cat no. a549-hace2tpsa) were maintained in DMEM with 10%FBS, 300µg/ml of hygromycin, 0.5 µg/ml of puromycin and antibiotics.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-hACE-TMPRSS2 (A549A/T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the neutralization assay a dose of VSV-S vector that infected ∼20-40 cells/well was selected.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VSV-S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Post-acquisition analyses were performed with FlowJo (TreeStar, Ashland, OR).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The analyses were carried out by GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.16.22272513: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants provided written informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">PROFISCOV phase 3 clinical trial: To assess the safety and efficacy of the CoronaVac vaccine in Brazil, a randomized, double-blind, placebo-controlled phase 3 multicenter clinical trial was performed in healthy healthcare professionals on the front line of COVID-19 patients treatment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Study design and participants: After the breaking of the participants’ blinding code, these 120 individuals were filtered based on vaccination status, age and specimen availability to compose the cohort used to assess cellular and humoral response after immunization with CoronaVac.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were incubated with 0,5μg/mL anti-CD40 antibody (Miltenyi Biotec, NRW, Germany) and then stimulated in the presence of specific MPs (1μg/mL), 10μL/mL positive control phytohemagglutinin (PHA, Sigma-Aldrich, Darmstadt, Germany) or 0.1% negative control dimethyl sulfoxide (DMSO, Sigma-Aldrich, Darmstadt, Germany).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD40</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CoronaVac (Sinovac Life Sciences, Beijing, China) is an inactivated vaccine derived from the CN02 strain of SARS-CoV-2 grown in Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Acquisition was performed with the BD FACSDiva™ Software v6.0 and FlowJo™ v10.8 was used for data analysis (both from BD Biosciences, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD FACSDiva™</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div><div style="margin-bottom:8px"><div>FlowJo™</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Binding antibody (bAb) assay: Plasma samples were tested for quantitative IgG bAbs against nine SARS-CoV-2 antigens: S, RBD and N from the Wuhan/WH04/2020 strain and S and RBD from the VOCs Alpha (B.1.1.7), Beta (B.1.351) and Gamma (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gamma</div><div>suggested: (GAMMA, RRID:SCR_009484)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Graphs and statistical analysis were performed at GraphPad Prism version 9.0.0 for Windows (GraphPad Software, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04456595</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed …</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.17.22272516: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wells were seeded with Vero E6-TMPRSS2 cells, to which 100μl of participant specimen was added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All specimens were tested by RT-PCR using either the CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel (EUA CDC-006-00019; with N1 and N2 gene targets and RNase P control; CDC assay) or the ThermoFisher TaqPath™ COVID-19 ComboKit (with S and N gene and ORF1ab targets and MS2 spike control; ThermoFisher assay).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher TaqPath™</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Sample size and study period are also limitations, especially in our ability to assess the impact of vaccination status or dissociate vaccination or other demographics from age. Ct values also cannot be converted to a quantitative representation of viral load, and cannot be used to directly infer differences in infectiousness. However, despite these limitations, clinical interpretation of Ct values (or their trajectories) may be “tempting “ (IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making, page 3) [14]. The present data are directly relevant to these interpretations. Specifically, specimens that were collected within 4 days of symptom onset may represent periods when Ct values are still declining. These findings contribute to our understanding of RT-PCR Ct values during SARS-CoV-2 infections over a broad range of ages, in a community setting with mostly mildly symptomatic illness, and among individuals with a known date of first shedding. While these data were collected prior to Delta and Omicron circulation, and prior to widespread vaccination, they may provide context for interpreting trajectories in Ct values in similar populations during later SARS-CoV-2 outbreaks.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.17.484640: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: The participants were ≥18-years-old male and female subjects who provided written informed consent before enrollment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The participants were ≥18-years-old male and female subjects who provided written informed consent before enrollment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry of Whole Blood: The levels of CD3+ CD4+ T cells and CD3+ CD8+ T cells/µl were measured using BD Trucount™ Tubes (BD Multitest™ 340491, BD Biosciences) with FITC-conjugated anti-CD3, PE-conjugated anti-CD8, PerCP-conjugated anti-CD45 and APC-conjugated anti-CD4 antibodies (BD Multitest™, 342417, BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD8,</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>PerCP-conjugated</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD45</div><div>suggested: (BD Biosciences Cat# 342417, RRID:AB_2868785)</div></div><div style="margin-bottom:8px"><div>anti-CD4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IFNγ-ELISPOT Assay: 96-well plates (Millipore Multiscreen Filtration, Merck Millipore, Sweden) were pre-treated with coating buffer (0.1M Na-Carbonate–Bicarbonate buffer pH 9.5), after which, wells were coated with human anti-IFN-γ monoclonal antibodies (1-D1K, Mabtech Sweden) at a concentration of 5μg/ml and diluted with the same coating buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 48 hours of incubation, the plates were washed four times with 0.05% Tween 20 in PBS, followed by 2 hours of incubation at 37°C with biotinylated anti-human IFN-γ monoclonal antibodies (clone 7-B6-1, Mabtech) diluted at 1μg/ml in PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-SARS-CoV-2 Spike and Nucleocapsid IgG: Qualitative measurement of anti-SARS-CoV-2 spike IgG, including anti-spike neutralizing IgG antibodies directed against the receptor binding domain (RBD) of S1 subunit was performed using a commercial chemiluminescent microparticle-based immune assay (Abbott SARS-CoV-2 IgG II Quant/6S60 ARCHITECT SARS-CoV-2 IgG kit) and anti-SARS-CoV-2 nucleocapsid IgG (6R86 ARCHITECT SARS-CoV-2 IgG) using a commercial ARCHITECT Abbott (Abbott Laboratories Diagnostics Division, Abbott Scandinavia AB) kit.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Nucleocapsid IgG: Qualitative measurement of anti-SARS-CoV-2 spike IgG, including anti-spike neutralizing IgG antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 spike IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-spike neutralizing IgG</div><div>suggested: (Sino Biological Cat# 40592-R001, RRID:AB_2857936)</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 nucleocapsid IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The anti-SARS-CoV-2 spike IgG are expressed as standardized binding antibody units (BAU)/mL, calibrated to the WHO International Standards for anti-SARS-CoV-2 immunoglobulin (human) (NIBSC Code 20-136) [43] with a positivity cut-off of 7.1 BAU/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 immunoglobulin</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The PBMCs were washed again and resuspended in 200μl FACS buffer and run/acquired on a Cytek® Aurora (Cytek Biosciences, France) flow cytometry system.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytek Biosciences</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The spectral flow data was analyzed/processed using OMIQ (OMIQ, Inc, Santa Clara, CA, USA) and FlowJo™ v10.8 Software (BD Life Sciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo™</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After overnight incubation at 4°C, the wells were washed 4 times with PBS (Cytiva HyClone™ Dulbecco’s PBS, Fisher Scientific), and quenched in 5% PHS in RPMI supplemented with gentamicin (20 µg/ml) and HEPES (10 mM), before seeding the wells with PBMCs at up to 300,000 per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fisher Scientific</div><div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-SARS-CoV-2 Spike and Nucleocapsid IgG: Qualitative measurement of anti-SARS-CoV-2 spike IgG, including anti-spike neutralizing IgG antibodies directed against the receptor binding domain (RBD) of S1 subunit was performed using a commercial chemiluminescent microparticle-based immune assay (Abbott SARS-CoV-2 IgG II Quant/6S60 ARCHITECT SARS-CoV-2 IgG kit) and anti-SARS-CoV-2 nucleocapsid IgG (6R86 ARCHITECT SARS-CoV-2 IgG) using a commercial ARCHITECT Abbott (Abbott Laboratories Diagnostics Division, Abbott Scandinavia AB) kit.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott Laboratories</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: Data and statistical analyses were carried out using GraphPad PRISM v9.0 (GraphPad Software, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad PRISM</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
It is important to note that the current investigation has limitations. A critical factor to consider is the pre-selection of patients for this cohort, with most of the patients included already having moderate to severe COVID-19. It is also noteworthy to consider that health systems vary across geographical locations so patients in other counties might be more diverse due to different thresholds of illness required for hospital admission. Additionally, due to severe disease presentations, there were challenges with obtaining clinical samples from some patients and, in some cases, the cell numbers were low and/or of poor quality. During the study some COVID-19 patients were vaccinated against SARS-CoV-2 and therefore were excluded from our data set as this interfered with some results. Despite the immensely challenging conditions during the pandemic, we do believe that the cohort presented in this investigation is well characterized and of high quality and value. Altogether, this study highlights the alterations in the immune response incurred during hospital treated SARS-CoV-2 infection and convalescence. These novel longitudinal data illustrate the substantial changes to the T cell landscape, with a persistent increase in markers of activation, exhaustion and senescence lasting for more than 6 months. We further showed an accompanying decay in SARS-CoV-2-specific antibody responses at the same time. Our findings, in combination with others, are valuable in providing insight...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
SciScore for 10.1101/2022.03.16.484099: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: SPARTA participants: Eligible participants between 18 and 90 years old were enrolled starting in April 2020 with written informed consent in Athens and Augusta, GA, Memphis, TN, and Los Angeles, CA.<br>IRB: The study procedures, informed consent, and data collection documents were reviewed and approved by the WIRB Copernicus Group Institutional Review Board (WCG IRB #202029060).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Of the ∼3,800 SPARTA enrolled participants, 1,081 were randomly selected to be included in this study (Table S1). 68.5% of them identified as females, and 31.4% as males.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Of the ∼3,800 SPARTA enrolled participants, 1,081 were randomly selected to be included in this study (Table S1). 68.5% of them identified as females, and 31.4% as males.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IgG antibodies were detected using horseradish peroxidase (HRP)-conjugated goat anti-human IgG detection antibody (Southern Biotech, Birmingham, AL, USA) at a 1:4,000 dilution and colorimetric development was accomplished using 100 μL of 0.1% 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS, Bioworld, Dublin, OH, USA) solution with 0.05% H2O2 for 18 minutes at 37ºC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The conditioned cell culture supernatants were serially diluted to assess total and antigen-specific IgG antibody levels by ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen-specific IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The USA-WA1/2020 SARS-CoV-2 strain (100 TCID50/50µl; NCBI accession number: PRJNA717311) was co-incubated with serially diluted serum samples for 1 hour at 37°C and then added to a monolayer of Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were acquired on Agilent NovoCyte Quanteon and analyzed using FlowJo v10.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Comparison of the four groups (naïve unvaccinated, infected unvaccinated, naïve vaccinated, infected vaccinated) based on previous infection and vaccination as well as different timepoints were investigated by one-way ANOVA and paired t tests using GraphPad Prism 9.3.1 (RRID: SCR_002798).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>detected: GraphPad Prism ( RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
One of the limitations of this study is that we relied on accurate reporting of demographic information, comorbidities, previous SARS-CoV-2 testing and symptoms, and vaccine information by the participants. While the sample size for each of the four infected/vaccinated groups compared is robust, not all timepoints were available for all participants. Only participants who were convalescent prior to vaccination were reported in the infected vaccinated group, participants who had breakthrough infections after vaccination will be included in a future study. The sample size for the in vitro differentiation experiment was low due to the uncommon nature of losing seroprotective status amongst our participants. All participants who lost their confirmed seroprotected status were included in the analysis; future studies are necessary to strengthen our findings with additional participants. In conclusion, vaccinated groups seroconverted to higher antibody levels and experienced significant antibody waning regardless of pre-immunity. In contrast, infected unvaccinated participants had no significant waning during the first 14 months after infection. The rate of antibody waning was not significantly different between pre-immune and immunologically naïve participants. Antibody levels are greatly increased by the administration of a booster dose, to a level 3-fold higher than their previous peak antibody level 2-4 weeks after the second dose. Memory B cell recall responses were absent in a...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.14.484208: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Handling and working with SARS-CoV-2 were conducted in a BSL3 facility in accordance with the biosafety guidelines of the Israel Institute for Biological Research (IIBR), or in a BSL3 facility at The University of Texas Medical Branch (UTMB).<br>Euthanasia Agents: Golden Syrian hamsters (females; 4-5 weeks old) were intranasally infected with 1000 pfu of virus in 50 μl of inoculum while under isoflurane anesthesia.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">A DIG-labeled random-primed probe, corresponding to nucleotides 28,999 to 29,573 of the SARS-CoV-2 genome (Kamitani et al., 2006; Xie et al., 2020), was used to detect SARS-CoV-2 mRNAs and visualized by DIG luminescent detection kit (Roche, Indianapolis, IN), according to the manufacturer’s protocol.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: Calu3 and 293T cells were authenticated by ATCC using STR profiling.<br>Contamination: All cell lines tested negative for mycoplasma.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, paraffin-embedded sections were firstly subjected to immunostaining with a commercially available and diluted (1:5,000) rabbit-anti-SARS-CoV-2 spike (S) protein (ab272504, Abcam Plc., Cambridge, UK), followed by staining with a peroxidase-conjugated secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>rabbit-anti-SARS-CoV-2 spike ( S ) protein ( ab272504</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the detection of N protein, an affinity-purified rabbit anti-SARS-CoV N polyclonal antibody (Harcourt et al., 2020) was used as the primary antibody, followed by Alexa Fluor 488-conjugated secondary antibody (Invitrogen) and DAPI counterstaining, using SlowFade Gold antifade reagent (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the detection of nsp1 protein, the anti-SARS-CoV-1 nsp1 antibody was used as the primary antibody, followed by Alexa Fluor 594-conjugated secondary antibody (Invitrogen) and DAPI counterstaining.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-1 nsp1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed and labeled with anti-rabbit FITC conjugated antibody at a 1:200 dilution and with DAPI (4′,6-diamidino-2-phenylindole) at a 1:200 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit FITC</div><div>suggested: (Bioss Cat# bs-0708R-FITC, RRID:AB_11075028)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies used were Goat anti-rabbit or Goat anti-mouse (IRDye 800CW or IRDye 680RD, Li-Cor).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An affinity-purified rabbit anti-SARS-CoV-1 nsp1 polyclonal antibody (Narayanan et al., 2015) was used as the primary antibody, and an HRP-linked anti-rabbit IgG (Cell Signaling Technology) was used as the secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG ( Cell Signaling Technology )</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">African green monkey kidney clone E6 cells (Vero E6, ATCC® CRL-1586™) were grown in growth medium DMEM containing 10% FBS, MEM NEAA, 2 mM L-glutamine, 100 Units/ml penicillin, 0.1 mg/ml streptomycin, 12.5 Units/ml nystatin (P/S/N), all from Biological Industries, Israel]</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu3 and 293T cells were authenticated by ATCC using STR profiling.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral titers: For determination of growth rate of SARS-CoV-2 WT or SARS-CoV-2 mut viruses, Vero E6 and Calu3 cells were seeded in 12-well plates (5E5 and 1E6 cells/well respectively).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: RRID:CVCL_EQ19)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus titers in the tissues were determined on confluent Vero E6/TMPRSS2 cells obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (1819).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6/TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 nsp1 ORF, carrying a C-terminal myc-tag, was cloned into pCAGGS-MCS, resulting in pCAGGS-nsp1-WT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-MCS</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCAGGS-nsp1-WT</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, SARS-CoV-2 nsp1 carrying a deletion of the amino acids 155 to 165, and SARS-CoV-2 nsp1 carrying R124A and K125A mutations, were cloned into pCAGGS to generate pCAGGS-nsp1-ΔRB and pCAGGS-nsp1-CD, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div><div style="margin-bottom:8px"><div>pCAGGS-nsp1-ΔRB</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCAGGS-nsp1-CD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luciferase assay: Vero E6 cells in 24-well plates were co-transfected, in triplicate, with pRL-EMCV-FL reporter plasmid and the indicated pCAGGS-based nsp1 expression plasmids using TransIT-LT1 reagent (Mirus).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pRL-EMCV-FL</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids and cloning: pLVX-EF1alpha-SARS-CoV-2-nsp1-2XStrep-IRES-Puro (nsp1-WT) was kindly provided by N. Krogan.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLVX-EF1alpha-SARS-CoV-2-nsp1-2XStrep-IRES-Puro</div><div>suggested: RRID:Addgene_141367)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mutations to generate nsp1-ΔRB and nsp1-CD were introduced by amplifying the nsp1-WT plasmid so that it became a linear fragment containing the desired mutations (primers 1-4 listed in Supplementary Table 1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>nsp1-WT</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The images for SARS-CoV-2 N protein were collected using an Olympus BX53 microscope with a 40X objective lens at UTMB and processed with ImageJ (NIH) software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UTMB</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alignment was performed using Bowtie v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bowtie</div><div>suggested: (Bowtie, RRID:SCR_005476)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential expression analysis was done using DESeq2 (Love et al., 2014)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Output.bam files from STAR were used as input for the GRAND-SLAM analysis(Jürges et al., 2018) with default parameters and with trimming of 5 nucleotides in the 5′ and 3′ends of each read.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reactive bands were detected by Odyssey CLx infrared imaging system (Li-Cor) and quantified using Fiji (ImageJ) as detailed in https://imagej.nih.gov/nih-image/manual/tech.html.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphics: Figure 1a and extended figure 2c were created using BioRender.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fluorescence-activated cell sorting figures were created with FlowJo and the rest of the figures were drawn with ggplot2 in R.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
However, a major limitation of these measurements is that viral mRNA replication and transcription is massive, and occurs within a unique endomembrane system (Wolff et al., 2020) that would thus render much of the viral mRNA inaccessible to ribosomes. This inaccessibility of potentially large portions of viral RNA will skew our measurements and it is likely the true translation efficiency of viral transcripts is significantly higher. Comparing the translation efficiencies of viral and cellular transcripts in cells infected with CoV2-wt or with CoV2-mut allowed us to overcome this limitation and to demonstrate that in infected cells nsp1 indeed specifically promotes the translation of viral transcripts compared to cellular transcripts, as we observed that in cells infected with CoV2-mut, viral genes are translated even less efficiently compared to their cellular counterparts. However, at the same time our measurements of the overall translation capacity in infected cells, using incorporation of OPP into nascent chains, show that nsp1-WT leads to a major reduction in the absolute levels of translation in infected cells. Since the vast majority of mRNA in infected cells is viral mRNA this means that viral mRNAs translation is likely also inhibited in the presence of nsp1. Together these results support a model in which nsp1 acts as a strong inhibitor of translation that tightly binds to ribosomes and thus inhibits the translation of both viral and cellular mRNAs. Viral transcrip...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.15.484542: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: donors: Convalescent plasma, Ad26.COV2.S, and some BNT162b2 samples were obtained from the HAARVI study approved by the University of Washington Human Subjects Division Institutional Review Board (STUDY00000959).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: None of the cell lines used were authenticated or tested for mycoplasma contamination.<br>Contamination: None of the cell lines used were authenticated or tested for mycoplasma contamination.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infected cells were then washed an additional five times with DMEM prior to adding media supplemented with anti-VSV-G antibody (I1-mouse hybridoma supernatant diluted 1:25, from CRL-2700, ATCC) to reduce parental background.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VSV-G</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Cell lines used in this study were obtained from ThermoFisher Scientific (HEK293T) or were kindly gifted by Florian</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: RRID:CVCL_HA71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK-293T cells seeded in poly-D-lysine coated 100 mm dishes at ∼75 % confluency were washed five times with Opti-MEM and transfected using 24 μg of the S glycoprotein plasmid with Lipofectamine 2000 (Life Technologies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudotyped VSV neutralization assay: To evaluate neutralization of SARS-CoV-2 G614 and Omicron BA.1 and BA.2 pseudotypes by plasma of vaccinees or previously infected individuals, Vero-TMPRSS2 cells in DMEM supplemented with 10% FBS, 1% PenStrep, and 8 ug/mL puromycin were seeded at 60-70% confluency into white clear-bottom 96 well plates (Corning) and incubated at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Media was removed from the cells and 40 μL from each well (containing plasma and pseudovirus) was transferred to the 96-well plate seeded with Vero-TMPRESS2 cells and incubated at 37°C for 2 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRESS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plasmids encoding the SARS-CoV-2 Omicron S variants BA.1 and BA.2 were generated by overlap PCR mutagenesis of the wildtype plasmid, pcDNA3.1(+)-spike-D19 (Table S1) (64)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Relative luciferase units were plotted and normalized in Prism (GraphPad): 100% neutralization being cells lacking pseudovirus and 0% neutralizing being cells containing virus but lacking plasma.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Prism (GraphPad) nonlinear regression with “[inhibitor] versus normalized response with a variable slope” was used to determine ID50 values from curve fits with 2-3 repeats.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www21.in.tum.de www21.in.tum.de
-
Exercises
2.1.b
Counterexample: \(\to := {(a, c), (b, c)}\)
2.3
\(a \to b\) iff \(a\) encodes Turing machine \(M_a\) and \(b\) encodes a valid terminating computation (sequence of states) of \(M_a\).
2.9
Let \(|w|_a := \varphi_a(w)\).
\(\varphi(w) := 3^{|w|_a} 2^{|w|_b}\)
Proof
- Let \(u \to_1 v\). Then \(\varphi(v) = 3^{|v|_a} 2^{|v|_b} = 3^{|u|_a+1} 2^{|u|_b-2} = 3^{|u|_a} 2^{|u|_b} \frac{3}{4} = \varphi(u) \frac{3}{4} < \varphi(u)\).
- Let \(u \to_2 v\). Then \(\varphi(v) = 3^{|v|_a} 2^{|v|_b} = 3^{|u|_a-1} 2^{|u|_b+1} = 3^{|u|_a} 2^{|u|_b} \frac{2}{3} = \varphi(u) \frac{2}{3} < \varphi(u)\).
2.17
No.
Let \(a > b\). Then \([b^n a | n \in [0, 1, \ldots]]\) is an infinite chain according to \(>_{Lex}\).
Note: This exercise completes the discussion of Lemma 2.4.3.
4.2
Let \(s, t\) be terms. Run BFS from \(s\) using \(\leftrightarrow^E\). If \(t\) is encountered, conclude that \(s \approx_E t\). If the BFS finishes enumerating the equivalence class without encountering \(t\), conclude that \(\lnot s \approx_E t\).
4.4
Let \(x \in Var(r) \setminus Var(l)\). Let \(p\) be a position of \(x\) in \(r\).
Infinite chain:
- \(t_0 = x\)
- \(t_{i+1} = r[t_i]_p\)
4.18
- a
- Unifier: \({x \to h(a), y \to h(a)}\)
- Matcher: \({x \to h(a), y \to x}\)
- b
- Unifier: Unsolvable
- Matcher: \({x \to h(x), y \to x}\)
- c
- Unifier: \({x \to h(y), z \to b}\)
- Matcher: Unsolvable
- d
- Unifier: Unsolvable
- Matcher: Unsolvable
5.2
Counterexample TRS \(R\):
- \(a \to b\)
- \(b \to b\)
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
In their manuscript, Hattori et al., put forward evidence that the knock-out of CD38 expression in astrocytes at approximately post-natal day 10 (referred to as CD38 AS-cKO P10) leads to a specific deficit in social memory in adult mice, while other types of memory remain unaltered. Using immunohistochemistry (IHC), the authors found a reduced number of excitatory synapses in the medial prefrontal cortex (mPFC) of CD38 AS-cKO P10 mice. Switching to in vitro primary cell culture models, the authors identify the astrocyte secreted protein SPARCL1 as a relevant synaptogenic factor. Using pharmacological dissection of relevant signaling pathways, Hattori et al., propose that cADPR formation and calcium released from intracellular stores, is essential for SPARCL1 secretion from astrocytes. Finally, the authors analyzed the transcriptome of primary CD38 KO astrocytes using bulk mRNA sequencing, and found that genes related to calcium signaling were downregulated in these cells.
Major commments:
- Are the key conclusions convincing?
- From a global perspective, the multiple lines of evidence provided by the authors strongly suggest that expression of CD38 in astrocytes is important for synaptogenesis in the mPFC of P10 mice, with ablation of CD38 and reduced synapse formation leading to social memory deficits at P70. However, the data concerning the role of astrocyte-secreted SPARCL1 is not particularly strong: further experiments are needed to support this claim (see below).
- Are the claims preliminary or speculative?
- As it stands, there is no proof that the claimed astrocyte-specific deletion of CD38 is actually astrocyte specific. This evidence is crucial: without it the reported effects could be due to non-specific CD38 knock-out in other CNS cells. In this respect, the Western Blot in Supplementary Figure 1A does not provide information on astrocyte-specific deletion, merely that CD38 was globally reduced in the mPFC. Interestingly, the authors have previously published data (Hattori et al., 2017, 10.1002/glia.23139) showing that CD38 expression is mostly astrocyte-specific, peaking at p14, which coincides with the peak period of synaptogenesis. The degree of CD38 heterogeneity is also an issue that I think the authors need to consider. Do they information on this? Is CD38 expressed in every astrocyte of the CNS, or are there some astrocytes that are CD38 negative at P14? Is the mPFC a region specifically enriched in CD38 positive astrocytes and does this explain the observed behavioral deficit? I think if this is known, the authors should mention it in the "Introduction" or "Discussion". If this is not known, maybe the authors could provide data addressing the issue.
- I think the authors should take more caution in claiming that SPARCL1 is the main factor secreted through the CD38 signaling pathway and responsible for increased synaptogenesis. This is for several reasons, all centered on data displayed in Figure 4 and Supplementary Figure 6:
- a) Western Blot (WB) data: The "Materials and Methods" section for WB does not indicate how protein loading and transfer efficiency were controlled for. Normalizing to β-Actin levels is an acceptable way to control for loading and transfer efficiency when using cell lysates. However, in the absence of such an abundant structural protein in conditioned media it is unclear how loading and transfer was controlled for under these conditions. Do the authors normalized the CD 38 KO AS ACM data by expressing protein levels relative to those from WT AS ACM? Is BDNF being used as a control, based on proteomics data? If so, why is proteomics data not given in the manuscript and why is this control not shown for all ACM blots? I realize that (quantitative) blotting using ACM is difficult, but I am also not convinced that the methodology used is sufficiently rigorous. Simple steps to give confidence would be Coomassie staining of gels both before and after membrane transfer, to show that i) the total protein amount loaded was the same in each lane of the gel and ii) the transfer to the nitrocellulose membrane was complete. In addition, Ponceau S staining of the nitrocellulose membrane should also have been performed and displayed, to show (roughly) equal amounts of protein were transferred for each lane. In summary, the WB data quantification needs to be better controlled. The values of the Y axis in these graphs (and throughout the manuscript) are simply too small to be read properly. Finally, I want to highlight the general lack of precision regarding the nature of the replication unit (the "n"). For example, the legend of Figure4C-D states "n = 6", but we have no idea if these are 6 independent primary cultures originating from 6 mice, 6 independent cultures from the same mouse, 6 repeats of the Western Blot using the same sample etc. This issue is valid for the whole manuscript: in my opinion, the authors should be more much careful when it comes to these crucial elements of scientific reporting.
- b) While the data hint at an important role of SPARCL1 in synapse formation, when the authors tested if ACM from CD38 KO astrocytes supplemented with exogenous SPARCL1 could rescue synapse formation, the effect was incomplete, with only a trend to an increase in synapse number (Figure 4J-K). Perhaps the authors simply forgot to indicate the statistical significance of differences between the experimental groups (Figure 4K)? However, if there really were no statistically significant differences observed, the authors should reduce the strength of their conclusions regarding SPARCL1. This protein may well be pro-synaptogenic but, as it stands, other factors could well be in play. Perhaps the authors should have tried higher concentrations of SPARCL1 to further boost synaptogenesis? In this respect, the SPARCL1 knockdown (KD) experiment in Supplementary Figure 6B-D is an important addition, but should be supplemented by rescue with an siRNA-resistant recombinant SPARCL1? If SPARCL1 is a major player in synaptogenesis, the prediction is that synapse numbers would be close to wild type levels with this approach.
- c) In my opinion, there are also issues with the data displayed in Figure 4H-I. The authors want to convince the reader that SPARCL1 is mostly an astrocytic protein using immunohistochemistry on mouse mPFC sections, co-labelled with antibodies against neuronal and astrocytic markers. In these panels, we are presented with images showing a few cells, in which it seems SPARCL1 is absent from NeuN positive cells, present in WT astrocytes and reduced in CD38 AS-cKO P10 astrocytes. However, the numbers of cell counted and lack of quantification severely impact on the strength of this conclusion. In my opinion, the authors should have quantified their IHC data by counting cells and establishing the ratios of SPARCL1 positive over NeuN or S100β positive cells, in both control and CD38 AS-cKO P10 animals. This experiment would provide critical information that the conditional gene targeting strategy is robust. The authors should also consider quantifying the intensity of the SPARCL1 signal in astrocytes. This is recommended as the image displayed in Figure 4I for the CD38 AS-cKO is problematic: are the authors really claiming that the reduction in SPARCL1 expression following cKO of CD38 in astrocytes is at best only partial? Is 11 days between the first tamoxifen injection and tissue fixation actually sufficient to allow for CD38 turnover? With low levels of protein turnover, the possibility exists that residual levels of CD38 are still sufficient to impact SPARCL1 levels. What would happen if there is a greater interval between tamoxifen administration and tissue recovery? Would levels of synaptogenesis be further reduced? Is this an issue of production versus secretion or a combination of factors?
- The heatmap (Figure 5E-F) is simply too small to interpret. The color choice is also not accessible for colorblind readers. The authors might consider displaying this heatmap in a separate figure. The authors should also provide a supplementary table where all the genes detected are listed along with their respective counts. Furthermore, it is surprising that the authors only found genes being downregulated in CD 38 KO astrocytes. Were they really no genes up-regulated? The authors might also want to indicate the genes belong to each of the ontological categories listed in Figure 5F. On p. 11, Figure 5E: The authors should indicate in the main text they performed bulk RNA-sequencing and not another type of RNA sequencing (like single cell RNA sequencing for instance). The authors indicate n = 2 but we have no indications of the nature of the replicate (also see earlier comments). Please amend.
- Are additional experiments necessary?
I think supplementary experiments are essential to support the claims of the paper. Most are described in the section above, but to summarize:
- Show data to prove that the CD38 AS-cKOP10 model is astrocyte-specific and leads to a total loss of CD38 in these cells.
- WB data: The issue of protein loading and transfer efficiency should be dealt with. Quantifications should be revisited.
- The authors should quantitatively analyze the different IHC performed in Figure 4H-I.
- The authors should provide more information on their RNA sequencing data: list of genes detected with their FPKM values etc. The authors should display the RNA sequencing data in a separate figure, allowing the heatmap to be enlarged.
- LC-MS/MS data: the authors should provide the list of all the proteins they identified in their LC-MS/MS experiment. As a supplementary table for instance? The majority of these experiments should be able to be performed with pre-existing samples/tissue slices. If not, the experimental pipeline necessary exits and these supporting experiments should not be too burdensome.
- Data and methods presentation
Methods:
The authors need to work on this aspect of the manuscript. Most of the important details are already described, but some crucial ones are missing, while the phrasing used to describe methods is sometimes misleading. I will give some examples here, but this is not an exhaustive list. The fact that the manuscript is riddled with small mistakes, inconsistencies and/or oversights makes it difficult to read and creates a negative impression. The whole manuscript would benefit from a thorough proof-reading, preferably by a native speaker.
- in the "Immunohistochemistry and Synaptic Puncta Analysis" section on p. 21-22, we have no indication of which antibodies against "GFAP, NDRG2, VGlut1, PSD95, S100β, NenN(?) and SPARCL1" were used. It is standard practice to indicate the company, product number and lot number. The authors must also indicate the dilution at which they use these antibodies. On p.22, the authors write the cells were incubated with "Alexa- or Cy3-conjugated secondary antibodies". The excitation wavelengths of the Alexa dyes used need to be given.
- The authors need to provide more details on the microscope they used. Merely writing "using a 63× lens on a fluorescence microscope" (p.23) is insufficient.
- In the "LC-MS/MS" method the authors wrote: "Briefly, these proteins were reduced, alkylated, and digested by trypsin". I think that in the reduction and alkylation steps, chemicals other than trypsin were actually used. This sentence should be modified to reflect this.
- p.19: "uM" is written when the authors very likely mean "µM". Please check the whole manuscript for repeat examples. I know this is often lab "short-hand", but it should be avoided in scientific publications.
- The authors should be careful when describing their data to always indicate whether they referring to experiments performed using cultured astrocytes or not. As it stands, the text is confusing: for instance, when describing RNA-sequencing data in Figure 5, the main text appears to indicate that these astrocytes were acutely isolated from adult mice, when in fact they were obtained from primary cultures. Given concerns in the literature about potential differences between acutely isolated and cultured astrocytes (Foo et al., Neuron, 2011), this is essential. Data presentation: The figures appear to have been produced in a rush - and almost have a "screenshot" feel to them. This is not a scientific issue per se, but does impact on the overall impression given by the manuscript. The following is a non-exhaustive list of issues with the figures. I list the major ones that the authors should correct.
- Almost all Y axis labels are too small. The authors should comply to the basic journal requirements in terms of font sizes. Some axes do not end on a tick (e.g. Figure 3R). This is not dramatic, but should be corrected. Globally, the authors need to display bigger bar plots - most of them are extremely hard to read. Labeling should also be checked: Figure 4K, the Y axis label indicates values displayed are in %, when I think the axis graduation displays ratio values. Some of the IHC pictures are also too small to be easily interpreted.
- The heatmap in Figure 5E is impossible to read and, as such, has little or no value for the manuscript.
- Scale bars: where is the scale bar in Figure 2A? Figure 3A-H: Is the scale bar really representing 10 millimeters? Supplementary Figure 3A: scale bar is missing. Please check for similar issues throughout the manuscript.
- Figure Legends are problematic, and often contain incorrect or incomplete information. Examples include: Supplementary Figure 1: The description of panels J, L and N appears to be missing. Please also use the Greek letter beta and not 'b' for S100β. Supplementary Figure 5: I think the term "KO" is missing after CD 38 in the legend title. Figure 3: why state that nuclei were counterstained with DAPI in Figure 3P,Q, when this precision is not given for panels Figure 3A-H? Figure 3A-H: If the authors choose to explicitly state PSD95 is a post-synaptic marker, why not indicate that VGlut1 is a pre-synaptic marker? Same issue in Supplementary Figure 4.
- There are multiple instances of panels being wrongly referred to in the main text. On p.10, Figure 4H is referenced, when I think the authors mean Figure 4I; on p.10, Figure 4I-J are referred to when the authors clearly describe data found in Figure 4J-K. These types of mistakes are problematic and recur throughout the manuscript.
- Statistical analysis As mentioned above, the exact nature of the replicates is often not stated, when the "n" number is indicated. The authors must correct this issue and give the information either at the appropriate point in the main text or in the figure legend.
The authors should also be more consistent in the way they indicate which statistical tests were performed. This should also be indicated either at the appropriate point in the main text or in the figure legend. Furthermore, care should be taken to ensure statistics are presented in an appropriate manner: at the end of legend for Figure 4, it is indicated #p < 0.05 vs. CD38 KO ACM. This hashtag symbol is completely absent from the figure. In Figure 4F-G, the lack of statistical symbols seems to indicate no statistical tests were performed on these data, when the legend covering these panels states "*p < 0.05 versus P70", indicating some tests were done. We cannot interpret this panel without knowing which comparisons were done exactly and which were significant.
In the "Materials and Methods", the authors give no indication that the assumptions of the statistical test they used were met (normality of data distribution for t-tests, homogeneity of variances for ANOVA...). This needs to be checked, and if not met, appropriate non-parametric tests should be used instead.
Minor commments:
- Specific experimental issues that are easily addressable. Most of the experimental issues that need to be addressed are given in previous sections and should be easily addressable.
- Citation of previous studies? Adequate
- Clarity and accuracy of text and figures There are issues with the clarity and accuracy of text and figures - which are described above. The text is also often problematic in its phrasing and other, more fundamental aspects. For instance, the authors spent a considerable amount of time speaking about the role of oxytocin, when they only performed one measurement of oxytocin levels in mice.
- Suggestions to improve the presentation of data and conclusions? All my suggestions to improve the presentation of data can found in previous sections. As for improving the authors presentation of their conclusions, the authors should make a considerable re-drafting effort, particularly for the "Discussion", which lacks clarity in how supporting arguments are built and presented. For example, on p.13, I am confused with the argument made by the authors. Their data are focused on synapses onto pyramidal neurons of the mPFC, but here the discussion states that the behavioral phenotype they observed in CD38 AS-cKOP10 might be explained by a lack of mPFC neurons synapsing onto neurons in the Nucleus Accumbens (assuming that "NAc" really refers to this brain region, as the definition is missing from the text). I think the authors should make it clear if this is their interpretation of their own result, which essentially renders their focus on mPFC pointless, or a speculation on possible other mechanisms that could also explain their behavioral results. Personally, given the data shown, I believe the authors should focus on explaining how their data in mPFC might explain the behavioral output observed. The authors could also provide perspectives on how the hypothesis laid down in this paragraph would be tested. When the authors write on p.14 "We identified SPARCL1 as a potential molecule for synapse formation in cortical neurons" why use the word "potential"? Does this mean the authors consider their data on SPARCL1 (one of the key messages of the paper) invalid? If the authors themselves think the role of SPARCKL1 is ambiguous based on their own data, they should perform further experiments. P. 13, the authors write: "Moreover, many studies have shown that astrocyte-specific molecules, including extracellular molecules such as IL-6, are involved in memory function"; Interleukin 6 (Il-6, abbreviation not defined in the manuscript) is definitely not an astrocyte-specific molecule (see, for example, Erta et al., 2021 10.7150/ijbs.4679).
Significance
NATURE AND SIGNIFICANCE OF THE ADVANCE: I think that despite the issues described above, this manuscript, once revised, could have a strong impact in the field. It would fuel the current paradigm shift which puts astrocytes at the forefront of neuronal circuit wiring during development with links to adult behavior. By identifying clear molecular targets involved in astrocyte-driven synaptogenesis, this article could help the clinical field to find new druggable targets, which may help reverse aging-related cognitive decline.
COMPARISON TO EXISTING PUBLISHED KNOWLEGDE: This work adds new data in the specific and growing line of research that study how astrocytes control synaptogenesis. Recent reviews have summarized advances in this field (Shan et al., 2021, 10.3389/fcell.2021.680301; Baldwin et al., 2021, 10.1016/j.conb.2017.05.006).
AUDIENCE: Neuroscientists in general, clinicians interested in cellular and molecular causes of neurodevelopmental disorders leading to social dysfunctions.
REVIEWER EXPERTISE: Astrocyte biology; Astrocyte-neuron interactions and synapse assembly; Neuronal circuit formation and plasticity
Referees cross-commenting
After careful reading of the other comments, I feel that there is considerable agreement/overlap between the reviewers on the main issues with this manuscript. Perhaps the major difference relates to the amount of further work necessary for the manuscript to be publication ready.
As Reviewer 3 rightly points out, this is always a moot point: how much is it reasonable for reviewers to ask authors to do? While I agree with all of Reviewer 1's comments regarding the rigour of the mass-spec/western blot analysis, it seems to me that from a molecular/cell biological point of view, the key issue is whether Sparcl1 is a synaptogenic factor released from astrocytes following CD38/cADPR/calcium signaling (irrespective of whether other factors may be in play); and whether raising Sparcl1 levels is sufficient to recover spine morphology and synapse numbers. Of course, if these experiments were performed in vivo using AAV-mediated overexpression of Sparcl1, it is also reasonable to think that the deficit in social memory may be reversed on testing.
The issues of whether there is a difference in observable behavioral phenotypes between the astrocyte-specific and constitutive CD38 knock-outs is an interesting one, as is why there is only a deficit in social memory seen following astrocyte-specific CD38 ablation. These issues should at least be discussed.
- Are the key conclusions convincing?
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.16.22272465: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: As this method has only been validated for non-enveloped viruses (34), via RNA detection, to validate it for assessing the presence and infectivity of SARS-CoV-2, 10 l of Milli-Q water was spiked with murine hepatitis virus (MHV-A59) to a final concentration of 1.5 × 104 gc/L, and run through the TFUF to test processing efficiency.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NCTC 1469 cells were used for propagation and infectivity assays of MHV using the manufacturers protocol using DMEM high glucose with 10% horse serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCTC 1469</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation, samples were vortexed, filtered through a 0.22 μM filter and serially diluted to achieve a starting dilution of 200 TCID50/well on Vero E6 cells (41).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
The positive sample was collected downstream from the largest CSO on the Danube River (Pančevo Bridge), where there is a high dilution potential due to an average discharge of 5,600 m3/s in this section of river (13), highlighting the limitations of point samples from surface water for environmental monitoring. Research suggests that high percentages of enveloped viruses (26%) can adsorb to the solid fraction of wastewater (43), that suspended solids may protect viruses from inactivation (44), and that sediments can provide a source of pathogens to the water column (45). Studying the presence of viruses in sediments, rather than water, may provide greater insight into sites that are susceptible to accumulating and harbouring potential pathogens, rather than taking water column point samples, that can suffer from high variability (46). While most studies have focused on the presence of SARS-CoV-2 RNA in wastewater (reviewed by (5), and river water (13,14), very little is known about the potential survival of SARS-CoV-2 in aquatic environments (47,48). Here we tested whether a validated TFUF protocol for the concentration of human non-enveloped enteric viruses from river water (34) could also be used to concentrate an enveloped betacoronavirus, Murine hepatitis virus (MHV). Considering the rigorous biosafety requirements necessary for working with infectious SARS-CoV-2, surrogate viruses, such as MHV, are useful for assessing method performance during monitoring campaigns (49)....
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.15.484379: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Euthanasia Agents: Viral inocula were made in sterile phosphate buffered saline (PBS) and delivered via intranasal instillation (200μL total with 100μL per nare) with animals sedated using isoflurane.<br>IACUC: UKHSA) Porton Down by the Animal Welfare and Ethical Review Body (AWERB) as required by the Home Office Animals (Scientific Procedures) Act 1986.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The animals were randomly assigned into groups and individually housed, with equal allocation of male and female animals to each study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The animals were randomly assigned into groups and individually housed, with equal allocation of male and female animals to each study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">All slides were evaluated subjectively by a qualified pathologist, blinded to treatment details and were randomised prior to examination to limit bias (blind evaluation).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Staining was performed with the BOND Polymer Refine Detection kit, a rabbit anti-SARS-CoV-2 nucleocapsid antibody (Sinobiological; clone: #001; dilution: 1:5000) and counterstained with haematoxylin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: (Leinco Technologies Cat# LT5000, RRID:AB_2893962)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were blocked in 5% milk in PBS/0.1% Tween-20 and incubated with anti-HIF-1α (BD Biosciences), anti-β-Actin (Sigma) or SARS-CoV-2 nucleocapsid (EY-2A, a kind gift from Prof Alain Townsend) primary antibodies and appropriate HRP-conjugated secondary antibodies (DAKO).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-HIF-1α</div><div>suggested: (Cayman Chemical Cat# 10006421, RRID:AB_409037)</div></div><div style="margin-bottom:8px"><div>anti-HIF-1α (BD Biosciences), anti-β-Actin (Sigma)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-β-Actin</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus infectivity was determined by plaque assay on Vero-TMPRSS2 cells as previously reported (Wing et al., 2021a)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 cells were infected with the above strain of SARS-CoV-2 at an MOI of 0.01 for 2h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: KCLB Cat# 30055, RRID:CVCL_0609)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FPKM values were enumerated, and differential expression quantified using the DeSeq2 package (Love et al., 2014).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DeSeq2</div><div>suggested: (DESeq2, RRID:SCR_015687)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were blocked in 5% milk in PBS/0.1% Tween-20 and incubated with anti-HIF-1α (BD Biosciences), anti-β-Actin (Sigma) or SARS-CoV-2 nucleocapsid (EY-2A, a kind gift from Prof Alain Townsend) primary antibodies and appropriate HRP-conjugated secondary antibodies (DAKO).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Biosciences</div><div>suggested: (BD Biosciences, RRID:SCR_013311)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">P values were determined using the Mann-Whitney test (two group comparisons) or with the Kruskal–Wallis ANOVA (multi group comparisons) using PRISM version 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PRISM</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.15.484018: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Experimental procedure involving live animals were carried out in agreement with the protocol (#HA20M310) approved by the Institutional Animal Care and Use Committee (IACUC) at The Johns Hopkins University School of Medicine.<br>Euthanasia Agents: Animals were randomly assigned to be euthanized by isoflurane overdose at end points (day 4 and day 7) following SCV2 infection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals: In vivo experiments involving BCG vaccination and SCV2 infection were carried out using male golden Syrian hamsters (Mesocricetus auratus).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Individual seed-stock vial was randomly picked from frozen stock and was subsequently propagated in 7H9 medium before immunization.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Protein expression was scored by a board-certified pulmonary pathologist blinded to cohort status or treatment group.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following antibodies were used for cell surface staining: anti-CD3 (Bio-Rad, #MCA1477PB, CD3-12), anti-CD4 (BioLegend, #100451, GK1.5), anti-CD11b (Novus, #NB110-89474PECY7, Poly), and anti-RT1D (BioLegend, #110211, 14-4-4S).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD4</div><div>suggested: (BioLegend Cat# 100451, RRID:AB_2564591)</div></div><div style="margin-bottom:8px"><div>anti-CD11b</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RT1D</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibody for CD3 (1:200 dilution; Cat# RM-9107-S1, Thermo Fisher Scientific) was incubated for 30m at 4 °C and detection was achieved using UltraView DAB detection kit (Roche).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD3</div><div>suggested: (Thermo Fisher Scientific Cat# RM-9107-S1, RRID:AB_149924)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero C1008 [Vero 76, clone E6, Vero E6] (ATCC CRL-1586) cells were used for viral growth and determination of virus stock titers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero C1008</div><div>suggested: ECACC Cat# 85020206, RRID:CVCL_0574)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were grown in MEM with 10% fetal bovine serum (FBS), L-glutamine, and penicillin-streptomycin at 37°C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were passed through a 70 μm filter and washed twice using ice-cold PBS followed by RBC lysis using ACK lysis buffer (Thermo Fisher Scientific: A1049201) at room temperature for 5 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Scientific</div><div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following antibodies were used for cell surface staining: anti-CD3 (Bio-Rad, #MCA1477PB, CD3-12), anti-CD4 (BioLegend, #100451, GK1.5), anti-CD11b (Novus, #NB110-89474PECY7, Poly), and anti-RT1D (BioLegend, #110211, 14-4-4S).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Poly</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed three times using FACS buffer and acquired using BD LSRII with FACSDiva Software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analyses was carried out using FlowJo (v10) (TreesStar).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differentially expresses genes (DEGs) and pathway analysis: The FindMarker function in Seurat package was performed to identify differentially expressed genes between BCG-WT + SCV2 and SCV2 groups in a particular cell cluster.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Seurat</div><div>suggested: (SEURAT, RRID:SCR_007322)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GO term enrichment analysis of the DEGs was performed using Metascape (www.metascape.org) (63).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Metascape</div><div>suggested: (Metascape, RRID:SCR_016620)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Despite being a well-defined animal model of COVID-19 with human-like pathology, one key limitation of using golden Syrian hamsters is the limited immunological resources such as well-characterized and validated antibodies (anti-CD8 Abs for example) and the relative paucity of immunologic data on hamster immune responses for correlation with our scRNAseq data. Along these lines, it was surprising that no CD8+ T cells were observed across the hamster groups even though they have been well-described in human scRNAseq studies of BAL samples in SCV2 (57, 58). While BCG vaccination is routinely used in most countries as a TB prevention, the vaccine is generally given intradermally, and recent human studies showing protection by BCG against COVID-19 disease also used intradermal BCG (13). Like other animal studies using BCG in animal models of SCV2 (28) we used the intravenous route based on literature that IV BCG is far more potent against tuberculosis in non-human primates, and evidence that IV BCG reprograms bone marrow hematopoietic stem cells towards a more protective state against bacterial challenge (22). Nevertheless, SCV2 animal studies using percutaneous BCG have shown significant immunologic benefits at the level of flow cytometry (29), and we anticipate that many of the scRNAseq shifts which we observed in IV BCG vaccinated hamsters would be present following intradermal BCG albeit potentially at a lower level. In summary, our study reveals that BCG vaccination reduces ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.11.484006: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero cells (ATCC) were seeded in 96-well clear CellBind plates (Sigma Aldrich) 24 hours prior to the experiment at a density of 40,000 cells/well in a 100 μL volume of complete DMEM supplemented with 10% inactive FBS and 1% of penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, plasmids expressing a lentiviral backbone encoding the luciferase reporter gene (BEI NR52516), the HIV structural and regulatory proteins Tat (BEI NR52518), Gag-pol (BEI NR52517) and Rev (BEI NR52519), and the full-length SARS-CoV-2 S protein were co-transfected into human kidney HEK293T cells (ATCC, CRL-3216) using the BioT transfection reagent (Bioland Scientific) following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization was determined in a single-cycle neutralization assay using HeLa cells expressing ACE2 (HeLa-ACE2), kindly provided by D.R. Burton; The Scripps Research Institute, and Vero E6 cells constitutively expressing the transmembrane protease, serine 2 (Vero-TMPRSS2), obtained from the Centre For AIDS Reagents (National Institute for Biological Standards and Control) [51, 52].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: CLS Cat# 300194/p772_HeLa, RRID:CVCL_0030)</div></div><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HeLa-ACE2 and Vero-TMPRSS2 cells were prepared following the above-mentioned protocol, where 10,000 cells/well of pre-seeded cells were co-cultured with the same serial dilutions of the sample compounds at 37°C for 2 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa-ACE2</div><div>suggested: JCRB Cat# JCRB1845, RRID:CVCL_B3LW)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Authentic SARS-CoV-2 Neutralization and Titer Assay: Authentic SARS-CoV-2 experiments were conducted using Vero’76 (ATCC, CRL-1587) or Calu-3 (ATCC, HTB-55) cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero’76</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The assay was performed using Vero-TMPRSS2 cells following the above protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, the wild-type S plasmid was substituted with plasmids codifying for the B.1.117 or B.1.351 SARS-CoV-2 S proteins (kindly provided by David Ho, Columbia University) or B.1.1.529 (synthesized and cloned by GeneArt, LifeTechnologies into pcDNA3.4 expression vector) to generate the corresponding SARS-CoV-2 pseudoviral particle (PsV) variants.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was plotted using Prism 9 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.10.22272213: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sampling strategies included random sampling (ranging from 5-100% of cases at different periods) and targeted sampling (outbreaks and targeted populations such as travellers)25.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Consensus sequences were generated using the Connor Laboratory pipeline (https://github.com/connor-lab/ncov2019-artic-nf) with consensus bases called at a frequency of 0.75 with a subsampling read count strategy.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Connor Laboratory</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Consensus sequences were aligned and trimmed to Wuhan-Hu-1 reference sequence (Accession MN908947, Version MN908947.3) using MAFFT (v7.471) 27 prior to phylogenetic tree production.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenetic analyses: A multiple sequence alignment of the full SARS-CoV-2 genome was used to construct maximum-likelihood (M-L) phylogenetic trees with IQ-TREE (v.2.1.3) 28.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IQ-TREE</div><div>suggested: (IQ-TREE, RRID:SCR_017254)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
One limitation of our study is that we do not have exposure, contact or location information to explore this application. Sequences belonging to a P.1 sublineage (P.1.14) form a single, large cluster (illustrated as the red cluster in the delta wave dataset in Figure 2), coinciding with a high number of low-diversity P.1 cases present in BC from April 2021 onwards 22, where almost all P.1 samples were within 0-1 SNPs of another P.1 sequence. This phenomenon is also expected with the recent Omicron variant, where rapid spread has led to high numbers of low diversity cases 23. Increasing the probability threshold to 0.9 (or conducting phylogenetic clustering with a smaller maximum clade divergence threshold) breaks up the cluster into smaller groups of identical or near-identical sequences, but this does not reflect genuine underlying clustering (Supplementary figure S2). In such circumstances, we recommend including additional metadata to refine clusters into genetically related groups with shared demography and epidemiology. Alternatively, our approach could be used as a surveillance tool focusing on a particular individuals or settings of interest, identifying sequences that are linked to the focal individuals or exposure sites, moving outwards to a desired number of “rings”. While COVID-19 remains at pandemic levels with high case numbers in many regions globally, it is anticipated that there will be a shift to endemicity characterized by persistent, lower levels of the dis...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.11.483867: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The protein band was detected with HRP-conjugated anti-Hisx6 antibody (Proteintech, #HRP-66005).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Hisx6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixture was diluted 50 times with HBSS and incubated at 37 °C for 1 h, 100 μL of which was subsequently added to 1.5 × 105 ACE2-expressing 293T cells and incubated at 37 °C for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus stocks were prepared in Vero E6 (ATCC) and titers were determined by plaque assays on Vero-E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralizing assays were performed in 293T-ACE2 cells (15,000 cells per well) in a white opaque 96-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nanobody expression and purification: Plasmid pBAD-H11D4, pBAD-MR17K99Y, or pBAD-SR was transformed into E. coli BL21(DE3) for wildtype protein expression.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBAD-SR</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid pBAD-H11D4 (27TAG), pBAD-H11D4 (30TAG), pBAD-H11D4 (100TAG), pBAD-H11D4 (112TAG), pBAD-H11D4 (115TAG), pBAD-H11D4 (116TAG), pBAD-MR17K99Y (99TAG), pBAD-MR17K99Y (101TAG), pBAD-SR4 (37TAG), pBAD-SR4(54TAG), or pBAD-SR4 (57TAG) was co-transformed respectively with plasmid pEVOL-FSYRS into E. coli BL21(DE3) for FSY incorporated protein expression.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBAD-H11D4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBAD-MR17K99Y</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBAD-SR4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pEVOL-FSYRS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were transfected with 25 μg pcDNA-ACE2-34TAG and 25 μg pMP-FSYRS plasmids according to manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA-ACE2-34TAG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pMP-FSYRS</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
A potential caveat is that the cross-linking rate can be negatively impacted when the binding affinity between protein drug and target decreases drastically due to target mutation, such as mNb6(108FFY) and Beta RBD. In rare cases, mutation can even occur at the cross-linking residue, which would abolish cross-linking at that site. However, as we demonstrated here and previously,19 44 PERx is a general strategy that can be applied on diverse nanobodies and each nanobody can have FFY incorporated at multiple sites to target different natural residues on Spike RBD to achieve crosslink (Figure 3). Therefore, other nanobodies able to bind mutated Spike RBD could be similarly engineered, and diverse covalent nanobodies could be used in combination to ensure the cross-linking and inhibition of future potential variants. When in use, the irreversible cross-linking ability together with multi-targeting of these covalent nanobodies should achieve complete viral inhibition and mechanistically prevent drug resistance. Nonetheless, animal tests and clinical trial are warranted to confirm these potential benefits of covalent protein drugs. Fast reaction kinetics would be critical for effective inhibition of viral infection, as it enables covalent crosslinks to promptly form between the protein drug and the target within a shorter contact time, and to reach higher extent for more effective neutralization. By introducing electron withdrawing fluorine substitution we designed and genetically ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.12.484088: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: In all studies, written informed consent was obtained from each participant.<br>IRB: Blood samples were obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study at the Africa Health Research Institute approved by the Biomedical Research Ethics Committee at the University of KwaZulu–Natal (reference BREC/00001275/2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For RBD expression experiments, 45 OD units of yeast were labeled in 1:100 diluted chicken-anti-Myc-FITC antibody (Immunology Consultants CMYC45F) to detect the RBD’s C-terminal Myc tag.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Myc tag .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These measurements were used in downstream steps to computationally filter library variants that were highly deleterious for RBD expression or ACE2 binding and would likely represent spurious antibody-escape mutations (see below for details).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After the plasma incubations, the libraries were secondarily labeled for 1 hour with 1:100 fluorescein isothiocyanate-conjugated anti-MYC antibody (Immunology Consultants Lab, CYMC-45F) to label for RBD expression and 1:200 Alexa Fluor-647-conjugated goat anti-human-IgA+IgG+IgM (Jackson ImmunoResearch 109-605-064) to label for bound plasma antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-MYC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human-IgA+IgG+IgM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, version 0.8.10) to process Illumina sequences into counts of each barcoded RBD variant in each pre-selection and antibody-escape population.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-escape population .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">S4B), and are the counts of variant v in the RBD library after and before enriching for antibody-escape variants with a pseudocount of 0.5 added to all counts, and and are the total counts of all variants after and before the antibody-escape enrichment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-escape enrichment .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody binding was detected with TMB/E HRP substrate (Millipore Sigma, ES001) and 1 N HCl was used to stop the reaction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ES001</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The multidimensional scaling in Fig 4 and 5 that projects the antibody-escape maps into two dimensions was performed using the Python scikit-learn package, version 1.0.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-escape</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate spike-pseudotyped lentiviral particles (58), 6 × 105 HEK-293T (ATCC CRL-3216) cells per well were seeded in 6-well plates in 2 mL D10 growth media (Dulbecco’s Modified Eagle Medium with 10% heat-inactivated fetal bovine serum, 2 mM l-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: ATCC Cat# CRL-3216, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">100 µL of serially diluted spike-pseudotyped lentiviral particles were added to 1.25 × 104 293T-ACE2 cells (BEI Resources NR-52511), grown overnight in 50 µL of D10 growth media in a 96-well black-walled poly-L-lysine coated plate (Greiner Bio-One, 655936)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Note that these assays were performed in 293T cells over-expressing human ACE2, which emphasize contributions of ACE2-competitive antibodies to viral neutralization (3,34,60).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For experiments involving D614G spike, we used spike-pseudotyped lentiviral particles that were generated essentially as described in (58), using a codon-optimized SARS-CoV-2 spike from Wuhan-Hu-1 strain that contains a 21-amino-acid deletion at the end of the cytoplasmic tail (59) and the D614G mutation that is now predominant in human SARS-CoV-2 (25).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Wuhan-Hu-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Depletion of RBD-binding antibodies from polyclonal sera: Magnetic beads conjugated to the SARS-CoV-2 Wuhan-Hu-1 RBD (ACROBiosystems, MBS-K002) or Delta RBD (ACROBiosystems, MBS-K037) were prepared according to the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 Wuhan-Hu-1 RBD</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AWY101 yeast containing an empty vector pETcon plasmid were grown overnight, shaking, at 30°C in SG-CAA media.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pETcon</div><div>suggested: RRID:Addgene_41522)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PacBio HiFi circular consensus sequences (CCSs) were generated on-instrument (Sequel IIe control software version 10.1.0.119549) and demultiplexed with lima using SMRTLink version 10.1.0.119588.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SMRTLink</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The multidimensional scaling in Fig 4 and 5 that projects the antibody-escape maps into two dimensions was performed using the Python scikit-learn package, version 1.0.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div><div style="margin-bottom:8px"><div>scikit-learn</div><div>suggested: (scikit-learn, RRID:SCR_002577)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our study has several limitations. First, each cohort in this study consists of a relatively small sample size. Due to patterns of SARS-CoV-2 viral circulation and competition among variants (e.g., early 2020, Beta, and Delta viruses circulated during different time periods and in different geographic regions), as well as the introduction of SARS-CoV-2 vaccination in 2021, the cohorts differ with regards to geographic location, age, and time of sample collection. Second, the antibody-escape mapping experiments were performed in a yeast-displayed deep mutational scanning system which only measures antibody binding to the RBD. There is not always a direct relationship between antibody binding and neutralization, as some epitopes are more immunodominant with regards to neutralization than others, and the relative contributions to neutralization of antibodies targeting different spike epitopes may depend on cell type and ACE2 expression level used in the experimental assays (3,34,35). Despite these caveats, our results have important implications for future viral evolution and vaccine design. Due to the rapid antigenic evolution of SARS-CoV-2, public health experts must decide if and when to update SARS-CoV-2 vaccines (51,52). But because each variant elicits an antibody response with its own susceptibilities to erosion by mutation, the impacts of mutations in future variants may depend on prior exposure history. This knowledge will help to understand which vulnerabilities may ex...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.11.22271912: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: This study was approved by the Medical Ethics Committee of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and the Institutional Review Board of the LUMC for observational studies.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The 4C mortality score includes the following eight predictors, collected on the day of admission: age in years (categorical variable: <50, 50-59, 60-69, 70-79, ≥80); sex at birth (dichotomous variable: male, female); respiratory rate in breaths/min (categorical variable: >20, 20-29, ≥30); oxygen saturation on room air (dichotomous variable: ≥92%, <92%); Glasgow coma scale (dichotomous variable: 15 points, <15 points); urea (categorical variable: <7 mmol/L, ≥7 to ≤14 mmol/L,</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
(as this was not possible) Limitations: It has been suggested that the minimum sample size for external validation should be at least 100 events and 100 non-events. [35] The Leiden cohort had 41 deaths, falling below the number suggested by this rule of thumb. The sample size of the Lombardy cohort was acceptable for external validation. However, the Lombardy cohort consisted of patients that were enrolled in the first months of 2020. After this period, the incidence COVID-19 related mortality has changed a lot due to many treatment changes. This limits the applicability of the recalibrated 4C risk score as the population in which the scores were recalibrated may not be representative of the current patient population in 2022. Furthermore, some patients who were already very ill before being hospitalized for COVID-19 would have chosen to receive end-of-life care at home. Despite not dying in the hospital (in-hospital mortality was the study outcome), the 4C mortality score would have assigned these patients a very high predicted in-hospital mortality risk. This will have reduced the model performance (especially model discrimination), depending on the proportion of patients that received end-of-life care at home. Lastly, missing data may have influenced model performance. For example, the oxygen saturation on room air (a predictor in the 4C mortality score) was missing in more than half of all patients in both the Lombardy cohort and the Leiden cohort. This is most likely bec...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.09.22272155: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Metabolites of significant features (p < 0.001 and intensity ≥10,000) were putatively identified by the integration of the METLIN database with XCMS Online.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>METLIN</div><div>suggested: (METLIN, RRID:SCR_010500)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To further characterize and visualize the differences in profiles of compounds among different facilities, partial least squares-discriminant analysis (PLS-DA) was performed and heatmap was generated via the web-based tool MetaboAnalyst (Wishart Research Group, University of Alberta, Alberta, Canada) [47]. 2.8</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MetaboAnalyst</div><div>suggested: (MetaboAnalyst, RRID:SCR_015539)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Due to the limitations of the instrument and limited availability of chemical references standards, fourteen compounds out of thirty were detected and quantified (Table 4) and (Table 5). Table 4 summarizes the molecular ions, product ions, retention times, and ionization modes for targeted LC-MSMS analysis of these compounds. The results showed that most of the bioactive compounds had higher concentrations in the wastewater of facilities exhibiting SARS-CoV-2 signal suppression than the control facilities. Four compounds had much higher concentrations in the suppression facilities than the control facilities. In particular, 4-nonylphenol, palmitelaidic acid, sodium oleate, and polyethyleneglycol dioleate exhibited concentrations that were 73.3%, 35.3%, 54%, and 58.8% higher in the suppression facilities than the control facilities, respectively (Figure 6). These compounds are mainly used in the production of surfactants and detergents in various industries [53, 54] The concentrations of 4-nonylphenol in the urban wastewaters were determined in Japan, China, and USA. The concentrations were about 190 µg/L [55], 2 µg/L [56], and 400 µg/L [57], respectively. In this study, average concentrations of 4-nonylphenol were 1169 ± 13.3 µg/L and 2025.7 ± 247 µg/L in the control and suppression facilities, respectively. No information was found regarding the concentrations of the other three compounds in wastewater. Palmitelaidic acid was reported to be used to produce cosmetics, soaps, ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
docs.neurodata.io docs.neurodata.io
-
from graspologic.simulations import sbm from graspologic.utils import to_laplacian # Make network B = np.array([[0.8, 0.1], [0.1, 0.8]]) n = [25, 25] A2, labels2 = sbm(n=n, p=B, return_labels=True) # Form new laplacian L2 = to_laplacian(A2) # decompose k = 2 U2, E2, Ut2 = svd(L2) k_matrices = U2[:, k] low_rank_approximation = U2[:,0:k] @ (np.diag(E2[0:k]) @ Ut2[0:k, :]) # Plotting fig, axs = plt.subplots(1, 2, figsize=(12, 6)) l2_hm = heatmap(L2, ax=axs[0], cbar=False, title="$L$") l2approx_hm = heatmap(low_rank_approximation, ax=axs[1], cbar=False, title="$L_2 = \sum_{{i = 1}}^{2} \sigma_i u_i u_i^T$") l2_hm.set_xlabel("Full-rank Laplacian for a 50-node matrix", fontdict={'size': 15}) l2approx_hm.set_xlabel("Sum of only two low-rank matrices", fontdict={'size': 15}); fig.suptitle("Summing only two low-rank matrices approximates the normalized Laplacian pretty well!", fontsize=24) plt.tight_layout() Copy to clipboard
hide
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.01.22271507: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The trial protocol was reviewed and approved by the Independent Ethics Committees of the involved sites and the Ethics Council of the Ministry of Health of the Russian Federation.<br>Consent: To be included, participants needed to be able to understand the content of the informed consent documents and be willing to sign the informed consent form.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Men and women aged 18–85 years with a body mass index (BMI) between 18.5 and 30.0 kg/m2 were selected to participate if they had no indication of a current or previous SARS-CoV-2 infection (e.g., respiratory infection in last 14 days, axillary temperature ≥37.0 °C) or close contact with a suspected or confirmed case of SARS-CoV-2 infection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Study Design and Participants: Prometheus is a multicentre, randomised, double-blind, placebo-controlled, clinical trial being conducted in six centres in the Russian Federation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Initially, as part of the interim analysis and to ensure 90% power for the between-group comparison of the primary variable, 180 subjects were to be included.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: Eligible participants were randomly allocated to the Ad5-nCoV group or the Placebo group, in a 3:1 ratio, by an independent statistician using a validated system including a pseudorandom number generator with a seed value; allocation used block randomisation and stratification by study site.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Screening included the detection of SARS-CoV-2 RNA using real-time polymerase chain reaction (PCR) via a swab, and SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody testing to ensure negative results, as well as testing for human immunodeficiency virus (HIV), syphilis, hepatitis B and hepatitis C viruses via blood serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 immunoglobulin M (IgM</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>immunoglobulin G (IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Determination of serum antibodies against the S protein and RBD of SARS-CoV-2 and the presence of neutralising antibodies against SARS-CoV-2 were conducted on Day 0, Day 14, Day 28 and after Month 6; neutralising antibodies against Ad5 were assessed on Day 0, Day 28 and after Month 6.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Ad5</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Horseradish-peroxidase conjugated mouse monoclonal anti-human IgG antibody was used to detect antibodies, visualised with tetramethylbenzidine substrate solution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-coronavirus neutralising antibodies were determined with a microneutralisation assay in which Vero cell (#ССL-81, American Type Culture Collection) monolayers were incubated in 96-well plates with 2-fold serial dilutions (1:10 to 1:1280) of participant serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-coronavirus neutralising antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-coronavirus neutralising</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-adenovirus neutralising antibodies were also determined using microneutralisation assay; A549 cell monolayers were incubated in 96-well plates with serial dilutions (1:10 to 1:1280) of participant serum and working dilutions of Ad5 (Adenovir; Smorodintsev Research Institute of Influenza).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-adenovirus neutralising</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed twice with PBS, washed twice with PBS + 0.05% Tween-20, and then incubated at room temperature with biotinylated anti-human IFN-γ detection antibody for 2 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The primary and secondary endpoints used the quantitative definition: the proportion of participants with at least a 4-fold increase in antibody titres against SARS-CoV-2 S protein and/or its RBD, specifically.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 S protein</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-coronavirus neutralising antibodies were determined with a microneutralisation assay in which Vero cell (#ССL-81, American Type Culture Collection) monolayers were incubated in 96-well plates with 2-fold serial dilutions (1:10 to 1:1280) of participant serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-adenovirus neutralising antibodies were also determined using microneutralisation assay; A549 cell monolayers were incubated in 96-well plates with serial dilutions (1:10 to 1:1280) of participant serum and working dilutions of Ad5 (Adenovir; Smorodintsev Research Institute of Influenza).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence encoding ΔFurin variant of SARS-CoV-2 S protein (amino acids 1–1213) containing a C-terminal Gly-Gly-6xHis tag was subcloned into the pMCAG-2T vector using the GeneArt Type IIs Assembly Kit, BbsI (Thermo Fisher Scientific), according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMCAG-2T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Methods: Statistical analysis was performed using SPSS Statistics, Version 26.0 (IBM Corp.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
This study has several limitations. First, the participants included in this study were all white, although conversely, this also provided the first data in a non-Chinese, European population. Second, this trial did not include children or pregnant women, and there were only a small number of older adults (35 were ≥60 years in the Ad5-nCoV group). An ideal candidate vaccine for COVID-19 should cover vulnerable populations of all ages. Anti-S protein-specific antibodies have been reported to decline rapidly in individuals who have recovered from COVID-19, especially those who were asymptomatic or had mild symptoms [23]. Third, the sample size was relatively small and some of the calculated 95% CIs were wide. Finally, virus mutation, an emerging problem, may reduce the effectiveness of current vaccines [24]. It is not known whether participants of this study were exposed to any COVID-19 variants. Further study is underway to determine neutralising antibodies to the widely circulating variants following vaccination with Ad5-nCoV, which include but are not limited to the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1 ) variants. Conclusions: Analysis of data from this phase 3 trial demonstrated the immunogenicity and safety of this Ad5-vector based COVID-19 vaccine. More data are required to determine whether this vaccine reduces infections and transmission. Overall, this stable, single-dose vaccine could contribute to the global fight against the evolving SARS-CoV-2 virus.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04540419</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Clinical Trial of Recombinant Novel Coronavirus Vaccine (Ade…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.nature.com www.nature.com
-
Shen, X.-R., Geng, R., Li, Q., Chen, Y., Li, S.-F., Wang, Q., Min, J., Yang, Y., Li, B., Jiang, R.-D., Wang, X., Zheng, X.-S., Zhu, Y., Jia, J.-K., Yang, X.-L., Liu, M.-Q., Gong, Q.-C., Zhang, Y.-L., Guan, Z.-Q., … Zhou, P. (2022). ACE2-independent infection of T lymphocytes by SARS-CoV-2. Signal Transduction and Targeted Therapy, 7(1), 1–11. https://doi.org/10.1038/s41392-022-00919-x
-
-
www.reseau-canope.fr www.reseau-canope.fr
-
L’autisme est un trouble neuro-développemental caractérisé par des anomalies dans l’interaction sociale, dans la communication et dans le comportement (activités répétitives et stéréotypées). Ces anomalies causent, pour la personne atteinte d’autisme, de grandes difficultés cognitives : d’attention, d’apprentissage, de mémorisation et de décodification de l’information.
L’autisme est un trouble neuro-développemental caractérisé par des anomalies ==>problème de définition du champ dans l’interaction sociale, dans la communication et dans le comportement (activités répétitives et stéréotypées). Ces anomalies causent, pour la personne atteinte d’autisme, de grandes difficultés cognitives ==>elles ne sont pas conséquence des interactions sociales ni des stéréotypies mais liées au développent du cerveau
Qu’est-ce que le trouble du spectre de l’autisme : Jadhav, M., & Schaepper, M. A. (2021, août). What is Autism Spectrum Disorder? American Psychiatric Association. Consulté le 11 mars 2022, à l’adresse https://www.psychiatry.org/patients-families/autism/what-is-autism-spectrum-disorderDiagnosis of Autism Spectrum Disorders : signs and symptoms on Social communication & Restricted interests and repetitive behaviors
-
-
knovigator.com knovigator.com
-
Of Course Philosophy like language will loop back on itself
Of Course Philosophy will loop back on itself
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.04.479488: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: COVID-19 infected-vaccinated donors: Sera and PBMC samples from convalescent COVID-19 donors, vaccinated donors, and COVID-19-recovered vaccinated donors, were provided through the “Collection of Biospecimens from Persons Under Investigation for 2019-Novel Coronavirus Infection to Understand Viral Shedding and Immune Response Study” UCSD IRB# 200236 as reported earlier (35).<br>Consent: All human donors were assessed for medical decision-making capacity using a standardized, approved assessment, and voluntarily gave informed consent prior to being enrolled in the<br>IACUC: S Animal Welfare Assurance Number: D16-00256 (A3410-01), under approved IACUC protocols.<br>Euthanasia Agents: Immediately prior to infection, mice were anesthetized by injection of ketamine and xylazine intraperitoneally and weighed.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">12-month-old female Balb/c mice (strain 047) were purchased from Envigo for Sarbecovirus challenge experiments (65, 85).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fluorescently labeled antibodies specific for cell surface markers were prepared as 1:100 dilution as a master mix in FACS buffer, to stain the PBMC samples for CD3 (APC-Cy7, BD Pharmingen cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For recombinant protein ELISA, mouse anti-His antibody (Invitrogen cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-His</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After another washing, alkaline phosphatase-conjugated goat anti-human IgG Fc secondary antibody (Jackson ImmunoResearch cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">902360) were used to determine the reactivity of monoclonal antibodies to human epithelial type 2 (HEp2) by indirect immunofluorescence.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>human epithelial type 2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: FreeStyle293-F cells (Thermo Fisher Scientific cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FreeStyle293-F</div><div>suggested: RRID:CVCL_D603)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">R79007) were grown in FreeStyl 293 Expression Medium (Gibco cat.# 12338018), and Expi293F cells (Gibco cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Adherent HEK293T cells and HeLa-ACE2 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated FBS, 4mM L-Glutamine and 1% P/S, maintaining in the incubator at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa-ACE2</div><div>suggested: JCRB Cat# JCRB1845, RRID:CVCL_B3LW)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The stable hACE2 or hDPP4-expressing HeLa cell line was generated using an ACE2 lentivirus protocol previously described (7).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: CLS Cat# 300194/p772_HeLa, RRID:CVCL_0030)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA using peptides or recombinant proteins: N-terminal biotinylated peptides corresponding to stem helix of SARS-CoV-1/2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-229E and HCoV-NL63 were synthesized at A&A Labs (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HCoV-229E</div><div>suggested: JCRB Cat# JCRB1838, RRID:CVCL_B3M4)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus production: HIV-based lentivirus backbone plasmid pCMV-dR8.2 dvpr (Addgene #8455), pBOB-Luciferase (Addgene #170674) were co-transfected into HEK293T cells along with full-length or variously truncated SARS-CoV1, WIV1, SHC014, Pang17, SARS-COV2, SARS-CoV-2 variants of concern [(B.1.1.7(alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta) and B.1.1.529 (Omicron)] and MERS-CoV spike using Lipofectamine 2000 (ThermoFisher Scientific cat.# 11668019) to produce single-round infection-competent pseudoviruses (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEp2 epithelial cell polyreactive assay: According to manufacturer’s instructions, HEp2 slides (Hemagen cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEp2</div><div>suggested: CLS Cat# 300397/p694_Hep-2, RRID:CVCL_1906)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mock-transfected 293T cells were used as a negative control.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus titration: SARS-CoV-2-MA10, SARS-CoV-1-MA15 and MERS-CoV-M35c4 were grown and titered using VeroE6 cells as previously described (87).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">12-month-old female Balb/c mice (strain 047) were purchased from Envigo for Sarbecovirus challenge experiments (65, 85).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Balb/c</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">C57Bl/6 288/330+/+ mice, which encode two human codons in the mouse dipeptidyl peptidase gene, were used for MERS-CoV mouse adapted challenge experiments (66).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl/6 288/330+/+</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid construction: To generate soluble S ectodomain proteins from SARS-CoV-1 (residues 1-1190; GenBank: AAP13567) ,SARS-CoV-2 (residues 1-1208; GenBank: MN908947) , HCoV-HKU1 (residue 1-1295; GenBank: YP_173238.1) , HCoV-OC43 (residues 1-1300; GenBank: AAX84792.1), MERS-CoV (residues 1-1291; GenBank: APB87319.1), HCoV-229E (residues 1-1110; GenBank: NP_073551.1) and HCoV-NL63 (residues 1-1291; GenBank: YP_003767.1) , we synthesized the DNA fragments from GeneArt (Life Technologies) and cloned them into the phCMV3 vector (Genlantis cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>phCMV3</div><div>suggested: RRID:Addgene_173431)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the pBOB-hACE2 or hDPP4 plasmid and lentiviral packaging plasmids (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBOB-hACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>hDPP4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">pMDL, pREV, and pVSV-G (Addgene #12251, #12253, #8454)) were co-transfected into HeLa cells using Lipofectamine 2000 reagent (ThermoFisher Scientific cat.# 11668019).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMDL</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pREV</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pVSV-G</div><div>suggested: RRID:Addgene_138479)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus production: HIV-based lentivirus backbone plasmid pCMV-dR8.2 dvpr (Addgene #8455), pBOB-Luciferase (Addgene #170674) were co-transfected into HEK293T cells along with full-length or variously truncated SARS-CoV1, WIV1, SHC014, Pang17, SARS-COV2, SARS-CoV-2 variants of concern [(B.1.1.7(alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta) and B.1.1.529 (Omicron)] and MERS-CoV spike using Lipofectamine 2000 (ThermoFisher Scientific cat.# 11668019) to produce single-round infection-competent pseudoviruses (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV-dR8.2</div><div>suggested: RRID:Addgene_8455)</div></div><div style="margin-bottom:8px"><div>pBOB-Luciferase</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The protocol was approved by the UCSD Human Research Protection Program.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UCSD Human Research Protection Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">08-771-23) and sorted for S protein-specific memory B cells using BD FACSMelody sorter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD FACSMelody</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single colonies were picked for sequencing and analysis on IMGT V-Quest online tool (http://www.imgt.org) and downstream plasmid production.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>http://www.imgt.org</div><div>suggested: (IMGT - the international ImMunoGeneTics information system, RRID:SCR_012780)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fifty percent maximal response concentrations (EC50) were calculated using the Asymmetrical dose-response model of Richard’s version in GraphPad Prism 7 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following three washes with FACS buffer, the cells were resuspended and analyzed by flow cytometry (BD Lyrics cytometer), and the binding data were generated by calculating the Mean Fluorescence Intensity using FlowJo 10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.05.483092: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Total number of 80 BALB/c mice in four groups (15 females and 5 males per group), and 48 C57BL/6 mice in four groups (12 females in each group), were injected intramuscularly (IM) with either phosphate-buffered saline (PBS) or 0.05, 0.5, or 3 μg mRNA-LNP at days 0 and 21.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 2 hrs blocking in a buffer containing 5% fat-free dried milk and 0.5% Tween-20, the membrane was incubated with anti-SARS-CoV-2 spike polyclonal antibody (Sino biological) or anti-β-actin polyclonal antibody (Abcam) overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-β-actin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry: In order to analyze transfected cells for cell surface expression of S protein, 2×105 cells of each of transfected and untransfected cells stained with SARS-CoV-2 Spike antibody (SinoBiological) and Anti-human IgG FITC (Sigma-Aldrich®).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation with detection antibody (7-B6-ALP) and subsequent washing, 100 μl substrate solution (BCIP/NBT-plus) added to each well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>7-B6-ALP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro characterization of mRNA-LNP: 4-4-1 Cell transfection: Primarily, HEK 293T cells were seeded into a 12-well cell culture plate, 2×105 cells per well in HG-DMEM medium (Biowest).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 60 min incubation at 37°C, the virus-serum mixture was added to 96 well-plate previously seeded with 1.5 × 104 Vero cells per well (performed in triplicate).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animal models and immunization: Immunogenicity of COReNAPCIN® vaccine candidate was assessed in mice (BALB/c and C57BL/6) and rhesus macaques.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice immunization: BALB/c and C57BL/6 mice (16-18 g, 4-6 weeks old) were purchased from the Pasteur Institute of Iran.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This DNA sequence was cloned into ReNAP-IVT1 plasmid in between special 5’-UTR and 3’-UTR-polyA tail, for transcribing the mRNA under the control of a T7 promoter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ReNAP-IVT1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike pseudotyped lentivirus, produced by the co-transfection of plex307-egfp, pCMV3-spike (Wuhan-D614G), and pspax2 with Lipofectamine 3000 (Thermo)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV3-spike</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 was calculated using the percentage of GFP positive cell versus log (dilution factor) in GraphPad Prism V8. 4.9</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 20 minutes incubation and washing with permeabilization and staining buffer (Biolegend), cells were acquired on BD FACS Lyrics and analyzed by Flowjo V10 (BD Biosciences). 4.12.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flowjo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Graph Pad V8 Prism was used to illustrates the figures and analyze the results statistically.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.03.481940: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All animal studies were approved by the Institutional Animal Ethics Committee (IAEC no. CAF/ETHICS/799/2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, 100 μL cell culture supernatant from infected Vero E6 cells was combined with 300 μL TRIzol reagent (Thermo Fisher Scientific) and RNA was purified using a Direct-zol RNA Miniprep kit (Zymo Research; Irvine, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse immunisation: The purified protein antigens (20 μg per animal) were intramuscularly immunised in 6-8 weeks old female BALB/c mice (n=5) with ‘MF59’ equivalent squalene-based oil-in-water emulsion AddaVax or SWE adjuvants, on Day 0 (prime), Day 21 (first boost), and Day 42 (second boost).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Thermostable monomer-adjuvant formulations: The RBD of SARS-CoV-2 and its mutants were cloned in the pcDNA3.4 vector for expression in Expi293F cells as described earlier [10,11].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Denatured libraries were sequenced on an Illumina MiniSeq using a 300-cycle Mid-Output Reagent kit as per the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MiniSeq</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity (Required)): *
In this manuscript by Wang and colleagues, the authors analyse single-cell RNA-seq (scRNAseq) data by applying transition path theory to infer gene regulatory network (GRN) changes along the transition (reaction coordinate, trajectory) between free energy stable states (i.e. cell types). The work aims to understand how stable cell types, and their regulatory programs (combination of active and repressed genes) switches during differentiation/reprogramming/response (i.e. cell phenotypic transition/CPT). The premise of the work is to assess whether genes within GRNs undergo step-wise repression, state-change and activation (& vice-versa; analogous to SN1) or concurrently regulate gene expression (analogous to SN2). The GRNs are inferred based on highly variable genes and their expression dynamics from RNA velocity over CPT, across 3 scRNA-seq datasets.
The authors first analyse public scRNA-seq dataset of 3003 human A549 adenocarcinomic basal epithelial cells treated with TGF-b for 0hrs, 8hrs, 1 day and 3 days (4 timepoints). The authors select two stable states (Day0-untreated; Epithelial and Day 3-treatment; Mesenchymal) using local kernel densities and set transition paths using Dijkstra shortest path, dividing state space into Voronoi cells (i.e. reaction coordinate value), and constructed single-cell GRNs based on RNA velocity differences (n=500 genes) and a linear model (from Qiu et al). This GRN is based on expression and velocity estimates, and does not distinguish direct from indirect regulation. Calculating interaction frequency (edges) across two stable states over 4 louvain clusters, the authors find global increase in effective edges that correlates with increased active genes; but with variable trend within inter-cluster edges. To quantify the concerted GRN changes between clusters, the authors utilise a "frustration" score (from Tripathi et al 2020). The average frustration score increases and peaks at day 1 treatment, followed by a decline over terminal stable state (day 3-treatment); similar to interaction frequency trends. The author also separately measure network heterogeneity and repeat analysis using alternative transition matrix. The authors conclude that EMT proceeds through concerted regulation of multiple genes first with an increase in inter-cluster edges, frustration and heterogeneity followed by a decrease into final stable state. The authors apply the analysis to scRNA-seq data from (i) pancreatic endocrine differentiation where Ngn3-low progenitors give rise to Ngn3-high, then Fev-high and into glucagon producing a-endocrine cells; (ii) dendate gyrus; radial glial cell differentiation into nIPCs, neuroblast, immature granule and mature granule cells. In both cases, the authors observe concerted regulation with initial increase in inter-community edges, heterogeneity during differentiation followed by decrease towards final stable state. **
The study and ideas in the manuscript are interesting and the methods would be potentially be useful. However, there are a few specific and general comments stated below, which the authors should try to address.
1 • P4: "RC increases first and reaches a peak when cells were treated with TGF-β for about one day, then decreases (Fig. 1G)". It would be better to label the figure with the treatment information. *
Reply: Thanks for your advice. In the revised manuscript, we analyzed two additional datasets, and moved the EMT result in the supplemental Fig. EV8. In the new Fig. 1d, we marked the cell types along the reaction coordinate.
*2 • Fig. 1G and EV1D: Why are the trends different? *
Reply: In the original figures, ____Fig____.1g is the frustration score and EV1D shows the variation of pseudo-Hamiltonian along the reaction coordinate. The frustration score is the focus of this work. We also calculated the pseudo-Hamiltonian since it has been used in the literature. However, we realized that showing both of the results might lead to confusion, so we deleted all pseudo-Hamiltonian results in the revised manuscript.
* 3 • How is the appropriate community/cluster/Louvain resolution selected? This can have a major impact on number of cell states, types and transition path from initial to final state. *
Reply: The number of cell states, types and transition path from initial to final state____ are not determined from the community/cluster/Louvain analyses. For the EMT data, we assume most cells in the initial treatment time are epithelial cells, and those in the final time point are mesenchymal cells. For other datasets, we followed the original publications to assign cell types based on known marker expression.
The Louvain method was applied to coarse grain the gene regulation network, and it does not affect the number of cell states, types and transition path, which were determined separately. To address the reviewer’s question, we also use the Leiden method to adjust the resolution ____(1)____. The resolution does not affect the result. The results are added to Fig. EV12. We tried three different resolution values 0.8,1.0 and 1.2. The number of inter-community edges consistently shows the trend that it increases first then decreases.
Figure EV12 Cell-specific variation of the number of effective inter-community edges between communities calculated with different resolution parameter values for dentate gyrus neurogenesis (a), pancreatic endocrinogenesis (b), and bone marrow marrow hematopoiesis (c). Each dot represents a cell and the color represents the number of inter-community edges____.
-
* What effect does the Louvain resolution have on e.g. frustration scores? * Reply: The resolution of community division algorithm doesn’t affect the frustration scores, since the frustration score is based on the gene-gene interactions instead of community assignment.
-
* The authors match resolution to samples/timepoints/known prior cell types i.e. 3-4 communities. However it is unclear whether this is enough to describe entire differentiation/transition process. * Reply: This is a good question. In one above reply we have explained how the cell types were determined____. We also agree with the reviewer that these coarse-grained communities cannot reflect the overall heterogeneity and dynamics of the whole process. Notice in most of our analyses (e.g., reaction coordinate and transition paths), we treated the transition as continuous and the distribution of single cell data points in all datasets cover the whole space that involved in cell phenotype transition. The coarse-grained analyses are for further mechanistic insights on how gene regulatory networks are reorganized during the transition process.
-
* Gene selection: The selection based on minimum 20 counts as highly expressed genes is arbitrary and dependent on sequencing depth. Perhaps the authors could show distribution of gene counts for the datasets and have a data-driven filtering criteria * Reply: Thanks for the advice. The number 20 is a default value suggested in the package (scVelo) we use, and in another package dynamo the default number is 30. Following the reviewer’s suggestion (together with the next question on the influence of all highly variable genes), we looked for a data-drive filtering criterion. The method has been described in different tools ____(2-4)____. We first grouped the genes into 20 bins by their mean expression values, and____ scaled their dispersions by subtracting the mean of dispersions and dividing standard deviation of dispersions____. Figure EV9 shows the distribution of the minimum shared counts. ____As one can see, most genes counts are larger than 10, and using a smaller value causes error in the following velocity analysis. Therefore we set the minimum shared counts as 10 in the new results.
Figure EV9 Shared counts distribution of the datasets. (a) Dentate gyrus neurogenesis; (b) Pancreatic endocrinogenesis; (c) Bone marrow hematopoiesis.
-
* The choice of 500 variable genes (for human A549 cells) is also quite arbitrary. Perhaps, the authors could compare how additional genes (all highly variable genes) affects their analysis and interpretation. * Reply: ____Thanks. Following previous question on shared counts and ____data-driven filtering criteria____,____ we take all the highly variable genes into consideration. The details of gene selection and binarization are given in the Materialss and Methods (Materials and Methods 2) section.
-
* How are other factors (sequencing depth, genes detected, #of cell types, multiple branches) affects the connectivity between communities at different phases of transition/development? * Reply: This is a good question. The A549 EMT dataset has a sequence depth of 40000-50000. The ____dentate gyrus neurogenesis dataset____ has a sequence depth of 56,700 reads. A saturation depth would be close to 1,000,000, but there is a compromise between cell number and depth. There are genes that are not detected even under the saturation reads setting. That is why the preprocessing is needed. On the other hand, the network we inferred include both direct and indirect interaction, so the influence of sequence depth and gene number detected can be reduced to a certain extent. We used a random subset of the selected gene and performed the same analyses. The results are consistent with what we obtained using all the genes (Fig. EV11b). With the new gene selection criteria (Materials and Method 2), our analyses are not related with the number of cell types.
We did analysis on another beta branch of pancreatic endocrinogenesis data. The other branches show the same results (Fig. EV4). There are two additional branches in the pancreatic endocrinogenesis dataset. It has been reported that the RNA velocity estimation for the epsilon branch is incorrect ____(3)____. There are too few cells in the delta branch for reliable analyses. Therefore we didn’t present results for these two branches.
Figure EV4 Analyses on the branch of glucagon producing β-cells in pancreatic endocrinogenesis.
(a) Transition graph based on RNA velocity.
(b) The RCs and corresponding Voronoi cells. The large colored dots represent the RC points (start from blue and ends in red). The small dots represent cells with color as cell type.
(c) Frustration score along the RCs.
(d) Cell-specific variation of effective intercommunity regulation. Each dot represents a cell. Color represents the number of effective intercommunity edges within each cell in the GRN.
-
- Are the velocity graph, transition matrix and further shortest path estimation derived in a reduced latent space, and if so, how much (nPCs) and what impact does it have. Presumably, the density estimation is not performed in expression space. Reply: Yes. ____The calculation of transition matrix is based on neighbor information. The calculation of neighbors was in the reduced latent space in scVelo and Dynamo. We performed the same analysis by varying number of principal components. The results are similar because the first several components account for large proportion of variance. Figure R1 shows the results of dentate gyrus neurogenesis with the number of principal components being 10, 20 and 30, respectively. In the revised manuscript, we delete the step of using density estimation constrain to simplify the procedure. __Figure R1 Frustration scorer along RCs (left) and cell specific variation of number of effective intercommunity edges (Each dot represents a cell and color represents the number of effective intercommunity edges) in the GRN within each cell (right) when using different number of PCs in analyses (dentate gyrus neurogenesis): (a) number of PCs is 10.*__
(b) number of PCs is 20. (c) number of PCs is 30
* - The figure legends and labels were hard to read. These should be improved for better readability. *
Reply: Thanks. We modified the figure legends and labels.
* - A suggestion would be move the initial results section to methods and highlight the biological interpretation. *
Reply: Thanks for your advice. We moved large part of this section to the Materials and Methods.
*The authors could highly which GRN and representative genes/edge pairs are highest ranked within inter-community and to overall final stable states. *
Reply: Thanks. We list some representative gene pairs in the Table. EV 2&EV 3 &EV 4 for different datasets. And we performed gene enrichment analysis for each community.
* - How does the GRN inference compare to current state-of-the-art GRN inference scRNA-seq methods? *
Reply: we used the method GRISLI to perform the same analysis ____(5)____. The results are similar to what obtained with our current method (Figure EV6). We want to emphasize that the focus of this work is not on another GRN inference method, but discussing some general principles of GRN reorganization during a cell phenotypic transition process.
Figure EV6 Analyses of datasets of dentate gyrus neurogenesis (a), pancreatic endocrinogenesis (b), and hematopoiesis (c) based on GRN inferred with GRISLI.
(a) Frustration score along the RCs of dentate gyrus neurogenesis (left) and cell-specific variation of the number of inter-community edges (right). Each dot represents a cell and color represents the number of inter-community edges in GRN within each cell.
(b) Same as in panel (a), except for pancreatic endocrinogenesis.
(c) Same as in panel (a), except for hematopoiesis.
* - How do extremely noisy/stochastic genes vary in metrics between final stable states? How are the metrics affected by number of cells and stochasticity of expression within a given cluster/community. *
Reply: To address this question, we selected two genes, Id2 and Cdkn1c, with high variance and compare their distributions in the initial and final states. ____The gene distributions show significant shift between the Ngn3 low EP cells and Alpha cells (Fig. R2 a &b left).____ Then we randomly selected a subset (half) of cells and compared the distributions of these high-variance genes in the sub-population (Fig. R2 a&b right). The results are similar to the full-set results.
Fig. R2 Comparison of gene distribution in the initial and final states in pancreatic endocrinogenesis. (a) Comparison of the distribution of gene Id2 at the initial and final states (left), and in the randomly selected sub-population at the initial and final states (right). (b) Comparison of the distribution of Cdkn1c at the initial and final states (left), and in the randomly selected sub-population at the initial and final states (right).
* - Given that the author's approach includes both direct and indirect genes effects, the authors could further prune genes based on existing TF databases or protein-protein validated networks. *Reply: This is a good suggestion. We will work on this idea in future work. As we mentioned, due to constrains of data quality, only tens of transcription factors can be analyzed in these dataset. We list some regulations of transcription factors inferred with current method in Table EV1.
- *It is unclear which GRNs are already known and which ones are novel and biologically relevant * Reply: We compare some regulations inferred with the method and compare these interactions w____ith some references in Table. EV1____.
* - It would be good for authors to comment when there are multiple bifurcations instead of A-B transitions. Particularly in datasets with multiple discrete stable states. *Reply: This is a good question.____ In our analysis, we focus on the transition from one stable state to another stable state. For transition process with multiple bifurcations like____ the pancreatic endocrinogenesis, the results are similar across different branches. For the transition that goes through multiple discrete stable states, for example, a transition from state A____à____B____à____C, we expect to observe two peaks in the frustration score and the number of inter-community edges. We added some discussions in the Discussion section.
- *Another suggestion would be to highlight gene expression of selected markers based on f-regression and mi over the trajectory * Reply: As we modified the criteria of gene selection, we plotted trajectories of some high-variance genes versus the reaction coordinate obtained with different datasets in Fig. EV10 based on current criteria.
Figure EV10 ____Typical trajectories of high variance genes versus RCs of dentate gyrus neurogenesis (a), pancreatic endocrinogenesis (b) and bone marrow ____hematopoiesis ____(c).
* - If possible, a proof of principle could be re-analysis of a perturbation scRNA-seq dataset (e.g. where one path/transition path is stalled) *
Reply: Thanks. This is a really a good suggestion. We will perform more systematic studies in future work.
* Reviewer #1 (Significance (Required)): Nature and significance of advance: The study and ideas in the manuscript are interesting and the methods would be potentially be useful to community. Compare to existing published knowledge: *
*Audience: Predominantly computational audience *
*Your Expertise: PI with background in experimental, computational biology and expertise in single-cell genomic tools and developmental biology *
*
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
Understanding the cellular and molecular basis of cell type or cell state transitions occurring during development or reprogramming is a fundamental challenge. scRNA-seq has provided a window into gene expression programs across thousands of cells undergoing such transitions. Wang and colleagues leverage scRNA-seq and develop an approach to reverse engineer gene regulatory network underlying cells along a path from one cell type/state to another, and characterize community-level properties of this network associated with various stages of the cell phenotype transition. The study is innovative and rigorous, and their results point to how intercommunity interactions increase and then decrease, indicating a concerted regulatory rewiring that orchestrates transitions. Application of their approach to three different datasets also shows that this trend is consistent across three different transitions and maybe a general trend. However, there are some major and minor concerns that need to be addressed.
**Major comments and questions**
- The analogy to SN1 and SN2 mechanisms of chemical bond formation is very nice.
- What is the basis for the two statements made in paragraph 3 of Introduction (beginning with "A question arises ...") about transitions being sequential or concurrent? Please *Reply: Thanks. We added references in this paragraph.
* 2.1. Provide references to previous experimental and computational studies that have investigated developmental and reprogramming gene expression programs. *
Reply: Thanks. We added a paragraph in the Introduction.
*
2.2. Describe specific examples of findings that support the two possible transitions highlighted here. Why couldn't transitions happen through an entirely gradual process involving changes to overlapping subsets of genes. *
Reply: Thanks. In the review paper of Naomi Moris et. al., they proposed the hypothesis that cell phenotype transition is similar to a chemical reaction ____(6)____. Thus we extrapolate this hypothesis and test it in our study. For the example of SN1 mechanism, ____Kalkan et al. showed that mouse embryonic stem cells can exit from ____naïve pluripotency____ but remain uncommitted ____(7)____.
Just like the SN1 and SN2 mechanisms are two extremes in chemical reactions and there are cases lie in between, for cell phenotypic transitions we agree with the reviewer that such gradual process may exist. Actually the result in Fig. EV4d shows that the frustration score remains flat for the Fev+ ____à____ Beta transition, suggesting a possible gradual process. With the analyses provided in this work, such as the reaction coordinate, frustration score, heterogeneity, and inter-/intra- community edges, one may perform more systematic studies on a larger number of datasets and enumerate/classify possible patterns of transitions.
- Please make plots of the number of effective intra-community edges vs. number of active genes to support the statement that these two numbers are correlated. *
Reply: We plotted the corresponding intra-community active genes and calculated its correlation coefficient with the number of effective intra-community edges in dentate gyrus neurogenesis (Fig. EV1d). ____The correlation coefficients are 0.91,0.96, 0.99 and 0.96 for community 0, 1, 2 and 3 separately.
* A bunch of notations are not clear:
4.1. What is the "r" in "strongest intercommunity interactions at r = 10 (Fig. 1F)"? Is it the same as the "r" mentioned in the Methods section? *
Reply: r____ is the index number of the discretized reaction coordinate. We added it when we define the reaction coordinate. We modified the conflict usage of r in Materials and Method 4.
4.2. What is "s_i" in "cell-specific effective matrix, Fbar_ij = (2*s_i - 1)*F_ij"? Also, that description of F_ij, f_ij, and H should be moved to the Methods section, and a more high-level, intuitive description should instead be included in this Results paragraph. Reply: represent the binarized gene expression state. is 0 for when gene is in low expression level (silence) and is 1 when gene is in high express level (active). We modified this part following your advice.
* How were the h_f and h_m thresholds chosen? *
Reply: and are based on the distribution of each dataset. Following suggestions from another reviewer, we modified this part. All the highly variable genes were selected and the genes were binarized with the Silverman’s bandwidth method and ____K____means (Materials and Methods 2).
* What is the "density of each single cell" ("⍴_t")? The formulation of the penalty of the distance between cells i and j (the expression with -logP_ij...) is unclear. What is the intuition behind it? What is r? How were the values of r (0.5 and 0.8) chosen? *
Reply: The probability density of cells in the expression space is based on the kernel density estimation. Intuitively, a region in the expression space with more cells is more likely passed by more cell trajectories. The values are based on the distribution of kernel density estimation in different datasets.
In the modified manuscript, we used trajectory simulation and deleted this assumption for simplification.
* One of the reasons the authors state to justify the choice of PLSR is "In the scRNA dataset, the number of genes is often comparable to or larger than the number of cells." This is not true most of the time. In nearly all recent studies, the number of cells is way larger than the number of genes measured. *
Reply: The PLSR method definitely can be used for the data whose number of cells is larger than the number of genes. Also the PLSR method was applied on cells that are the k nearest neighbors of each reaction coordinate, which are a subset of the whole dataset (Materials and Methods 5). While we mainly presented results with the PLSR method, in this revised manuscript we also added results with another method of GRISLI (Materials and Methods 9). The results are similar with what we obtained with PLSR.
* There is a fleeting reference to a nice previous finding that supports their observations: "several lines of evidence support that EMT proceeds through a concerted mechanism. Indeed, both in vivo and in vitro studies have identified intermediate states of EMT that have co-expressed epithelial and mesenchymal genes (Pastushenko et al, 2018; Zhang et al, 2014)". The authors should thoroughly survey the literature related to EMT transition, development of pancreatic endocrine cells, and development of the granule cell lineage in dentate gyrus, to find more previously identified molecular/cellular features relevant to cell state/type transitions, compared and contrasted with findings from this study. *
Reply: Thanks. We added references on these cell phenotype transitions and modified the corresponding part. We do want to point out that the main focus of this work is that all these processes share a common feature of transient increase of intercommunity interactions.
* What is the "dynamo" package, which is supposed to contain a Python notebook? As of now, the code and data have not been made available. Both need to be released along with thorough documentation on how to run the code to reproduce the analyses described here. *Reply: Thanks. Dynamo is a python package accompanying our recent publication ____(8)____. We uploaded the code on Github and added the link of Dynamo.
* **Minor comments and questions**
- Replace "confliction" throughout the manuscript with "conflict" or "conflicting" as appropriate. *
Reply: Thanks. We modified them.
* Paragraph two of the Introduction (beginning with "Another example of transitions ...") is missing multiple references, esp. for the last four sentences. *
Reply: Thanks. We added references.
* There are direct quotes from previous papers like "predicts the future state of individual cells on a timescale of hours". The authors are highly encouraged to check for usage of exact phrasing using available text software such as iThenticate. *
Reply____: ____Thanks a lot for pointing out this severe mistake. We re-edited the manuscript and checked with iThenticate. *
*
- "Each community contains both E and M genes": what does this mean? *
Reply: The E (M) genes are defined as those genes that are active or have high expression levels in epithelial (mesenchymal) state or sample. As we reorganized the manuscript, we add this explanation for all datasets in the caption of Fig.1i.*
*
- Reference to Qui 2021 is missing in the "Path analysis" subsection under Methods. *
Reply: We added it in the Methods.
* Fix: "transition between the cells that their sample time points are successive" in Methods. *
Reply: Thanks. ____We modified it.
* In Methods, under "Network inference", it is "partial least square regression" (not *least* s square). *
Reply: Thanks. We modified it.
* Figure 1: The cyan, magenta, and lime in 1C are very hard to see and, perhaps, the grey of the points can be made lighter. Also, change the red and green colors for the arrows in 1I to something else. These colors are not colorblind-friendly. *
Reply: Thanks. We re-plotted the figures and changed the colormap.*
*
- Periods and commas are missing at several places. Reply: Thanks. We modify these and re-edit the manuscript.
Reviewer #2 (Significance (Required)):
The study uses RNA-velocity calculated from scRNA-seq data in an inventive way to characterize paths that reflect cell phenotype transitions. Then, a sparse gene regulatory network is reverse engineered from the data and the community structure within this network is examined at various stages along the transition to make observations about inter- and intra-community regulation and network "frustration". However, the study lacks the context of existing literature in terms of previous work studying cell transitions both experimentally and computationally. Adding this context (as suggested in the comments) will considerably improve the utility and significance of the findings. Overall, this study will be of broad interest to researchers interested in development and reprogramming as well as computational scientists developing and applying methods for scRNA-seq data analysis, trajectory inference, and network reconstruction. All the comments and questions raised here are based on my background and expertise in omics data (including scRNA-seq) analysis and network biology.
Reviewer #3 (Evidence, reproducibility and clarity (Required)):
The authors analyze three datasets of Single cell RNA velocity measured during phenotypic transition. They infer the gene regulatory network in each case and characterize the transition between the initial and final expression states (in which different sets of genes are expressed). Their motivating question was to find whether during such transitions first genes characterizing the initial state are no longer expressed and only then the genes associated with the final state start expressing or alternatively there is gradual transition through an intermediate state in which subsets of both initial and final state genes are transiently expressed.
They define a measure of regulatory frustration representing the mismatch between regulatory signals a gene receives and its current expression state. They conclude that phenotypic transitions involve transient interactions between otherwise non-interacting gene modules and a temporary increase of gene frustration, which is relaxed once the final expression state is reached.
The study uses of advanced inference and machine learning methods.
I find the question studied in this manuscript interesting, opening avenue to further questions and studies and relevant to different scientific communities. Personally I think that the focus of the paper should be the exposition of the methods used this manuscript would benefit from a longer format, but that depends of course on the journal they are aiming at. *
*
Statistical analysis is missing. Especially since the authors mention the potential of over-fitting due to large number of genes (on the order of the number of cells) - I think the authors should provide a sensitivity analysis testing how sensitive are the conclusions to the choice of cells or genes by applying the methods to subsets of the cells / genes. *
Reply: Thanks. For the subset of cells, we randomly selected cells from the dataset and performed the analyses (Fig. EV11a). For the subset of genes, we selected a subset of genes randomly and performed the analyses (Fig. EV 11b). We found the results are not affected. We also perform another statistical analysis by varying the value of resolution in community detection algorithm. And we found that the conclusion on variation of inter-community edges is not affected (Fig. EV12).
Figure EV11 Statistical analyses of dentate gyrus neurogenesis. Each dot represents a cell and color represents the number of inter-community edges.
(a) Frustration score along the RCs (left) and cell-specific variation of the number of inter-community edges (right) of a randomly selected sub-population of 2000 cells (from a total of 3184 cells);
(b) Frustration score along the RCs (left) and cell-specific variation of the number of inter-community edges) (right) of cells on the space of 400 randomly selected genes (from a total of 678 genes).
*What is the meaning of the distribution in the frustration plots? *
Reply: For each cell we calculated a frustration score. Therefore for cells in each Voronoi cell (which is a geometric cell, don’t be confused with the biological “cells”) along the reaction coordinate (Fig.1d, Fig. 2b &2g), we obtained a distribution of the frustration scores.*
In general, the conclusions are well-justified, but I think some statements in the discussion are inaccurate: "intercommunity interactions of a GRN are indeed minimized' - are they minimal or are they only lower at the stable states? There are two stable states - for which of them is intercommunity interaction lower? *
Reply: Thank. We agree with the reviewer and modified the writing. Comparing with the transition state, the number of intercommunity interactions is less for the stable states. ____The datasets' quality are not high enough for us to investigate whether ____"intercommunity interactions of a GRN are indeed minimized”.*
It is written in the discussion that 'for all three datasets frustration decreases with differentiation', but then Fig. 1g shows the opposite (final state is more frustrated than initial state). It is interesting to discuss the differences between the datasets analyzed in that respect and what could cause transition to a more frustrated state. I suggest that the authors also refer in the discussion to related questions and possible follow-up studies, such as: what determines the duration of the phenotypic transition? A relevant number is the switching time of a single gene. *
Reply: Good suggestion. Compared to other datasets, we found that the result of EMT shows larger variances. The relative difference of the frustration score is also affected by the GRN inference algorithm. For example, the difference between initial and final frustration scores of the pancreatic endocrinogenesis is more significant when using the GRISLI method (Figure EV6b). Given these, the trend that the frustration scores in the transition states transiently increase keep consistent.
Our conclusion is limited by the quality of the data. So we delete this part of discussion in the manuscript.
Qiu et al. have shown that splicing-based ____RNA velocities are relative, while metabolic-labeling-based RNA velocities are more quantitative and accurate____(8)____. We will re-analyze this problem if data with metabolic labeling becomes available.
* The authors mention at the end that the networks can often reach multiple final states from a common initial states. Do such transitions share some of their path (and in particular the intermediate frustrated state)? Given the intermediate connected state, it would be interesting to characterize the network stability to perturbations. *
Reply: This is a very important question. To reliably address these questions, we need higher quality data. We plan to characterize the network stability to perturbations in future studies, while in our recent paper using a full nonlinear modeling framework____(8)____, we performed in silico perturbations.
* While interesting, the manuscript itself is unfortunately hard to read and would benefit from major editing, including better exposition of the science and language editing. *
Reply: Thanks. We revised the manuscript extensively.*
Methods: Description of PCA and 'revised finite temperature string method' are missing in the Methods section. *
Reply:____ Thanks. PCA is used in RNA velocity analysis for dimension reduction. We added this in Materials and Methods 3. The revised string method is in Materials and Methods ____4.
*
Some examples:
Figure captions are very short and often non-informative. Some variables are not defined (or only defined later on) and the reader then needs to guess their meaning: it took me a while to understand what is 'r' in Fig. 1f and what 'r=10' (p. 4) means. *
Reply: Thanks. ____r____ represents the index number of reaction coordinates. We added this in the manuscript where we define reaction coordinates.*
p. 4: what are 'f' (as opposed to F) and 's_ij' and 's_j' (expression states?) Or is fs_ij one variable? What does a Hamiltonian of a cell mean (p. 4, bottom)? *
Reply: is the regulation of gene ____j on gene i, and is the expression state of gene i (0 for silence, and 1 for active expression). is the frustration value of regulation from gene j to gene i.
The pseudo Hamiltonian value is proposed in the literature as an analogy of ____the magnetic systems following the work of Boolean model in EMT ____(9)____. A high Hamiltonian value indicates that the cell is in an unstable state. In the original manuscript we included this quantity since it has been discussed in the literature. However we found it causes confusion and is not necessary for our discussions, so we removed the pseudo-Hamiltonian results in the revised manuscript. * P. 4: how are 'E and M genes' defined? *
Reply: The E (M) genes are defined as those genes that are active or have high expression levels at the epithelial (mesenchymal) state or sample. We explained our general strategy in the caption of Fig.1i . * What does 'network heterogeneity' (p. 5) mean? *
Reply: Network heterogeneity measures how homogenously the connections are distributed among the genes____(10)____. A high heterogeneity ____means that some genes have high degree of connectivity (the so-called hubs), while some have low degree of connectivity.
*
Fig. 1 is too tiny and hard to read and details are missing. *
Reply: Thanks. We modified this figure and caption.*
A glossary for all the acronyms used would be very helpful. *
Reply: Thanks. We added glossary in the manuscript.*
Language (some examples):
p. 5 bottom: Another system is on development... invitro -> in vitro
p. 6: 'measure on developmental potential' -> measure of... *
Reply: Thanks. We modified these and re-edited the whole manuscript.*
Reviewer #3 (Significance (Required)):
This study presents a methodological advance in demonstrating the application of data analysis methods to study developmental phenotypic transitions. High throughput measurements and computation power available today enable putting to test theoretical conjectures, as made by Waddington. I think this is a promising line of research, which could be used to further develop the computational methods as well as to further our understanding of developmental transitions and potentially develop associated mathematical modeling frameworks.
This study should be of interest to a diverse readership composed of developmental biologists as well as to quantitative biologists and CS researchers applying optimization techniques and data analysis methods to high-throughput biological data.
I am not an expert on the computational methods applied in this manuscript and hence cannot assess their correct use and statistical analysis.
*
- Traag VA, Waltman L, & van Eck NJ (2019) From Louvain to Leiden: guaranteeing well-connected communities. Scientific Reports 9(1):5233.
- Stuart T, et al. (2019) Comprehensive Integration of Single-Cell Data. Cell 177(7):1888-1902.e1821.
- Bergen V, Lange M, Peidli S, Wolf FA, & Theis FJ (2020) Generalizing RNA velocity to transient cell states through dynamical modeling. Nature Biotechnology 38(12):1408-1414.
- Wolf FA, Angerer P, & Theis FJ (2018) SCANPY: large-scale single-cell gene expression data analysis. Genome Biology 19(1):15.
- Aubin-Frankowski P-C & Vert J-P (2020) Gene regulation inference from single-cell RNA-seq data with linear differential equations and velocity inference. Bioinformatics (Oxford, England) 36(18):4774-4780.
- Moris N, Pina C, & Arias AM (2016) Transition states and cell fate decisions in epigenetic landscapes. Nature reviews. Genetics 17(11):693-703.
- Kalkan T, et al. (2017) Tracking the embryonic stem cell transition from ground state pluripotency. Development 144(7):1221-1234.
- Qiu X, et al. (2022) Mapping Transcriptomic Vector Fields of Single Cells. Cell 185(4):690-711.
- Font-Clos F, Zapperi S, & La Porta CAM (2018) Topography of epithelial–mesenchymal plasticity. Proceedings of the National Academy of Sciences 115(23):5902-5907.
- Gao J, Barzel B, & Barabási A-L (2016) Universal resilience patterns in complex networks. Nature 530(7590):307-312.
-
-
-
-
Immunoblot (IB)
Figure 3: How does p300 acetylation effect MER/ERK signaling A) Different mutations, arginine mutation was similar to WT, but other mutants had lots of MEK/ERK phospho B) C) Kinase activity --> increased MEK/ERK phosphorylation D-E) Meh F) KQ results in higher tumor volume G) Qualitative tumor size comparison --> KQ is bigger H) Graphically I) Rat with tumors J) KSR with mutant are higher than wt K) Mutations effect on heterodimers L) CRAF heterodimers M) N) Myc-p300 increased scaffold protein binding O) Arginine mutant isn't as active Mutants result in increased protein interactions
-
) Immunoblot (IB) ana
Figure 2: Focusing on K601 of BRAF, what is the deacetylase? --> p300 A) Shows B) C) Meh D) shRNA knockdown enhances MEK and ERK signaling E) Meh F) Knockout has more MEK ERK signaling G) Sirt1 has more MEK ERK signaling H) Insulin activates p300, activates acetylation I) Small difference in pERK --> pathway turned off sooner, then later, 5 min and 40 min. J) Meh K) Knockdown effect on colony formation --> Sirt1 depends on BRAF L) Sirt1 depends on BRAF M) Xenograph into mice and graphed. Sirt1 depends on BRAF
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.03.03.22271601: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The clinical study was approved by the Siriraj Institutional Ethics Review Board (approval no.Si537/2021).<br>Consent: Procedures: Participants were recruited into the study following informed consent and were randomised to one of seven prime-boost groups: CoronaVac-ChAdOx1, CoronaVac-BNT162b2, ChAdOx1-CoronaVac, ChAdOx1-BNT162b2, BNT162b2-CoronaVac, BNT162b2-ChAdOx1 or homologous BNT162b2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The exclusion criteria were unstable underlying disease, having acute illness, had a history of anaphylaxis; were pregnant females, were immunocompromised or receiving immunosuppressants at screening.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Procedures: Participants were recruited into the study following informed consent and were randomised to one of seven prime-boost groups: CoronaVac-ChAdOx1, CoronaVac-BNT162b2, ChAdOx1-CoronaVac, ChAdOx1-BNT162b2, BNT162b2-CoronaVac, BNT162b2-ChAdOx1 or homologous BNT162b2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Participants who had a positive anti-nucleoprotein (anti-NP) or anti-RBD IgG antibody at baseline were excluded.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-nucleoprotein</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-NP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The anti-RBD IgG antibody responses were presented as geometric mean concentrations (GMC) with 95% confidence intervals (CI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After removing the culture medium from Vero cell culture plates, 200 ul of the virus-serum antibody mixture were inoculated into monolayer Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Human embryonic kidney (HEK) 293T/17 cells were transfected with the pCAGGS-S expression vector (Delta or Omicron) in conjunction with p8.9171 and pCSFLW72 using polyethylenimine (PEI, Polysciences, Warrington, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293T cells overexpressing human ACE2 were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 200mM L-glutamine, 100μg/ml streptomycin and 100 IU/ml penicillin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Human embryonic kidney (HEK) 293T/17 cells were transfected with the pCAGGS-S expression vector (Delta or Omicron) in conjunction with p8.9171 and pCSFLW72 using polyethylenimine (PEI, Polysciences, Warrington, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-S</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCSFLW72</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 24 hours before the assay, cells (5×105 cells/ml cells in 10 mm dish) were transfected with pCAGGS expressing codon-optimized human TMPRSS2 using Fugene HD transfection reagent (Promega)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The qualitative anti-NP IgG was also measured by CMIA using the SARS-CoV-2 IgG (Abbott, List No. 06R86) on the ARCHITECT i System.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody titer was then calculated by interpolating the point at which infectivity had been reduced to 50% of the value for the no serum control samples using GraphPad Prism 9.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analyses were conducted using STATA version 17 (StataCorp, LP, College Station, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STATA</div><div>suggested: (Stata, RRID:SCR_012763)</div></div><div style="margin-bottom:8px"><div>StataCorp</div><div>suggested: (Stata, RRID:SCR_012763)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Limitations of this study were that the participants were not blinded for the study vaccine, which may have influenced the reporting of adverse reactions. Secondly, the small sample size in each group did not allow us to identify any potential rare AEs. However, findings from this study have been used to inform the Thailand National COVID-19 vaccination program recommendation by including the CoronaVac-ChAdOx1 regimen during the time when mRNA vaccines were not available. Ongoing surveillance of any rare AEs and the clinical effectiveness of this heterologous schedule will inform the feasibility of such schedule against the SARS-CoV-2 variants. Lastly, the BNT162b2 booster in this study was only given to two groups who received CoronaVac and ChAdOx1, and there was no homologous three-dose BNT162b2 group for comparison of their immunogenicity. Despite this, it was clear that BNT162b2 as the third booster vaccination provided high neutralizing activity against Delta and Omicron, which is likely to provide protection against these two predominant variants. Future studies incorporating mRNA booster to other heterologous primary schedules will be of interest, particularly with other COVID-19 vaccines that have recently received WHO EUL. In conclusion, we found that heterologous COVID-19 primary series using either ChAdOx1 or BNT162b2 as second dose were highly immunogenic against SARS-CoV-2 ancestral strain, Beta and Delta variants, but low neutralizing antibody against Omicron. A...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.03.02.482639: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.2 In vitro cells culturing and incubation with vaccine: The studies were performed on normal human astrocytes (Clonetics NHA), human astrocytoma CCF-STTG1 (ATTC CRL-1718) and human glioblastoma cell line U87-MG (ATCC HTB-14) purchased from Lonza (Lonza Walkersville. Inc.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>U87-MG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The U87MG cells were maintained in Eagle’s Minimal Essential Medium with L-glutamine (ATCC 30-2003) supplemented with 10% fetal bovine serum (ATCC 30-2020) without antibiotics in a humidified incubator at 37 ° C and 5% CO2 atmosphere.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>U87MG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The CRL-1718 cells were maintained in RPMI 1640 Medium (ATCC 30-2001) supplemented with 10% fetal bovine serum (ATCC 30-2020) without antibiotics in a humidified incubator at 37 °C and 5% CO2 atmosphere.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CRL-1718</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data processing: Data acquisition and processing were performed using WITec Project Plus software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Project Plus</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The background subtraction and the normalization (model: divided by norm (divide the spectrum by the dataset norm)) were performed by using Origin software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Origin</div><div>suggested: (Origin, RRID:SCR_014212)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Reviewer #1 (Public Review):
The authors investigated spindle growth dynamics during anaphase B in S. pombe, a unicellular eukaryote which undergoes closed mitosis. In order to accurately quantify spindle growth speeds, the authors tagged Alp7, a protein that localizes to plus ends of microtubules, with 3xGFP, and tracked its position in the dividing cell during mitosis, resulting in precise measurements of both the duration and velocity of microtubule growth events for the first time. By performing these experiments across a set of different genotypes (e.g. in strains with knock-outs of specific microtubule-associated proteins (MAPs)) the authors conclude that (1) microtubule rescues preferentially occur at the midzone edges, (2) microtubule growth speed decreases throughout anaphase B, independent of several known anaphase MAPs and (3) wrapping of the nuclear membrane around the spindle is responsible for this reduction in MT growth speed.
The data in this study is of very high quality and the conclusions are largely well supported by the data, but some changes could be made in the interest of simplicity and clarity, and some additional experiments should ideally be performed to strengthen the third claim.
Many changes occur in the nuclear bridge in late anaphase, including the disassembly of nuclear pore complexes and the fenestration of the nuclear envelope (Lucena et al. 2015, Exposito-Serrano et al. 2020, Dey et al. 2020). This opens up the possibility for a different interpretation of some of the authors' data - for example, that local alterations in the permeability barrier directly alter microtubule polymerisation dynamics, rather than the wrapping of the nuclear envelope in the bridge per se. This could help explain the ark1-as3 data, for example, in which (non-physiological) membrane tubes wrap around the spindle but local NEB is prevented (Dey et al. 2020).
The authors state that 'transition from fast to slow microtubule growth occurs in the absence of known anaphase MAPs' (heading paragraph 3 (239-240) and Figure 2), yet two paragraphs later, they show that the MAP Ase1 does in fact impact this transition. This distinction might prove confusing for readers, especially those unfamiliar with the S. pombe spindle.<br /> The authors state that Ase1 is required for the decrease in growth speed during anaphase. While the example kymograph in Figure 5B looks convincing, there seem to be too few points at the right side of Figure 5F to properly see the two distributions. Without any statistics to compare wt to ase1∆, it is difficult to tell if the apparent absence of decrease is real. In addition, as the authors also show in Figure 1C-E, the spindle collapses, causing the final spindle length to be shorter than wt. It could be that the spindle collapses before the characteristic drop in growth rate could be observed.<br /> One of Ase1's direct interactors, Cls1, was shown to not have an impact on the transition of fast to slow microtubule growth (Figure 2). In Ase1's case, a full deletion of the gene was necessary to reveal loss of the transition. The ase1off strain with reduced Ase1 expression showed a similar transition to wt, similar to the cls1off strain. cls1 is an essential gene and cannot be deleted, but similar to its interactor, its phenotype might be hidden even at low expression values.
Some observations, such as Figure 2G-L, lack associated statistics. In addition, since Alp7 tagged with 3xGFP is used throughout the paper, it seems important to test whether this tag influences microtubule dynamics.
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.28.22271643: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">We rated down for risk of bias when only studies having high risk for case ascertainment contributed to an outcome (e.g., passive surveillance where we assume there is under-ascertainment), and for indirectness for comparisons across both sexes or if the age group reported did not match one of our groups of interest (e.g., 13-39 year olds) and the incident rates may vary substantially among ages.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Literature Search: We worked with an experienced medical information specialist to develop the search strategy, which was peer-reviewed (see Acknowledgements).18 Searches combined concepts for COVID-19, vaccines, and myocarditis/pericarditis/cardiovascular manifestations/adverse events/surveillance; each concept included various key word and Medical Subject Heading (MeSH) terms.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MeSH</div><div>suggested: (MeSH, RRID:SCR_004750)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">& Other Non-Indexed Citations and Daily <1946 to January 10, 2022> and Embase <1974 to 2022 January 10>.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Embase</div><div>suggested: (EMBASE, RRID:SCR_001650)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In January, we searched L-OVE, CT.gov, Cochrane COVID Reg, WHO Covid reg, and Google Scholar for additional grey literature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cochrane COVID</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Google Scholar</div><div>suggested: (Google Scholar, RRID:SCR_008878)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Several limitations exist in the mechanistic literature we identified: i) little direct empiric evidence was available to support or refute the proposed hypotheses; where direct empiric evidence was available, it often derived from case reports or small series, ii) when assessing laboratory findings in case reports/series/retrospective studies, it is not clear whether any differences seen (e.g., increases in NK cells, autoantibodies) reflect a causal pathological immune response or reactive adaptive responses to the myocardial inflammation, iii) the emergence of new studies refuting some of the proposed mechanisms; for example, articles stating no reports of eosinophilia, are out-dated due to reports finding evidence of this, iv) there has been a lack of invasive investigations (e.g., biopsy, tissue morphology, special studies to detect injury, immune activity, virus, etc.) given the typically mild course of the clinical conditions observed, and v) it is difficult to confirm a causal link; for example, an important proportion of cases observed or reported may not be vaccine-related and this will contribute to the heterogeneity of presentations, clinical characteristics, and resulting hypotheses. Choi et al.87 described a fatal case of myocarditis after mRNA vaccination and compared the case to another fatality reported by Verma et al.69 both of which had comprehensive clinicopathological analysis. The two cases were remarkably different, suggesting “that myocarditis after COV...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
-
P. Wardman and L. P. Candeias, Radiat. Res., 1996, 145, 523–531.23 (a) C. Kim, K. Chen, J. Kim and L. Que Jr, J. Am. Chem. Soc.,1997, 119, 5964–5965; (b) M. S. Chen and M. C. White,Science, 2007, 318, 783–787.24 B. J. Groendyke, A. Modak and S. P. Cook, J. Org. Chem.,2019, 84, 13073–13091.25 L. Liguori, H.-R. Bjørsvik, F. Fontana, D. Bosco, L. Galimbertiand F. Minisci, J. Org. Chem., 1999, 64, 8812–8815.26 J. F. Perez-Benito, J. Phys. Chem. A, 2004, 108, 4853–4858.27 H. Shalit, A. Libman and D. Pappo, J. Am. Chem. Soc., 2017,139, 13404–13413.28 T. Horibe, S. Ohmura and K. Ishihara, J. Am. Chem. Soc.,2019, 141, 1877–1881.29 H. Albright, P. S. Riehl, C. C. McAtee, J. P. Reid, J. R. Ludwig,L. A. Karp, P. M. Zimmerman, M. S. Sigman andC. S. Schindler, J. Am. Chem. Soc., 2019, 141, 1690–1700.30 J. Bur ́es, Angew. Chem., Int. Ed., 2016, 55, 2028–2031; Angew.Chem., 2016, 128, 2068–2071.
no errors
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.22.481551: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Deer sample collection and study area: Between November 1 and December 31, 2021, adult and yearling free-ranging WTD were sampled as part of the Ontario Ministry of Northern Development, Mines, Natural Resources and Forestry’s (NDMNRF) annual Chronic Wasting Disease (CWD) surveillance program.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Phylogenetic analyses were performed using CFIA-NCFAD/scovtree Nextflow workflow (v1.6.0) (https://github.com/CFIA-NCFAD/scovtree/) with the consensus sequences contextualised with closely related sequences identified by UShER and randomly sampled representative sequences from major WHO SARS-CoV-2 clades from GISAID (Shu & McCauley, 2017) (downloaded 2022-02-10).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells (ATCC) were cultured in Dulbecco’s Minimum Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Sigma), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.3 mg/mL L-glutamine (Invitrogen) and maintained at 37°C, 5% CO2 and 100% relative humidity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All constructs were cloned in pCAGGS and verified by Sanger sequencing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T seeded in 10-cm dishes were co-transfected with lentiviral packaging plasmid psPAX2 (gift from Didier Trono, addgene #12260)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">lentiviral vector pLentipuro3/TO/V5-GW/EGFP-Firefly Luciferase (gift from Ethan Abela, addgene#119816), and plasmid encoding the indicated S construct at a 5:5:1 ratio using jetPRIME transfection reagent according to the manufacturer protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLentipuro3/TO/V5-GW/EGFP-Firefly</div><div>suggested: RRID:Addgene_119816)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reverse-transcription polymerase chain reaction (RT-PCR) was performed using the Luna Universal Probe One-Step RT-qPCR kit (New England BioLabs; https://www.neb.ca).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>New England BioLabs</div><div>suggested: (New England Biolabs, RRID:SCR_013517)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantstudio 3 software (Thermo Fisher Scientific; https://www.thermofisher.com) was used to determine the cycle threshold (Ct).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Scientific</div><div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Paired-end (2×150 bp) sequencing was performed on a MiniSeq with a 300–cycle reagent kit (Illumina, USA) with a negative control library with no input SARS-CoV-2 RNA extract.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MiniSeq</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">WGS performed at CFIA used extracted nucleic acid quantified using the Qubit™ RNA High Sensitivity (HS) Assay Kit on a Qubit™ Flex Fluorometer (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>WGS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(Di Tommaso et al., 2017; Ewels et al., 2020; Patel et al., 2022) which ran: FASTQC (v0.11.9) (Andrews, 2010) read-level quality control, fastp (v0.20.1) (Chen et al., 2018) quality filtering and adapter trimming, Bowtie2 (v2.4.2) (Langmead & Salzberg, 2012) read mapping to Wuhan-Hu-1 (MN908947.3) (Wu et al., 2020) SARS-CoV-2 reference, Mosdepth (v0.3.1)(Pedersen & Quinlan, 2018)/Samtools (v.1.12) (Li et al., 2009) read mapping statistics calculation, iVar (v1.3.1) (Grubaugh et al., 2019) ARTIC V4 primer trimming, variant calling, and consensus generation; SnpEff (v5.0) (Cingolani, Platts, et al., 2012)/SnpSift (v4.3t) (Cingolani, Patel, et al., 2012) for variant effect prediction and annotation; and Pangolin (v3.1.20) (O’Toole et al., 2021) with PangoLEARN (2022-01-05), Scorpio (v0.3.16) (Colquhoun & Jackson, 2021), and Constellations (v.0.1.1) was used for PANGO lineage (Rambaut et al., 2020) assignment. iVar primer trimmed soft-clipped read alignments were converted to hard-clipped alignments with fgbio ClipBam (http://fulcrumgenomics.github.io/fgbio/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FASTQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div><div style="margin-bottom:8px"><div>Bowtie2</div><div>suggested: (Bowtie 2, RRID:SCR_016368)</div></div><div style="margin-bottom:8px"><div>SnpEff</div><div>suggested: (SnpEff, RRID:SCR_005191)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This workflow generated a multiple sequence alignment using Nextalign CLI (v1.10.1) (Aksamentov et al., 2021) and inferred a maximum-likelihood (ML) phylogeny using IQ-TREE (v2.2.0_beta) (Minh et al., 2020) using the GTR model for visualisation with Phylocanvas (Abudahab et al., 2021) via shiptv (v0.4.1) (https://github.com/CFIA-NCFAD/shiptv) and ggtree (Yu et al., 2017).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IQ-TREE</div><div>suggested: (IQ-TREE, RRID:SCR_017254)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Multiple sequence alignment of this subset of sequences was performed with MAFFT (v7.490)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additional figures were generated and annotated using BioRender (BioRender, 2022) and Inkscape (Inkscape Project, 2020)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization half-maximal inhibitory dilution (ID50) was calculated using Graphpad Prism and represents the plasma dilution that inhibits 50% of pseudotype transduction in 293T-ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, EHDV 6 isolate OV208 (NCBI MG886400 - MG886409), and Elk circovirus Banff/2019 (NCBI MN585201) (Fisher et al., 2020) were imported into Geneious (v.9.1.8) (Kearse et al., 2012).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Geneious</div><div>suggested: (Geneious, RRID:SCR_010519)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
It should be noted there were some limitations in genome quality and coverage that may have resulted in failure to detect additional mutations that were present. All Ontario WTD clade samples (including the associated human case) had missing terminal domains and contained internal regions with no or low coverage when sequenced using the ARTIC v4 amplicon scheme. This is a widespread issue that may explain the rarity of the 3’ proximal ORF10:L37F in GISAID. Significantly in our samples this meant there was no or <10x coverage in all 5 WTD sequences from ∼27000-27177 (dropout of ARTICv4 amplicons 90-91) which includes regions of the M gene. However, by combining the ARTIC v4 sequencing with additional sequencing using probe-based enrichment we were able to compensate for this dropout and generate high coverage and completeness (<100 positions with no coverage in all WTD and <100 positions with <10X coverage in 3/5 WTD genomes; see Table S3). The neutral non-synonymous to synonymous mutation ratio (dN/dS ∼ 1) and evenly distributed mutations in the WTD lineage contrasts with the signatures of strong selection in the equivalently divergent Omicron VOC (dN/dS ∼6 and accumulation of spike mutations). In combination with the most recent common ancestor being phylogenetically distant and dating from 2020, we infer that the WTD lineage likely diverged in 2020 and has been maintained in wildlife under relatively neutral selection since that time. It is possible that the absence of pre-...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.24.481899: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To quantify ACE2 expression levels, HEK-293T cells expressing high, low or no ACE2 were resuspended in FACS buffer (PBS+2% BSA) and incubated for 1 h with 1:500 rabbit anti-ACE2 antibody (Abcam ab272500).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: (LSBio (LifeSpan Cat# LS-C349-500, RRID:AB_1271970)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Entry titers of spike-pseudotyped lentiviral particles were determined on HEK-293T cell lines expressing high levels of human ACE2 (BEI Resources NR-52511) (34) and low levels of human ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For titering, ACE2-high and ACE2-low cells were seeded at 1.2e4 cells per well in poly-L-lysine-coated 96-well plates (Greiner 655930) in 50 uL D10 media (plus 1 μg/mL doxycycline for the ACE2-low cell line).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-low</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Library generation: Site-saturation mutagenesis libraries spanning all 201 positions in variant RBDs were created as described for the Beta library by Greaney et al. (14).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Beta</div><div>suggested: (BETA, RRID:SCR_007556)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw CCS reads are available on the NCBI Sequence Read Archive, BioProject PRJNA770094</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI Sequence Read Archive</div><div>suggested: (NCBI Sequence Read Archive (SRA, RRID:SCR_004891)</div></div><div style="margin-bottom:8px"><div>BioProject</div><div>suggested: (NCBI BioProject, RRID:SCR_004801)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nucleotide mutations annotated on the tree were converted to amino acid mutations using matUtils (version 0.4.8) (20), using the Wuhan-Hu-1 genome (NCBI RefSeq NC_045512.2) as a reference.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>matUtils</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RefSeq</div><div>suggested: (RefSeq, RRID:SCR_003496)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture supernatant was collected five days after transfection and supplemented to a final concentration of 80 mM Tris-HCl pH 8.0, 100 mM NaCl, and then incubated with BioLock (IBA GmbH) solution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioLock</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Several subsequent rounds of model building and refinement were performed using Coot (38), ISOLDE (39), Refmac5 (40), Phenix (41) and MOE (https://www.chemcomp.com), to arrive at a final model of the quaternary complex.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following force fields were used: Amber ff14SB for the protein (44), GLYCAM_06j-1 for glycans (45), TIP3P for water (46) and for the neutralizing 0.15 M of NaCl Joung & Cheatham parameters (47) were used, and the Li parameters (48) for Zn and divalent ions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Amber</div><div>suggested: (AMBER, RRID:SCR_016151)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figures were generated using matplotlib.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>matplotlib</div><div>suggested: (MatPlotLib, RRID:SCR_008624)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structures were aligned in PyMol to minimize RBD structure RMSD.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.24.481778: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: , location AMC, in the Netherlands and approved by the local ethical committee of the AMC (NL 73281.018.20).<br>Consent: All individuals included in this study gave written informed consent before participating.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All S constructs were verified by Sanger sequencing and the protein was subsequently produced in human embryonic kidney (HEK) 293F cells (Thermo Fisher Scientific) and purified as previously described (4, 8).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: RRID:CVCL_6642)</div></div><div style="margin-bottom:8px"><div>293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudo-viruses were produced by co-transfecting the SARS-CoV-2-S expression plasmid with the pHIV-1NL43 ΔEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268), as previously described (13).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Shortly, HEK293T/ACE2 cells, kindly provided by Dr. Paul Bieniasz (13), were seeded at a density of 20,000 cells/well in a 96-well plate coated with 50 μg/mL poly-L-lysine one day prior to the start of the neutralization assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The genes were ordered as gBlock gene fragments (Integrated DNA Technologies) and cloned Pst I/Not I in a pPPI4 expression vector containing a hexahistidine (his) tag with Gibson Assembly (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pPPI4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudo-virus construction: The WT, Alpha, Beta and Gamma pseudovirus S constructs were ordered as gBlock gene fragments (Integrated DNA Technologies) and cloned using SacI and Apal in the pCR3 SARS-CoV-2-SΔ19 expression plasmid (13) using Gibson Assembly (ThermoFisher).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCR3 SARS-CoV-2-SΔ19</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudo-viruses were produced by co-transfecting the SARS-CoV-2-S expression plasmid with the pHIV-1NL43 ΔEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268), as previously described (13).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHIV-1NL43 ΔEnv-NanoLuc</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The LC was directly coupled to an Orbitrap Exploris 480 mass spectrometer with BioPharma option (Thermo Fisher Scientific, Bremen, Germany).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioPharma</div><div>suggested: (TransCelerate BioPharma, RRID:SCR_003728)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis: The retention times and masses of each of the Fab molecules were retrieved from the generated RAW files using BioPharmaFinder 3.2 (Thermo Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioPharmaFinder</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Further data analysis was performed using in-house scripts using Python 3.8.3 (with libraries: Pandas 1.0.5, Numpy 1.18.5, Scipy 1.5.0, matplotlib 3.2.2 and seaborn 0.11.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div><div style="margin-bottom:8px"><div>Numpy</div><div>suggested: (NumPy, RRID:SCR_008633)</div></div><div style="margin-bottom:8px"><div>Scipy</div><div>suggested: (SciPy, RRID:SCR_008058)</div></div><div style="margin-bottom:8px"><div>matplotlib</div><div>suggested: (MatPlotLib, RRID:SCR_008624)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The inhibitory concentration (IC50) and neutralization titers (ID50) were determined as the NAb concentration and plasmadilution at which infectivity was inhibited by 50%, respectively, using a non-linear regression curve fit (GraphPad Prism software version 8.3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.16.22271053: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: No medical ethical approval was needed for this study as evaluated by the Medical Research Ethics Committee of University Medical Centre Utrecht; a declaration of non-compliance with the scope of the Dutch Medical Research Involving Human Subject Act was obtained.<br>Consent: Oral informed consent was obtained from patients and/or from an authorised legal representative or family member.<br>Field Sample Permit: Collection of surface samples: High- and low-touch surface samples were collected using dry surface swabs (Medical Wire Dry Swabs, MW730, Corsham, UK) as described previously 19,20.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NIOSH BC 251, kindly provided to us by William G.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NIOSH BC 251</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Culturing was performed on Vero cells, clone 118 at 37°C, and 5% CO2 and was completed after 7 days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An airflow of 12.5 L/min through the BioSampler was established by connecting the outlet of the sampler to an inhouse designed pump unit.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioSampler</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">cDNA was synthesized using LunaScript® RT SuperMix Kit (New Engeland Biolabs, USA) and library preparation was performed using EasySeqTM RC-PCR SARS-CoV-2 Whole Genome Sequencing kit (Nimagen, The Netherlands) according to manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>New Engeland Biolabs</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genomes with >90% genome coverage were uploaded to GISAID (https://www.gisaid.org/)40, with accession IDs EPI_ISL_3047866, EPI_ISL_3047867, EPI_ISL_2259188, EPI_ISL_2259136 and EPI_ISL_2259122 and phylogenetic and analysis performed using MAFFT alignment software (Galaxy Version 7.221.3,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div><div style="margin-bottom:8px"><div>Galaxy</div><div>suggested: (Galaxy, RRID:SCR_006281)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FFT-NS method) 41 and phylogenomic software IQ-TREE 2.1.3 (Galaxy Version 1.5.5.3)42–44, using ModelFinder (with best predicted method GTR+F+I), ultrafast bootstrapping (1000 replicates) and maximum likelihood tree reconstruction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IQ-TREE</div><div>suggested: (IQ-TREE, RRID:SCR_017254)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
giove.isti.cnr.it giove.isti.cnr.it
-
He thought b a c k o f h i s f a m i l y w i t h e m o t i o n a n d l o v e . I f i t w a s possible, he felt that he must go away even more strongly than his sister. He remained in this state of empty and peaceful rumination until he heard the clock tower strike three in the morning. He watched as it slowly began to get light everywhere outside the window too. Then, without his willing it, his head sank down completely, and his last breath flowed weakly from his nostrils.
love
-
After that, the three of them left the flat together, which was something they had not done for months, and took the tram out to the open country outside the town. They had the tram, filled with warm sunshine, all to themselves. Leant back comfortably on their seats, they discussed their prospects and found that on closer examination they were not at all bad - until then they had never asked each other about their work but all three h a d j o b s w h i c h w e r e v e r y g o o d a n d h e l d p a r t i c u l a r l y good promise for the future. The greatest improvement for the time being, of course, would be achieved quite easily by moving house; what they needed now was a flat that was smaller and cheaper than the current one which had been chosen by Gregor, one that was in a better location and, most of all, more practical. All the time, Grete was becoming livelier. With all the worry they had been having of late her cheeks had become pale, but, while they were talking, Mr. and Mrs. Samsa were struck, almost simultaneously, with the thought of how their daughter was blossoming into a well built and beautiful young lady. They became quieter.
change
-
- Feb 2022
-
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov
-
Kok, K.-H., Wong, S.-C., Chan, W.-M., Lei, W., Chu, A. W.-H., Ip, J. D., Lee, L.-K., Wong, I. T.-F., Lo, H. W.-H., Cheng, V. C.-C., Ho, A. Y.-M., Lam, B. H.-S., Tse, H., Lung, D., Ng, K. H.-L., Au, A. K.-W., Siu, G. K.-H., & Yuen, K.-Y. (2022). Cocirculation of two SARS-CoV-2 variant strains within imported pet hamsters in Hong Kong. Emerging Microbes & Infections, 1–39. https://doi.org/10.1080/22221751.2022.2040922
-
-
www.medrxiv.org www.medrxiv.org
-
Stegger, M., Edslev, S. M., Sieber, R. N., Ingham, A. C., Ng, K. L., Tang, M.-H. E., Alexandersen, S., Fonager, J., Legarth, R., Utko, M., Wilkowski, B., Gunalan, V., Bennedbæk, M., Byberg-Grauholm, J., Møller, C. H., Christiansen, L. E., Svarrer, C. W., Ellegaard, K., Baig, S., … Rasmussen, M. (2022). Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection (p. 2022.02.19.22271112). medRxiv. https://doi.org/10.1101/2022.02.19.22271112
-
-
sites.google.com sites.google.com
-
Managed to save just a little bit of money
This suggests that the speaker is not looking for a more grand life as she only saves just a ‘little bit of money’ to get out of her situation.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.23.481620: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mice and mouse procedures: Female C57Bl/6 mice (6–8 weeks of age) were purchased from the Jackson Laboratories (Bar Harbor, ME).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression of ACE-2: Cells diluted to 1 × 106 per microtiter plate well were incubated for 45 min at room temperature with a 1 in 100 dilution of a mouse IgG2a antibody to human/hamster ACE-2 (clone 171606 R&D Systems, Minneapolis, MN)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>mouse IgG2a</div><div>suggested: (Millipore Cat# 171606-100UG, RRID:AB_10690063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In parallel the membrane was probed with a mouse monoclonal IgG antibody to ß-actin (Sc-47778, Santa Cruz Biotechnology, Dallas, TX) as a loading control for 1 hr at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ß-actin</div><div>suggested: (RayBiotech Cat# 168-10656, RRID:AB_2885189)</div></div><div style="margin-bottom:8px"><div>Sc-47778</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The loading control antibody was probed with HRP-conjugated goat anti-mouse secondary IgG (SAB3701047, Sigma, St. Louis, MO) for 1 hr at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse secondary IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An alkaline-phosphate-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich, St Louis, MO) diluted to 1:1500 in 3%BAS-PBS was added at 60 μl/well for 1 hr at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>An alkaline-phosphate-conjugated goat anti-mouse IgG antibody</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE binding inhibition assay: Sera were tested for inhibition of ACE binding to the RBD of S by the Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit from Acro Biosystems (Newark, DE) following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A positive standard with a known concentration provided by the kit was used to extrapolated anti-S antibody concentrations in μg in the mouse sera.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: HEK 293 cells and VeroE6 cells were grown in Dulbecco’s Modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics in a 5% CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">66 BHK-21/WI-2 cells were plated into a 6 well plate, the next day cells were first transfected with 1 μg/well of the paT7 plasmids using polyethyleneimine (PEI) (Polysciences, Inc. Warrington, PA); 2 hours later, the cells were treated with a predetermined optimal amount of ΔG-GFP (G*ΔG-GFP) rVSV.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice and mouse procedures: Female C57Bl/6 mice (6–8 weeks of age) were purchased from the Jackson Laboratories (Bar Harbor, ME).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl/6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">66 BHK-21/WI-2 cells were plated into a 6 well plate, the next day cells were first transfected with 1 μg/well of the paT7 plasmids using polyethyleneimine (PEI) (Polysciences, Inc. Warrington, PA); 2 hours later, the cells were treated with a predetermined optimal amount of ΔG-GFP (G*ΔG-GFP) rVSV.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>paT7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VNA assay with VSV-S: VSV-S vectors was initially titrated on BHK-21/WI-2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VSV-S</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
VNAs to the vaccine vectors will likely pose limitations to repeated booster immunization using the same Ad vector by not only reducing, but also, as we reported previously, modifying transgene product-specific immune responses.56 To avoid interference by Ad vector-specific VNAs, we developed a vaccine regimen composed of two serologically distinct E1-deleted AdC vectors. We selected AdC vectors as pre-existing VNAs to these chimpanzee viruses are rare in humans and individuals who have VNAs in general have low titers.44 We developed two serologically distinct AdC vectors to prevent blunting of booster immunizations by VNAs induced by the AdC vector used for priming. The two AdC vectors express the S protein of an isolate from Sweden, which is identical to that of the original Wuhan virus. We did not codon-optimize the S sequence, nor did we incorporate the K986P and V987P stabilizing mutations into the S2 sequence which both were used for the S gene expressed by the RNA vaccines,57 mutations of the S1/S2 furin cleavage site which, in addition to the stabilizing mutations, were incorporated into the S gene carried by the J&J COVID-19 vaccine,58 or AstraZeneca’s engineered leader sequence.59 Phase III trial results of the different Ad vector vaccines fail to indicate that any of these modifications have a major impact on vaccine efficacy. In our study, as expected, the magnitude of S protein-specific antibody responses after a single immunization increased with higher vaccine ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We would like to thank all the reviewers for their time and for their positive and constructive review of our study. We are happy that they all regard this as a highly significant piece of work. We have addressed some of their suggestions in our updated preprint and indicate below where we are planning further revisions.
Reply to Reviewer 1 Point 1
The reviewer pointed out a possibility that the Golgi polarisation leads to local/centre-most regional E-cadherin junction “maturation”, then contribute to AMIS seeding. To address this suggestion, we did fluorescence recovery after photobleaching (FRAP) using a mESC line that expresses E-cadherin-GFP in the updated manuscript. We compared the recovery speed and rate in the centre-most region and side regions to discuss whether E-cadherin junctions have different stability at these regions. What we found is that though the E-cadherin and E-cadherin-GFP protein level is at the same level at the two regions in mESC doublets (Figure S3), the mobile fraction of E-cadherin-GFP is lower in the centre-most region than the side regions (Figure 3 I, J). This implies that E-cadherin junctions in the centre-most region are more stable. We have included corresponding description of this data in Results, Methods and Discussion. We will also include equivalent data from non-mitomycin c treated control cells in the final manuscript.
Still, we do not know whether the more stable E-cadherin junctions were due to the Golgi polarization, but we have included the possibility of Golgi polarisation leads to local E-cadherin maturation in our Discussion in the transferred manuscript as follows:
“In addition, a recent study of chick neural tube polarisation (where N-Cadherin is the dominant Cadherin) has demonstrated that the interaction of β-catenin with pro-N-cadherin in the Golgi apparatus is necessary for the maturation of N-Cadherin, which is in turn important for apicobasal polarity establishment (Herrera et al, 2021). This provides the possibility that the polarised Golgi apparatus that we observe in the mESC clusters might be directionally delivering mature E-cadherin to the central-most region of cell-cell contact.”
Reply to Reviewer 1 Point 2
The reviewer suggests it would be interesting to know whether there is a role for the proteins JAM-1 or Nectin in AMIS formation and in polarising the Golgi and centrosomes towards the cell-cell contact. Like E-Cadherin, these are transmembrane junctional proteins that are present at the initiation of spot adhesions in epithelial 2D monolayers and are known to be part of a complex network of interactions between PAR-complex, junctional molecules, MAGUK scaffolding proteins and the actin cytoskeleton. Whilst we don’t propose to untangle this network here, we agree that it would be interesting to know more about the potential role of JAM-1 and Nectin in initiating polarity in mESC 3D cultures. However, it is important to note that, regardless of whether JAM-1 and Nectin also play a role in polarisation and AMIS formation, our results already demonstrate that E-cadherin-based adhesions are sufficient to initiate AMIS localisation. For example, our results from figure 4C-E demonstrate that, in a reductionist system of a single cell plated on E-Cadherin covered glass, a centrally located AMIS still forms. Precisely unravelling the mechanisms by which this happens would be better for a future study (which we have now stated in the Discussion).
Nevertheless, we now have new FRAP data (Figure 3I and J), which demonstrates that E-Cadherin is relatively more stable at the central-most point of contact between two adhering cells. This suggests that E-Cadherin is more stably bound via its downstream partners to the internal actin cytoskeleton at this point and may provide at least a partial explanation for why AMIS localisation occurs precisely at this region. We therefore suggest that the most relevant information to our study would be to determine whether either JAM or Nectin proteins are specifically localised at the AMIS, alongside PAR-3 and ZO-1, and might therefore be somehow enabling this stabilisation of E-Cadherin. We therefore plan to carry out IHC stains for JAM-A (new name for JAM-1), which has been found to be present in the mouse inner cell mass, to determine where it is localised within the mESC cell clusters with/without cell division and in WT/Cdh1 KO cells. We will update the supplementary results and discussion accordingly in the final manuscript.
Depending on these results, we might also try to knock down the function of JAM-A, using siRNA. If successful knock down were achieved, we would carry out FRAP to determine whether E-cadherin junctional stability had been altered and would also stain for AMIS markers such as PAR-3 and determine whether Golgi and centrosomes were polarised. However, it is important to note that, although we were able to achieve E-cadherin RNAi to a certain degree, it is not always possible to achieve sufficient knock down of protein by the 24-hour AMIS timepoint. Since the results of these experiments would not alter the impact of our pre-existing data, we do not propose to create new knock out cell lines in the current study. Also, possible redundancy between different paralogs may affect the interpretation of this experiment so we would only include these results if they allowed for clear interpretation.
A previous study (Gao L ,et al. Development. 2017) has already shown that knocking out Afadin (which would therefore disable Nectin junctions) in MDCK cell 3D cultures did not affect initial AMIS formation or localisation, although later cell division orientation and therefore lumen positioning was affected. Afadin was also not localised to the AMIS. Therefore, it is less likely that Nectin is involved in AMIS localisation and while we will stain for its localisation by IHC, we don’t propose to try to knock down its function.
Reply to Reviewer 2 Point 1
The reviewer pointed out using a different mitosis blocker beside Mitomycin C. a) In the updated manuscript, we included one additional drug treatment: Aphidicolin. The results showed the AMIS could form in the centre of cell-cell contacts in Aphidicolin treated, division-blocked cells. AMIS (PAR3, ZO1) and the Golgi network was also polarised towards this point (Figure S1 G-I). In the final manuscript, we will include a full data set with N=3 independent experiments. Though the same as Mitomycin C, Aphidicolin is a DNA replication blocker, it confirmed that the AMIS formation upon treatments is not a Mitomycin-only artefact. b) As the reviewer suggested to block mitosis at the M phase, we are testing using microtubule polymerization inhibitors, Nocodazole and Taxol and will include these results if appropriate. However, these treatments will also affect the cytoskeleton, significantly affecting the cell shape and potentially interrupting the cell-cell contact interface. Therefore, it may not be possible to include these experiments.
Reply to Reviewer 2 Point 2
The reviewer suggested to include more examples of movies showing 2 and 4 cell cluster formation in division blocked conditions. We will be happy to provide more examples of the movies included in Figure 2 and Movie 2 in the final submission. The puncta in submitted Movie 2 was not as clear as the in Figure 2D as the reviewer pointed out. This was largely due to the reduce-sized movie in the original submission. We will provide full-resolution movies in the final submission. We do often see the ‘perfect’ 4-cell shape in division-blocked cells (e.g. the last frame of movie 2, shown at timepoint 19:00 in figure 2D). The shape of the clusters appears largely dependent on how many cells fuse together.
Reply to Reviewer 2 Points 3 & 5 and Reviewer 3 Point 2
We appreciate the comments from the reviewers regarding qualifying some of the discussion of our results.
Reviewer 2 points out that E-cadherin is not providing a ‘Symmetry breaking’ step, since cells are eventually able to polarise in the absence of E-cadherin (even though they can’t make an AMIS). We have therefore modified our discussion of this point to read: “Our results therefore suggest that Cadherin-mediated cell-cell adhesion may provide the spatial cue required for AMIS localisation during de novo polarisation.”. The last paragraph of the manuscript now reads: “In summary, our work suggests that Cadherin-mediated cell-cell adhesion is necessary for localising the AMIS during de novo polarisation of epithelial tubes and cavities.”
Reviewer 3 points out that the E-Cadherin molecule by itself is not sufficient to recruit the AMIS proteins to the centre-most region of the cell-cell contacts since E-cadherin is localised all along the cell-cell contact. We have now included a FRAP analysis demonstrating that E-cadherin is more stable in the centre-most region of cell-cell contacts (Figure 3I,J), which supports the role of E-Cadherin in directing AMIS localisation to this centre-most region. Nevertheless, we accept the reviewer’s point that we still do not know the downstream mechanism by which the AMIS is precisely localised to the central region of cell-cell contacts, and we have extended our discussion of this point in the updated manuscript. To clarity the language, we have also altered our results heading and other references to this point to read: “E-Cadherin adhesions are sufficient to initiate AMIS localisation, independent of ECM signalling and cell division”. We believe our experiments with two methods support this claim that the formation of E-cadherin-based adhesions without cell divisions and ECM signals are sufficient to initiate AMIS localisation; in particular Figure 4C-E, in which a centrally located AMIS formed even in a reductionist system of only 1 cell plated on E-cadherin covered glass.
Reply to Reviewer 2 Point 4
The reviewer reasoned that the WT and Cdh1 KO mESC were from different genetic backgrounds. The WT (ES-E14) mESCs were generated from 129P2/Ola mice and the Cdh1 KO mESCs were generated from 129S6/SvEvTacArc mice. To confirm the results acquired based on the two cells lines, we are doing two approaches: 1) As the reviewer suggested, we are using siRNA knock-down of E-cadherin in the Wild-type mESCs (ES-E14) to confirm the results we had of the AMIS absence in the E-cadherin knock-out mESC cultures. As Figure S2C,D now shows, the concentrated PAR3 between two mESCs was largely reduced after E-cadherin knock-down. We will also include Mitomycin-treated conditions in this experiment for the final publication. 2) As an alternative approach, not dependent on RNAi functionality, we have acquired a 129S6/SvEvTacArc background mESC (the W4 line) as the wild-type mESC line that has the same background as the Cdh1 KO mESC line. We are using this line to perform the control experiments of Figure 3A-C to confirm the previous results, which so far are comparable in both the ES-14 and W4 mESC cell lines. Our preliminary data below show the same results as we had with the ES-E14 cells in the current Figure 3A. We will finish the full data set of N = 3 experiments and replace the current Figure 3A-C, S2A data with that from the W4 mESC cell line. In the meanwhile, we have labelled the type of wide type mESC used for each experiment in the manuscript.
Reply to Reviewer 3 Point 1
The reviewer pointed out we should include three independent experiments for our data in Figure 4E. We agree with the reviewer. We are very happy to do the suggested experiments and data analysis and will be able to provide the data of N=3 independent experiments in the final manuscript.
Reply to Review 3 Point 3
We agree with the reviewer. Our current data set of live imaging at day 3 are used to confirm the idea from the fixed images that a wrapping process does happen for lumenogenesis during the Cdh1 KO cyst formation. The current dataset could not exclude the possibility that the hollowing might co-exist. The reviewer therefore suggests including a live movie depicting early stages (before 78:00) of E-Cadherin knock-out cluster development. We did try to collect this data before we first submitted the manuscript but encountered significant technical problems due to the high sensitivity of early stage Cdh1 KO cells to phototoxicity. This meant that we could not image with less than one hour interval nor over longer than 24 hour and were therefore unable to analyse how the cell clusters behave before forming the cup-shaped cavity. We will attempt these experiments again (e.g. imaging from 12-24 hours and 24-36 hours). However, there is a high likelihood that the experiments will not be technically possible, which is why we list them in section 4 of our review plan. Instead, we include the following sentence in our discussion: “We were unable to live-image earlier stages of Cdh1 KO cluster development due to the sensitivity of these cells to phototoxicity so we can’t exclude the possibility that hollowing lumenogenesis occurs in parallel, although our IHC analysis does not indicate that this is the case.”
Reply to reviewers’ minor points
We have revised our texts, made the nomenclature of protein PAR3 consistent, and included the information of antibody suppliers, as the reviewers pointed out. Specific response to Reviewer 2; in p2 and p7, the texts were referring to zebrafish studies, where PAR3 is referred to as Pard3. We have marked it with “Pard3 (PAR-3)” now. We have increased the size of images in figure 5B and inverted the colour to make it more visible. Since this made the figure too big, we moved the ZO1 images to Figure S5A. We will provide a co-staining of mCherry (to label mCherry-PAR6B), Phalloidin and PAR-3 in a more updated manuscript to replace Figure 2A.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.19.481110: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Mice experiments were reviewed and approved by the Research Ethics Review Committee of Shanghai Public Health Clinical Center.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mouse vaccination: Female C57BL/6J mice, 6-8-week-old, were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and housed in the SPF animal facility of Shanghai Public Health Clinical Center.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, 100μl of a HRP labeled goat anti-mouse IgG antibody (Cat# 115-035-003, Jackson Immuno Research, USA) diluted in 1×PBS containing 5% milk were added to each well and incubated for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 115-035-003, RRID:AB_10015289)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, Vero cells were added into each well (2×104 cells/well) and the plates were incubated at 37°C in a humidified incubator with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: RRID:CVCL_ZW93)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse vaccination: Female C57BL/6J mice, 6-8-week-old, were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and housed in the SPF animal facility of Shanghai Public Health Clinical Center.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE/Cyanine7-labeled anti-mouse CD3, Cat# 100220, BioLegend;</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioLegend</div><div>suggested: (BioLegend, RRID:SCR_001134)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data were analyzed using the FlowJo 10 software (BD Biosciences, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc., La Jolla, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
We note two major limitations in our study. First, we were not able to conduct a live-virus challenge experiment, therefore, we do not know whether the observed improvements of humoral and cellular immunities can be translated into superior protection. Second, the results were generated using a mouse model, which might not completely mimic the characteristics of human immune responses. The Omicron variant challenge studies in animals and vaccination in humans will be required for corroboration.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.21.481223: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: This study protocol was approved by the Institutional Review Board of UCSD’s Human Research Protections Program (181180).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The foreground was a bed file of significant IDR peaks; the background was randomly defined peaks within the same annotated region as the foreground peaks.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: Cell culture and cell line generation: BEAS-2B, HEK293T and Vero E6 cells were purchased from the American Type Culture Collection and were not further authenticated.<br>Contamination: Cells were routinely tested for mycoplasma contamination with a MycoAlert mycoplasma test kit (Lonza) and were found negative for mycoplasma.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The remaining lysates were immunoprecipitated using 15 µl anti-Strep or 10 µl anti-FLAG antibody (depending on the epitope tag of the construct; Supplementary Table 4) on Sheep Anti-Mouse IgG Dynabeads M-280 (ThermoFisher) overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-FLAG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-Mouse IgG</div><div>suggested: (Thermo Fisher Scientific Cat# 11201D, RRID:AB_2783640)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Negative control samples are wild type (WT) BEAS-2B cells, and performed using both anti-Strep and anti-FLAG antibodies (separately).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Strep</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were fixed with 4% paraformaldehyde for 30 min, which inactivates the virus, before transferring from BSL3 to BSL2, and proceeding with immunofluorescence staining using anti-Nucleocapsid antibody (40143-R019, Sino Biological).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BSL2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Nucleocapsid</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, cells were incubated with primary antibodies (Supplementary Table 4) at 1:250-2000 dilutions in blocking buffer for 16 h at 4 °C, washed with PBS+0.01% Triton X-100 three times for 5 min each at room temperature, and then incubated with secondary antibody (goat anti-rabbit secondary IgG (H+L)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture and cell line generation: BEAS-2B, HEK293T and Vero E6 cells were purchased from the American Type Culture Collection and were not further authenticated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The ACE2-overexpressing A549 cell line (A549-ACE2) was clonally generated and a gift from Benjamin tenOever52.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BEAS-2B cells were cultured on Matrigel (Corning) coated plates and maintained in the PneumaCult-Ex Plus Medium (Stem Cell Technologies), supplemented with 33 µg/ml hydrocortisone (Stem Cell Technologies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BEAS-2B</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T, Vero E6 and A549-ACE2 cells were cultured in DMEM (ThermoFisher) supplemented with 10% FBS (ThermoFisher) and passaged every three days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 virus infection: SARS-CoV-2 isolates USA-WA1/2020 (BEI Resources, #NR-52281), hCoV-19/USA/CA_UCSD_5574/2020 (lineage B.1.1.7) and hCoV-19/South Africa/KRISP-K005325/2020 (lineage B.1.351 BEI Resources NR-54009) were propagated and infectious units quantified by plaque assay using Vero E6 cells for the WA1 variant, and Vero-TMPRSS2 cells for variants B.1.1.7 and B.1.351.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture and cell line generation: BEAS-2B, HEK293T and Vero E6 cells were purchased from the American Type Culture Collection and were not further authenticated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BEAS-2B</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid construction: 2xStrep-tagged plasmids in a pLVX vector expressing SARS-CoV-2 proteins were a gift from Nevan Krogan1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLVX</div><div>suggested: RRID:Addgene_174088)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cloning into the pcDNA3.4 was performed using FastDigest restriction enzymes EcoRI and BshT1 (Invitrogen) and Gibson assembly (NEB).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: RRID:Addgene_131198)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 ORFs were amplified by PCR (KAPA HiFi HotStart ReadyMix, Roche) from the 2xStrep-tagged or 3xFLAG-tagged plasmids with oligonucleotide primers containing attB recombination sites and recombined into pDONR221 using BP clonase II (ThermoFisher) (Supplementary Table 6).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pDONR221</div><div>suggested: RRID:Addgene_63743)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This study protocol was approved by the Institutional Review Board of UCSD’s Human Research Protections Program (181180).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Human Research Protections Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For reads mapped to the SARS-CoV-2 genome, bedgraph densities were generated using SAM tools v1.9 to obtain read densities at each nucleotide position.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAM</div><div>suggested: (SAM, RRID:SCR_010951)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For reads mapped to the African Green Monkey genome, peaks were called on the usable reads by CLIPper54 and assigned to gene annotations in Ensembl ChlSab1.1 release 102 and Sars_cov_2 ASM985889 v3.101 were used to annotate peaks mapped to the African Green Monkey and SARS-CoV-2 genome.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ensembl</div><div>suggested: (Ensembl, RRID:SCR_002344)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene Ontology analysis of eCLIP target genes was performed using ENRICHR (https://maayanlab.cloud/Enrichr/https://maayanlab.cloud/Enrichr/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ENRICHR</div><div>suggested: (Enrichr, RRID:SCR_001575)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cluster maps were visualized using Cytoscape version 3.8.1</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GENCODE v19 gene annotations and featureCounts (v.1.5.30) were used to create read count matrices.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>featureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequencing reads are first processed as RNA-seq libraries, where RNA-seq reads were trimmed of adaptor sequences using cutadapt (v1.4.0) and mapped to repetitive elements (RepBase v18.04) using STAR (v2.4.0i).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Multiple sequence alignment was performed using MAFFT v7.453 and default parameters, and sequence alignment was visualized using Jalview (version 1.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div><div style="margin-bottom:8px"><div>Jalview</div><div>suggested: (Jalview, RRID:SCR_006459)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">De novo motif analysis: HOMER was used to identify de novo motifs using reads from IDR peaks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HOMER</div><div>suggested: (HOMER, RRID:SCR_010881)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The length of each region within the metagene was then scaled to 8%, 62% and 30%, corresponding to the average length of regions from the most highly expressed transcripts in ENCODE HepG2 RNA-seq control datasets.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ENCODE</div><div>suggested: (Encode, RRID:SCR_015482)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Interval features such as introns and exons were extracted from the Gencode v19 coordinates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gencode</div><div>suggested: (GENCODE, RRID:SCR_014966)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were collected via Zeiss ZEN software and converted to tiff for downstream analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zeiss ZEN</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were analyzed using a custom-developed pipeline in CellProfiler (v.3.1.09).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CellProfiler</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 64. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.21.481324: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Thomas Jefferson University (TJU) is an AAALAC-accredited institution, and the IACUC Committee approved all animal work of TJU.<br>IACUC: Thomas Jefferson University (TJU) is an AAALAC-accredited institution, and the IACUC Committee approved all animal work of TJU.<br>Euthanasia Agents: Five of the animals in each group were euthanized by an overdose of CO2 inhalation on day 3 (day 42), day 7 (day 46), and day 14(53) p.c.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Six to eight-week-old golden Syrian female hamsters (Envigo) were anesthetized with 5% isoflurane before immunization, blood collection, and the SARS-CoV-2 challenge.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enzyme-linked immunosorbent assay: To determine antibody responses to the S protein of SARS-CoV-2, an indirect ELISA was developed utilizing purified S1 or receptor-binding domain (RBD) protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>receptor-binding domain (RBD) protein.</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed three times the next day, followed by the addition of HRP-conjugated goat anti-Syrian hamster IgG secondary antibody (Jackson Immunoresearch, Cat# 107-035-142, 1:8000 in PBST) or mouse anti-hamster-IgG2/3-HRP (Southern Biotech, Cat# 1935–05, 1:8000 in PBST) or mouse anti-hamster-IgG1-HRP (Southern Biotech, Cat# 1940–05, 1:8000 in PBST) for 2 h at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Syrian hamster IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 107-035-142, RRID:AB_2337454)</div></div><div style="margin-bottom:8px"><div>anti-hamster-IgG2/3-HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-hamster-IgG1-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS CoV-2 neutralizing antibody response: Sera collected from animals were tested for neutralizing capabilities against SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The primary antibody, human Anti-SARS COV-2 Nucleocapsid monoclonal (E16C) (Thermo Fisher, MA1-7403, 0.1 mg/mL), was incubated as a 1:100 dilution, at room temperature, for 45 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>The primary antibody, human Anti-SARS COV-2 Nucleocapsid monoclonal (E16C)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-SARS COV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus stocks were obtained at passage 4 (GenBank: MN985325.1) and propagated in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The stock used in this study is passage 5. Cells: Vero (ATCC, CCL81), Vero E6 (ATCC, CRL-1586), BSR (a clone of Baby hamster kidney cells), HEK-293T (ATCC, CRL 3216), Effector cells (murine FcγRIV ADCC Bioassay Effector Cells, Promega-M1201) Vaccine production and purification: Recombinant RABV were recovered, purified, inactivated, and tittered as described previously11.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: ATCC Cat# CCL-81, RRID:CVCL_0059)</div></div><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Recombinant proteins for ELISA: Purification of the HA-tagged S1 protein from the supernatant of transfected cells for ELISA: Sub-confluent T175 flasks of 293T cells (human embryonic kidney cell line, ATCC) were transfected with a pDisplay vector encoding amino acids 16 to 682 of SARS-CoV-2 S (S1) fused to a C-terminal hemagglutinin (HA) peptide using X-tremeGENE 9 reagent (Millipore Sigma, Cat# 6365809001).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody-dependent effector functions: The assay was performed in 96-well, flat, white-bottom plates (Corning) preseeded with 30,000 Vero CCL81 cells and infected after 24 h with Measles vaccine (Edmonston B) vector expressing full-length SARS CoV-2 spike at an MOI of 0.5.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero CCL81</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genetically modified Jurkat cells expressing mouse FcγR IV with a luciferase reporter gene under the transcriptional control of nuclear-factor-activated T cell (NFAT) promoter were added at 1.5 × 105 cells in 25 μl per well, which is approximately a 5:1 ratio of effector cells (Promega) to target cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jurkat</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Recombinant proteins for ELISA: Purification of the HA-tagged S1 protein from the supernatant of transfected cells for ELISA: Sub-confluent T175 flasks of 293T cells (human embryonic kidney cell line, ATCC) were transfected with a pDisplay vector encoding amino acids 16 to 682 of SARS-CoV-2 S (S1) fused to a C-terminal hemagglutinin (HA) peptide using X-tremeGENE 9 reagent (Millipore Sigma, Cat# 6365809001).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pDisplay</div><div>suggested: RRID:Addgene_51053)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed with GraphPad Prism (Version 8.0 g) using 4-parameter nonlinear regression to determine the titer at which the curves reach 50% of the top plateau value (50% effective concentration [EC50]).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.nature.com www.nature.com
-
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., Lee, G. S., Choi, S. K., Takhar, H. S., Aragones, M., & Qian, L. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nature Medicine, 1–1. https://doi.org/10.1038/s41591-022-01753-y
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.20.480711: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Female BALB/c mice (age 6-8 weeks, Envigo), housed in specific-pathogen free environments, were immunized intramuscularly by injection of 50 μL of vaccine formulated in endotoxin-free PBS (Gibco) into both hind limbs of each animal (100 μL total).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse monoclonal anti-hexon antibody (B025/AD51, Thermo-Fisher) was added at 1:1000 dilution in 1% w/v milk in PBS and incubated for 1 h at 25°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hexon</div><div>suggested: (DSHB Cat# TC31-27F11.C2, RRID:AB_1553403)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed with 1% w/v milk in PBS prior to addition of a secondary goat anti-mouse alkaline phosphatase (ALP) conjugated antibody (STAR117A, BioRad) at 1:1000 dilution in 1% w/v milk in PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse alkaline phosphatase (ALP</div><div>suggested: (CEDARLANE Cat# CLF004ALP, RRID:AB_10060171)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coupling efficiency was assessed by comparing band intensities of unconjugated hexon-Tag in ligand decorated samples to undecorated (control) samples using Image J: Anti-vector antibody neutralization assay: For assessment of vector neutralization by potent neutralising mouse monoclonal antibody (mAb) 9C12 (24) (Developmental Studies Hybridoma Bank, University of Iowa), Ad5 vectors expressing GFP were incubated with serially diluted mAb 9C12 antibody at a 1:1 ratio in complete media for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-vector</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For assessment of vector neutralization by serum containing anti-adenovirus antibodies, serum samples were obtained by immunizing C57BL/6 mice with 1E+8 ifu of an Ad5 vector expressing ovalbumin (vector had an unmodified hexon).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-adenovirus</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Linearized DNA was transfected (Lipofectamine 2000, Invitrogen) into E1-complementing Human Embryonic Kidney (HEK) 293 cell lines; either 293A cells (Invitrogen) for Ad vectors expressing GFP and DogCatcher-NANP18, or 293TREX cells (Invitrogen) for Ad vectors expressing SARS-CoV-2 spike.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293A</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293TREX</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Titration of recombinant adenoviruses: Infectious titer of vector preparations was assessed by single cell infectivity assay on HEK293A cells or 293TREX cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293A</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Diluted serum was incubated with Ad5(GFP) vectors, the mix incubated on HEK293 cells, and bulk GFP fluorescence read 24 h later as described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Assessment of coagulation Factor X-mediated vector transduction of SKOV3 cells: SKOV3 cells (human ovary adenocarcinoma) were obtained from Public Health England and cultured in McCoy’s 5a media with 2 mM Glutamine and 15% v/v fetal bovine serum (complete McCoy’s).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SKOV3</div><div>suggested: RRID:CVCL_5J11)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 pseudovirus neutralization (pVNT) assay: Pseudotyped HIV-1 viruses incorporating the SARS-CoV-2 full-length spike (Wuhan strain or B.1.1.7, B.1.617.2 or B.1.351 variants of concern) were generated and SARS-CoV-2 pVNT assays performed as previously described using Hela cells stably expressing ACE2 as target cells (28).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Hela</div><div>suggested: CLS Cat# 300194/p772_HeLa, RRID:CVCL_0030)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For assessment of vector neutralization by serum containing anti-adenovirus antibodies, serum samples were obtained by immunizing C57BL/6 mice with 1E+8 ifu of an Ad5 vector expressing ovalbumin (vector had an unmodified hexon).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Female BALB/c mice (age 6-8 weeks, Envigo), housed in specific-pathogen free environments, were immunized intramuscularly by injection of 50 μL of vaccine formulated in endotoxin-free PBS (Gibco) into both hind limbs of each animal (100 μL total).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bacterial artificial chromosome (BAC) sequences from pBELOBAC11 (NEB) were amplified using forward (5’-TTAATTAAcgtcgaccaattctcatg) and reverse (5’-TTAATTAAgtcgacagcgacacacttg) primers to introduce PacI sites at either end of the BAC cassette.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBELOBAC11</div><div>suggested: RRID:Addgene_60342)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The entire Ad5(GFP) genome was subsequently cloned into the BAC with PacI, to generate pBAC-Ad5(GFP).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBAC-Ad5</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Recombinant vectors expressing DogCatcher-NANP18 and SARS-CoV-2 spike (residues 1-1208 Wuhan strain, codon-optimized for mammalian expression and including stabilizing mutations K986P and V987P and mutation of the furin cleavage site 682-GSAS-685 (60)) were generated through cloning of gene constructs into pENTR4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pENTR4</div><div>suggested: RRID:Addgene_26366)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein production and purification: DNA sequences for expression of DogCatcher, DogCatcher-NANP9, DogCatcher-NANP18 and SpyCatcher were cloned into expression plasmid pET45(+) (EMD Millipore) for protein production in BL21(DE3) E. coli (NEB).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET45</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DNA sequences for expression of DogCatcher fused to SARS-CoV-2 spike receptor binding domain (Wuhan strain, residues 319-532) (DogCatcher-RBD), were cloned into mammalian protein expression plasmid pcDNA3.4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: RRID:Addgene_131198)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coupling efficiency was assessed by comparing band intensities of unconjugated hexon-Tag in ligand decorated samples to undecorated (control) samples using Image J: Anti-vector antibody neutralization assay: For assessment of vector neutralization by potent neutralising mouse monoclonal antibody (mAb) 9C12 (24) (Developmental Studies Hybridoma Bank, University of Iowa), Ad5 vectors expressing GFP were incubated with serially diluted mAb 9C12 antibody at a 1:1 ratio in complete media for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Image J</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Automated data-collection was performed with Leginon software (65) at a nominal magnification of 28,000×, corresponding to a pixel size of 5.19 Å.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Leginon</div><div>suggested: (Leginon, RRID:SCR_016731)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: Statistical analyses were performed in GraphPad Prism 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Further investigation will be required to comprehensively determine limitations for capsid display in terms of size and structure of ligands, but similar sized receptor-binding domains of other viral proteins, including influenza hemagglutinin (∼25 kDa), have been expressed independently as recombinant proteins and displayed on VLPs (56) implying that this could be a generalizable concept. Capsid decoration using our protein superglue technology is simple, requiring only co-incubation of spontaneously and irreversibly reacting components with no chemical modification required. A similar conjugation process has already been scaled under good manufacturing practice (GMP) during development of a VLP-based SARS-CoV-2 vaccine currently in Phase I/II clinical trials (19). The ability of our adenovirus-based platform to induce both robust cellular and humoral immunity and to enhance efficacy of multi-shot regimens could be advantageous for applications beyond prophylactic vaccines, including therapeutic vaccines against chronic viral pathogens and cancer. Methods of rapid and customizable covalent decoration of Ad capsids could also be utilized for development of personalized therapies. In prophylactic settings, adenovirus capsid decoration could be utilized in the design of pan-coronavirus and pan-influenza vaccines; combining broad and conserved T cell immunity from encoded antigens with exchangeable capsid ligands delivering potent neutralizing humoral immunity.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 27. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.19.481107: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The monoclonal antibodies SARS-CoV-1/SARS-CoV-2 Spike Protein S2 (1A9) and SARS-CoV-1/SARS-CoV-2 Nucleocapsid (6H3) were purchased from ThermoFisher Scientific.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-1/SARS-CoV-2 Nucleocapsid ( 6H3 )</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The rabbit polyclonal Anti-GAPDH antibody were purchased from Abcam.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-GAPDH</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The rabbit polyclonal Anti-HIV-1 p24 antibody was purchased from MilliporeSigma.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-HIV-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mouse anti-N protein antibody (clone 1C7) was purchased from Bioss Antibodies, and the rabbit anti-SARS-CoV-2 spike protein (clone 007) antibody, was purchased from Sino Biological.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-N protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">protein primary antibody and an anti-mouse IgG HRP secondary antibody in conjunction with SIGMAFAST™ OPD developing solution</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In parallel and after blocking, the second plate was incubated for one hour with a primary antibody solution formulated in PBS + 1% non-fat milk containing both mouse anti-N protein (1 μg/mL, clone 1C7) and rabbit anti-SARS-CoV-2 spike protein (1:500 dilution, clone 007) antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-N protein ( 1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 spike protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">donkey anti-rabbit IgG Alexa Fluor Plus 594 (2 μg/mL, Invitrogen) antibodies and DAPI (1:1000, Millipore Sigma) in PBS + 0.5% BSA consisting of.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: (Thermo Fisher Scientific Cat# A48284, RRID:AB_2896348)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines, inhibitors, and antibodies: HEK293T (ATCC), HEK293T-ACE2 (kind gift of Hyeryun Choe, Scripps Research), HT1080 cells (ATCC) and Calu3 (ATCC) were cultured in Dulbecco’s Minimum Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Sigma), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.3 mg/mL L-glutamine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fusion assays: For the syncytium formation assay HEK293T and HEK293T-Ace2 cells were seeded in 24-well plates and grown to approximately 80% confluency.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-Ace2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell-cell fusion assay with soluble ACE2, effector HEK293T cells were transiently transfected with plasmid DNA encoding mCherry, and SARS-CoV2 spike and target HEK293T cells were transiently transfected with plasmid DNA encoding LTR-GFP, TMPRSS2 or pCAGGS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gelatin zymography: HEK293T, HEK293T-ACE2, Calu3 and HT1080 cells were analyzed for MMP2 and MMP9 activity through zymographic analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HT1080</div><div>suggested: CLS Cat# 300216/p517_HT-1080, RRID:CVCL_0317)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HT1080-ACE2 cells were cultured in DMEM supplemented with penicillin (100 U/mL), streptomycin (100 µg/mL), HEPES, L-Glutamine (0.3 mg/mL), 10% FBS (all from Thermo Fisher Scientific) and puromycin (1 μg/mL, InvivoGen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HT1080-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Twenty-four hours before infection, 2.5×104 HT1080 ACE2 cells were seeded per well of duplicate 96 well plates in puromycin-deficient DMEM and cultured overnight (37°C/5% CO2) for cell monolayer to adhere.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HT1080 ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HT1080 cells stably expressing ACE2 were generated by infection with lentiviral particles generated with psPAX2, pMDG and pLENTI_hACE2_PURO (gift from Raffaele De Francesco</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>pMDG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pLENTI_hACE2_PURO</div><div>suggested: RRID:Addgene_155295)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The full gene, untagged or with a N-terminal FLAG tag, was reconstituted by Gibson assembly, amplified by PCR, and cloned in pCAGGS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Time-course imaging of the syncytia formation was performed using an Incucyte-Zoom (EssenBioscience), and images were analyzed in imageJ to measure the percentage of green surface area over background.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>imageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed with GraphPad Prism 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.20.481163: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Clinical Recruitment and Sample Collection: 61 individuals (45 SARS-CoV-2 naïve, 16 SARS-CoV-2 recovered) were consented and enrolled in the longitudinal vaccine study with approval from the University of Pennsylvania Institutional Review Board (IRB# 844642).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, 50 uL of 1:5000 diluted goat anti-human IgG-HRP (Jackson ImmunoResearch Laboratories) or 1:1000 diluted goat anti-human IgM-HRP (SouthernBiotech) was added to each well and plates were incubated for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, 2-fold serially diluted serum samples were mixed with VSVΔG-RFP SARS-CoV-2 pseudotype virus (100-300 focus forming units/well) and incubated for 1 hour at 37⁰C. 1E9F9, a mouse anti-VSV Indiana G, was also included in this mixture at a concentration of 600 ng/ml (Absolute Antibody, Ab01402-2.0) to neutralize any potential VSV-G carryover virus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VSV</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of SARS-CoV-2 Neutralizing Antibodies: 293T cells were seeded for 24 hours at 5 × 106 cells per 10 cm dish and were transfected using calcium phosphate with 25 μg of pCG1 SARS-CoV-2 S D614G delta18, pCG1 SARS-CoV-2 S B.1.617.2 delta 18, or pCG1 SARS-CoV-2 S B.1.1.529 delta 18 expression plasmid encoding a codon optimized SARS-CoV-2 S gene with an 18-residue truncation in the cytoplasmic tail.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells stably expressing TMPRSS2 were seeded in 100 μl at 2.5×104 cells/well in a 96 well collagen coated plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum-virus mixture was then used to replace the media on VeroE6 TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6 TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of SARS-CoV-2 Neutralizing Antibodies: 293T cells were seeded for 24 hours at 5 × 106 cells per 10 cm dish and were transfected using calcium phosphate with 25 μg of pCG1 SARS-CoV-2 S D614G delta18, pCG1 SARS-CoV-2 S B.1.617.2 delta 18, or pCG1 SARS-CoV-2 S B.1.1.529 delta 18 expression plasmid encoding a codon optimized SARS-CoV-2 S gene with an 18-residue truncation in the cytoplasmic tail.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCG1 SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCG1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using FlowJo v10 (BD Bioscience).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">High Dimensional Analysis and Statistics: All data were analyzed using custom scripts in R and visualized using RStudio.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RStudio</div><div>suggested: (RStudio, RRID:SCR_000432)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For heatmaps, data were visualized with pheatmap.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pheatmap</div><div>suggested: (pheatmap, RRID:SCR_016418)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
sites.google.com sites.google.com
-
peaceful man stands tall
the diction of "peaceful" connotes calmness and quiet, illustrating a turning point where the fighting stops
the visual imagery of "stands tall" depicts the "peaceful man" as preeminent and superior, a representation of those who were fighting for peace eventually winning, causing all the violence to finally end. I feel happy for them, as I reflect on the theme of peace as I learn to appreciate peace and not to take it for granted
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.19.22271215: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All studies were approved by the Institutional Review Board of FAH-SYSU and written consent was obtained from all participants.<br>Consent: All studies were approved by the Institutional Review Board of FAH-SYSU and written consent was obtained from all participants.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines were passaged less than 15 generations and examined the mycoplasma by PCR and fluorescence labeling methods.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 5 times by PBST, and incubated with 100 μl/well goat HRP conjugated anti-human IgG antibody (2040-05, SouthernBiotech, 1:3000) in PBST at room temperature for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (SouthernBiotech Cat# 2040-05, RRID:AB_2795644)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Jurkat-Lucia™ NFAT-CD16 Cells (jktl-nfat-cd16, InvivoGen) was cultured in IMDM (BL312A, Biosharp) supplemented with 10% FBS, NEAA, 100 U/ml penicillin and 100 μg/ml streptomycin, 100 μg/ml Zeocin (ST-1450, Beyotime) and 10</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NFAT-CD16</div><div>suggested: RRID:CVCL_A7ZT)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the generation of the B.1.1.529 Omicron-variant spike pseudovirus, pcDNA3.1(+)-Omicron-spike, pSPAX2 and pLenti-CMV-puro-Luc (168w-1) were co-transfected to HEK293T using Lipo8000.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plasmid pcDNA3.1-2019-nCoV-Spike is a gift from Dr. Lu Lu at Fudan University, encoding the spike protein from an ancestral SARS-CoV-2 reference strain (Wuhan-Hu-1) which is called as wild type (WT) throughout the manuscript.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1-2019-nCoV-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plasmid pcDNA3.1(+)-Envelope encodes envelope protein from WT was full-genome synthesized by Genewiz China according to the reference sequence NC_045512.2 in NCBI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids pSPAX2 and pLenti-CMV-Puro-Luc (168w-1) were a gift from Dr. Jianping Guo and purchased from MiaolingBio (P1216), respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSPAX2</div><div>suggested: RRID:Addgene_12260)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate WT SARS-CoV-2-Spike (Wuhan-Hu-1) pseudovirus, pcDNA3.1-2019-nCoV-Spike, pSPAX2 and pLenti-CMV-puro-Luc (168w-1) were co-transfected to HEK293T using Lipo8000 (C0533, Beyotime) according to the manufacturer’s instruction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLenti-CMV-puro-Luc</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 50% pseudovirus neutralization titer (PVNT50) was determined by a four-parameter nonlinear regression curve (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analysis was performed using Graphpad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our study has several limitations. First, the result came from a cohort of young HCWs. The effect of the 4th dose on very young and elderly populations may be different. Second, only a pseudovirus neutralization assay was used in the current study 13. Nevertheless, our neutralization results regarding the ratio of NAb titers between WT and Omicron are in line with results from pseudovirus neutralization assay or authentic virus neutralization assay from other groups 8,16,20. Third, we did not assess other aspects of humoral immune responses such as antibody-dependent cellular cytotoxicity (ADCC) or the cellular arm of immunity. They may contribute to disease prevention even in the absence of NAbs. In conclusion, our study demonstrated that the 4th dose of inactivated SARS-CoV-2 vaccine is safe but the ability to further strengthen the protection against Omicron is compromised by suppression of RBD-NAbs and a further shift of humoral response away from RBD. Updated vaccines based on VOC sequences that take the advantage of RBD, NTD, and other antigenic domains would be an ideal alternative for future boosters.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
The paper tackles an important problem regarding the effect of demographic dependent vaccination protocols on the reduction in the number of deaths with respect to the situation of no vaccination (say J). A compartmental SIRD model with reinfection Y is proposed, stratified in two (age dependent) groups, based on a binary reduction of a given contact map, and given infection fatality risk (IFR). Several countries are then analyzed.
As far as I understand we have a control variable v, parameters of the stratified model (i=1,2) tuned to match IFRi, and a control objective, i.e. minimization of J over one year.
The paper is well written. The final message and some theoretical passages are not completely clear, at least to me. I have the following observations that the authors may want to consider.
We thank the referee for the revision and are very glad that the overall evaluation is positive. Comments and suggestions have been thoroughly addressed, as we discuss in the following.
1) The study of stability of infection free and endemic equilibria should be better developed. The 5 equations can be reduced to 4 (neglecting D) and the characteristic of the reduced Jacobian used to characterize the local asymptotic stability of equilibria, instability, bifurcation points etc... Alternatively, one can use a co-positive Lyapunov function (LF). For instance, if we take the LF V=S+I+Y+R, we get $\dot V=-\mu_I I-\mu_Y Y \le 0$. If $\mu_I$ and $\mu_y$ are strictly positive all equilibria are characterized by (S*,0 0,R*) and D=1-S*-R*. So, I don't understand the phrase after (7,8), notice that Y cannot be zero in finite time. For $\mu_y=0$ then Y* can be nonzero. I guess that closed-form computation of S* and R* is possible as function of the parameters at least in the case v=0. The stability result should be cast in function of the current reproduction number (not explicitated) wrt to S and R.
The authors are invited to have a look at
1.1) Pagliara et al, "Bistability and Resurgent Epidemics in Reinfection Models", IEEE CSLetters, 2018,
for a theoretical analysis of stability on a similar (just a little bit simpler) model.
We appreciate the suggestions of the referee for improvement of this material. We have carried out an in-depth revision of the stability analysis and significantly extended it. The major addition has been, as suggested, a section relating the current reproductive number at equilibrium (we call it the asymptotic reproductive number in the text) to the fixed points of the dynamics for three different scenarios: general model, no vaccination, and zero mortality of reinfected individuals. As Pagliara et al. show in their paper, the connection between the fixed points and the reproductive number is not trivial, but it is possible to derive it through the next-generation matrix technique, as we now do. Additional references regarding this technique have been added. We have included a Table summarizing the stability analysis (page 2 in SI 3) at the end of this new section.
Other modifications include the reduction of 5 equations to 4 for the stability analysis and a clarification of possible equilibria (page 1 of SI 3), rephrasing and correcting our sentence after eqs. (7) and (8). We also attempted to obtain a closed-form computation of S* and R* but, to the best of our knowledge, concluded that it is not possible. We would be happy to pursue any insight in this respect the referee may have.
What said before should be also extended to the stratified model, where a "network" Rt could be defined, see for instance
1.2) L. Stella et al, "The Role of Asymptomatic Infections in the COVID-19 Epidemic via Complex Networks and Stability Analysis", SIAM J Cont. Opt., 2021, (arxiv.org/pdf/2009.03649.pdf)
We thank the referee for pointing out this reference. Following the analysis in Stella et al., we have carried out a stability analysis for the stratified model as well. The results are included in a new section (pages 7-10 in the SI 3).
2) It is not clear whether the free contagion parameters of the model have been fitted on real data (identification from infection and reinfection data). Notice that the interplay between vaccination strategies and NPI is important, see e.g.
*2.1) Giordano et al, Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy", Nature Medicine 2021, *
where progressive vaccination in reverse age order is considered together with different enforced NPI countermeasures.
In the first part of our study, parameters are intendedly left free because we aim at describing the generic behavior of the model. Still, we derive several inequalities and relationships between parameter ratios that seem to be sensible attending to what the different classes in the model stand for. This is as described in sections regarding model parameters when the two generic models (SIYRD and S2IYRD) are introduced. The aim is to represent both the generic dependence with some variables and a broad class of contagious diseases, so parameters are mostly free. In agreement with this approach, parameters can be also freely varied in the companion webpage.
In the second part of our study, the model is applied to COVID-19. In that case, we have used parameter values in agreement with observations, as (admittedly poorly) explained in pages 9-10 of the main text. Indeed, not enough information on parameter estimation was provided in the main text, and the SI 2 also needed some additional information. This has been amended. Let us explicitly mention that we have not fitted the dynamics of the model to any actual data set to fix specific values, as Giordano et al. do. In our case, we have first used different demographic data sets to evaluate contact rates and IFRs of the two population groups (these are parameters Mij and Ni in eqs. (7-10)). Secondly, recovery and death rates are estimated through the IFRi values for each age group i and the infectious period of COVID-19, that we fix at dI=13 days. Third, infection rate βSI=R0/dI has been estimated fixing R0=1, since the reproductive number of COVID-19 all over the world fluctuates around this value (Arroyo-Marioli et al. (2020) Tracking R of COVID-19: A new real-time estimation using the Kalman filter, PLoS ONE 16(1):e0244474). The reinfection rate is defined through its relationship with the infection rate, βRI= α1 βSI, where α1 was in the range 0-0.011 at early COVID-19 stages (Murchu et al. (2022), Quantifying the risk of SARS‐CoV‐2 reinfection over time, Rev Med Virol 32:e2260) and seems to be about 3-4 fold larger for the omicron variant (Pulliam et al., Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa, www.medrxiv.org/content/10.1101/2021.11.11.21266068v2). Given the relationships derived among parameters, our only free parameter was α2RY= α2 βRI, and we fixed it to α2=0.5 (i.e., reinfected individuals recover twice as fast as individuals infected for the first time).
Once more, it was not our goal to precisely recover specific trajectories of COVID-19 or to point at possible future scenarios, but to illustrate the dependence of major trends with model parameters. Also, the appearance of new variants requires the reevaluation of parameters. For example, omicron has different IFR (therefore different mortality and recovery rates), a different infectious period, and higher infection and reinfection rates. In this context, the interactive webpage (where we will update demographic profiles and IFR data as they become available) is a useful resource to simulate any situation different from current or past ones.
3) In the model the immunity waning is not explicitly considered (flux from R to S or better from a vaccinated compartment to S). It is clear that this complicates the model. Please discuss why the indirect way the waning is considered here is justified.
3.1) Batistela et al, "SIRSi compartmental model for COVID-19 pandemic with immunity loss", Chaos Soliton and fractals, 2021.
3.2) McMahon et al, "Reinfection with SARS-CoV-2: Discrete SIR (Susceptible, Infected,Recovered) Modeling Using Empirical Infection Data", JMIR Public health and surveillance, 2020.
Though the model does not consider an incoming flux of individuals to compartment S, the existence of a "backward" flux from R to Y yields a transient phenomenology analogous to models with increases in the S class. Indeed, it is these fluxes that cause persistent endemic states; otherwise, the S class is monotonously depleted until infection extinction.
In Batistela's et al. work, the possibility that individuals become reinfected is effectively implemented through a flux between the R and S classes, since only one class of infected individuals is considered and recovered individuals cannot be infected again. In our case, feeding back to S would mean that previous immunity is completely lost or that vaccines are not effective at all for some individuals. This is neither what McMahon et al. conclude when evaluating real data nor what more recent surveys indicate (see for instance the Science Brief published in October 2021 by the CDC, SARS-CoV-2 Infection-induced and Vaccine-induced Immunity, https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html).
This nonetheless, complete immunity waning (feedback to the S class) and reinfections (feedback to a partly immune class experiencing overall lower severity of the disease) are equivalent to a large extent: the trend of COVID-19 seems to indicate that our Y class will be the "new S", and that fully naive individuals would arrive mostly due to demographic dynamics (birth and death processes, as also implemented by Batistela et al.). Summarizing, complete immunity waning is rare in the time scales considered in our simulations, while partial immunity that decreases the severity of the disease (after infection or vaccination) is the rule, in agreement with our choices.
4) Reduction of deaths wrt no vaccination is of course important, but also reduction of stress in hospitals. This is particularly important now with the advent in Europe of the omicron variant. Please discuss on the real message you want to convey to policy makers in the actual scenario of the pandemic.
The model in this work is deliberately simple. Our main goal was to explore the qualitative effects of demographic structure and disease parameters in protocols for vaccine administration. This was the reason to consider a mean-field model in a population structured into two groups. The main conclusion is that optimal vaccination protocols are demography- and disease-dependent. If this is so in our streamlined model, the more it will be in more realistic models, where one should include a finer stratification and, in all likelihood, heterogeneity in contagions. Our main message, therefore, is that there is no unique protocol for vaccine roll-out, valid for all populations and diseases. The abstract has been modified to highlight this conclusion.
Some qualitative considerations also allow us to draw preliminary conclusions on the reduction of stress in hospitals. Since the number of hospital admissions is proportional to the incidence of the disease, the number H of hospitalized individuals can be represented as H=a I + b Y, with a>>b due to the partial immunity of vaccinated or recovered individuals (which belong to class Y upon (secondary) contagion). Therefore, minimizing the burden on the healthcare system amounts to minimizing the number of individuals in the I class. Beyond non-pharmaceutical measures, I is minimized when individuals are transferred as fast as possible to the Y class, that is, maximizing vaccine supply and acceptance. In terms of our model parameters, this entails maximizing v and also θ (the maximum fraction of individuals eventually vaccinated), for instace through devoted awareness campaigns. These ideas have been included in the Discussion section.
Reviewer #1 (Significance (Required)):
The final message and some theoretical passages are not completely clear, at least to me.
Please discuss on the real message you want to convey to policy makers in the actual scenario of the pandemic.
As discussed above, we have modified the manuscript following the advice given by the Reviewer. We think that both the presentation and the theory are clearer now.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
In this paper, a compartmental model of the propagation of an infection with vaccination and reinfection is studied. The impact that changes in the rates of these two processes have on disease progression and on the number of deaths is analyzed. In order to highlight the overall effect of the demographic structure of populations and the propagation of a given disease among different groups, the population is divided into two subpopulations and the model is extended to the two-dimensional case. In addition to the study of equilibria and their relative stability, the model is then applied in the case of COVID-19. Different vaccination strategies are studied using real demographic data and with a population split between under 80 and over 80 individuals. It is observed that for low vaccination rates, the advisable strategy is to vaccinate the most vulnerable group first, in contrast to the case of sufficiently high rates, where it is appropriate to vaccinate the most connected group first. The simulations show also that with a low fatality ratio, the strategy that yields the greatest reduction in deaths is vaccination of the group with the most contacts, while the situation is reversed for higher fatality ratio.
The model and simulations presented are interesting and valuable. The comparison of the behavior of the model in the 4 different countries is very interesting, as well as the webpage created by the authors.
We thank the referee for the very positive evaluation and are very glad that the study is found interesting and valuable.
As minor comment, I think that the introduction of the model needs a more extensive literature review. For example, there is no mention of the classic SIR model of Kermack and McKendrick (1927) and other works on the introduction to epidemic models, which form the basis of the model presented by the authors.
The referee is right. There is a long history of extensions and applications since Kermack & McKendrick introduced the SIR model that we obviated. This has been amended by adding an introductory paragraph with several new references at the beginning of the Models section, page 3 in the main text.
Reviewer #2 (Significance (Required)):
The model presented by the authors is quite original and simple enough to be suitable to different contexts and scenarios.
Compared to previous work, this paper makes a twofold contribution, as explained by the authors. First, the introduction of reinfections shows the existence of long transients (or quasi-endemic states) that may precede the transition to a truly endemic state predicted for COVID-19. Second, the simplicity of model allows the characterization of systematic effects due to, at least, group size, demographic composition, and IFRs.
I am involved in the study and analysis of epidemic models accompanied by network effects. I think this paper is a good contribution, although preliminary, in the analysis of the vaccination process and in the search for the optimal strategy.
We thank the Reviewer and are glad that our goal, offering a model as simple as possible to obtain meaningful conclusions, is appreciated.
-
-
www.biorxiv.org www.biorxiv.org
-
Author Response:
Reviewer #1 (Public Review):
In this paper, Qin et al. investigated the molecular mechanism of phospholamban (PLN) linked dilated cardiomyopathy (DCM), using structural approaches combined with biophysical measurements. Structures of the catalytic domain of protein kinase A (PKAc) in complex with PLN peptides (both wild-type and the R9C and A11E DCM mutants) provide insights into the mechanism of substrate recruitment and how it is perturbed in the disease state. Qin et al. show convincingly that the mutant peptides all have lower affinity for PKA than the wild-type peptide, suggesting models in which heterozygous DCM mutations act via sequestering PKA and thereby preventing phosphorylation of the wild-type peptide may be incorrect.
The authors highlight significant differences between their structure of the WT-PLN:PKAc complex, which has a 1:1 stoichiometry, and a previous structure of the complex (PDB 3O7L), which has 1 PLN bound between two PKAc monomers (a 1:2 complex). The authors posit that the stoichiometry observed in 3O7L is an artifact of the crystal lattice, and does not occur in solution, supporting this with analysis of the elution volumes of the peptide complexes on size exclusion chromatography compared to PKAc alone. They further suggest that the AMP-PNP ligand included in the 3O7L structure is not bound, based on analysis of Fo-Fc maps calculated from the deposited coordinates. Inspecting 3O7L I am not convinced of this last point - it seems more likely that a technical error was made in assigning or refining the B-factor of the ligand in 3O7L, because there is clearly density present in SA-omit maps for the nucleotide.
Taking these results together, the authors suggest a mechanism for DCM, whereby mutations in PLN result in lower affinity for PKA, and consequently reduced phosphorylation. This seems plausible and well supported by the data, although in the ADP-Glo assay used here, the reductions in phosphorylation observed for some of the mutant peptides are rather modest. However, as the authors state, it is plausible that even relatively subtle changes in PLN phosphorylation could have substantial effects on Ca2+ homeostasis via increasing SERCA inhibition.
We thank the reviewer for the appreciation of our work.
Reviewer #2 (Public Review):
Strengths:
The authors presented new high-resolution 3D crystal structures of the PKA catalytic domain (PKAc) in complex with PLN WT or mutant peptides (residues 8-22) containing the DCM-associated PLN mutations (R9C or A11E). These are novel and important data given that the present structures are dramatically different from those reported previously. The authors made convincing argument that the 3D model reported previously may result from a crystallization artifact.
By characterizing the interactions between the PKAc domain and PLN WT or DCM-associated mutant peptides using surface plasmon resonance (SPR) analysis, the authors convincingly showed that the DCM-associated PLN mutations at positions 9, 14, and 18 alter the conformation of the PLN peptide and reduce the binding affinity of the PLN peptide with PKAc. These data provide an explanation how some DCM-associated PLN mutations at these positions reduce the level of PKA-dependent phosphorylation of PLN.
The authors also performed nuclear magnetic resonance (NMR) to determine the structural dynamics of PLN WT, R9C, P-Ser16, and P-Thr-17 peptides. These NMR structures combined with the SPR analysis also support their conclusion that PLN phosphorylation and DCM-associated PLN mutations have an impact on its conformation.
We thank the reviewer for the comments.
Weakness:
The present study used PLN-derived peptides (aa 8-22). Although technically challenging, it is important to consider if the full-length WT or mutant PLN will behave the same as those observed with the peptides. This is especially crucial in light of the prior work showing substantially different structures using a different segment of PLN.
We are fully aware of the potential risk to draw conclusion from an isolated peptide instead of the full-length PLN as a transmembrane protein. In the previous study, people showed that the PLN peptide could be used as a good model substrate that gets phosphorylated as efficiently as the full-length PLN protein (L. R. Masterson et al., Dynamics connect substrate recognition to catalysis in protein kinase A. Nat Chem Biol 6, 821-828 (2010); D. K. Ceholski, C. A. Trieber, C. F. Holmes, H. S. Young, Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A. The Journal of biological chemistry 287, 26596-26605 (2012)). These results together with our biochemistry results suggest the tail peptides are indeed active substrates of PKA. Due to the technical difficulty, we were not able to crystallize PKAc in complex with the full-length PLN. To explain the potential difference between the peptides and the full-length PLNs, we added more text in the discussion section “Additionally, the trend of the reduced phosphorylation by DCM mutations can be significantly affected by the oligomerization state of PLN. Ceholski et al. showed that R9C severely inhibits PKA phosphorylation in the context of full-length pentameric PLN, but has a much milder effect in the context of full-length monomeric PLN or an isolated tail peptide [41].”
Although it is convincing that DCM-associated PLN mutations likely reduce the interaction between PKAc and PLN (assuming that the peptides behave the same as the full-length PLN with respect to interaction with PKA) and, as a result, the PKA dependent phosphorylation of the mutant PLN, it is unclear how this impaired interaction between PKA and PLN mutant could explain the effects of the DCM-associated PLN mutations on SERCA function (either reduced or enhanced PLN-dependent inhibition of SERCA, as proposed previously). In this regard, can the authors predict if the DCM-associated PLN R9C mutation reduces or increases SERCA inhibition based on the results of their present study?
It is indeed controversial how PLN mutations cause DCM. Previous studies have shown that the DCM mutations in PLN might change this regulation in either a phosphorylation-dependent or phosphorylation-independent manner. Our results show that the mutations may act through both manners: 1) the mutations reduce the phosphorylation level of PLN, which has been shown to enhance the inhibition of SERCA and inhibit the uptake of Ca2+; 2) the mutations change the conformation of PLN before binding to PKA or SERCA, which could have additional consequences, such as altered assembly state of PLN, phosphorylation of PLN by CaMKII, or changes in interactions of PLN with the lipid membrane. This could impact in either directions, reducing or increasing SERCA inhibition, which is difficult to predict based on our data. We added the explanation in the discussion “While decreased PLN phosphorylation is likely an important contributor to the physiological dysfunction associated with familial DCM, disease-causing mutations in PLN may have additional consequences, such as altered assembly state of PLN, phosphorylation of PLN by CaMKII, or changes in interactions of PLN with the lipid membrane. The influence of such factors on SERCA inhibition are unclear. In principle, they might further increase inhibition of SERCA and act in conjunction with lower PKA-mediated phosphorylation to manifest the disease symptoms. Conversely, it is possible that these factors could decrease the inhibition of SERCA, partially compensating for the decreased phosphorylation level, and mitigating the symptoms.”
It is also unclear how reduced PKA phosphorylation of mutant PLN could lead to DCM. PLN is unlikely to be significantly phosphorylated by PKA at rest (in other words, PLN is likely to be phosphorylated by PKA during stress, i.e. during the adrenergic fight-or-flight response). Therefore, it is puzzling how such reduced PKA-dependent phosphorylation of PLN would significantly affect the PLN function during the absence of flight-or-flight response.
As explained above, we think that this regulation could be through both phosphorylation-dependent and phosphorylation-independent manner. Even only considering the phosphorylation-dependent manner, the DCM phenotype could be due to an accumulation of the Ca2+ imbalance in the cell over repeated cycles of cardiac muscle contraction upon chronic accumulation of the sporadic phosphorylation events. It is also possible that the mutations affect the CaMKII-dependent regulation of PLN, which leads to DCM.
Given that the DCM-associated PLN mutations have significant effects on the conformation of PLN itself, at least in the form of short-peptides, it is possible that these mutations could affect the folding, oligomerization, trafficking, degradation, etc., in addition to PKA-dependent phosphorylation. The relevance and contribution of reduced PKA-dependent PLN phosphorylation to DCM remain unresolved.
We agree with the reviewers that both phosphorylation-dependent and phosphorylation-independent manners could contribute to the DCM disease phenotype. It remains unresolved which factor is the major contributor. We have added a statement in the discussion (see point above).
Reviewer #3 (Public Review):
This manuscript describes an elegant study utilizing the crystal structures for the elucidation of the disease mechanism of familial dilated cardiomyopathy. It has been known for decades that the mutations in PLN are associated with DCM, but the underlying mechanism remains controversial. In my opinion, Prof Yuchi and co-authors did excellent job on revealing the high-resolution crystal structures of PKA-phospholamban complexes, representing both the native and diseased states. Combined with various of biophysical and biochemical methods, including SPR, ADP-glo, thermal melts, NMR, etc, the authors systematically investigated the correlations between the PLN conformation, the binding affinity, and the phosphorylation level. The mechanism of PKA phosphorylation on another related substrate, ALN, was also convincingly revealed. The results are very helpful for understanding the pathological mechanism of PLN-related DCM. More importantly, the atomic structures of PKA-phospholamban complexes lay a solid foundation for the structure-based rational design of therapeutic molecules that can reverse the effects of the DCM-causing mutations in the future, e.g. by stabilizing the interactions between PLN and PKA.
We thank the reviewer for the appreciation of our work.
-
-
www.cubahora.cu www.cubahora.cu
-
Y he aquí que llegó una mujer pecadora que había en la ciudad, la cual, sabiendo que Jesús estaba comiendo en casa del fariseo, tornó un frasco de alabastro de ungüento, se puso det r á s d e é l, junto a sus pies, llorando, y comenzó a lavárselos con lágrimas en los ojos; le enjugaba los pies con los cabel l o s d e s u c a b e z a , l o s besaba y los ungía con el ungüento. Viendo esto, el fariseo que lo había invitado dijo para sí: «Si éste fuera profeta, conocería quién es la mujer que lo toca, porque es una pecadora». Tomando Jesús la palabra, le dijo: «Simón, tengo algo que decirte». Él dijo: «Maestro, habla». « Un prestamista tenía dos deudores: uno le debía quinientos denarios; el otro, cincuenta. No teniendo ellos con qué pagar, le condonó la deuda a ambos. ¿Quién, pues, lo amará más?», y Simón respondió: «Supongo que aquel a quien condonó más». Dijo: «Bien has respondido. -Y señalando a la mujer, le dijo a Simón:- ¿Ves a esta mujer? Entré en tu casa y no me diste agua en los pies; mas ella los ha regado con sus lágrimas y los ha enjugado con sus cabellos. No me diste el ósculo; pero ella, desde que entré, no ha cesado de besarme los pies. No ungiste mi cabeza con óleo, pero ella ha ungido mis pies con ungüento. Por lo cual te digo que le son perdonados sus muchos pecados, porque amó mucho. Pero a quien poco se le perdona poco ama». LUCAS, 7, 37-47
Once minutos es obra que inicia con unos versículos de la Biblia, donde parece que su autor en esta obra muestra o representa ciertos moralismos que existe en la comunidad Latina.
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.18.22270995: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following antibodies were used: Anti-SARS-CoV-2 nucleoprotein (NP) antibody (clone ID: 019, dilution 1:100, rabbit IgG; Sino Biological, Beijing; detection-system: Dako REAL TM EnVision TM HRP rabbit/mouse Dako K5007); CD68 (Ventana anti-CD68 (KP-1) monoclonal mouse 790-2931; detection-system: Ventana Ultra View DAB); TTF1 (Cell marque 343M-96 Clone 8G7G3/1 monoclonal mouse 1:200; detection-system: Dako K5007); TGFß1 (Santacruz polyclonal rabbit AB; clone SC-146 1:50; detection-system: Ventana Ultra View DAB); LAG3 (Abcam polyclonal rabbit; clone ab180187 1:5000; detection-system: Dako K5007); C1q (Dako polyclonal rabbit, clone A0136 1:5000; detection-system: Dako K5007); CD163 (Ventana monoclonal mouse, clone MRQ-26 1:50; detection-system: Ventana Ultra View DAB).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2 nucleoprotein (NP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD68</div><div>suggested: (LSBio (LifeSpan Cat# LS-C88159-200, RRID:AB_1792428)</div></div><div style="margin-bottom:8px"><div>KP-1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>AB</div><div>suggested: (Abcam Cat# ab180187, RRID:AB_2888645)</div></div><div style="margin-bottom:8px"><div>LAG3</div><div>suggested: (Abcam Cat# ab180187, RRID:AB_2888645)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently, the membranes were incubated with antibodies against C1q (Dako Denmark A/S 1:5000), TGFß1 (Cell Signaling Technology, 1:1000), and GAPDH (Cell Signaling Technology, 1:1000) overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C1q</div><div>suggested: (LSBio (LifeSpan Cat# LS-C20978-5000, RRID:AB_10638452)</div></div><div style="margin-bottom:8px"><div>GAPDH</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Thereafter, membranes were washed and incubated with the appropriate HRP-conjugated secondary antibody (Amersham, ECL Anti-Rabbit IgG, 1:5000).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1500 rcf) the supernatants were filtered through a 0.45µm membrane filter (Millipore) and inoculated on Vero CCL-81 cells with OptiPro SFM medium with 4mM L-Glutamine and 1% penicillin-streptomycin in T25 flasks (ThermoFisher).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero CCL-81</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNAs from VeroE6 cell cultures were isolated by using the QIAamp Viral RNA Mini Kit (Qiagen) without addition of carrier RNA and transcribed into cDNA with the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems) according to manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amplification data was downloaded and processed using the qpcR package of the R project (https://www.r-project.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>https://www.r-project.org/</div><div>suggested: (R Project for Statistical Computing, RRID:SCR_001905)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequences were aligned to the SARS-CoV-2 reference genome (acc. no.: NC_045512.2) using TMAP (v5.10.11) and variants were called with the Torrent Variant Caller (v5.10-12).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TMAP</div><div>suggested: (TMAP, RRID:SCR_000687)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Libraries were pooled in two pools of 13 samples each by concentration measured with Qubit (ThermoFisher), followed by a bead-cleanup step and an additional QC with Qubit (ThermoFisher) and BioAnalyzer (Agilent).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher</div><div>suggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)</div></div><div style="margin-bottom:8px"><div>BioAnalyzer</div><div>suggested: (BioAnalyzer 2100, RRID:SCR_019715)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Read counts on plus-/minus-strand were counted using custom python scripts.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Exact positioning of the reads on plus-/minus-strand was done splitting the bam files aligned to NC_045512.2 using samtools -f 0×10 and samtools -F 0×10 (v0.1.19-44428cd) and bedtools genomecov -ibam BAM NC_045512.2 -d (bedtools v2.17.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>samtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div><div style="margin-bottom:8px"><div>bedtools</div><div>suggested: (BEDTools, RRID:SCR_006646)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA profiling: Gene counts were determined using HTSeq (v0.12.4) and normalized as fragments per kilobase per million (FPKM) after TMM correction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HTSeq</div><div>suggested: (HTSeq, RRID:SCR_005514)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential gene expression was conducted using edgeR (https://doi.org/doi:10.18129/B9.bioc.edgeR) [77].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>edgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clustering of differentially expressed genes was performed using hclust hierachical clustering and subsequent cutting of the gene tree at R function cutree with h=0.25.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hclust</div><div>suggested: (HCLUST, RRID:SCR_009154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Microbiome analysis based on RNAseq: Microbiome analysis was performed with the following steps using all reads from STAR alignment not mapping to the human reference: quality filtering using fastx -q 30 -p 26 -Q33 (v0.0.13, http://hannonlab.cshl.edu/fastx_toolkit/), cleaning of the fasta file using seqclean-x86_64 -N -M -A (https://sourceforge.net/projects/seqclean/), realigning to the human reference using blastn against all databases and removal of all reads with 94% similarity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Remaining reads were annotated using MetaPhlAn2 (v2.6.0) [80] and Pathseq (GATK v4.1.0.0) [81] with default settings.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MetaPhlAn2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>GATK</div><div>suggested: (GATK, RRID:SCR_001876)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quality control and preprocessing of sequences was performed using FastQC (version 0.7), MultiQC (version 1.7) and trimmomatic (version 0.36.5) using following parameters: LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:200.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div><div style="margin-bottom:8px"><div>MultiQC</div><div>suggested: (MultiQC, RRID:SCR_014982)</div></div><div style="margin-bottom:8px"><div>trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">16S-based analysis was performed with the latest SILVA 138 taxonomy and the Naive Bayes classifier trained on Silva 138 99% OTUs full-length sequences.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SILVA</div><div>suggested: (SILVA, RRID:SCR_006423)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For ITS-based analysis a classifier was trained on the UNITE reference database (ver8-99-classifier; 04.02.2020) according to John Quensen (http://john-quensen.com/tutorials/training-the-qiime2-classifier-with-unite-its-reference-sequences/; assessed 20/08/2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UNITE</div><div>suggested: (UNITE, RRID:SCR_006518)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For metagenomic biomarker discovery taxonomic feature-tables were introduced to LEfSe (linear discriminant analysis effect size) method (Galaxy version 1.0; p<0.05, LDA>2, All-against-all) [84].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Galaxy</div><div>suggested: (Galaxy, RRID:SCR_006281)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plots were generated with R (version 3.6.2)6 in RStudio (1.1.463)7 using following packages: tidyverse (1.3.0)8, qiime2r (0.99.6)9, ggplot2 (3.3.3)10, dplyr (1.0.6)11 and ggpubr (0.4.0.999)12 and GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RStudio</div><div>suggested: (RStudio, RRID:SCR_000432)</div></div><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The graphical abstract was created with BioRender (www.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GAPDH was used as loading control to determine protein abundance and band density was quantified and compared by using ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
The limitations of our descriptive study are that causalities cannot be directly inferred and that the relatively small cohort cannot show the entire picture of severe covid-19 and associated secondary infections. Varying clinical courses and different comorbidities might also have influenced our findings. In addition, treatment of covid-19 has changed since the early pandemic, thus, current severe courses and developing sequels might also have changed. We also cannot be sure whether the two described forms of DAD might represent just a spectrum of pathophysiological states or are specific pathotypes. Moreover, post-mortem effects like RNA degradation might have introduced additional noise in our investigation. Nevertheless, we found autopsy complemented with microbiology and molecular measures as a powerful tool to gain relevant clues about covid-19 pathophysiology. Importantly, there exists an obvious knowledge gap in the understanding of the molecular mechanisms driving the development of secondary infections on top of in viral lung diseases. This should initiate further studies to understand the molecular pathways in more detail and to unravel chronological phases of immuno-suppression which could also lead to development of rational therapies counteracting this sequel not only in covid-19. For these investigations, autopsy specimens and associated molecular data might serve as a valuable resource.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.18.480994: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal procedures were performed under the approval of the Institutional Animal Care and Use Committee (DSUA-2021-006-008) of Duksung Women’s University (Seoul, Korea).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Human embryonic kidney cells (HEK293T) is a female human embryonic kidney cell line (ATCC) and the HEK-ACE2 (derived from HEK293T cells) adherent cell line was obtained through BEI Resources, NIAID,</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pathology and immunohistochemistry: For histopathological examination, mouse lung samples harvested at 5 dpi were fixed in 10% formalin neutralization buffer (Sigma Aldrich) and stained with H&E. Additionally, IHC staining was performed to detect the viral antigen with primary antibodies, rabbit SARS-CoV-2 nucleocapsid pAb (40589-T62, Sinobiological, Beijing, China), at a dilution of 1:10,000 and HRP-conjugated secondary antibodies, using the Ventana discovery ULTRA system (Roche, Indianapolis, IN, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 nucleocapsid pAb ( 40589-T62 , Sinobiological , Beijing , China)</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and animals: Expi293F cells derived from the 293F cell line (Life Technologies, Carlsbad, CA, USA) were grown in Expi293 expression medium (Life Technologies), cultured at 37°C with 8% CO2 and shaking at 150</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T expressing human angiotensin-converting enzyme 2 (hACE2), HEK293T-hACE2 cell line (NR-52511).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK293T-hACE2</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T and HEK-ACE2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Texas, USA) supplemented with 10% fetal bovine serum (FBS) (Atlas Biologicals, Colorado, USA) and 1% penicillin-streptomycin (P/S) (Hyclone, Waltham, MA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were maintained in DMEM containing 10% FBS, 4.0 mM L-glutamine, 110 mg/L sodium pyruvate, 4.5 g/L D-glucose and 1% antibiotic-antimycotic at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Six-week old female B6.Cg-Tg(K18-ACE2)2Prlmn/J mice were obtained from Jackson Laboratory (Bar Harbor, Maine, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fusion proteins, SARS-CoV-2 RBD-SD1 WT-PCNA1-SARS-CoV RBD-SD1, MERS-CoV RBD-SD1-PCNA2-SARS-CoV-2 RBD-SD1 VAR, and hCoV 229E RBD-SD1-PCNA3-hCoV HKU1 RBD-SD1, were constructed with SGG linker sequences by overlapping PCR, which were termed S-PCNA1, M-PCNA2, and H-PCNA3, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 RBD-SD1 WT-PCNA1-SARS-CoV RBD-SD1 , MERS-CoV RBD-SD1-PCNA2-SARS-CoV-2 RBD-SD1 VAR</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RBD-SD1-PCNA3-hCoV HKU1 RBD-SD1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids encoding each antigen were amplified in E. coli strain DH5α, which were prepared in high purity and concentration using the PureLink HiPure plasmid kit (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DH5α</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse immunizations: Female BALB/c mice aged five weeks old were purchased from Koatech (Pyeongtaek, Kyunggi-do, Korea).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate HEK293T cell line stably expressing hACE2, HEK293T cells were transfected with pCEP4-myc-hACE2 and cells were selected using 100 μg/mL of hygromycin B (Invitrogen, Logan, Utah, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCEP4-myc-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For 6RBD-SD1 proteins, residues from 319 to 592 for SARS-CoV-2 WT and variant (VAR), 306 to 578 for SARS-CoV S, 367 to 657 for MERS-CoV S, 284 to 499 for hCoV 229E S, and 313 to 674 for hCoV HKU1 spike proteins as well as PCNA1, PCNA2, PCNA3_S170V were amplified from the pSecTag2A vector (Addgene) using the primers described in Extended Data Table 2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSecTag2A</div><div>suggested: RRID:Addgene_17839)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All sequences were confirmed by automated sequencing (Macrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Macrogen</div><div>suggested: (Macrogen, RRID:SCR_014454)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The IC50 values were calculated with non-linear regression using GraphPad Prism 8 (GraphPad Software, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Reviewer #1 (Public Review):
Qi J, et l. investigated how trabeculation is regulated during early cardiogenesis of zebrafish. They claim an essential role for protrusion from the endocardial cells (EdCs) in cardiac trabeculation. The protrusions originate from EdCs express Apelin receptor B (Aplnrb) and respond to Apelin released by monolayered myocardium. Conversely, monolayered cardiomyocytes expressing ErbB proliferate to become multilayered cardiomyocytes (trabeculation) in response to Neuregulin 2a (Nrg2a). Nrg2/Erb2 signaling activates Erk in the cardiomyocytes, thereby leading to proliferation as evidenced by the Erk signaling monitoring transgenic zebrafish line. The authors further confirmed that not only Nrg2a-ErbB signaling but also protrusion is necessary for trabeculation by showing that the lack of protrusion in the endocardium (overexpression of dominant negative form of IRSp53) resulted in failure of trabeculation in the endocardium-specific Nrg2-overexpressingtransgenic fish.<br /> The explanation and interpretation steps overall support their conclusions, because the experiments were well designed and were done by high-quality imaging techniques and by using several important transgenic zebrafish lines. The present manuscript would be improved by some revision to convince readers interested in the role of protrusions in trabeculation.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.18.481058: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies (anti-Flag-HRP or anti-Human Fc-HRP) were prepared with the same 5% milk at a dilution of 1:1000. 50 μL of secondary antibody was added into each well and incubated at room temperature for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Flag-HRP</div><div>suggested: (Shanghai Genomics Technology Cat# GNI4310-FG, RRID:AB_2885081)</div></div><div style="margin-bottom:8px"><div>anti-Human Fc-HRP </div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VH-Fc ab8, F6-ab8-Fc, and RBD-Fc were expressed with Expi293 cells as previously described[48, 62]</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells (ATCC, cat#CRL-3216) were used to produce pseudotyped retroviral particles as described previously[79].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# CRL-3216, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T-ACE2-TMPRSS2 cells (BEI Resources cat# NR-55293) were seeded in 384-well plates at 20 000 cells for neutralization assays.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One day before the assay, the Vero E6 cells (3 × 105 cells) were seeded in 24-well tissue culture plates per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Evaluation of F6-ab8-Fc Prophylactic and Therapeutic Efficacy with SARS-CoV-2 mouse Models: Eleven to twelve-month old female immunocompetent BALB/c mice (Envigo, stock# 047) were used for SARS-CoV-2 in vivo Prophylactic and Therapeutic experiments as described previously[51].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus Neutralization Assay: SARS-CoV-2 spike Wuhan-Hu-1 (+D614G), Alpha, Beta, Gamma, Delta, and Omicron protein genes were synthesized and inserted into pcDNA3.1 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The ELISA results were analyzed using GraphPad Prism 9.0.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">On-the-fly data pre-processing including patch mode motion correction (EER upsampling factor 1, EER number of fractions 40), patch mode CTF estimation, reference free particle picking, and particle extraction were carried out in cryoSPARC live.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">0.9.3[69], followed by iterative rounds of refinement in COOT and Phenix v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1.1.1[72], and PyMOL (v.2.2 Schrodinger, LLC)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All MD simulations were performed using NAMD (version 2.13)[76] with the protocol adopted from earlier work[77].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NAMD</div><div>suggested: (NAMD, RRID:SCR_014894)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 7. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.16.480801: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The separated proteins were transferred onto the PVDF membrane and probed using mouse anti-Flavivirus envelope 4G2 primary antibody and anti-mouse-HRP conjugated secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Flavivirus envelope 4G2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For IFA, Anti-mouse Influenza virus NP (HT103) was used as the primary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-mouse</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen, A11001) was used as the secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Mouse IgG</div><div>suggested: (Thermo Fisher Scientific Cat# A-11001, RRID:AB_2534069)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibody incubation for western blot was done with Anti-mouse Influenza virus NP (HT103) and secondary antibody with Goat Anti-Mouse IgG - H&L Polyclonal Antibody, HRP conjugated (Abcam, ab6789).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HT103</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibodies used for IFA include SARS-CoV-2 spike primary antibody (GTX632604, GeneTex) and goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GTX632604</div><div>suggested: (GeneTex Cat# GTX632604, RRID:AB_2864418)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After a 15 min chase, cells were fixed with 4% PFA, labeled with anti-influenza virus HA antibody (PY102) followed by anti-mouse Alexa 488 secondary antibody to label the virus particles.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-influenza virus HA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression levels of VP1 protein were detected by western blot using monoclonal mouse anti-enterovirus primary antibody Clone 5-D8/1 (Dako, M7064,) and anti-mouse antibody-HRP (Sigma Aldrich, A4416)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-enterovirus</div><div>suggested: (Agilent Cat# M7064, RRID:AB_2118128)</div></div><div style="margin-bottom:8px"><div>M7064</div><div>suggested: (Agilent Cat# M7064, RRID:AB_2118128)</div></div><div style="margin-bottom:8px"><div>anti-mouse antibody-HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A4416</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 12hr, cells were fixed with 4% formalin and immunolabeled with primary mouse anti VP6, and anti-mouse secondary Alexa Fluor 488 antibodies to detect virus-infected cells by IFA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti VP6,</div><div>suggested: (Acris Antibodies Cat# AM10217SU-N, RRID:AB_11216263)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DMEM containing 2% FBS was used for infection in Vero E6 cells and complete DMEM was used for HEK293T-ACE2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6, Calu-3, and HEK293T-ACE2 cells were seeded in 24-well cell culture dishes to reach 80% confluency post 24hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IAV plaque assay: MDCK cells were seeded in 12-well plates to reach complete confluency after 24hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MDCK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flavivirus infection: Confluent A549 cells in a 24-well cell culture plate were pre-treated for 3hr with 2 mM PA and infected with 100 µL per well DMEM containing 0.1 MOI JEV clinical strain P20778 or ZIKV Cambodia.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Influenza polymerase Assay: HEK293293T cells were seeded in a poly-L-lysine (Sigma Aldrich, P915</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293T cells were seeded in 2 X T75 flasks to reach 50-60% confluency the next day.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infection with AAV6 particles: HEK293 293T cells were seeded in a poly-L-lysine coated 24-well dish to reach 60-70% confluency the next day.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Adenovirus 5 infection: For infection studies, HEK293 cells were pre-treated for 3hr with 2mM PA and infected with 10 MOI AAV5-eGFP in the presence of the drug.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The infectious RNA was transfected in HeLa cells and the cell culture supernatant was harvested after 48hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plaque assay: Vero E6 cells were seeded in a 12-well plate at a confluency of approximately 90% and infected with serially diluted CVB3-containing cell culture supernatant and incubated at 37℃ for 1hr with gentle swirling of the medium at every 10-15 min interval.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For each flask, the following plasmids were transfected using Lipofectamine 2000 transfection reagent (Invitrogen, 11668019) as per manufacturer instructions: 17.7 μg pAdDeltaF6(Addgene 112867), 7.9 μg pRepCap6 (Addgene 110770), and 5.9 μg pAAV-CAG-GFP (Addgene 37825).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pAdDeltaF6</div><div>suggested: RRID:Addgene_112867)</div></div><div style="margin-bottom:8px"><div>pRepCap6</div><div>suggested: RRID:Addgene_110770)</div></div><div style="margin-bottom:8px"><div>pAAV-CAG-GFP</div><div>suggested: RRID:Addgene_37825)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, pCB3/T7 DNA was linearized using SalI-HF enzyme (R3138S, NEB) and CVB3 RNA was produced by in vitro transcription reaction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCB3/T7</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The fluorescence intensity of Tf-647 labeled vesicles was then measured along this distance using ImageJ/Fiji.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ/Fiji</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The number of GFP positive cells was analyzed using a Cytoflex (Beckman Coulter) flow cytometer and results were analyzed using CytExpert software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CytExpert</div><div>suggested: (CytExpert Software, RRID:SCR_017217)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 54, 55, 56, 57 and 60. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.17.479764: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of HEK293T cells with stable expression of human ACE-2: HEK293T cells were transduced with a lentiviral vector (pHAGE2-EF1aInt-ACE-2-WT) that expresses human ACE-2 under an EF1a promoter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of (SARS-CoV-2) S protein Pseudotyped Lentivirus: PVs were prepared by co-transfecting 293T cells with plasmids for (1) lentiviral backbone containing fluorescent reporter (pHAGE2-CMV-ZsGreen-W), (2) HIV virion formation proteins under CMV promoters (HDM-Hgpm2, pRC-CMV-Rev1b, and HDM-tat1b; and (3) viral entry proteins SARS-CoV-2 S protein (WT, D614G mutant) or VSV G as a positive control for infectivity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 cells were maintained in EMEM (with EBSS and L-glutamine, BioWhittaker, Lonza) supplemented with 20% FBS (heat-inactivated, Gibco), 0.1 mM MEM non-essential amino acids (Gibco), and 10 mM HEPES (Gibco) at pH 7.4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE-2 HEK 293T cells were cultured in DMEM + GlutaMax™-I medium (Gibco) supplemented with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE-2 HEK 293T</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids for lentiviral backbone expressing fluorescent reporter under CMV promoter (pHAGE2-CMV-ZsGreen-W) or human ACE-2 gene (GenBank ID NM_021804) under an EF1a promoter (pHAGE2-EF1aInt-ACE-2-WT) were obtained from BEI resources as NR-52520 and NR52512, respectively [35].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHAGE2-EF1aInt-ACE-2-WT</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The envelope vector expressing VSV-G (vesicular stomatitis virus glycoprotein) was obtained from Cell Biolabs (pCMV-VSV-G, Part No. RV-110).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VSV-G</div><div>suggested: RRID:Addgene_138479)</div></div><div style="margin-bottom:8px"><div>pCMV-VSV-G</div><div>suggested: RRID:Addgene_8454)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of (SARS-CoV-2) S protein Pseudotyped Lentivirus: PVs were prepared by co-transfecting 293T cells with plasmids for (1) lentiviral backbone containing fluorescent reporter (pHAGE2-CMV-ZsGreen-W), (2) HIV virion formation proteins under CMV promoters (HDM-Hgpm2, pRC-CMV-Rev1b, and HDM-tat1b; and (3) viral entry proteins SARS-CoV-2 S protein (WT, D614G mutant) or VSV G as a positive control for infectivity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHAGE2-CMV-ZsGreen-W</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pRC-CMV-Rev1b</div><div>suggested: RRID:Addgene_164443)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The ZsGreen expression area was quantified and normalized to the cell area estimated from the DRAQ5 staining using a custom ImageJ script.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical differences were analyzed using GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.17.480851: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: This study was part of an ongoing study and was reviewed by the Institutional Review Board (0278-18-HMO).<br>Consent: All the participants provided written informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Eligible participants were both male and female adults prior to or after receiving the BNT162b2 vaccine.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sandwich ELISA for total IgG or IgA: MAXISORB 96 wells plates were coated ON with secondary anti-IgG or anti-IgA antibodies, blocked as for direct ELISA and incubated for 30 min with sera and saliva samples, serially diluted in blocking buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>total IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgA</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Vero E6 and HEK293T cell lines were obtained from the American Type Culture Collection (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 and 293T cells were grown in DMEM medium supplemented with 10% (v/v</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">P0 generation was produced according to the original Michael Whitt(Whitt, 2010) protocol with minor modification, using co-transfection of the 5 plasmids (pVSV-ΔG-GFP, pBS-N-Tϕ, pBS-P-Tϕ, pBS-L-Tϕ and pBS-G) into HEK293 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Constructs and plasmids: The following plasmids were used for VSV-pseudovirus production: pVSV-ΔG-GFP, pCAGGS-G or pBS-N-Tϕ, pBS-P-Tϕ, pBS-L-Tϕ and pBS-G(Whitt, 2010).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pVSV-ΔG-GFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCAGGS-G</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBS-L-Tϕ</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBS-G(Whitt</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plasmids for expression of the Receptor Binding Domain of SARS-CoV2 spike (RBD) and full-length spike (SARS-CoV-2 S (Δ19 aa) were cloned into the pcDNA3.4 backbone (Thermo).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: RRID:Addgene_131198)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">P0 generation was produced according to the original Michael Whitt(Whitt, 2010) protocol with minor modification, using co-transfection of the 5 plasmids (pVSV-ΔG-GFP, pBS-N-Tϕ, pBS-P-Tϕ, pBS-L-Tϕ and pBS-G) into HEK293 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBS-N-Tϕ</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBS-P-Tϕ</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBS-G</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">P1 generation of VSV-G pseudotyped VSVdeltaG-GFP particles was generated by transfection of pCAGGS-VSV(G), followed by infection with P0 particles.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-VSV(G</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The images were captured from several fields of each well and the green cells were calculated by using automated image analysis by ImageJ (NIH).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The graphs were plotted to get the 50% neutralization titer (NT50), in GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
psycnet.apa.org psycnet.apa.org
-
Our findings suggest that not only do children noticeinterruptions during face-to-face interactions with their parents,but also that these interruptions have cognitive consequences, atleast for young word learners. They sidetrack language learning.ReferencesAdamson, L. B., Bakeman, R., Deckner, D. F., & Nelson, P. B. (2012).
findings
-
-
asulearn.appstate.edu asulearn.appstate.edu
-
1. Foxman B . Epidemiology of urinary tract infections: incidence, morbid-ity, and economic costs . Am J Med . 2002 ; 8 ( 113 ): 5-13 . 2. Hu B , Tao L , Rosenthal VD , Liu K , Yun Y , Suo Y , et al. Device-associat-ed infection rates, device use, length of stay, and mortality in intensive care units of 4 Chinese hospitals: International Nosocomial Control Consortium fi ndings . Am J Infect Control. 2013 ; 41 : 301-306 . 3. Webster J , Hood RH , Burridge CA , Doidge ML , Phillips KM , George N . Water or antiseptic for periurethral cleaning before urinary catheterization: a randomized controlled trial . Am J Infect Control’ . 2001 ; 29 : 389-394 . 4. Conway LJ , Larson EL . Guidelines to prevent catheter-associated uri-nary tract infection: 1980 to 2010 . Heart Lung . 2012 ; 41 ( 3 ): 271-283 . 5. Flores-Gonzaleza JC , Hernandez-Gonzaleza A , Rodriguez-Lopeza C , et al. [ Nosocomial urinary tract infection in critical pediatric patients] . Med Intensiva . 2011 ; 35 ( 6 ): 344-348 . 6. Arda B , Ates ̧ K , Bakır M , et al. Uriner kateter infeksiyonlarının önlenme-si kılavuzu . Hastane Infeksiyonları Dergisi. 2012 ; 16 ( 1 ): 1-18 . 7. Aygün P. Katater I.lis ̧ kili Üriner Enfeksiyonların Önlenmesi. Hastane Enfeksiyonları Korunma ve Kontrol . 1.baskı. Istanbul, Turkey : Aksu BasımYayın ; 2008 . 8. National Nosocomial Infections Surveillance (NNIS) system report. Data summary from January 1992-June 2004 . J Am Infect Control . 2004 ; 32 : 470-485 . 9. Rosenthal VD , Maki DG , Mehta Y , et al. International Nosocomial In-fection Control Consortium (INICC) report, data summary of 43 coun-tries for 2007-2012. Device-associated module . Am J Infect Control. 2014 ; 42 : 942-956 . 10. Brindha SM , Jayashree M , Singhi S , Taneja N . Study of nosocomial urinary tract infections in a pediatric intensive care unit . J Trop Pediatr . 2011 ;57(5): 357-362 . 11. Ulusal hastane enfeksiyonları sürveyans ag ̆ ı (UHESA) raporu özet veri . Sag ̆ lık Bakanlıg ̆ ı Sag ̆ lık Hizmetleri Genel Müdürlüg ̆ ü Sag ̆ lık Hizmet Standartları Dairesi Bas ̧ kanlıg ̆ ı. Türkiye Hastane Enfeksiyonları Sür-veyans Sistemi Web site . http://uhes.saglik.gov.tr/public . Published 2013. Accessed January 14, 2015. 12. Cheung K , Leung P , Wong YC , et al. Water versus antiseptic periure-thral cleansing before catheterization among home care patients: a randomized controlled trial . Am J Infect Control . 2008 ; 36 : 375-380 . 13. Wong E , Hooton T . Guidelines for the Prevention of Catheter-Associat-ed Urinary Tract Infections. Guidelines for the Prevention and Control of Nosocomial Infections . Atlanta, GA : Centers for Disease Control and Prevention ; 1982 . http://www.cdc.gov/ncidod/dhqp/gl_cathe-ter_assoc.html . Published 2008. Accessed January 16, 2015. 14. Willson M , Wilde M , Webb ML , et al. Nursing interventions to reduce the risk of catheter-associated urinary tract infection . J Wound Osto-my Continence Nurs. 2009 ; 36 ( 2 ): 137-154 . 15. Jordan S , Pogorzelska M , Larson E , Stone PW . Range of policies for prevention of catheter-associated urinary tract infections in intensive care units. Paper presented at: Association for Professionals in Infec-tion Control and Prevention Annual Educational Conference and Inter-national Meeting ; 2010 ; New Orleans, LA. http://www.sciencedirect.com.ezproxy.cul.columbia.edu/science . Accessed February 4, 2015. 16. Gould CV , Umscheid CA , Agarwal RK , Kuntz G , Pegues DA ; Health-care Infection Control Practices Advisory Committee (HICPAC) . Guideline for prevention of catheter-associated urinary tract infections 2009 . Infect Control Hosp Epidemiol . 2010 ; 31 ( 4 ): 319-326 . 17. Al-Farsi S , Oliva M , Davidson R , Richardson SE , Ratnapalan S . Periurethral cleaning prior to urinary catheterization in children: sterile water versus 10% povidone-iodine . Clin Pediatr . 2009 ; 48 ( 6 ): 656-660 . 18. Dossaji S , Çelik Ü , Alhan E , Yıldızdas D , Ünal I . Nozokomiyal enfeksiy-onlariçin enfeksiyon belirteçleri . J. Pediatr Inf. 2008 ; 2 : 12-18 . 19. Leblebicioglu H , Erben N , Rosenthal VD , et al. International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003-2012 . Ann Clin Microbiol Antimicrob. 2014 ; 13 : 51 . 20. Leblebicioglu H , Rosenthal VD , Arikan OA , et al. Turkish Branch of INICC. Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC) . J Hosp Infect. 2007 ; 65 : 251-257 . 21. Ozinel MA , Bakir M , Cek M . Üriner kateter infeksiyonlarının önlenmesi kılavuzu . Hastane Infeksiyonları Dergisi. 2004 ; 8 ( 1 ): 3-12 .
- Most sources more than 5 years old.
-
-
indylab1.fission.app indylab1.fission.appmemex1
-
Engelbart understood the uniqueness behind Bush’s memex machine, particularly the notion of duplicating a trail so that information could be shared with others. “Making it easy to establish and follow the associative trails makes practical a new symbol-structuring process whose use can make a significant difference in the concept structuring and b[a]sic methods of work. It is also probable that clever usage of associative-trail manipulation can augment the human’s process structuring and executing capa[b]ilities so that he could successfully make use of even more powerful symbol-
associative trails
new porofession of TrailNlazers
Marking their trails with TrailMarks
When these annotations form integral parts of your Mind'Graph they cam be llinked to and from any node in the gloabl giant interplanetary social graph of commons based mutual learnings
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.14.480430: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-dsRNA antibody was obtained from Millipore (identifier MABE1134); anti-mouse IgG AlexaFluor 647 was obtained from Invitrogen (Identifier A32628); anti-llama secondary HRP, goat IgG was obtained from Novus (identifier NB7242).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-llama secondary HRP, goat IgG</div><div>suggested: (Thermo Fisher Scientific Cat# A16060, RRID:AB_2534733)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were stained overnight with an anti-dsRNA antibody diluted 1:50 in blocking buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-dsRNA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed three times with PBS and then stained with an A647 secondary antibody for 1 hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A647</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were permeabilized in perm buffer (0.1% saponin, 0.1% BSA in PBS) for 30 minutes, then incubated with 50 μL primary antibody (alpaca anti-SARS-CoV-2 serum, diluted 1:5,000 in perm buffer) for either 2hr room temperature or overnight at 4 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were incubated with 50 μL secondary antibody (anti-llama HRP, goat IgG) for either 2hr room temperature or overnight at 4 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-llama HRP, goat IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Materials: Cell lines: Cell lines (HEK293T, HEK293T-ACE2, Vero-E6, and Caco2) were obtained from ATCC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral strains: SARS-CoV-2 viral strains (isolate USA-WA1/2020: Identifier #NR-52281; isolate USA/CA_CDC_5574/2020: Identifier #NR-54011; isolate hCoV-19/South Africa/KRISP-K005325/2020: Identifier #NR-54009; hCoV-19/Japan/TY7-503/2021: Identifier #NR54982; isolate hCoV-19/USA/PHC658/2021: Identifier # NR-55611) were obtained from BEI resources and propagated in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Media for Vero-E6 cells, 293T (wt) and 293T-ACE2 cells was supplemented with 10% FBS while media for Caco2 cells was supplemented with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wild-type 293T cells were seeded in 6cm dishes and transfected with varying amounts viral plasmids (based on optimal expression for each plasmid, see Table S1), as well as a PLVX empty vector control, using Lipofectamine 3000 (ThermoFisher Scientific) as per manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lipid droplet immunofluorescence — Infection: 293T-ACE2 or Caco2 cells were seeded at 70% cell density in 24-well plates and allowed to grow overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco2</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.14.480338: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Hokkaido University (approval no. 20-0060).<br>Euthanasia Agents: Virus infection and treatment of hamsters: Five-week old male Syrian hamsters (Japan SLC) were intranasally inoculated with 5,000 pfu of SARS-CoV-2 in 200 μl of PBS under anesthesia with isoflurane inhalation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Pharmacokinetics studies: Five-week old male Syrian hamsters (Japan SLC) were orally administered at 10, 30, and 100 mg/kg of S-217622 under the non-fasting conditions (n = 3, each).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-TMPRSS2 cells at 24 hpi and Calu-3 cells at 72 hpi were fixed with 3.7% formaldehyde in PBS, followed by permeabilization with 0.5% Triton X-100 in PBS for 5 min and staining with anti-SARS-CoV-2 nucleocapsid rabbit monoclonal antibody (GTX635679, GeneTex) in 25% Block Ace (KAC) in PBS for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 nucleocapsid</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>GTX635679</div><div>suggested: (GeneTex Cat# GTX635679, RRID:AB_2888553)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alexa Fluor 488-conjugated anti-rabbit IgG antibody (Invitrogen; Thermo Fisher Scientific) was used as the secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Alexa Fluor 488-conjugated anti-rabbit IgG antibody</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tissues were further incubated for 4 days with secondary antibody staining solution; Alexa Fluor Plus 647-conjugated anti-rabbit IgG (A32795, Invitrogen) diluted in PBSBT with 0.1% saponin and filtrated though a 0.45 μm syringe filter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A32795</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-TMPRSS2 cells [Vero E6 cells (ATCC, CRL-1586</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T (RIKEN BRC, RCB2202) cells were maintained in high glucose DMEM containing 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RCB2202</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T-ACE2-TMPRSS2 cells stably expressing human TMPRSS2 and ACE2 were established by a lentiviral vector transduction system as previously described35 and maintained in high glucose DMEM containing 10%</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-TMPRSS2 cells at 24 hpi and Calu-3 cells at 72 hpi were fixed with 3.7% formaldehyde in PBS, followed by permeabilization with 0.5% Triton X-100 in PBS for 5 min and staining with anti-SARS-CoV-2 nucleocapsid rabbit monoclonal antibody (GTX635679, GeneTex) in 25% Block Ace (KAC) in PBS for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fluorescent images were captured using IX73 fluorescence microscope (Olympus). qRT-PCR: Vero-TMPRSS2 and Calu-3 cells were inoculated with SARS-CoV-2 at MOIs of 0.01 or 0.1, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biosensor assay for viral protease activity: The DNA fragments encoding SARS-CoV-2 NSP3 or NSP4, NSP5, N-terminal NSP6 (NSP4/5/6N) were cloned into pCMV-derivative pCXSN vector to generate pSARS-CoV-2 PLpro and pSARS-CoV-2 Mpro, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV-derivative pCXSN</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The amino acid sequence AVLQS (for the cleavage by Mpro) or RLKGG (for the cleavage by PLpro) were inserted into pGloSensor-30F vector backbone (CS182101, Promega) to generate firefly luciferase-based biosensor expressing plasmid pGS-AVLQS or pGS-RLKGG, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGloSensor-30F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T cells on 96-well plate were co-transfected with a set of pGS-AVLQS and pSARS-CoV-2 Mpro or a set of pGS-RLKGG and pSARS-CoV-2 PLpro using TranIT-LT1</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGS-AVLQS</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pGS-RLKGG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSARS-CoV-2 PLpro</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 24 h post transfection, the luminescence signals of biosensors and renilla luciferase (an internal control reporter) from pGS vectors were measured by Dual-Glo Luciferase Assay System (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGS</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The concentration achieving 50% inhibition of cytopathic effect (effective concentration; EC50) was defined in GraphPad Prism version 8.4.3 (GraphPad Software) with a variable slope (four parameters)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image data was converted and processed into 3D reconstruction by Imaris software (Oxford Instruments).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Imaris</div><div>suggested: (Imaris, RRID:SCR_007370)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
We note some limitations of our study. First, therapeutic treatment with S-217622 was insufficient to control pneumonia in SARS-CoV-2-infected hamsters, although they regained lost body weight earlier compared to vehicle controls. We assume that the initial virus proliferation stimulated host immunity and subsequent inflammation31, 32, and combination with antiviral and anti-inflammatory medication may lead to better results and outcomes33. Second, this study was conducted using hamsters as a COVID-19 model and the efficacy in human patients cannot be inferred. However, S-217622 is currently under evaluation in a phase II/III clinical trial. Third, the development of a resistant viral clone against S-217622 and its virological properties will need to be investigated in future studies. In summary, our study has demonstrated the remarkable antiviral activity of S-217622 through in vitro and in vivo experiments. This scientific evidence will be invaluable when considering the application of S-217622 as a medication for COVID-19.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 41. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Author Response
Reviewer #1 (Public Review):
This is a very solid and exciting study.
We thank the reviewer for finding our study to be very solid and exciting.
I have several suggestions, comments and questions:
- The authors focused on examining the role of C129 as a regulator of PTPN22 redox sensitivity based on a published crystal structure of the catalytic domain. It would be great if they could demonstrate the existence of the disulfide bond between C129 and C227 also experimentally (in T cells).
As we understand it, it is requested that the disulfide bond between C227 and C129, as previously suggested by Tsai et al. (2009) (1) with pure protein, should be documented to actually occur in the activated T cells. We fully agree that this would improve the study and we have therefore made several attempts to demonstrate this oxidation, or the oxidation state of the active site Cys residue in PTPN22 in situ. However, as we had also expected, it has proven to be technically very challenging. Nevertheless, as the functional consequence of the PTPN22 oxidation and the effect of the C129S mutation is clearly documented in the mouse, using in vivo experiments, we still think it is valid to conclude that the reversible oxidation state of PTPN22 as well as the involvement of the Cys129 residue regulates the function of PTPN22 in vivo, which is the main conclusion of our study.
- To this end, there are other cysteine residues in the vicinity of C227 such as the C231 that might be involved in the redox regulation PTPN22. The authors should at least discuss the their possible involvement.
It is correct that Tsai et al. (2009) (1) found that mutating C231 to serine dramatically reduced phosphatase activity, thus suggesting its importance in catalysis. Reactivation assays showed higher reactivation rates for C231S mutants, and they suggested that C231 suppresses reactivation in a reducing environment by competing with C227 for reduction in the catalytic pocket. Therefore, C231 could also be a target for negative regulation of PTPN22. However, our project was from the start limited to the intention of studying whether PTPN22 could be shown to be redox regulated in vivo through modification of key cysteine residues, and the aim has not been to give the full picture of how the molecule is regulated. We have now extended this point in the discussion in the paper.
- How is mutation of C227 affecting T cell function? Are the effects similar with those of C129S?
This would be interesting but to analyze if also the cysteine at 227 is regulating the T cell activation by creating another transgenic C227S mouse is outside the scope of the study. As said above and clearly described in the study, we have focused on the redox-mediated effects through C129 and hope that the reviewer can agree with us that this rather focused study is solid and fully sufficient for publication on its own merits.
- Although the in vitro evaluation of the PTPN22 activity is of highest quality, it would be good to demonstrate that C227 redox status is modified under physiological conditions. 25-100 µM H2O2 is a high concentration that might not be reached within a cell and might be lethal for T cells.
See response to point 1.
- C129 seems not to be mutated in patients with autoimmunity but is an excellent tool to test the importance of C227 redox regulation and the findings of this study suggest that its over-oxidation will support autoimmune responses. When considering the clinical relevance of the study, a drug that will protect the oxidation of the catalytic cysteine and/or stabilize the disulfide bond would have beneficial effects. The authors could test such pharmacological modulators in isolated T cells.
Indeed, such modulators would be very interesting to test; however, developing such drugs can hardly be demanded to be within the scope of this study. We have however included a statement on this topic in the Discussion of the manuscript.
- The authors discuss that NOX2-derived ROS most likely originate from antigen presenting cells. I fully agree with this discussion. However, some studies have proposed that NOX2 plays an important role also in T cells, a finding which was not confirmed by other following studies. It would be great if the authors could address this controversial issue in regards to their findings.
The finding that the ROS that modify PTPN22 in fact come from the interacting APC rather than from the T cell itself we believe is very important. However, we have not made a major point of this as we have shown that aspect before in other studies, and we wanted in the current paper to focus on the take home message that PTPN22 could hereby be shown to be redox regulated in vivo. However, the last word about the source of ROS has not been said. The controversy whether the Ncf1 containing NOX2 complex is functionally expressed in T cells stems from the paper by Jackson et al. in Nat Immunol 2004 (2). We have not been able to reproduce those findings and in addition we have never detected a NOX2 dependent response in pure T cells, which has also been shown in several of our papers. There are certainly many pitfalls, contaminating NOX2 expressing cells, NOX2 containing exosomes and peroxides, and even NOX2 complexes picked up by interactions with antigen presenting cells. However, it is dangerous to completely exclude that Ncf1 could be expressed at minimal levels or to exclude that functional NOX2 complex can indeed be formed in T cells, and we all know that minute levels of any peroxide as produced by cells could have an impact on cellular functions. But, based on the present knowledge we conclude that T cells do not functionally express Ncf1-containing NOX2 complexes. We have now added two references to enlighten this point, (3, 4; refs. 38 & 39 in the manuscript).
- Fig. 1: Is the addition of bicarbonate affecting the pH and thus the activity of PTPN22?
No, we believe that addition of bicarbonate is not acting by an altered pH but is instead required for formation of peroxymonocarbonate when reacting with H2O2, which is subsequently the molecular species that bypasses the cellular antioxidant systems in order to oxidize the active site Cys residues of target PTPs. This was shown by us in an earlier publication (Dagnell et al, ref. 11 in the manuscript) (5) and a sentence has now been added in the Discussion to further emphasize this point.
- The H2O2 concentration dependence of PTPN22_C129S should also be shown as for WT (see Fig. 1B)
We agree with the reviewer that titration of the mutant with additional H2O2 concentrations could potentially have been done, but we thought that the comparison of WT and C129S enzyme side-by-side using either 0 µM, 25 µM or 50 µM as in Fig. 1D was a sufficient comparison in H2O2 sensitivity. Unfortunately, we do not have the possibility to analyze more purified C129S mutant protein at the moment and it would require a major effort to run those additional experiments. We thereby hope that the reviewer would agree with having the data presented as they currently are to be sufficient.
- Quantification of the slope based on only 3 measuring points is not accurate (Fig. 1D).
Each data point in those curves represents the mean ± S.D. derived from duplicate samples ran three different times, with clearly very low standard deviations. Thus, we believe that the data are reliable and that the statistically significant difference when comparing the slopes between WT and the C129S mutant as shown in the figure, should be trustworthy.
- The pinna thickness measurements shown in Fig. 3B and C suggest that in NCF1 mice C129S has no effect. However, the thickness in NCF1 mice is already much higher than in WT mice (compare B and C). Does this mean that NOX2-derived ROS are the only factor that affects C227 redox properties?
The effects of the decreased ROS due to the Ncf1 mutation is likely to have consequences for the functions of many proteins, in different pathways, and not only of PTPN22. The sum effect is that the Ncf1 mutated mice responds stronger than the wild type, which explains the difference. However, the main message here is that if there is no ROS from the NOX2 complex, the effect of the PTPN22 mutation is lost.
- The results shown in Fig. 5D could be moved to a supplementary figure.
We prefer to keep it within Fig 5 as it is more logical in the context or the other parts of this figure. Of course, if there is a space layout problem, we can consider moving it.
- The calcium measurements are not convincing and the differences are rather small. The y axis labels show 50K, 100K etc. Are this ratio values? If yes the imaging settings need to be optimized. Why is the mutant labeled as Pep? How is the C129S affecting calcium signaling? These observations need be examined in more detail or maybe calcium is not playing an important role.
We agree that the differences in calcium measurements are not very large but have nevertheless been repeated several times, and there is a significant difference as shown. The calculation is done on the slope of the curve, which is independent of the absolute values given on the y-axis. We agree that the figure was not properly labeled and have now changed this.
- I would suggest a more extensive evaluation of the proteomic data presented in Fig. 6D. The results might be very exciting and can further increase the impact of this study.
We fully agree with this. We have chosen not to go into details of the results of the proteomic analysis. The data shown confirms our conclusion and we did not plan to identify the downstream targets of the PTPN22 oxidative regulation. Highlighting some of these targets will require biological confirmation, which can be done but must await future work. The full dataset has however been deposited in PRIDE for any reader interested to analyze the results further.
- Is 24h BSO treatment not toxic for the T cells (ferroptosis)?
We have not seen any evidence for toxicity upon the BSO treatment of T cells in vitro, which however has been more thoroughly checked by others. Gringhuis et al (JI, 2000) (6) have shown immunofluorescence staining on T cells 72 hours post BSO treatment with intact cell membranes. Additionally, Carilho et al. (Chem. Cent. J., 2013, 7:150) (7) noted no changes in Jurkat T cell viability after 24 hours at a maximum dose of 100 µM BSO.
Reviewer #3 (Public Review):
The manuscript by James, Chen Hernandez et al. reveals a novel function for PTPN22 oxidation in T-Cell activation. The authors used a broad array of methods to demonstrate that PTPN22 is catalytically impaired in addition to being more sensitive to reversible oxidation in vitro. In the characterization process, the authors found that PTPN22 could be directly reduced by Thioredoxin Reductase and that oxidation of PTPN22 oxidation could be easily monitored by the appearance of a faster migrating band in non-reducing gels. Supporting the hypothesis that the catalytic Cysteine forms a disulfide with a backdoor Cysteine (Cys129), the authors found that this C129S mutant is prone to oxidation and cannot be reduced back to its active form by Thioredoxin Reductase. Using a new mouse model in which this key Cysteine of PTPN22 is mutated to a Serine residue (PTPN22C129S mutant) and can presumably not form a stabilizing redox intermediate between the catalytic Cys residue and this backdoor Cys (C227-C129), the authors study how the oxidation prone mutant affects T-Cell activation. The authors find that the C129S mutant mouse showed an increased T-Cell dependent inflammatory response that was dependent on activation of the reactive oxygen species-producing enzyme NOX2. This data adds an interesting redox twist to the function of PTPN22 in T-Cells that contributes to conversation on the protective effects of reactive oxygen species against inflammatory diseases in vivo.
Strengths:
The in vitro characterization of the WT and C129S mutant form of PTPN22 is very thorough. Determination of the Km and Kcat highlights the differences between the two enzymes that go beyond redox regulation of the phosphatase. The reduction studies are masterfully done and highlight a novel reduction mechanism that merits to be further studied in cells. Demonstrating that PTPN22C129S is prone to oxidation in vitro is a key and technically challenging result that may be applicable to other members of the PTP family that also form disulfides with a backdoor cysteine. Showing that PTPN22C129S mice (backcrossed to B6Q mice making them susceptible to autoimmune arthritis) displayed higher T cell activation in two models (DTH and GPI), in addition to studies in T cells stimulated with collagen, increased this reviewer's confidence that the PTPN22C129S mouse exhibited T-cell-dependent inflammatory response phenotype similar to the PTPN22 knockout phenotype. Validation of T-cell signaling events in PTPn22C129S T cells were in line with the in vitro characterization of the phosphatase.
We thank the reviewer very much for the detailed summary of our findings and the appreciative words.
Weaknesses: Although the paper has many strengths, some important weaknesses need to be addressed by the authors. In particular, the authors need to characterize better their mouse model and determine if PTPN22 is reversibly oxidized following TCR activation. If PTPN22 is oxidized, does it form an intramolecular disulfide between C227 and C129? The proposed model, that PTPN22C129S is more prone to oxidation, also has to be validated in vivo. Although this could be technically challenging in theory, the authors have shown that the migration pattern of the oxidized enzyme is different that of the reduced enzyme. Another major issue is that PTPN22 does not appear to be expressed in CD4+ T cells unless these cells are activated in vitro with anti-CD3/CD28 for 24 hours. This makes acute CD3-stimulation of CD4+ T cells studies - such as the measurement of acute calcium influx in Fig. 5E - very difficult to interpret. Perhaps the authors should explain why acute signal transduction studies in Figure 6 were performed in lymph node cells. If the reason is that PTPN22 (WT and C129S mutant) expression is higher, the authors should provide immunoblots for PTPN22 in these cells. Since the PTPN22C129S mouse model has not been sufficiently validated, the claims of the authors are unfortunately weakened and the underlying molecular mechanisms do not completely support their conclusions. However, given the clear in vitro work provided in figures 1 and 2, it is this Reviewer's opinion that the authors can address the issues related to the oxidation status of PTPN22 and of PTPN22C129S in vivo, support their claims, and make a significant contribution to the field.
We again thank the reviewer for the detailed summary of our findings and for the suggestions. With regards to the in vivo oxidation status of PTPN22, please see the discussion above.
- Tsai SJ, Sen U, Zhao L, Greenleaf WB, Dasgupta J, Fiorillo E, et al. Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation. Biochemistry. 2009;48(22):4838-45.
- Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol. 2004;5(8):818-27.
- Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci U S A. 2006;103(34):12831-6.
- Gelderman KA, Hultqvist M, Pizzolla A, Zhao M, Nandakumar KS, Mattsson R, et al. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species. J Clin Invest. 2007;117(10):3020-8.
- Dagnell M, Cheng Q, Rizvi SHM, Pace PE, Boivin B, Winterbourn CC, et al. Bicarbonate is essential for protein-tyrosine phosphatase 1B (PTP1B) oxidation and cellular signaling through EGF-triggered phosphorylation cascades. J Biol Chem. 2019;294(33):12330-8.
- Gringhuis SI, Leow A, Papendrecht-Van Der Voort EA, Remans PH, Breedveld FC, Verweij CL. Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol. 2000;164(4):2170-9.
- Carilho Torrao RB, Dias IH, Bennett SJ, Dunston CR, Griffiths HR. Healthy ageing and depletion of intracellular glutathione influences T cell membrane thioredoxin-1 levels and cytokine secretion. Chem Cent J. 2013;7(1):150.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.14.480449: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mouse vaccination: Vaccine immunogenicity study used 6 weeks old female C57BL/6Ncr (B6) mice purchased from Charles River.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Replication, randomization, blinding and reagent validations: Biological or technical replicate samples were randomized where appropriate.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Replication, randomization, blinding and reagent validations: Biological or technical replicate samples were randomized where appropriate.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines tested negative for mycoplasma.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed twice after the primary stain and incubated with PE–anti-human Fc antibody (Biolegend, 410708) in MACS buffer for 20 min on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PE–anti-human Fc antibody ( Biolegend , 410708</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-mouse secondary antibody (Fisher, Cat# A-10677) at 1:2500 dilution in blocking buffer was incubated at room temperature for one hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-mouse</div><div>suggested: (Thermo Fisher Scientific Cat# A-10677, RRID:AB_2534060)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Validation of LNP-mRNA mediated spike expression in vitro and receptor binding capability of expressed Omicron HexaPro spikes: On day 1, HEK293T cells were seeded at 50% confluence in 24-well plate and mixed with 2 μg Omicron LNP-mRNA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293FT cells were seeded in 150 mm plates, and transfected with 21 μg pHIVNLGagPol, 21 μg pCCNanoLuc2AEGFP, and 7.5 μg of corresponding plasmids, in the presence of 198 μl PEI (1mg/ml, PEI MAX, Polyscience).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293FT</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To normalize pseudovirus tilter, 0.01 x106 293T-hACE2 cells were plated in each well of a 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse vaccination: Vaccine immunogenicity study used 6 weeks old female C57BL/6Ncr (B6) mice purchased from Charles River.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6Ncr</div><div>suggested: RRID:MGI:2160593)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The accessory plasmids for pseudovirus assay including pHIVNLGagPol and pCCNanoLuc2AEGFP were from Dr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCCNanoLuc2AEGFP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1.1.529 variant S protein (Omicron variant-Δ19) were made based on the pSARS-CoV-2-Δ19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSARS-CoV-2-Δ19</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was collected on BD FACSAria II Cell Sorter (BD) and analyzed using FlowJo software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 50% inhibitory concentration (IC50) was calculated with a four-parameter logistic regression using GraphPad Prism (GraphPad Software Inc.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The statistical significance was labeled as follows: n.s., not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Prism (GraphPad Software) and RStudio were used for these analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Schematic illustrations: Schematic illustrations were created with Affinity Designer or BioRender.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
While a limitation of our study is that these are animal data, although the antibody responses to vaccination is highly conserved between mouse and human (and that the mouse is a widely used preclinical model by major vaccine makers36,37). In fact, a very recent report showed waning immunity in vaccinated individuals24 and that a booster shot using the original WA-1 based mRNA vaccine helps recover partial immunity. However, the neutralizing antibody titers even after the boost with a WA-1 based vaccine titer were still significantly lower against Omicron as compared to WA-1 and other variants, urging for development and testing of an Omicron-specific vaccine not studied before. We tested the Omicron-specific LNP-mRNA vaccine candidate in the context of WA-1 vaccinated animals. While animals almost completely lost antibody protection against Omicron even though they received two doses of WA-1 mRNA vaccine 3.5 months ago, our results showed that a single dose of Omicron mRNA vaccination boosted neutralizing antibody titers over 1000-fold against Omicron. In addition, the Omicron-specific vaccine also brought back neutralizing titers against WA-1 and Delta variants to a level comparable to peak titers by WA-1 mRNA vaccine. The Omicron booster shot provided superior protection against Omicron variant and comparable humoral defense against WA-1 and Delta variants. Such surge of antibody titer by Omicron booster shot, and the neutralization activities against WA-1 and Delta, two o...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 32. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.12.480218: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The Institutional Animal Use and Care Committee approved these experiments (study protocol# 21702).<br>Field Sample Permit: Trachea collection and cell processing: Upon necropsy, tracheobronchial tissues were collected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">All animals were challenged through combined intratracheal (IT, 2.0 mL for dams, 1 ml for infants) and intranasal (IN, 0.2 5 mL per nostril) inoculation with an infectious dose of 2.5 × 10^6 PFU for the dams and 1.5 × 10^6 PFU for the infants of SARS-CoV-2 (2019-nCoV/USA-WA1/2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Radiographs were scored for the presence of pulmonary infiltrates by a board-certified veterinary radiologist, who was blinded to the experimental group and time point, according to a standard scoring system (0: normal; 1: mild interstitial pulmonary infiltrates; 2: moderate pulmonary infiltrates perhaps with partial cardiac border effacement and small areas of pulmonary consolidation; 3: severe interstitial infiltrates, large areas of pulmonary consolidation, alveolar patterns and air bronchograms).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Paraffin sections were treated in an antigen unmasking solution (Vector) at 100°C for 20 minutes before incubation with a primary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen unmasking solution (Vector)</div><div>suggested: (Vector Laboratories Cat# H-3301, RRID:AB_2336227)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293 T/ACE2 cells were provided by M. Farzan and H. Mu at Scripps Florida.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>T/ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK 293T cells expressing ACE2 receptors were suspended using TrypLE Select Enzyme solution (Thermo Fisher Scientific) and immediately added to all wells (10,000 cells in 100 μl of growth medium per well).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions were produced in HEK293 T/17 cells (American Type Culture Collection, catalog no. CRL-11268) by transfection using Fugene 6 (Promega, catalog no. E2692) and a combination of S plasmid, lentiviral backbone plasmid (pCMV ΔR8.2), and firefly Luc reporter gene plasmid (pHR’ CMV Luc) (78) in a 1:17:17 ratio.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV ΔR8.2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis of the bulk RNA-seq data: RNA-Seq data was quality checked with FastQC (59) and preprocessing was carried out using TrimGalore (60) toolkit to trim low-quality bases and Illumina adapter sequences using default settings.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads were aligned to the ENSEMBL Homo_sapiens.GRCh38.dna.primary_assembly genome using the ENSEMBL Homo_sapiens.GRCh38.100 transcript (61) annotation file with STAR (62) splice-aware RNA-seq alignment tool in paired mode allowing maximum multimapping of 3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ENSEMBL</div><div>suggested: (Ensembl, RRID:SCR_002344)</div></div><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene level counts were quantified using FeatureCounts (63) tool, counting unique features in non-stranded mode and retaining both gene ID, gene name, and gene biotype mapping from the ENSEMBL annotation file.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FeatureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Normalization and differential expression were carried out with DESeq2 (64)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bioconductor (65) package, utilizing the ‘apeglm’ Bioconductor package (66) for log fold change shrinkage, in R statistical programming environment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bioconductor</div><div>suggested: (Bioconductor, RRID:SCR_006442)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The RNA-seq data was processed using the TrimGalore toolkit1 which employs Cutadapt2 to trim low quality bases and Illumina sequencing adapters from the 3’ end of the reads.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TrimGalore</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene counts were compiled using the HTSeq tool5.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HTSeq</div><div>suggested: (HTSeq, RRID:SCR_005514)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Normalization and differential expression was carried out using the DESeq26 Bioconductor7 package with the R statistical programming environment8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq26</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Bioconductor7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene set enrichment analysis9 was performed to identify gene ontology terms and pathways associated with altered gene expression for each of the comparisons performed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene set enrichment</div><div>suggested: (Gene Set Enrichment Analysis, RRID:SCR_003199)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our study has limitations. Firstly, we only infected two dam-infant macaque pairs and more animal numbers are needed to determine statistical differences. Additionally, a mock-inoculated control group is necessary to decipher whether the differences observed are due to SARS-CoV-2 infection alone, the age-dependent maturation of tissues and the immune response, and/or experimental procedures. Finally, the time of euthanasia was not focused on evaluating acute inflammatory responses in tissues, as at 2 weeks, virus replication is mainly gone and tissue responses reflect repair in this animal model, and we evaluated trachea instead of lung responses. However, our study is valuable in that it agrees with currently published data in SARS-CoV-2-infected pediatric and adult cohorts and furthers our understanding of why younger populations are less susceptible to severe COVID-19 compared to adults. Additionally, this model will allow further definition of molecular mechanisms of age-dependent SARS-CoV-2 pathogenesis and assess efficacy of medical countermeasures.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.12.480188: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Golden Syrian hamsters comprising equal numbers of males and females were purchased from an approved vendor.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum IgG ELISA: Indirect ELISA was performed to analyze sera for binding antibodies to SARS-CoV-2 spike protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary detection antibody (goat anti-species-HRP IgG; Abcam) was added at a dilution of 1:10,000 in 100 µl per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>goat anti-species-HRP IgG; Abcam</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-species-HRP IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, 2.4 x105 Sf9 insect cells were plated into a well of a 24 well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sf9</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plaque reduction neutralization test (PRNT): Vero 76 cells were cultured in 24-well plates at 175,000 cells/well in DMEM + 10% v/v FBS + Gentamicin and incubated at 37 °C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero 76</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently, Vero cell culture medium was removed from 24-well plate and 250 μl of titrated serum samples were added in duplicates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Baculovirus production: The Beta variant spike protein ectodomain gene (amino acids 1-1201) containing the native signal peptide, 3Q mutations to the furin cleavage site and 2P mutations, was codon-optimized for insect cell protein expression, using GenScript proprietary algorithm and was directly synthesized into pFAST-BAC1 transfer plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pFAST-BAC1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate a control for the amplification reaction, RNA was isolated from the applicable SARS-CoV-2 plasmid control using the same procedure. qPCR was set up using TaqMan Fast Virus 1-Step Real-time RT-PCR protocol with assay setup performed using Qiagen Qiagility automated PCR setup platform and analyzed in Applied Biosystems on QuantStudio 3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: RRID:Addgene_164583)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Encapsulation of antigen were quantified by densiometric analysis using a known S1S2 protein standards in Fiji ImageJ software (v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum titration curves were analyzed by 5-parameter, non-linear regression using GraphPad Prism version 8.4.3 to determine antibody titers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
The main limitation of the present study was that T cell responses had not been investigated, as commercialized antibodies required for assessment of hamster T cell subsets and function were largely unavailable 66. Concerns over such constraints of the hamster model had been raised 67. Nevertheless, our previous mouse study did establish the presence of functional, memory CD4+ and CD8+ T cells after primary vaccination 34. Unlike neutralizing antibodies, which generally exhibited narrow target specificity as evidenced by moderate to severe reduction in potency against different variants, T cell epitopes were remarkably conserved 24. Studies had shown CD4+ and CD8+ T cells from previous vaccination or infection to retain robust activity against Omicron, despite the variant’s extensive mutations and increased resistance to neutralizing antibodies 22, 23. It was believed that cross-reactive T cells may contribute to the control Omicron infection and possibly account for the reduction in disease severity compared to the earlier Delta wave 68.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Author Response
Reviewer #1 (Public Review):
Dias et al proposed a new method for genotype imputation and evaluated its performance using a variety of metrics. Their method consistently produces better imputation accuracies across different allele frequency spectrums and ancestries. Surprisingly, this is achieved with superior computational speed, which is very impressive since competing imputation softwares had decades of experience in optimizing software performance.
The main weakness in my opinion is the lack of software/pipeline descriptions, as detailed in my main points 36 below.
We have made the source code and detailed instructions available publicly at Github. The computational pipeline for autoencoder training and validation is available at https://github.com/TorkamaniLab/Imputation_Autoencoder/tree/master/autoencoder_tuning_pipeline.
- In the neural network training workflow, I am worried it will be difficult to compute the n by n correlation matrix if n is large. If n=10^5, the matrix would be ~80GB in double precision, and if n=10^6, the matrix is ~2TB. I wonder what is n for HRC chromosome 1? Would this change for TOPMed (Taliun 2021 Nature) panel which has ~10x more variants? I hope the authors can either state that typical n is manageable even for dense sequencing data, or discuss a strategy for dealing with large n. Also, Figure 1 is a bit confusing, since steps E1-E2 supposedly precede A-D.
We included more details in the methods section to address this question. It is true that computing the entirety of this matrix is computationally intensive, thus, in order to avoid this complexity, we calculated the correlations in a sliding box of 500 x 500 common variants (minor allele frequency (MAF) >=0.5%). In other words, no matter how dense the genomic data is, the n x n size will always be fixed to 500 x 500. Larger datasets will not influence this as the additional variants fall below the MAF>=0.5% threshold. Thus, memory utilization will be the same regardless of chromosome length or database size. Please note that this correlation calculation process is not necessary for the end-user to perform imputation, since we already provide the information on what genomic coordinates belong to the local minima or “cutting points” of the genome. This computational burden remains on the developer side. The reviewer is right to point out that Figure 1 is misleading in its ordering, we have corrected this in the revision.
- I have a number of questions/comments regarding equations 2-4. (a) There seems to be no discussion on how the main autoencoder weight parameters were optimized? Intuitively, I would think optimizing the autoencoder weights are conceptually much more important than tuning hyper-parameters, for which there are plenty of discussions.
These parameters are optimized through the training process described in “Hyperparameter Initialization and Grid Search / Hyperparameter Tuning” - where both the hyperparameters and edge weights are determined for each autoencoder for each genomic segment. There are 256 genomic segments in chromosome 22, and each segment has a different number of input variables, sparsity, and correlation structure. Thus, there is a unique autoencoder model that best fits each genomic tile (e.g.: each autoencoder has different weights, architecture, loss function, regularizes, and optimization algorithms). Therefore, while there are some commonalities across genomic tiles, there is not a single answer for the number of dimensions of the weight matrix, or for how the weights were optimized. Instructions on how to access the unique information on the parameters and hyperparameters of each one of the 256 autoencoders is now shared through our source code repository at https://github.com/TorkamaniLab/imputator_inference.
We included an additional explanation clarifying this point in the Hyperparameter Tuning subsection of the Methods.
(b) I suppose t must index over each allele in a segment, but this was not explicit.
That is correct, t represents the index of each allele in a genomic segment. We included this statement in the description of equation 2.
(c) Please use standard notations for L1 and L2 norms (e.g. ||Z||_1 for L1 norm of Z). I also wonder if the authors meant ||Z||_1 or ||vec(Z)||_1 (vectorized Z)?
We included a clarification in the description of equation 3. ‖𝑾‖𝟏 and ‖𝑾‖𝟐 are the standard L1 and L2 norms of the autoencoder weight matrix (W).
(d) It would be great if the authors can more explicitly describe the auto-encoder matrices (e.g. their dimensions, sparsity patterns if any...etc).
As we answered in comment 2.a, each one of the 256 autoencoders for each genomic segment is unique, so it would be unfeasible to describe the architecture, parameters, optimizers, loss function, regularizes, of each one of them. We realized it would be more suitable to share this information in a software repository and have now done so.
- It is not obvious if the authors intend to provide a downloadable software package that is user-friendly and scalable to large data (e.g. HRC). For the present paper to be useful to others, I imagine either (a) the authors provide software or example scripts so users can train their own neural network, or (b) the authors provide pretrained networks that are downloaded and can be easily combined with target genotype data for imputation. From the discussion, it seems like (b) would be the ultimate goal, but is only part dream and part reality. It would be helpful if the authors can clarify how current users can benefit from their work.
We have now shared the pre-trained autoencoders (including model weights and inference source code) and instructions on how to use them for imputation. These resources are publicly available at https://github.com/TorkamaniLab/imputator_inference. We have added this information to the Data Availability subsection of the Methods.
- Along the same lines, I also found the description of the software/pipeline to be lacking (unless these information are available on the online GitHub page, which is currently inaccessible). For instance, I would like to know which of the major data imputation formats (VCF/BGEN..etc) are supported? Which operating systems (window/linux/mac) are supported? I also would like to know if it is possible to train the network or run imputation given pre-trained networks, if I don't have a GPU?
We have now made the github repository publicly available. The description of the requirements and steps performed in the hyperparameter tuning pipeline is available at https://github.com/TorkamaniLab/Imputation_Autoencoder/tree/master/autoencoder_tuning_pipeline.
- Typically, imputation software supplies a per-SNP imputation quality score for use in downstream analysis. This is important for interpretability as it helps users decide which variants are confidently imputed and which ones are not. For example, such a quality score can be estimated from the posterior distribution of an HMM process (e.g. Browning 2009 AJHG). Would the proposed method be able to supply something similar? Alternatively, how would the users know which imputed variants to trust?
We included further clarification in the data availability session of methods: Imputation data format. The imputation results are exported in variant calling format (VCF) containing the imputed genotypes and imputation quality scores in the form of class probabilities for each one of the three possible genotypes (homozygous reference, heterozygous, and homozygous alternate allele). The probabilities can be used for quality control of the imputation results.
We included this clarification in the manuscript and in the readme file of the inference software repository https://github.com/TorkamaniLab/imputator_inference.
- I think the authors should clarify whether input genotypes must be prephased. That is, given a trained neural network and a genotype data that one wishes to impute, does the genotype data have to be phased? The discussion reads "our current encoding approach lacks phasing information..." which can be understood both ways. On a related note, I hope the authors can also clarify if the validation and testing data (page 7 lines 1423) were phased data, or if they were originally unphased but computationally phased via softwares like Eagle 2 or Beagle 5.
The input genotypes are not phased, nor pre-phased, and no pre-phasing was performed before imputation. We included further clarification on the method section, stating “All input genotypes from all datasets utilized in this work are unphased, and no pre-phasing was performed.”. We also included further clarification in the Discussion session.
- It is unclear if the reported run times (Figure 6) includes model training time, or if they are simply imputing the missing genotypes given a pre-trained autoencoder? For the later, I think the comparison may still be fair if users never have to train models themselves. However, if users currently have to train their own network, I feel it is imperative to also report the model training time, even if in another figure/table.
The end-users do not have to train the models, the computational burden of training the models remains on the developer side, so the runtimes refer to the task of imputing the missing genotypes given a pre-trained autoencoder set. This allows for distribution without reference datasets. We included further clarification on the Performance Testing and Comparisons subsection of Methods.
Reviewer #2 (Public Review):
In this manuscript the authors introduce a segment based autoencoder (AE) to perform genotype imputation. The authors compare performance of their AE to more traditional HMM-based methods (e.g. IMPUTE) and show that there is a slight but significant improvement on these methods using the AE strategy.
In general the paper is clearly presently and the work in timely, but I have some concerns with respect to the framing of the advances presented here along with the performance comparisons.
Specific Points:
- The authors aren't doing a good enough job presenting the work of others in using deep neural networks for imputation or using autoencoders for closely related tasks in population genetics. For instance, the authors say that the RNN method of Kojima et al 2020. is not applicable to real world scenarios, however they seem to have missed that in that paper the authors are imputing based on omni 2.5 at 97% masking, right in line with what is presented here. It strikes me that the RNNIMP method is a crucial comparison here, and the authors should expand their scholarship in the paper to cover work that has already been done on autoencoders for popgen.
This is an important comparison that we erroneously misrepresented. We have now separated out this particular application of the RNN-IMP in the introduction of the manuscript. The major difference is that RNN-IMP needs to be retrained on different input genetic variants, much like a standard HMM-based method. The computational burden of RNN-IMP remains on the end-user side. It appears that computational complexity is tremendous in this model, given that the only example the authors provided with their software consists of 100 genomes from 1000 Genomes Project to perform the imputation on Omni by de novo training of the data. Given their approach does not achieve the benefits of distributing a generalizable pre-trained neural network, and the computational burden associated with training these models on the 60K+ genomes we use in our manuscript, we have opted for stating the benefits and downsides of their approach in the introduction.
- With respect to additional comparisons-Kenneth Lange's group recently released a new method for imputation which is not based on HMM but is extremely fast. The authors would be well served to extend their comparisons to include this method (MendelImpute)-it should be favorable for the authors as ModelImpute is less accurate than HMMs but much faster.
We appreciate the reviewer pointing out this additional method, however their parent manuscript clearly shows substantially inferior imputation performance relative to BEAGLE/Minimac etc. which we already compare against. There is not much to gain by performing this comparison. Our autoencoder-based approach is already generating results that are competitive with the best and most cited imputation tools, which are all HMM-based and outperforming MendelImpute. The outcome of this comparison is forecasted based upon the parent manuscript.
- The description of HMM based methods in lines 19-21 isn't quite correct. Moreover-what is an "HMM parameter function?"
Thank you for catching this. We were referring to parameter *estimation and have corrected this in the manuscript.
- Using tiled AEs across the genome makes sense given the limitations of AEs generally, but this means that tiling choices may affect downstream accuracy. In particular-how does the choice of the LD threshold determine accuracy of the method? e.g. if the snp correlation threshold were 0.3 rather than 0.45, how would performance be changed?
This choice is driven by the limitations of cutting-edge GPUs. 0.45 is the threshold that returns the minimum number of tiles spanning chromosome 22 with an average size per tile that fits into the video memory of GPUs. While developing the tiling algorithm, we tested lower thresholds, which made the tiles smaller and more abundant, and thus made the GPU memory workload less efficient (e.g. many tiles resulted in many autoencoders per GPU, which thus caused a CPU-GPU communication overhead). Due to the obstacles related to computational inefficiency, CPUGPU communication overhangs, and GPU memory limits, we did not proceed with model training on tiles generated with other correlation thresholds. We’ve added a paragraph explaining this choice in the manuscript.
- How large is the set of trained AEs for chromosome 22? In particular, how much disk space does the complete description of all AEs (model + weights) take up? How does this compare to a reference panel for chr22? The authors claim that one advance is that this is a "reference-free" method - it's not - and that as such there are savings in that a reference panel doesn't have to be used along with the genome to be imputed. While the later claim is true, instead a reference panel is swapped out for a set of trained AEs, which might take up a lot of disk space themselves. This comparison should be given and perhaps extrapolated to the whole genome.
This is an interesting point. For comparison, the total combined uncompressed size of all pre-trained autoencoders together is 120GB, or 469MB per autoencoder. The size of the reference data, HRC chromosome 22 across ~27,000 samples is 1GB after compression – or nearly 10X the autoencoder size. Moreover, unlike in HMM-based imputation, the size of the pre-trained autoencoders does not increase as a function of the reference panel sample size. The size of the autoencoders remains fixed since the number of model weights and parameters remains the same regardless of sample size – though it will expand somewhat with the addition of new genetic variants. Another point to consider is that privacy concerns associated with distribution of reference data are mitigated with these pretrained autoencoders.
- The results around runtime performance (Figure 6) are misleading. Specifically HMM training and decoding is being performed here, whereas for the AE only prediction (equivalent to decoding) is being done. To their credit, the authors do mention a bit of this in the discussion, however a real comparison should be done in Figure 6. There are two ways to proceed in my estimation - 1) separate training and decoding for the HMM methods (Beagle doesn't allow this, I'm not sure of the other software packages) 2) report the training times for the AE method. I would certainly like to see what the training times look like given that the results as present require 1) a separate AE for each genomic chunk, 2) a course grid search, 3) training XGBoost on the results from the course grid search, and 4) retraining of the individual AEs given the XGBoost predictions, and 5) finally prediction. This is a HUGE training effort. Showing prediction runtimes and comparing those to the HMMs is inappropriate.
We consider the prediction only during the runtime comparisons because only the prediction side is done by the enduser, whereas the computational burden remains on the developer side. For the HMMs, we included only the prediction time as well (excluded the time for data loading/writing, computing model parameters and HMM iterations). The pre-trained autoencoders, when distributed, can take as input any set of genetic variants to produce the output without any additional training or fine-tuning required.
- One well known problem for DNN based methods including AEs is out-of-sample prediction. While Figure 5 (missing a label by the way) sort of gets to this, I would have the authors compare prediction in genotypes from populations which are absent from the training set and compare that performance to HMMs. Both methods should suffer, but I'm curious as to whether the AEs are more robust than the HMMs to this sort of pathology.
Our test datasets in Figures 4 and 5 are independent of the reference dataset. MESA, Wellderly, and HGDP are all independent datasets, never used for training, nor model selection. Only HRC was used as reference panel or for training, and ARIC was used for model selection during tuning. We included a statement in the methods clarifying this point.
Reviewer #3 (Public Review):
Over the last 15 years or so genotype imputation has been an important and widely-used tool in genetic studies, with methods based on Hidden Markov Models (HMMs) and reference panels emerging as the dominant approach. This paper suggests a new approach to genotype imputation based on denoising autoencoders (DAE), a type of neural network. This approach has two nice advantages over existing methods based on Hidden Markov Models (HMMs): i) once the DAE is trained on a reference panel the reference panel can be discarded, and users do not need access to the reference panel to use the DAE; ii) imputation using a DAE is very fast (training is slow, but this step is done upfront so users do not need to worry about it). The paper also presents data showing that the tuned DAE is competitive in accuracy with HMM methods.
I have two main concerns.
First, it is unclear to me whether the accuracy presented for the tuned DAE (eg Figure 3, Table 4) is a reliable reflection of expected future accuracy. This is because the tuning process was quite extensive and complex, and involved at least some of the datasets used in these assessments. While the paper correctly attempts to guard against overfitting and related issues by using separate Training, Validation and Testing data (p7), it seems that the Testing data were used in at least some of the development of the methods and tuning (eg p14, "A preliminary comparison of the best performing autoencoder..."; Figure 2 and Table 2, all involve the Testing data). Because of the complexity of the process by which the final DAE was arrived at it is unclear to me whether there is a genuine concern here, but it would seem safest and most convincing at this point to do an entirely independent test of the methods on genotype data sets that were not used at all up to this point.
MESA, Wellderly, and HGDP were not used for training, nor for tuning, they are completely independent. So all the results showing these datasets are completely independent. Only HRC and ARIC were used for training and validation/tuning, respectively. We included a statement in the methods session clarifying this point.
Moreover, HGDP in particular includes 828 samples from 54 different populations representing all continental populations and including remote populations like Siberia, Oceania, etc. This reference panel is described in more detail in the reference below and likely represents the most diverse human genome dataset available. Thus, we have externally validated generalizability on a dataset with much greater diversity than our training dataset:
Bergström A, et al. Insights into human genetic variation and population history from 929 diverse genomes. Science. 2020 Mar 20;367(6484):eaay5012.
Second, there is a potentially tricky issue of to what extent distributing a black box DAE trained on a reference sample is consistent with data sharing policies. Standards of data sharing have evolved over the last decade. Generally there currently seems to be little hesitation to publicly share "single-SNP summary data" such as allele frequency information from large reference panels, whereas sharing of individual-level genotype data is usually explicitly forbidden. It is not quite clear to me where sharing the fit of a DAE falls here, or how much information on individual genotypes the trained DAE contains. The current manuscript does not adequately address this issue.
Currently there are no official data sharing restrictions on deep learning data. We are aware that future policies may rise, and we have started a collaboration with Oak Ridge National Laboratory to explore differential privacy techniques and privacy concerns for these autoencoders. Another point to consider is that the autoencoders segment the genome, making reconstruction of an individual genome impossible even if reference data were somehow recoverable from the neural networks. Regardless, this is an interesting and important point that should be addressed in the manuscript and we have added a paragraph discussing this point.
Reviewer #4 (Public Review):
In this manuscript, Dias et al proposed a novel genotype imputation method using autoencoders (AE), which achieves comparable or superior accuracy relative to the state-of-the-art HMM-based imputation methods after tuning. The idea is innovative and provides an alternative solution to the important task of genotype imputation. The authors also conducted some experiments using three different datasets as targets to showcase the value of their approach. The overall framework of the method is clearly presented but more technical details are needed. The results presented showed slight advantage of AE imputation after tuning but more comprehensive evaluations are needed. In particular, the authors didn't consider post-imputation quality control. The reported overall performance (R2 in the range of 0.2-0.6) seems low and inconsistent with the imputation literature.
Overall, the method has potential but is not sufficiently compelling in its current form.
We show average accuracy of 0.2-0.6 in Table 4, but that is the average R2 per variant across all variants (no MAF filtering or binning applied). The reviewer points that the accuracy should be R2>0.8, but this R2>0.8 refers to common variants only (allele frequency >1%), and we have shown r2>0.8 for these variants (Figure 4). The aggregate accuracy displayed in Table 4 is lower because the vast majority of variants fall below 1% allele frequency threshold.
The references bellow demonstrate this issue and agree with our results:
References:
Rubinacci S, Delaneau O, Marchini J. Genotype imputation using the positional burrows wheeler transform. PLoS genetics. 2020 Nov 16;16(11):e1009049.
McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM, Fuchsberger C, Danecek P, Sharp K, Luo Y. A reference panel of 64,976 haplotypes for genotype imputation. Nature genetics. 2016 Oct;48(10):1279.
Vergara C, Parker MM, Franco L, Cho MH, Valencia-Duarte AV, Beaty TH, Duggal P. Genotype imputation performance of three reference panels using African ancestry individuals. Human genetics. 2018 Apr;137(4):281-92.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.10.479867: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal experiments were executed by certified staff in Center for Animal Experiments of Wuhan University, approved by the Institutional Animal Care and Use Committee (AUP #WP2021-0607).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">2.5 Cell culture: HEK 293T/17 and ACE2-expressing 293T cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM L-glutamine, 10% FBS (sigma-aldrich) and 1% penicillin/streptomycin (BI) at 37 °C and 5% CO2. 2.6 Animals: Female BALB/c mice age of 6-8 weeks and heterozygous B6/JGpt-H11em1Cin(K18-ACE2)/Gpt mice (K18-hACE2 KI mice) age of 5-7 weeks and body weight of 18-20 g were used.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following washes, the secondary antibody, goat Anti-Mouse IgG H&L conjugated HRP (Abcam), was incubated in plate at room temperature for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>goat Anti-Mouse IgG H&L conjugated HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-Mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.11 SARS-CoV-2 Delta virus neutralization assay: SARS-CoV-2 Delta-neutralizing antibody was determined by in vitro inhibition of cytopathic effect (CPE), and was performed in the ABSL-3 lab at Center of Laboratory Animal Sciences, Wuhan University (Wuhan, China).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CPE</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.5 Cell culture: HEK 293T/17 and ACE2-expressing 293T cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM L-glutamine, 10% FBS (sigma-aldrich) and 1% penicillin/streptomycin (BI) at 37 °C and 5% CO2. 2.6 Animals: Female BALB/c mice age of 6-8 weeks and heterozygous B6/JGpt-H11em1Cin(K18-ACE2)/Gpt mice (K18-hACE2 KI mice) age of 5-7 weeks and body weight of 18-20 g were used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After that, the 293T-ACE2 cells are added and incubated for 24 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus-serum mixtures were added to Vero-E6 cells seeded in 24-well plate and cultured in a 5% CO2 incubator at 37 °C for 3 days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.5 Cell culture: HEK 293T/17 and ACE2-expressing 293T cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM L-glutamine, 10% FBS (sigma-aldrich) and 1% penicillin/streptomycin (BI) at 37 °C and 5% CO2. 2.6 Animals: Female BALB/c mice age of 6-8 weeks and heterozygous B6/JGpt-H11em1Cin(K18-ACE2)/Gpt mice (K18-hACE2 KI mice) age of 5-7 weeks and body weight of 18-20 g were used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>B6/JGpt-H11em1Cin(K18-ACE2)/Gpt</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>K18-hACE2 KI</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mRNA integrity was measured with a gel retardation assay [15] and microfluidic capillary electrophoresis (Agilent Fragment Analyser) [16], as previously reported.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Agilent Fragment Analyser</div><div>suggested: (OMICtools, RRID:SCR_002250)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis was mainly processed using Prism software version 8.3</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GraphPad Software Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 9. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.09.479781: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were washed once (500 μL FCM buffer) and resuspended in 100 μL of the FCM buffer with 5μL of the secondary Antibody (PE-anti human IgG Fc Recombinant, Biolegend, Catalogue 366903) and incubated for 30 minutes at 4°C., in the dark.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PE-anti human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The parental HEK293 cells were used as a control for binding specificity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All genes were purchased from Biomatik Corporation (Ontario, CA) and cloned into pET-32a (+) between the Nco I and Xho I restriction sites.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-32a</div><div>suggested: RRID:Addgene_120288)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biolisa COVID-19 Anticorpo Neutralizante kit (Ref: K243-1) was kindly provided by Bioclin®.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bioclin®</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were then washed twice with 500 μL FCM buffer, and the cell pellets were resuspended back in 500 μL of FCM buffer for analysis in Becton-Dickinson FACSCalibur.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Becton-Dickinson</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>FACSCalibur</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data were analyzed using FlowJo software (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.09.479840: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The blocking buffer was then aspirated and 50 μL of a 1:4000 dilution of rabbit anti-SARS-CoV-2 nucleocapsid (N) antibody (MA536086, Invitrogen) in blocking buffer was added and incubated for 2 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 nucleocapsid (N</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>MA536086</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-36086, RRID:AB_2866697)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549-ACE2 cells that stably express human angiotensin-converting enzyme 2 (hACE2) were established and provided by the University of Texas Medical Branch (46).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All viruses were propagated 1-2 times in Vero-TMPRSS2 cells as follows.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nucleoprotein ELISA: 3×104 A549-ACE2-TMPRSS2 cells in 100 μL DMEM (supplemented with 10% FBS and 1X penicillin/streptomycin) were seeded into each well of a 96-well plate and incubated overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antiviral activity assessment from recombinant luciferase containing viruses: For Nluc readouts, 1.2×104 A549-hACE2 cells per well were suspended in 50 μL infection medium and seeded into a white clear-bottom 96-well plate (Corning) and incubated overnight at 37°C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-hACE2</div><div>suggested: RRID:CVCL_A5KB)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Site-directed mutagenesis and recombinant virus rescue: To produce recombinant SARS-CoV-2 virus, we utilized a SARS-CoV-2 reverse genetics system previously described (24, 49) that was slightly modified by fusing plasmids F1-F3 single plasmid making it a 3-plasmid reverse genetics system producing infectious virus containing either Nano luciferase (Nluc) or the Firefly luciferase (Fluc) transgene.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>F1-F3</div><div>suggested: RRID:Addgene_87224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Desired substitutions in nsp12 of the SARS-CoV-2 genome were added to the nsp12 containing F4 plasmid using the Quick-Change PCR protocol using Platinum SuperFI II PCR master-mix (ThermoFisher Scientific cat. No. 12361010) following manufacturer’s protocols.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>F4</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">EC50 values were determined using GraphPad Prism 8.1.2 using non-linear regression curve fits.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.09.479835: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All experiments were approved and performed per the guidelines set forth by the Institutional Biosafety Committee (IBC) and the Environmental Health and Safety Office (EHSO) at the University of Illinois at Chicago.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cleavage of the spike protein was detected using anti-SARS-CoV Spike Protein (SDelta3) monoclonal antibody (7G12, Thermo Fisher Scientific, CA, USA)) raised against immunogen aa168-461 of the S1 domain.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV Spike Protein (SDelta3</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-35945, RRID:AB_2866557)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 1 x 10^6 293T ACE2 cells were nucleofected with sgRNA:TracrRNA: Cas9 complex using Amaxa Cell Line Nucleofector Kit V and cultured for 72h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus entry inhibition assay: SARS CoV2 pseudotyped virus particles were produced by transfecting HEK293T cells with the following plasmids 1) lentiviral backbone plasmid-pHAGE-CMV-Luc2-IRES-ZsGreen that expresses luciferase and ZsGreen reporters.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">25 x 103 human ACE2 expressing 293T cells were seeded in 96 well plates and infected with bald pseudovirus without spike glycoprotein (negative control) and SARS CoV2 spike protein-expressing pseudovirus and treated with 1 μM concentration (50μl Infection medium 2% FBS + 150 μl pseudovirus) of the candidate inhibitory small molecules.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CPE assay using infectious SARS CoV2: 25 x 103 hACE2-293T (BEI resources) and human TMPRSS2 expressing Vero E6 cells (Ordered from Japanese Collection of Research Bioresources Cell Bank (JCRB) and distributed by Sekisui XenoTech, LLC, KS) or Vero E6 cells (ATCC), Vero E6 Cells Expressing TMPRSS2 and Human ACE2 (Vero E6-TMPRSS2-T2A-ACE2) (NR-54970, BEI) were seeded in each well of 96 well plates in 100 μl of 5% DMEM medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2) pHDM-Hgpm2-lentiviral helper plasmid expressing HIV Gag-Pol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHDM-Hgpm2-lentiviral</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">3) pHDM-tat1b: lentiviral helper plasmid expressing HIV Tat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHDM-tat1b</div><div>suggested: RRID:Addgene_164442)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">4) pRC-CMV-Rev1b: lentiviral helper plasmid expressing HIV Rev, and pHDM expressing the SARS CoV2 Wuhan-Hu-1 Spike envelope Glycoprotein (Procured from BEI resources).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pRC-CMV-Rev1b</div><div>suggested: RRID:Addgene_164443)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analyses were performed using Prism GraphPad (V9.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.10.479919: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Experimental procedures were approved by the Austrian Ministry of Science and Research (66.009/0145-WF/II/3b/2014 and 66.009/0277-WF/V/3b/2017) and conformed to the 2010/63 European Communities Council Directive.<br>Euthanasia Agents: At the end of the post-immunization survival period, mice were deeply anesthetized by isoflurane (at 5% with 1 L/min flow rate of tubed air) and then perfusion-fixed by transcardially applying 4% (wt/vol) paraformaldehyde and 0.1% glutaraldehyde in 0.1 M phosphate buffer (PB; pH 7.0).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals, blood sampling and tissue processing: A total of 18 male and 4 female mice (C57BL/6J, 8–12-week-old) were group housed under standard conditions with a 12/12 light/dark cycle.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing in PBS for 10 min, Alexa Fluor 594-tagged goat anti-mouse antibody was applied for 1 h at room temperature under continued gentle agitation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody binding was determined with goat anti-mouse HRP-conjugate (1:10,000 in assay buffer supplemented with goat serum (2% V/V)) and incubated at room temperature for 60 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse HRP-conjugate</div><div>suggested: (Icosagen AS Cat# A1-900-100, RRID:AB_11135309)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals, blood sampling and tissue processing: A total of 18 male and 4 female mice (C57BL/6J, 8–12-week-old) were group housed under standard conditions with a 12/12 light/dark cycle.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For vector construction, the portion of the nucleocapsid (N100-300 aa) fused to the RBD (S300-685 aa) including 4 glycines as a hinge region was cloned into a pET-30a vector and designated ‘VieVac’ (Supplementary Figure 1A).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-30a</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Directional cloning into the Gateway pEntry/D-TOPO vector: A 4-nucleotide overhang (CACC) was placed in front of the forward primer CACCATGAAAGATCTCAGTCCGCG, while TCATCGCGCTCTTCGCGGGG served as reverse primer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pEntry/D-TOPO</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The original construct (engineered pET-30a/VieVac) has been used as template.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-30a/VieVac</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Insertion into baculovirus and amplification in insect cells: The pEntry/D-TOPO/VieVac construct (25 ng) was shifted into the baculovirus-compatible pDEST™ 10 expression vector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pEntry/D-TOPO/VieVac</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, Max Efficiency® DH10Bac™ competent E. coli were transformed with the engineered pDEST™ 10 containing the VieVac recombinant construct using the heat shock method at 42 °C for 30 s.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pDEST™</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression of the activation marker CD44 was measured on a FACS Canto II flow cytometer (Becton Dickinson) and analyzed using the FlowJo software (TreeStar).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell counting was performed in ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In histochemical experiments, data were normalized to a surface area of 1 mm2 and expressed as means ± s.e.m, followed by one-way ANOVA in GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
-
Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L., & Cevik, M. (2021). Public health actions to control new SARS-CoV-2 variants. Cell, 184(5), 1127–1132. https://doi.org/10.1016/j.cell.2021.01.044
-
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
SciScore for 10.1101/2022.02.07.479419: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: For studies (K18-hACE2 and 129S2 mice) at Washington University School of Medicine, the protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381–01).<br>Euthanasia Agents: (b) BALB/c mice: 6 to 8-week-old female BALB/c mice were immunized three weeks apart with 1 or 0.1 μg of mRNA vaccines (mRNA-1273 or mRNA-1273.529) or PBS (in 50 μL) via intramuscular injection in the quadriceps muscle of the hind leg under isoflurane anesthesia.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mouse experiments: (a) K18hACE2 transgenic mice: Seven-week-old female K18-hACE2 C57BL/6 mice were immunized three weeks apart with 5, 0.25, or 0.1 μg of mRNA vaccines (control or mRNA-1273) in 50 μl of PBS via intramuscular injection in the hind leg.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Experiments were neither randomized nor blinded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Experiments were neither randomized nor blinded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cells routinely tested negative for mycoplasma using a PCR-based assay.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed and sequentially incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57, and SARS2-71(Liu et al., 2021c) anti-S antibodies and HRP-conjugated goat anti-mouse IgG (Sigma Cat # A8924, RRID: AB_258426) in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS2-57</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS2-71</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-S</div><div>detected: (Sigma-Aldrich Cat# A8924, RRID:AB_258426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blood was sampled three weeks after the first immunization and two weeks after the second immunization, and anti-spike and neutralizing antibody levels were measured by ELISA and a VSV-based pseudovirus neutralization assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-hACE2-TMPRSS2 cells were supplemented with 10 μg/mL of puromycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-hACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody-virus complexes were added to Vero-TMPRSS2 cell monolayers in 96-well plates and incubated at 37°C for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate VSVΔG-based SARS-CoV-2 pseudovirus, BHK-21/WI-2 cells were transfected with the spike expression plasmid and infected by VSVΔG-firefly-luciferase as previously described (Whitt, 2010).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549-hACE2-TMPRSS2 cells were used as target cells for the neutralization assay and maintained in DMEM supplemented with 10% fetal bovine serum and 1 μg/mL puromycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-hACE2-TMPRSS2</div><div>suggested: RRID:CVCL_A5KB)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For studies with BALB/c mice, animal experiments were carried out in compliance with approval from the Animal Care and Use Committee of Moderna, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Heterozygous K18-hACE2 C57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J, Cat # 34860) were obtained from The Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:MGI:3589388)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">129S2 mice (strain: 129S2/SvPasCrl, Cat # 287) and BALB/c mice (strain: BALB/cAnNCrl, Cat # 028) were obtained from Charles River Laboratories.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>129S2/SvPasCrl</div><div>suggested: RRID:IMSR_CRL:287)</div></div><div style="margin-bottom:8px"><div>BALB/cAnNCrl</div><div>suggested: RRID:IMSR_CRL:028)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse experiments: (a) K18hACE2 transgenic mice: Seven-week-old female K18-hACE2 C57BL/6 mice were immunized three weeks apart with 5, 0.25, or 0.1 μg of mRNA vaccines (control or mRNA-1273) in 50 μl of PBS via intramuscular injection in the hind leg.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Four weeks later, K18-hACE2 mice were challenged with 104 FFU of B.1.1.529 by the intranasal route.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(c) 129S2 mice: Seven-week-old female 129S2 mice were immunized three weeks apart with 5 or 0.25 μg of mRNA vaccines (control, mRNA-1273) in 50 μl of PBS via intramuscular injection in the hind leg.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>129S2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Homogenates were analyzed for cytokines and chemokines by Eve Technologies Corporation (Calgary, AB, Canada) using their Mouse Cytokine Array/Chemokine Array 31-Plex (MD31) platform.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AB</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus neutralization assay: Codon-optimized full-length spike genes (Wuhan-1 with D614G, B. 1.351, B. 1.617.2, and B.1.1.529) were cloned into a pCAGGS vector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The percentage of neutralization was calculated based on relative light units of the virus control, and subsequently analyzed using four parameter logistic curve (Prism 8,0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">. QUANTIFICATION AND STATISTICAL ANALYSES: Statistical significance was assigned when P values were < 0.05 using GraphPad Prism version 9.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Limitations of study: We note several limitations in our study. (1) Female K18-hACE2 and 129S2 mice were used to allow for group caging, and some of our studies had smaller cohorts and were performed in different strains, due to animal availability. Follow-up experiments in male mice and with larger cohorts are needed to confirm and extend these results. (2) We used a B.1.1.529 Omicron isolate that lacks an R346K mutation; this substitution or ones in the emerging BA.2 lineage might further affect vaccine-induced virus neutralization and protection. (3) Our analysis focused on antibody responses and did not account for possible cross-reactive T cell responses, which could impact protective immunity. (4) The B.1.1.529 virus is less pathogenic in mice (Abdelnabi et al., 2021; Bentley et al., 2021; Halfmann et al., 2022). This could lead to an overestimation of protection compared to other more virulent strains in mice. (5) We analyzed mRNA-1273 and mRNA-1273.529 booster responses and protection one month after administration. A time course analysis is needed to assess the durability of the enhanced neutralizing antibody responses and protection against B.1.1.529. (6) Experiments were performed exclusively in mice to allow for analysis of multiple arms and comparisons. Vaccination, boosting, and B.1.1.529 challenge studies in other animal models and ultimately humans will be required for corroboration. In summary, our studies in mice show protection against B.1.1.529 infection a...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.07.479468: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal procedures were performed under the approvals of the Institutional Animal Care and Use Committee (IACUC) of University of Washington, Seattle, WA.<br>Euthanasia Agents: Mice were injected intramuscularly into the quadriceps muscle of each hind leg using a 27-gauge needle (BD, San Diego, CA) with 50 μL per injection site (100 μL total) of immunogen under isoflurane anesthesia.<br>IRB: This study was approved by the University of Washington Human Subjects Division Institutional Review Board (STUDY00010350)</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">BALB/c mice for RBD-NP, S ‘2P’, and HexaPro immunizations: Female BALB/c mice (Stock # 000651, BALB/c cByJ mice) four weeks old were obtained from Jackson Laboratory, Bar Harbor, Maine, and maintained at the Comparative Medicine Facility at the University of Washington, Seattle, WA, accredited by the American Association for the Accreditation of Laboratory Animal Care International (AAALAC).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One day post-transfection, cells were infected with VSV(G*ΔG-luciferase)29 and after 2 h were washed five times with DMEM before adding medium supplemented with anti-VSV-G antibody (I1-mouse hybridoma supernatant, CRL-2700, ATCC)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VSV-G</div><div>suggested: (LSBio (LifeSpan Cat# LS-C51761-50, RRID:AB_1277784)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293T cells in DMEM supplemented with 10% FBS, 1% PenStrep seeded in 10-cm dishes were transfected with the plasmid encoding for the corresponding S glycoprotein using lipofectamine 2000 (Life Technologies) following manufacturer’s indications.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus Neutralization: HEK293-hACE2 cells15 or VeroE6-TMPRSS214 were cultured in DMEM with 10% FBS (Hyclone) and 1% PenStrep and 8ug/mL puromycin for TMPRSS2 maintenance with 5% CO2 in a 37°C incubator (ThermoFisher).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS214</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate VSVΔG-based SARS-CoV-2 pseudovirus, BHK-21/WI-2 cells were transfected with the spike expression plasmid and infected by VSVΔG-firefly-luciferase as previously described30.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentivirus encoding hACE2-P2A-TMPRSS2 was made to generate A549-hACE2-TMPRSS2 cells which were maintained in DMEM supplemented with 10% fetal bovine serum and 1µg/mL puromycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-hACE2-TMPRSS2</div><div>suggested: RRID:CVCL_A5KB)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Both viruses were propagated on Vero-TMPRSS2 cells and subjected to deep sequencing to confirm the presence of expected substitutions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immune complexes were added to VeroE6-TMPRSS2 cell monolayers and incubated for 1 h at 37°C prior to the addition of 1% (w/v) methylcellulose in MEM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BALB/c mice for mRNA-1273 immunizations: Female BALB/c mice (6 to 8 weeks old) were obtained from Charles River Laboratories.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1292S mice for mRNA-1273 immunizations: 129S2 mice (strain: 129S2/SvPasCrl, Cat # 287) were obtained from Charles River Laboratories and housed in a pathogen-free animal facility at Washington University in St. Louis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>129S2</div><div>suggested: RRID:IMSR_CRL:287)</div></div><div style="margin-bottom:8px"><div>129S2/SvPasCrl</div><div>suggested: RRID:IMSR_CRL:287)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid construction: The SARS-CoV-2-RBD-Avi construct was synthesized by GenScript into pcDNA3.1-with an N-terminal mu-phosphatase signal peptide and a C-terminal octa-histidine tag, flexible linker, and avi tag (GHHHHHHHHGGSSGLNDIFEAQKIEWHE).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1-with</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 S ‘2P’ ectodomain trimer (GenBank: YP_009724390.1, BEI NR-52420) was synthesized by GenScript into pCMV with an N-terminal mu-phosphatase signal peptide and a C-terminal TEV cleavage site (GSGRENLYPQG)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV</div><div>suggested: RRID:Addgene_16459)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The RBD-16GS-I53-50A fusion was cloned into pCMV/R using the Xba1 and AvrII restriction sites and Gibson assembly25.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV/R</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus Neutralization Assay for BALB/c mRNA-1273 samples: Codon-optimized full-length spike genes (Wuhan-Hu-1 with G614, Beta, or Gamma) were cloned into pCAGGS vector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals were housed and maintained at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette, an AAALAC International accredited institution, in accordance with the rules and regulations of the Guide for the Care and Use of Laboratory Animal Resources.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NIRC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Relative luciferase units were plotted and normalized in Prism (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody-dose response curves were analyzed using non-linear regression analysis (with a variable slope) (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 10. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.08.479634: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines used in this study were regularly screened for mycoplasma contamination using the Universal Mycoplasma Detection Kit (ATCC, 30-1012K).<br>Authentication: All viruses were validated by genome sequencing.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed in PBS supplemented with 2 mM EDTA, permeabilized using Perm/Wash buffer (BD Biosciences), and subsequently stained for 1 h at room temperature with anti-NP mAb 1C7 antibody labeled with an Alexa488-fluorescent marker using the Alexa Fluor™ 488 Antibody Labeling Kit (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-NP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were subsequently fixed using 5% formaldehyde and immuno-stained using a monoclonal anti-SARS-CoV-NP antibody (Creative-Biolabs; NP1C7C7).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-NP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, plates were blocked (3% skim-milk TBS with 0.1% Tween20 for 1 h), stained for 90 min with anti-NP antibody (mAb 1C7, diluted 1:1000 in 1% skim-milk TBS with 0.1% Tween20), and finally secondary-stained with anti-mouse-HRP (antibody diluted 1:5000 in 1% skim-milk TBS with 0.1% Tween20 for 45 mins).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse-HRP</div><div>suggested: (Kindle Biosciences Cat# R1005, RRID:AB_2800463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, SARS-CoV-2 spike protein monoplex IHC was conducted using a Chromomap DAB IHC kit (Roche, Basel, Switzerland) with CC1 antigen retrieval at 95°C for 64 minutes, primary incubation at 1:900 for 40 min at room temperature, rabbit anti-IgG1+IgG2a+IgG3 antibody (ab133469) at 37°C for 20 minutes (1:1,000), and ImmPRESS HRP Goat Anti-Rabbit IgG polymer pre-dilute detection (Vector Laboratories) at 37°C for 20 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IgG1+IgG2a+IgG3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-Rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Vero E6 (ATCC, CRL-1586), A549 (ATCC, CRM-CCL-185)-derived, and HEK293T (ATCC</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">hACE2-A549 cells used in Fig.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hACE2-A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IFNAR KO A549 cells were generated by CRISPR-Cas9 ribonucleoprotein (RNP) complex (IDT) transfection using the Nucleofector system (Lonza Bioscience).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wild type and IFNAR KO A549 cells were then transduced with an Ace2 expression vector simultaneously using a pTRIP-SFFV-Blast-2A-myc-hACE2 construct, a kind gift from Nir Hacohen and Matteo Gentili (Massachusetts General Hospital and the Broad Institute), sequenced, and then functionally validated (Suppl. Fig. 3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IFNAR KO</div><div>suggested: RRID:CVCL_A8AL)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses: SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources NR-52281) stocks were grown in Vero E6 cells as previously described (Miorin et al., 2020). hCoV-19/Japan/TY7-503/2021 (P.1) was obtained from BEI Resources (NR-54982).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">. B.1.351, B.1.617.2, and P.1 viral stocks were grown on Vero TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus was reconstituted from lyophilized sample and then titered using Vero cells as described (Huang et al., 2020; Xie et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro antiviral growth assay: Vero E6, Ace2-A549, or Ace2-HEK293T cells were seeded in 96-well plates in DMEM (10% FBS) and incubated for 24 h at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ace2-HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike-induced syncytia assay: 30,000 Vero-TMPRSS2 cells were reverse transfected with 100 ng of pCAGGS-S plasmids in a black 96-wellplate using TransIT-LT1 Transfection reagent (Mirus) in complete growth medium (containing 10% FBS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wild type and IFNAR KO A549 cells were then transduced with an Ace2 expression vector simultaneously using a pTRIP-SFFV-Blast-2A-myc-hACE2 construct, a kind gift from Nir Hacohen and Matteo Gentili (Massachusetts General Hospital and the Broad Institute), sequenced, and then functionally validated (Suppl. Fig. 3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pTRIP-SFFV-Blast-2A-myc-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pCAGGS-S plasmids used in this assay have been previously described (Escalera et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 Delta variant (B.1.617.2 PV29995) was obtained from Dr. Viviana Simon (Mount Sinai Pathogen Surveillance Program)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pathogen Surveillance Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The IC50 was determined using GraphPad Prism software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NeonGreen fluorescent infected cells were evaluated using Flow-Jo software after gating on live cell populations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flow-Jo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live focused single cells were gated and NeonGreen fluorescent positive cells were evaluated using Ideas software and pixels were exported for further analysis on Prism to graph the dot plots and compare NTZ-treated to mock by the Mann-Whitney two-tailed test.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">iAT2s were serially passaged approximately every 2 weeks by dissociation into single cells via the sequential application of dispase (2 mg/mL; Thermo Fisher Scientific; 17105-04) and 0.05% trypsin (Invitrogen; 25300054) and replated at a density of 400 cells/μL of Matrigel (Corning; 356231), as previously described (Jacob et al., 2019).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Scientific</div><div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Manuscript number: RC-2021-01118
Corresponding author(s): Jun, Nakayama and Kentaro, Semba
1. General Statements
We are grateful to all of the reviewers for their critical comments and insightful suggestions that have helped us considerably improve our paper. As indicated in the responses that follow, we have taken all of these comments and suggestions into account in the revised version of our paper, including the supplementary information.
In the revised manuscript, we focus on the existence of two cancer stem cell-like populations in TNBC xenograft model and patients. The response to each reviewer is described below.
Sincerely,
Jun Nakayama
Kentaro Semba
Department of Life Science and Medical Bioscience
School of Advanced Science and Engineering
Waseda University
E-mail: junakaya@ncc.go.jp or jnakayama.re@gmail.com to JN
ksemba@waseda.jp to KS
2. Point-by-point description of the revisions
Reviewer #1 (Evidence, reproducibility and clarity (Required)): * **Summary:** Nakayama and colleagues use their previously developed automated tissue microdissection punching platform to perform spatial transcriptomics on a breast cancer xenograft model. Using transcriptomics on multiple clumps of 10-30 cells from different regions in a tumor and a lymph node metastasis they identified different cell-type clusters. Two of these clusters expressed different cancer stem cell markers. This led the authors to suggest that two distinct cancer stem cell(-like) populations may exist within one (breast) tumor, which could potentially make tumors more drug-resilient.
**Major comments:** While the quality of the presented sequencing data is good and the manuscript is mostly written in a clear and accessible style, there are some concerns that limit the impact of this story. Most importantly, the manuscript in its present form does not convince me that the MDA-MB-231 xenografts indeed contain two distinct populations of cancer stem(-like) cells.
1.The data obtained are not single cell data, which makes it difficult -if not impossible- to draw conclusions about presence of cancer stem cells. Each data point is the average of 10-30 cells, and the interpretation of the data is severely limited by this. How can the quantification of expression of CD44/MYC/HMGA1 in clumps of 10-30 cells teach us something about the stemness of tumor cells? *
Answer: We would thank the comment. The reviewer’s suggestion is an important point; however, this is technical limitation of spatial transcriptomics technology. Most advanced spatial transcriptomics technologies, e.g. Visium (10x Genomics), also have the same problem. It means that our technology and the advanced technologies are technics to analyze gene expression and characteristics of tissues from 10-30 cells in each spot. Although high resolution spatial transcriptomics has been developed in 2021 [1], it is not generally used yet as described in the comment (Significance) from reviewer1.
From our spatial analysis, we identified that CD44, MYC, and HMGA1 were expressed from human cancer cell. Their expression profiles were distinct among specific parts of the tumor section. To validate the existence of two types of cancer stem-like cells in TNBC tumors, we performed the additional analysis with the public scRNA-seq datasets of high-metastatic MDA-MB-23-LM2 xenograft model (GSE163210) [2]. This study performed scRNA-seq analysis of primary tumor and circulating tumor cells in MDA-MB-231-LM2 xenograft model. We analyzed it with Seurat/R (Figure A-1). As a result of reanalysis, HMGA1 and CD44 expression were confirmed at single-cell resolution (Figure A-2,3). These results verified the existence of two cancer stem cell-like populations (HMGA1-high, CD44-high) in MDA-MB-231 xenograft. Hence, the study of MDA-MB-231 xenograft supported our findings from spatial transcriptomics.
Additionally, we performed the immuno-staining of sections using anti-CD44 antibody and anti-HMGA1 antibody as described in reviewer’s comment 5. As a result, CD44 and HMGA1 were detected in primary tumor sections. There were cells that express either CD44 or HMGA1 and cells that co-express both CD44 and HMGA1 (Figure B). We believe that our findings are solid results because the findings were also validated by other methods.
In the revised manuscript, Figure A are incorporated as Figure 3B-E. Figure B is incorporated as Figure 3A. Hope our new results will be now accepted by the learned Reviewer and Editor.
Figure A-1. Reanalysis of scRNA-seq of metastatic MDA-MB-231 xenograft
Flowchart of the public single-cell RNA-seq (scRNA-seq) reanalysis using GSE163210 datasets.
Figure A-2. UMAP plots of xenograft and CD44/HMGA1 expression
UMAP plot of MDA-MB-231-LM2 xenograft tumors and circulating tumor cells (Left). Expression of CD44 and HMGA1 in the UMAP plot (Right).
Figure A-3. Pie chart of CD44/HMGA1 positive cancer cells in MDA-MB-231 xenograft
Pie chart of cancer stem cell-like population ratio in MDA-MB-231-LM2 xenografts.
Figure B. Fluorescent immuno-staining of MDA-MB-231 primary tumor
Representative images immunostained with CD44 and HMGA1 in primary tumor sections of the MDA-MB-231 xenograft model. Red: HMGA1, Green: CD44, and Blue: Nucleus. Scale bars, 20 μm (left), 10 μm (right). White arrows represent cancer cells that independently expressed or co-expressed.
* 2.Furthermore, the authors should better explain their data analysis strategy with identification of gene expression profiles. It is unclear how they found CD44, MYC, and HMGA1 other than by cherry-picking from the list of cluster markers. *Answer: In this research, to identify the characteristics of clusters, we analyzed differentially expressed genes (DEGs) by ‘FindAllMarkers’ function of Seurat. As a result, ‘Cluster 0’ significantly expressed HMGA1 gene, and ‘cluster 1’ significantly expressed CD44. HMGA1 and CD44 are popular cancer stem cell markers in triple-negative breast cancer [3, 4]. In this study, we focus on metastasis-related genes and cancer stem cell markers (described in introduction section). Therefore, we focus on cancer-stem cell markers in the presented study. Cancer stemness is an important concept in cancer metastasis [5-7]. These results suggested that the existence of two cancer stem cell-like populations could potentially make tumors more drug-resilient in xenograft models and clinical patients.
To improve the manuscript, we revised the description in the revised manuscript (Pages 5-6, Lines 97-105).
* 3.Following up on the above point: I looked in the supplementary tables, but couldn't find MYC. How did the authors conclude that MYC is involved in cluster 1? In fact, when I ran a quick analysis in EnrichR, I saw that putative MYC target genes were strongly enriched among the markers in the HMGA1 cluster, but not the CD44/MYC. That's opposite to what I would expect. *__Answer: __We apologize for our confusing data and description. First, we found the expression of CD44 and HMGA1 in each cluster. Therefore, we performed the up-stream enrichment analysis using gene signatures of FindAllMakers by Metascape. From the result of enrichment analysis, we found the MYC activation in CD44 high-cluster; therefore, we named the cluster “CD44/MYC-high” cluster.
To improve the manuscript, we revised the Figure2, Supplementary Table S3, and manuscript (Pages 5-6, Lines 103-106).
* 4.All data were produced from 1 primary tumor and 1 metastasis. Thus, reproducibility and robustness of the methodology cannot be evaluated. The interpretation of the data could be strengthened when xenografts from at least 3 different mice are shown. *__Answer: __We would thank the suggestion. As the reviewer’s comment, we performed 1 primary tumor and 1 metastasis lesion from a transplanted mouse. Since this experiment take a long time, we tried to validate the findings by other methods (Figure A: scRNA-seq analysis of MDA-MB-231 xenografts, Figure B: Immuno-staining of MDA-MB-231 primary tumor, Figure C: scRNA-seq analysis of TNBC patients).
First, we reanalyzed the public dataset which performed single-cell RNA-seq analysis of MDA-MB-231 xenografted tumor and circulating tumor cells in immunodeficient mice as shown in the answer to comment 1 (Figure A). Next, we performed the immuno-staining of sections using anti-CD44 antibody and anti-HMGA1 antibody as described in reviewer’s comment 5. As results, CD44 and HMGA1 were detected in primary tumor sections. There were cells that express either CD44 or HMGA1 and cells that co-express both CD44 and HMGA1 (Figure B). Next, we performed the reanalysis of 19 scRNA-seq samples from integrated 3 TNBC cohorts (Figure C-1). In a UMAP plot, differences between CD44-positive cancer cell and HMGA1-positive cancer cell were observed; however, these cells did not visually form the specific clusters (Figure C-2). CD44 and HMGA1 expressed globally in the UMAP plot, but CD44 makes some specific clusters (cluster at right side). Additionally, following the comment, we performed the population analysis in each patient (Figure C-3 and C-4). Detection of double-positive population in TNBC patients suggested that the population may be more undifferentiated cancer stem cells diving into both CD44-positive cells and HMGA1-positive cells.
In addition, we reanalyzed primary tumors and metastasis lesions from other mice as a test trial sample (Figure D-1). The microspots including test trial samples showed 3 human clusters which were classified into CD44/MYC, HMGA1, and Marker-low clusters. We believe that our findings are solid results because the findings were also validated by other methods.
In the revised manuscript, Figure A are incorporated as Figure 3B-E. Figure B is incorporated as Figure 3A. Figure C is incorporated as Figure 5. We only showed Figure D in the response to the reviewer’s comment. Hope our new results will be now accepted by the learned Reviewer and Editor.
Figure C-1. Reanalysis of integrated TNBC patients scRNA-seq
A flowchart of the reanalysis of a public scRNA-seq dataset. We downloaded GSE161529, GSE176078, and GSE180286 (scRNA-seq data of 19 TNBC patients). Integrated datasets were analyzed with Seurat. Log normalization, scaling, PCA and UMAP visualization were performed following the basic protocol in Seurat. To extract the cancer cells, cells expressing EPCAM/KRT8 (epithelial marker) were filtered. A UMAP plot of cancer cell from 19 TNBC patients (right).
Figure C-2. CD44/HMGA1 expression in TNBC patients
Expression analysis of CD44 (Expression level > 2) and HMGA1 (Expression level > 2) with UMAP plots.
Figure C-3. CD44/HMGA1-positive cancer cell with UMAP plot
UMAP plots of CD44-high, HMGA1-high, HMGA1/CD44-high, and Negative cancer cells.
Figure C-4. Ratio of CD44/HMGA1-positive cancer cell in each patient
The bar plot showed the ratio of cancer cells that expressed CD44 and HMGA1.
Figure D-1. Analysis of microspots of MDA-MB-231 xenografts including test trial samples
UMAP plots of CD44-high, HMGA1-high, and Marker-low clusters with test trial samples (2 primary tumors and 1 lung metastasis). ‘Primary tumor 1’ has 20 microspots, ‘Primary tumor 2’ has 24 microspots, and ‘lung metastasis’ has 7 microspots. Most microspots of lung metastasis failed extraction of RNA; therefore, these spots classified into Marker-low cluster.
Figure D-2. Expression analysis of CD44, HMGA1, and MYC
Feature plot of CD44-high, HMGA1-high, and Marker-low clusters with test trial samples.
* 5.The only methodology is single cell RNA-sequencing. Immuno-staining on relevant markers such as CD44, MYC, HMGA1 plus human epithelium and cell cycle markers would provide strong additional support for the claims made by the authors, because it's a complementary technique and it allows quantification at single cell resolution. *__Answer: __We would thank the comment. As described in the responses to the reviewer’s comment 1 and 4, we performed the immuno-staining of sections using anti-CD44 antibody and anti-HMGA1 antibody as described in reviewer’s comment 5. As a result, CD44 and HMGA1 were detected in primary tumor sections. There were cells that express either CD44 or HMGA1 and cells that co-express both CD44 and HMGA1 (Figure B).
In the revised manuscript, Figure B is incorporated as Figure 3A.
* 6.Line 173-175. The marker-low cluster look to me simply like spots containing a relatively high amount of dead/dying (tumor) cells. The identity/state of cells in the marker-low cluster should be characterized and discussed more extensively. *__Answer: __We would thank the comment. This suggestion is important. In fact, total count of RNA in the Marker-low cluster decreased as compared to HMGA1-high and CD44/MYC-high (Supplementary Figure S1B). Additionally, Ttr-high mouse cluster also has low total count of RNA (Supplementary Figure S1C).
Following the comment, we described that the Marker-low cluster and Ttr-high cluster have the possibility to include dead/dying cells (Page 13, Lines 268-279).
* 7.Figure 5 and accompanying text in line 182-194; the authors try to infer cell-to-cell interactions using a previously published tool. However, any biological interpretation is lacking. What can be concluded from this analysis? *__Answer: __Initially, algorithms of cell-to-cell interaction were reported with previously published tool [8, 9]; however, in this manuscript, we originally conducted the code for cell-to-cell interaction with the interaction database of the Bader laboratory from Toronto University (https://baderlab.org/CellCellInteractions#Download_Data) as previously described [10, 11]. We aimed to estimate the cell-to-cell interaction in each spot (including 10-30 cells). We think that this analysis will be helpful for discovering the cancer stem cell niche and metastatic niche [6].
However, in the revised manuscript, we focused on the existence of two cancer stem cell-like populations in TNBC xenograft and patients. Therefore, CCI analysis in previous Figure 5 moved to Supplementary Figure S7. Previous Figure 6 is removed from revised manuscript.
* 8.Figure 6. Can the authors please explain more clearly what they mean by "PT" and "Mix" groups? I had a very hard time to understand what the data in figure mean. Again, an overall interpretation at the end (line 211) is lacking. *__Answer: __We apologize for the confusing result. We examined the combinations of human cancer cell cluster and mouse stromal cell cluster. To summarize, there are 10 combinations in the MDA-MB-231 xenograft. The combination groups in only primary tumor were named “PT”; on the other hand, the combination groups in both primary tumor and lymph-node metastasis were named “Mix”. These CCI analysis focused on cluster types of cancer cell and stromal cell. However, according to this revision, our presented study mainly focuses on the existence of two types of cancer stem cell-like population in TNBC xenograft and patients. Therefore, CCI analysis with cluster types was deleted from revised manuscript.
In the revised manuscript, we focused on the existence of two cancer stem cell-like populations in TNBC xenograft and patients. Previous Figure 6 was removed from the revised manuscript.
* 9.Figure 7. I like the effort to align the results with public scRNA-seq data. But although the expression of the cluster-signatures is heterogeneous, there is no evidence for distinct (CSC-like) cell populations. Why don't these HMGA1 vs CD44 signature cells cluster away from each other in the UMAPs? Perhaps the patient-to-patient heterogeneity overwhelms differences within tumors, but in that case the authors could re-run their analysis for each patient separately, to make 6 patient-specific UMAPs. In its present form, this analysis does not convince me that two distinct CSC(-like) populations within one TNBC exist. *Answer: We would thank the comment. To improve the quality of reanalysis of clinical cohorts, we performed the reanalysis of 19 scRNA-seq samples from integrated 3 TNBC cohorts (Figure C-1). In a UMAP plot, there are differences between CD44-positive cancer cells and HMGA1-positive cancer cells; however, these cells did not visually form the specific clusters (Figure C-2). CD44 and HMGA1 were expressed globally in the UMAP plot, but CD44 made some specific clusters (cluster at right side). Additionally, following the comment, we performed the population analysis in each patient (Figure C-3 and C-4). There is double-positive population in TNBC patients suggesting that this population may be more undifferentiated cancer stem cells, dividing into both CD44-positive cells and HMGA1-positive cells.
In the revised manuscript, Figure C is incorporated as Figure 5.
* **Minor comments:** 10.In the Supplemental table 2 noticed that many of the marker genes have adjusted P values well above 0.05 (and even above 0.1). That makes the statistical analysis rather weak. This could especially be problematic since the authors entirely base their main claims on this marker analysis, and I recommend that the authors use more stringent P-value cut-offs in the cluster analysis. *Answer: We would thank the comment. We reshaped the list of differentially expressed genes (DEGs). Significantly expressed genes (adjusted p-value In mouse clusters, the enrichment analysis using significantly DEGs showed that only Tcell-like clusters had a lot of enriched terms. Citric acid (TCA) cycle, chemical stress response, and fatty acid oxidation were enriched in Tcell-like populations (Page 7, Lines 141-144).
In the revised manuscript, enrichment analyses are showed as Supplementary Figure S2 and S3B. We revised the sentence of enrichment analyses (Page 6, Lines 114-121), (Page 7, Lines 141-144). The network visualization of enrichment analysis was removed from the revised manuscript because this result did not support conclusions of the presented study.
* 11.Line 129/130. If I look at figure 3A, I don't see this tendency that the authors describe. Can the authors provide statistical support or visual aid to make their claim more apparent to the reader? *__Answer: __We would thank the suggestion. Following the comment, we performed the statistical analysis of spot position. The spots were categorized outer side (tumor edge) and Inner site (Center of tumor) in the primary tumor section (Figure E-1 upside). We counted the spot numbers of the clusters (Figure E-1 table) and performed statistical test by chi-test. As a result, CD44/MYC clusters significantly resided at outer side of primary tumor (Figure E-1 barplot). On the other hand, the spots in lymph-node metastasis are not readily defined the outer or inner. In addition, cell cycle analysis in the primary tumor and lymph node metastasis was performed with statistical test. As a result, HMGA1-high cluster and CD44/MYC-high cluster significantly proliferated in the lymph node metastasis section (Figure E-2).
Therefore, in the revised manuscript, we revised the sentence of spot position in lymph-node metastasis (Pages 8-9, Lines 159-172). Figure E-1 is incorporated as Figure 4D. Figure E-2 is incorporated as Figure 4F. Hope our new results will be now accepted by the Reviewer and Editor.
Figure E-1. Statistical analysis of spot position
Chi-test was performed by R. *p Figure E-2. Statistical analysis of cell cycle index
Fisher’s exact test was performed by R. *p * 12.Line 217; shouldn't this be 6 patients? I see six clusters and in the original paper six patients are mentioned. *Answer: We would thank the comment. ‘6 patients’ is correct, we revised it. However, in the revised manuscript, we added integrated analysis of TNBC as shown in the answer to comment 9.
Previous reanalysis of clinical scRNA-seq (previous Figure 7) was removed from the revised manuscript. The reanalysis using 3 integrated TNBC cohorts (Figure C) is incorporated as Figure 5.
Reviewer #1 (Significance (Required)): * Conceptual/biological impact: Showing the existence of distinct populations of CSCs within one (breast-)tumor potentially has a high impact on the field of fundamental and translational cancer research. As the authors state, it could be one key reason underlying drug resistance. However, the technology used by the authors does in my view not allow to make such a claim. First and foremost because the technology does not allow analysis at single cell resolution.
Technical impact: The platform used by the authors can be of interest for some applications, but they already published this in Scientic Reports a few years ago. I'm afraid that with the rapid recent developments in the field of spatial single cell transcriptomics (See for example Srivatsan et al Science 2021; 373: 111-117), the technical impact on the field is relatively low.
Audience: Researchers in the field of cancer biology with an interest to perform low-cost molecular analysis at low-resolution spatial-resolved tissue specimens (transcriptomics, but perhaps expanded with bisulfite sequencing, or ATAC sequencing) could be interested in the technology presented in this manuscript.
My expertise: single cell transcriptomics, (cancer) cell cycle, cancer drug resistance, cell plasticity, mouse models. *
**Referee Cross-commenting** I have read the comments and align mostly with reviewer #2. The authors need to improve this manuscript a lot before it's suitable for publication in any of the Review Commons journals. Answer: We are grateful to the reviewers. As indicated in the responses that follow, we have taken all of these comments and suggestions into account in the revised version of our paper, including the supplementary information.
*
*
Reviewer #2 (Evidence, reproducibility and clarity (Required)): * This manuscript uses spatial transcriptomics to perform single cell-like expression analysis between a breast cancer cell line and tumor microenvironment in mice xenografted with these cells. Unfortunately, from the title, abstract, and introduction, it is difficult to understand exactly what the authors are focusing and discussing. It is also unclear the advantage of their technique for evaluating the populations observed within this manuscript. Furthermore, there is very little explanation of the results, and it does not appear to be a scientific logical structure. Hence, this manuscript is not suitable for acceptance in the journal. In order to improve the scientific quality of this study, the following concerns are presented.
**Major concerns:** 1.Is cell-cell interaction (CCI) analysis novel method? If so, please specify detail in the manuscript. If the basic concept and the principle of CCI analysis have not been published, please mention in the discussion section as a limitation that a manuscript on CCI analysis is under submission to the preprint. In addition, please revise the abstract and related text. *__Answer: __Initially, algorithms of cell-to-cell interaction were reported with previously published tool [8, 9]; however, in this manuscript, we originally conducted the code for cell-to-cell interaction with the interaction database of the Bader laboratory from Toronto University (https://baderlab.org/CellCellInteractions#Download_Data) as previously described [10, 11]. We aimed to estimate the cell-to-cell interaction in each spot (including 10-30 cells). We think that this analysis will be helpful for discovering the cancer stem cell niche and metastatic niche [6].
However, in the revised manuscript, we focused on the existence of two cancer stem cell-like populations in TNBC xenograft and patients. Therefore, CCI analysis in previous Figure 5 is moved to Supplementary Figure S7. Previous Figure 6 are removed from the revised manuscript. We revised the description in the manuscript (Page 18, Lines 385-387).
* 2.The reviewer thinks that spatial transcriptomics plays an important role in your manuscript. Please describe the technique in the introduction. *__Answer: __We would thank the comments. Following the comments, we described the spatial technics in Introduction section. We revised the manuscript (Page 4, Lines 63-65) (Page 12, Lines 250-253).
* 3.The classification by expression profile (HMGA1, CD44/MYC and marker-low) lacks an explanation. Authors should mention in detail how these populations were extracted from breast cancer cell lines. *Answer: In this research, to identify the characteristics of clusters, we analyzed differentially expressed genes (DEGs) by FindAllmarkers function of Seurat. As a result, ‘Cluster 0’ significantly expressed HMGA1 gene, and ‘cluster 1’ significantly expressed CD44. Next, we performed the up-stream enrichment analysis using gene signatures of FindAllMakers by Metascape. From result of enrichment analysis, we found the MYC activation in CD44 high-cluster; therefore, we named the cluster “CD44/MYC-high” cluster.
HMGA1 and CD44 are popular cancer stem cell markers in triple-negative breast cancer [3, 4]; therefore, we focus on cancer-stem cell marker in presented study. Cancer stemness is an important concept in cancer metastasis [5-7].These results suggested that the existence of two cancer stem cell-like populations could potentially make tumors more drug-resilient in xenograft model and clinical patient.
To improve the manuscript, we revised the Figure2, Supplementary Table S2 and S4, and manuscript (Pages 5-6, Lines 97-106).
* 4.The description of the results is back and forth and confusing. Please reconsider the flow of the analysis. *__Answer: __We would thank the comment. We reconsidered the description and structure of manuscript. In revised manuscript, we focused on the existence of two cancer stem cell-like populations in TNBC xenograft and patients.
To improve the manuscript, we revised the Figure2 for examination of cluster characteristics by clustering and gene expression profiling. Figure 3 was revised for the validation of two cancer stem cell-like populations in TNBC xenograft model. Figure 4 was revised for the elucidation of spatial characteristics of each cluster. Figure 5 was revised for the validation of two cancer stem cell-like populations in TNBC patients.
* 5.How did you evaluate the outsides of the samples with very different spot positions in Figure 3A? Please mention your evaluation method in a scientific manner. In particular, authors should clearly indicate the outer evaluation for the metastatic case. *
Answer: We would thank the suggestion. Following the comment, we performed the statistical analysis of spot position. The spots were categorized outer side (tumor edge) and Inner site (Center of tumor) in primary tumor section (Figure E-1 upside). We counted the spot numbers of the clusters (Figure E-1 table) and performed statistical test by chi-test. As a result, CD44/MYC clusters significantly resided at outer side of primary tumor (Figure E-1 bar plot). On the other hand, the spots in lymph-node metastasis are not readily defined the outer or inner. In addition, cell cycle analysis in the primary tumor and lymph node metastasis was performed with statistical test. As a result, HMGA1-high cluster and CD44/MYC-high cluster significantly proliferated in the lymph node metastasis section (Figure E-2).
Therefore, in the revised manuscript, we revised the sentence of spot position in lymph-node metastasis (Pages 8-9, Lines 153-172). Figure E-1 are incorporated as Figure 4D. Figure E-2 are incorporated as Figure 4F. Hope our new results will be now accepted by the Reviewer and Editor.
Figure E-1. Statistical analysis of spot position
Chi-test was performed by R. *p Figure E-2. Statistical analysis of cell cycle index
Fisher’s exact test was performed by R. *p * 6.The spots in primary tumor have few counts derived from mouse stromal/immune cells, as shown in Figure S1A. Nevertheless, Figure 3C shows that mouse stromal/immune cells are evaluated in the same way in primary and metastatic sites. The reviewer thinks that the regions identified as Tcell-like in the metastatic site, where there are many mouse-derived counts, and in the primary, where there are few mouse-derived counts, do not have the same characteristics. If many mouse-derived counts were detected in a spot using the spatial transcriptomics, then there must be many mouse-derived cells in the spot. Please discuss how this expression is evaluated on this technique, which is not a single cell analysis. *__Answer: __We would thank the comment. The reviewer’s suggestion is an important point; however, this suggestion is technical limitation of spatial transcriptomics technology. Most advanced spatial transcriptomics technologies, e.g. Visium (10x Genomics), also have the same problem. It means that our technology and the advanced technologies are technics to analyze gene expression and characteristics of tissues from 10-30 cells in each spot.
In this spatial transcriptome analysis of mouse genes, we first performed the log normalization and scaling. Since Seurat used variable features among the samples for single-cell or spot clustering, we extracted the variable features for detection of clusters using the ‘FindVariableFeatures’ function. PCA and clustering using only mouse genes was performed for detecting the neighboring samples. After the clustering of mouse spots, we identified the character of clusters by finding the gene signatures. As the indication by the reviewer, the detected RNA counts and features are different, so it is difficult to define the exact character and cell type of stromal cells. Theoretically, spatial transcriptomics could only detect some kinds of stromal cells expressing the T-cell marker gene in the spot. Therefore, we named the cluster as “Tcell-like”. Not all of the Tcell-like cluster have the same characteristics or cell types, but they certainly express T-cell marker genes. This is also a technical limitation of spatial transcriptomics. Spatial transcriptomics with higher resolution probably is able to detect the stromal cells as a single-cell resolution, such as the one developed in previous research [1].
In the revised manuscript, we focused on the two types of cancer stem cell-like populations that were validated by other methods (scRNA-seq and Immuno-staining). As the method is not able to define the exact cluster characters, we moved CCI analyses to supplementary figures or removed partly.
We also revised the discussion in the revised manuscript (Pages 13-14, Lines 279-283).
* 7.Please explain how the gene symbols listed in Figure 4A were selected. Also, please indicate the characteristics of the gene groups that are not listed. *__Answer: __We selected the gene signature list from results of ‘FindAllMarker’ function in Seurat. ‘FindAllMarker’ function enables to extract the significantly expressed genes in each cluster. Heatmap in previous Figure 4A was drawn using these marker genes (Adjusted p-value 0.1). Highlighted genes in the heatmap have been reported as cancer-related genes or cell cycle-related genes.
The genes used for drawing heatmap are shown in Supplementary Table S2 and S4.
* 8.Please describe the details of the division and cycle index in lines 141-142. *__Answer: __Cell cycle index is a basic function of Seurat [12] (https://satijalab.org/seurat/archive/v3.1/cell_cycle_vignette.html). A list of cell cycle markers is loaded with Seurat. We can segregate this list into markers of G2/M phase and markers of S phase. We subjected this function into our spatial transcriptomics to estimate the cell cycle in each spot.
We revised the description manuscript (Page 16, Lines 331-332).
* 9.In Line 148-151, the expression and prognosis of TMSB10, CTSD, and LGALS1 is mentioned based on the previous reports. Aren't these findings the result of bulk? Is the HMGA1 cluster that the authors found involved in the prognosis of mice? Please clarify, as it is unclear what you want to discuss. *
Answer: We apologize for our confusing data and description. These highlighted genes (TMSB10, CTSD, LGALS1, CENPK, and CENPN) were extracted as DEGs of human cancer clusters (Supplementary Table S2). Previously, these genes have been reported as cancer-related genes or cell cycle-related genes, described in the manuscript (Page 6, Lines 107-110). To show the other expressed genes in each human cluster, we focused on these genes in the manuscript.
We extracted the gene signatures from DEGs and showed the gene signatures from HMGA1-high cluster correlated to poor prognosis in TNBC patients. Our data suggested that the HMGA1 signatures from the microspot resolution has the potential to be a novel biomarker for diagnosis, and HMGA1-high cancer stem cells may contribute to poor prognosis.
In this revision, since we reperformed DEGs analysis with significant threshold; therefore, survival analysis was reperformed with novel gene signatures with METABRIC TNBC cohorts (Figure F).
To improve the manuscript, we revised the description of DEGs extraction and heatmap (Page 6, Lines 106-112). Hope our Reviewer will approve this revised sentence.
Figure F. Survival analysis with gene signatures of HMGA1-high and CD44/MYC-high
Survival analysis of TNBC patients (claudin-low subtype and basal-like subtype) in METABRIC cohorts by the Kaplan-Meier method. (Left) Survival analysis with the expression of the HMGA1 signatures (High = 151, Low = 247). Shading along the curve indicates 95% confidential interval. Log-rank test, p = 0.012. (Right) Survival analysis with the expression of the CD44/MYC signatures (High = 333, Low = 65). Log-rank test, p = 0.079.
* 10.Please provide details of all statistical tests used in this manuscript and describe significance levels used in the p-values and FDR. *__Answer: __We performed the extraction of differentially expressed genes (DEGs) by ‘FindAllMarkers’ function with MAST method. MAST method identifies differentially expressed genes between two groups of cells using a hurdle model tailored to scRNA-seq data [13]. Adjusted p-value is calculated based on Bonferroni correction using all features in the dataset. In spatial spot analysis, statistical analyses were performed by Chi-test and Fisher’s exact test.
We revised materials and methods section in the manuscript (Page 19, Lines 391-394).
* 11.Please mention CCI score (line 198). *Answer: As described in answer to comment 1, the algorithms of CCI score calculation were performed using previously published tool [8, 9]; however, we originally conducted the code for cell-to-cell interaction with the interaction database of the Bader laboratory from Toronto University (https://baderlab.org/CellCellInteractions#Download_Data). We extracted the genes whose expression value was greater than 2. We selected the combinations representing ligand__-__receptor interactions, in which both ligand genes and receptor genes were expressed in the same spot.
We revised materials and methods section in the manuscript and Supplementary Legends (Page 18, Lines 385-387).
* 12.Lines 204-206 and Figure 6G show specific interaction of ITGB1 and CST3, but it is unclear why only these molecules were extracted. What about the other molecules? At least ITGB1 is not scored in mix5. *Answer: We selected genes that have been reported as cancer-related ones in breast cancer to discuss the interactions in primary tumor and lymph-node metastasis. However, according to this revision, our presented study mainly focused on the existence of two types of cancer stem cell-like population in TNBC xenografts and patients. Therefore, CCI analysis with cluster types moved to supplementary Figure or some were not shown now.
In the revised manuscript, previous Figure 6 is removed.
* 13.HMGA1 signature appears in Line 214, please explain in detail. *__Answer: __As described in answer to comment 7, we selected the gene signature list from results of ‘FindAllMarker’ function. ‘FindAllMarker’ function enables to extract the significantly expressed genes in each cluster. HMGA1 signature genes were selected from significantly differentially expressed genes of HMGA1-high clusters.
We revised the description in the revised manuscript (Pages 9-10, Lines 190-193).
* 14.Authors should discuss how the previously reported bulk expression data used in Figure 7E can be linked to the single-cell-like analysis in this study. *__Answer: __Previous research reported that gene signatures extracted from specific clusters in scRNA-seq study have the potential to be a prognosis marker [14]. We showed the gene signatures from HMGA1-high cluster correlated to poor prognosis in TNBC patients. Our results suggested that the gene signatures from the resolution of microspot (10-30 cells) could have the potential to be prognosis markers. This punching microdissection system enables to extract only the parts of a section that are necessary for diagnosis of cancer and to analyze at low-cost. It could be applied to diagnostics instead of the laser-capture microdissection methods.
We performed additional survival analysis with METABRIC cohorts. As described in this revision, since we reperformed DEGs analysis with significant threshold, survival analysis was reperformed with novel gene signatures with METABRIC TNBC cohorts (Figure F).
In revised manuscript, Figure F were incorporated as Figure 6. The usefulness of gene signatures from microspot resolution was additionally discussed (Page 12, Lines 242-245, 250-253).
* **Minor concerns:** 15.Please describe how the normalized centrality was calculated in UMAP algorithm and explain what this means in the results. __Answer: __The data showed that the expressional diversity in each cluster based on the network centrality of a correlational network with graph theory. The differences in the centrality among the clusters suggested expressional diversity in each (Supplementary Figure 4). Higher centrality represented lower expressional diversity and vice versa*. The detailed method for the calculation of centrality was previously shown to reveal the difference between smokers and never-smokers [10, 11].
We added the description in the Legend (Pages 7-8, Lines 145-150).
* 16.Please mention an explanation for the red X in Figure 1B to the legend. *__Answer: __The red X means failure spot for RNA extraction. We added the description in Figure 1B.
* 17.Please spell out the abbreviations in all figure legends. *__Answer: __We added the abbreviations in the legends of all figures.
* 18.Please explain what is meant by the color of the lines and the size of the circles in Figure 4D. *__Answer: __The network analysis was performed by Metascape (https://metascape.org/gp/index.html#/main/step1) [15]. The node size is proportional to the number of genes belonging to the term, and the node color represents the identity of the cluster. However, as described in the answer to reviewer’s comment 9, we reperformed enrichment analysis with significant DEGs. As a result, only CD44/MYC cluster had a lot of enrichment terms.
Therefore, network visualizations were removed from the revised manuscript.
* 19.Please mention an explanation for the color of the spots in Figure 5D and 5F to the legend. *__Answer: __The color showed the spots categorized into the selected group.
In the revised manuscript, previous Figure 5 was incorporated as Supplementary Figure S7. We added the description in Supplementary Figure S7 and S8 with the legends.
* 20.Is "S51" in Line 148 a typo for "S5A"? *Answer: Thank you. We revised “S5A”.
* 21.Please mention an explanation for the bars in Figure 6D and 6F to the legend. *__Answer: __The bars showed relative CCI scores. As described below, we removed the results of CCI analysis with cluster group (previous Figure 6) in the revised manuscript.
* 22.Please mention an explanation for the colors in Figure 7E to the legend. *__Answer: __The color showed patients’ group based on expression levels of gene signatures. We added the description in the Legend of Figure 6.
*
*
Reviewer #2 (Significance (Required)): * The approach in Figure 5 is interesting, but the rest of the results do not take full advantage of the technology developed by the authors. The structure of the manuscript should be re-examined and new perspectives added. I look forward to the future of the authors' research.
*
Reviewer #3 (Evidence, reproducibility and clarity (Required)): Microtissue transcriptome analysis of triple-negative breast cancer cell line MDA-MB-231 xenograft model using automated tissue microdissection punching techonology revealed that the existence of three cell-type clusters in the primary tumor and axillary lymph node metastasis. The CD44/MYC-high cluster showed aggressive proliferation with MYC expression, the HMGA1-high cluster exhibited HIF1A activation and upregulation of ribosomal processes. The cell-cell-interaction analysis revealed the interaction dynamics generated by the combination of cancer cells and stromal cells in primary tumors and metastases. The gene signature of the HMGA1-high cancer stem cell-like cluster has the potential to serve as a novel biomarker for diagnosis. The key conclusions are convincing. The data and methods are presented in a reproducible way. The experiments are adequately replicated and statistical analysis is adequate. Prior studies are appropriately referenced. The text and figures are clear and accurate. __Answer: __We would thank the valuable comments. As the reviewer mentioned, our findings showed that the existence of two cancer stem cell-like populations has the potential to make tumors more drug-resilient. Our results suggested that the gene signatures from the resolution of microspot (10-30 cells) could have the potential to be prognosis markers. This punching microdissection system enables to extract only the parts of a section that are necessary for diagnosis of cancer and to analyze at low-cost. It could be applied to diagnostics instead of the laser-capture microdissection methods.
In this revision, we focused on the existence of two cancer stem cell-like populations in TNBC xenografts and patients. Following the other reviewer’s comments, we performed the extraction of DEGs with significant threshold; therefore, we revised the results of enrichment analysis but it did not influence our main findings.
To validate the existence of two types of cancer stem-like cells in TNBC tumors, we performed the additional analyses (reanalysis of public scRNA-seq datasets and immuno-staining of MDA-MB-231 primary tumor). These results verified two cancer stem cell-like populations (HMGA1-high, CD44-high) in MDA-MB-231 xenograft and TNBC patients. We believe that our findings are solid results because the findings were also validated by other methods.
Again, we would thank kind reviewing our manuscript.
Reviewer #3 (Significance (Required)): * In the past several studies showed the heterogeneity of cell-cell interactions between cancer cells and stromal cells in situ (Andersson et al, 2021; Wu et al, 2021) and tumor microheterogeneity (Jiang et al, 2016; Liu et al, 2016; Zhang et al, 2020). Spatial transcriptomics methods are important to reveal microheterogeneity of cancer. As a physician working in gynecology and obstetrics in my opinion the results of the study and spatial transcriptomic methods could be relevant to detect new biomarkers for diagnosis and prognosis of breast cancer in future and to find novel therapeutic targets to overcome drug resistance and facilitate curative treatment of breast cancer.
*
References in response letter
- Srivatsan SR, Regier MC, Barkan E, Franks JM, Packer JS, Grosjean P, et al. Embryo-scale, single-cell spatial transcriptomics. Science. 2021;373(6550):111-7. Epub 2021/07/03. doi: 10.1126/science.abb9536. PubMed PMID: 34210887.
- Moravec JC, Lanfear R, Spector DL, Diermeier SD, Gavryushkin A. Cancer phylogenetics using single-cell RNA-seq data. bioRxiv. 2021:2021.01.07.425804. doi: 10.1101/2021.01.07.425804.
- Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A. 2010;107(42):18115-20. Epub 2010/10/06. doi: 10.1073/pnas.1006732107. PubMed PMID: 20921380; PubMed Central PMCID: PMC2964232.
- Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget. 2013;4(8):1293-308. Epub 2013/08/16. doi: 10.18632/oncotarget.1136. PubMed PMID: 23945276; PubMed Central PMCID: PMC3787158.
- Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer. 2022. Epub 2022/01/12. doi: 10.1038/s41568-021-00427-0. PubMed PMID: 35013601.
- Oskarsson T, Batlle E, Massagué J. Metastatic Stem Cells: Sources, Niches, and Vital Pathways. Cell Stem Cell. 2014;14(3):306-21. doi: https://doi.org/10.1016/j.stem.2014.02.002.
- Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M, et al. Meeting the Challenge of Targeting Cancer Stem Cells. Front Cell Dev Biol. 2019;7:16. Epub 2019/03/06. doi: 10.3389/fcell.2019.00016. PubMed PMID: 30834247; PubMed Central PMCID: PMC6387961.
- Armingol E, Officer A, Harismendy O, Lewis NE. Deciphering cell-cell interactions and communication from gene expression. Nat Rev Genet. 2021;22(2):71-88. Epub 2020/11/11. doi: 10.1038/s41576-020-00292-x. PubMed PMID: 33168968; PubMed Central PMCID: PMC7649713.
- Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, et al. Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics. Cell Rep. 2018;25(6):1458-68.e4. Epub 2018/11/08. doi: 10.1016/j.celrep.2018.10.047. PubMed PMID: 30404002; PubMed Central PMCID: PMCPMC7009724.
- Watanabe N, Nakayama J, Fujita Y, Mori Y, Kadota T, Shimomura I, et al. Single-cell Transcriptome Analysis Reveals an Anomalous Epithelial Variation and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease. medRxiv. 2020:2020.12.03.20242412. doi: 10.1101/2020.12.03.20242412.
- Nakayama J, Yamamoto Y. Single-cell meta-analysis of cigarette smoking lung atlas. bioRxiv. 2021:2021.12.09.472029. doi: 10.1101/2021.12.09.472029.
- Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177(7):1888-902.e21. Epub 2019/06/11. doi: 10.1016/j.cell.2019.05.031. PubMed PMID: 31178118; PubMed Central PMCID: PMC6687398.
- Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16:278. Epub 2015/12/15. doi: 10.1186/s13059-015-0844-5. PubMed PMID: 26653891; PubMed Central PMCID: PMCPMC4676162.
- Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792-809.e23. Epub 2021/02/06. doi: 10.1016/j.cell.2021.01.010. PubMed PMID: 33545035.
- Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. Epub 2019/04/05. doi: 10.1038/s41467-019-09234-6. PubMed PMID: 30944313; PubMed Central PMCID: PMC6447622.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.07.479352: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Euthanasia Agents: For intranasal infection, hamsters were infected with 104 or 105 TCID50 of GX_P2V in 50 μL RPMI 1640 containing 2% FBS after deep anesthesia with pentobarbital sodium.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Golden hamster model of both intranasal and intragastrical infection: Specific pathogen-free, 6-week-old male golden hamsters were purchased from Charles River and maintained under specific-pathogen-free conditions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Young and old mice were randomly divided into two groups, respectively.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: Sera were collected at 42 d.p.i for analysis of antibody responses by immunofluorescence assay (IFA), ELISA, and pseudovirus neutralization titer assay (pVNT).</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After being washed five times with PBS, cells were stained with secondary antibodies: fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG (1:300, ZSGB-BIO, Cat No. ZF-0312, Beijing, China) or goat anti-human IgG (1:300, ZSGB-BIO, Cat No. ZF-0308, Beijing, China), accordingly.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (ZSGB-Bio Cat# ZF-0312, RRID:AB_2716306)</div></div><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA binding assay: SARS-CoV-2 RBD, S1 and S1+S2 (ECD) antibody titer assay kits (Sino Biological, Cat No. KIT002, KIT003, KIT004, respectively, Beijing, China) were purchased.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ECD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>KIT003</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>KIT004 , respectively , Beijing , China </div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral growth kinetics: Confluent monolayers of BGM and Vero cells in 6-well plates were incubated with viral stocks at a multiplicity of infection (MOI) of 0.01 for 2 h at 37°C followed by washing twice with PBS and maintained in RMPI 1640 medium with 2% FBS and HEPES (20 mM) at 37°C in a 5% CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Confluent monolayers of 293T cells grown on coverslips in 12-well plates overnight were transfected with plasmids containing codon-optimized spike genes of SARS-CoV-2 and GX_P2V by using liposome (TransGen, Cat No. FT201-02, Beijing, China) according to the instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 pseudovirus was used as seed stock and combined with the GX_P2V spike protein expression plasmid to generate VSV-based GX_P2V pseudovirus in 293T-hACE2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For testing sera from hamsters and BALB/c mice, the secondary antibodies were replaced by HRP-goat anti-mouse IgG (1:5000, ZSGB-BIO).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, a standard plasmid was constructed through inserting a fragment amplified using P2VF and P2VR into a cloning vector pEASY-T1 (TransGen, Cat No. CT101-01 Beijing, China)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pEASY-T1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunofluorescence assay for cross-immunity responses: The full-length spike protein gene of SARS-CoV-2 (accession number NC_045512.2) and GX_P2V (accession number MW532698) were codon optimized, synthesized, and cloned into pcDNA3.1 vector by Beijing BioMed Gene Technology.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The clean reads were then mapped to the near complete genome of pangolin coronavirus GX_P2V (GenBank accession number MT072864) using Bowtie 231.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bowtie</div><div>suggested: (Bowtie, RRID:SCR_005476)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The reads that were mapped to the GX_P2V genome were then assembled de novo using Trinity with default settings32.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trinity</div><div>suggested: (Trinity, RRID:SCR_013048)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: The statistical analyses were performed with GraphPad Prism version 9.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.bmj.com www.bmj.com
-
Agarwal, A., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., Macdonald, H., Zeng, L., Amin, W., Barragan, F. A., Bausch, F. J., Burhan, E., Calfee, C. S., Cecconi, M., Chanda, D., Dat, V. Q., Sutter, A. D., … Vandvik, P. O. (2020). A living WHO guideline on drugs for covid-19. BMJ, 370, m3379. https://doi.org/10.1136/bmj.m3379
-
-
www.medrxiv.org www.medrxiv.org
-
Peña-Hernández, M. A., Klein, J., Malik, A. A., Coppi, A., Kalinich, C., Vogels, C. B. F., Silva, J., Initiative, Y. S.-C.-2 G. S., Peaper, D. R., Landry, M.-L., Wilen, C., Grubaugh, N. D., Schulz, W., Omer, S. B., & Iwasaki, A. (2022). Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals (p. 2021.12.28.21268460). medRxiv. https://doi.org/10.1101/2021.12.28.21268460
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.07.22270626: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All donors provided written informed consent in compliance with protocols set forth and approved by the Comité de Ética en Investigación and the Comité de Investigación (Research Ethics Committee and the Research Committee) from INER Institutional Review Board (study no. B01-21).<br>IRB: All donors provided written informed consent in compliance with protocols set forth and approved by the Comité de Ética en Investigación and the Comité de Investigación (Research Ethics Committee and the Research Committee) from INER Institutional Review Board (study no. B01-21).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additionally, SARS-CoV-2 infection was evaluated in all participants by detection of anti-N antibodies in plasma by ELISA (Elecsys Anti-SARS-CoV-2. Roche, Cat No 09203095190).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-N</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A purified human monoclonal antibody against SARS-CoV-2 Spike, C144, diluted 1:20 in 2% BSA/PBS and serially diluted, was used as a positive control.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>C144</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">50μl of reporter lysis buffer (Promega) was added to the beads and antibody-captured NanoLuc luciferase activity measured using the Nano-Glo Luciferase Assay System (Promega) with the Glomax Navigator (Promega).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-captured NanoLuc luciferase</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293Tcells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV-2-SΔ19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293Tcells</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The S-6P-NanoLuc protein was expressed in 293-Expi cells, captured on Ni2+-magnetic beads and the purified protein eluted following incubation with 3CL protease.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293-Expi</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293Tcells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV-2-SΔ19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3ΔEnv-nanoluc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSARS-CoV-2-SΔ19</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Non-parametric Spearmen’s correlation analysis (GraphPad Prism) was performed and p values calculated with a two-tailed analysis with 95% confidence interval.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Stained PBMC were acquired in a BD FACS Fusion using FACS DIVA software (v8.0) and data were analyzed using FloJo v10.8.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FloJo</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
This information could also guide the use of vaccines that are not widely used in wealthier nations and broaden options when confronting inequity in vaccine distribution, production limitations as well as hesitancy issues.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.sciencedirect.com www.sciencedirect.com
-
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., Vézina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, É., Guilbault, A., Delisle, B., Levade, I., … Finzi, A. (2022). SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2022.110429
-
-
www.cde.ca.gov www.cde.ca.gov
-
t is in the text or the readers may not believe you e sks m to ea s ment ng estashed tht the s s ment s to sto mpng n the ean ecse the eati nimas e see e ng to stat nishng Ms. Hatwal: So, what evidence did you find to support that claim—that all the animals will die if we don’t stop dumping? What evidence did you find that will help to strengthen tht ment, e t to eaers? s. tw then els ecnie the nfmatin e s ted s m a reliable source and is effective in supporting his argument. Satisfied that Bobby can move n s n to ncte s evence, she then sks m to evew the nitin s ment nd to et er no ere e e the evence. en es ths, t s event to s. tw tht e s some nfsin t the er strtue nd tht s ting needs to e eonied s s moment n the ntertin en she taets teang nt m. e evews the nitin th m nd tes the nitina elements on a self-adhesive note and includes specific instructional support, such as putting the evidence in order to help the flow or adding transitional sentences..FifgradarworkiofollowiCCCSSforELLiacy:(a)applyirdiardforiorol(RI.5.8);(b)wriard: (W.5.4);a(c)lauagard:(L.5.4-6),parcularlyaorrdkrcarofralviroIrrdiiucoalyzaidfylocaoof, ,appor.Irwri,arlrhoworgazrargufvy.WhildarivolviiwriparoflMHaalwiBobbydiuhiwriprogrShhaaribiopapagwihdiap:adiludiBobby’Shplawichofduriday’wrioMHaal’ialpurpowiBobbyifollowupofbackprovidhiodayagobaoidicifroaiacowihiiaiacodahprovidourcofidpporhiarguOioccaowahowhhauhpriorfback:MHaal: You’rworkioidTlabouiBobby: IfougoodioroibookofEvirolProoyaoIMHaal: whadoyouiabouwhayoufoufar?DoyouiaipporyourarguBobby: Igu....ipoiMHaalrBobbyapurpoofidipporhiargu
Hatwal found what Bobby needed to improve and guide him with clear and direct messages and specific questions.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.06.479285: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: All animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).<br>IACUC: All animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals, Vaccines, and Challenge Stock: 30 adult male and female cynomolgus macaques ages 4-12 years old were randomly allocated to 5 experimental groups (N=6/group; Fig. S1).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals, Vaccines, and Challenge Stock: 30 adult male and female cynomolgus macaques ages 4-12 years old were randomly allocated to 5 experimental groups (N=6/group; Fig. S1).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Immunologic and virologic assays were performed blinded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus neutralizing antibody assay: The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were used to measure pseudovirus neutralizing antibodies13.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibodies13</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were again washed 3 times and 50 μL of SULFO-Tagged anti-Human IgG detection antibody diluted to 1x in Diluent 100 was added to each well and incubated shaking at 700 rpm at room temperature for at least 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human IgG</div><div>suggested: (RevMAb Biosciences Cat# 31-1021-MK, RRID:AB_2783629)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">106 peripheral blood mononuclear cells well were re-suspended in 100 µL of R10 media supplemented with CD49d monoclonal antibody (1 µg/mL) and CD28 monoclonal antibody (1 µg/mL).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD49d</div><div>suggested: (BD Biosciences Cat# 347690, RRID:AB_647457)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, the cells were washed twice with DPBS, stained with aqua live/dead dye for 10 mins and then stained with predetermined titers of monoclonal antibodies against CD279 (clone EH12.1, BB700), CD38 (clone OKT10, PE), CD28 (clone 28.2, PE CY5), CD4 (clone L200, BV510), CD95 (clone DX2, BUV737), CD8 (clone SK1, BUV805) for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD279</div><div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div></div><div style="margin-bottom:8px"><div>CD38</div><div>suggested: (BD Biosciences Cat# 742074, RRID:AB_2871359)</div></div><div style="margin-bottom:8px"><div>CD28</div><div>suggested: (BD Biosciences Cat# 748474, RRID:AB_2872889)</div></div><div style="margin-bottom:8px"><div>CD4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD95</div><div>suggested: (BD Biosciences Cat# 741968, RRID:AB_2871273)</div></div><div style="margin-bottom:8px"><div>CD8</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed twice with 1X Perm Wash buffer (BD Perm/WashTM Buffer 10X in the CytoFix/CytoPerm Fixation/ Permeabilization kit diluted with MilliQ water and passed through 0.22µm filter) and stained with intracellularly with monoclonal antibodies against Ki67 (clone B56, FITC), CD69 (clone TP1.55.3, ECD), IL10 (clone JES3-9D7, PE CY7), IL13 (clone JES10-5A2, BV421), TNF-α (clone Mab11, BV650), IL4 (clone MP4-25D2, BV711), IFN-γ (clone B27; BUV395), CD45 (clone D058-1283, BUV615), IL2 (clone MQ1-17H12, APC), CD3 (clone SP34.2, Alexa 700)for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ki67</div><div>suggested: (Akoya Biosciences Cat# 4250019, RRID:AB_2895046)</div></div><div style="margin-bottom:8px"><div>CD69</div><div>suggested: (BD Biosciences Cat# 740220, RRID:AB_2739968)</div></div><div style="margin-bottom:8px"><div>IL10</div><div>suggested: (BD Biosciences Cat# 564083, RRID:AB_2738583)</div></div><div style="margin-bottom:8px"><div>IL13</div><div>suggested: (BD Biosciences Cat# 564288, RRID:AB_2738731)</div></div><div style="margin-bottom:8px"><div>TNF-α</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IL4</div><div>suggested: (BD Biosciences Cat# 743163, RRID:AB_2741316)</div></div><div style="margin-bottom:8px"><div>IFN-γ</div><div>suggested: (BD Biosciences Cat# 563563, RRID:AB_2738277)</div></div><div style="margin-bottom:8px"><div>IL2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After blocking, samples were stained with monoclonal antibodies against CD45 (clone D058-1283, brilliant ultraviolet (BUV) 805), CD3 (clone SP34.2, allophycocyanin (APC)-Cy7), CD7 (clone M-T701, Alexa Fluor700), CD123 (clone 6H6, Alexa Fluor 700), CD11c (clone 3.9, Alexa Fluor 700), CD19 (clone J3-119, phycoerythrin (PE)), CD20 (clone 2H7, PE-Cy5), IgD (IA6-2, PE), IgG (clone G18-145, BUV737), IgM (clone G20-127, BUV395), CD80 (clone L307.4, brilliant violet (BV) 786), CD95 (clone DX2, BV711), CD27 (clone M-T271, BUV563), CD21 (clone B-ly4, BV605), CD14 (clone M5E2, BV570).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD45</div><div>suggested: (Creative Biomart Cat# DMABT-H22043, RRID:AB_11439556)</div></div><div style="margin-bottom:8px"><div>CD3</div><div>suggested: (GenWay Biotech Inc. Cat# GWB-48F4B7, RRID:AB_10522262)</div></div><div style="margin-bottom:8px"><div>CD7</div><div>suggested: (BD Biosciences Cat# 741824, RRID:AB_2871159)</div></div><div style="margin-bottom:8px"><div>CD123</div><div>suggested: (Thermo Fisher Scientific Cat# 56-1239-41, RRID:AB_2815247)</div></div><div style="margin-bottom:8px"><div>CD11c</div><div>suggested: (Nanostring Cat# 121300104, RRID:AB_2893077)</div></div><div style="margin-bottom:8px"><div>CD19</div><div>suggested: (GenWay Biotech Inc. Cat# GWB-B7A22E, RRID:AB_10528952)</div></div><div style="margin-bottom:8px"><div>CD20</div><div>suggested: (BD Biosciences Cat# 563781, RRID:AB_2744325)</div></div><div style="margin-bottom:8px"><div>IgM</div><div>suggested: (BD Biosciences Cat# 563903, RRID:AB_2721269)</div></div><div style="margin-bottom:8px"><div>CD80</div><div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div></div><div style="margin-bottom:8px"><div>CD27</div><div>suggested: (BD Biosciences Cat# 748705, RRID:AB_2873109)</div></div><div style="margin-bottom:8px"><div>CD21</div><div>suggested: (BD Biosciences Cat# 740395, RRID:AB_2740125)</div></div><div style="margin-bottom:8px"><div>CD14</div><div>suggested: (BioLegend Cat# 301831, RRID:AB_10897803)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For intracellular staining, cells were permeabilized using Caltag Fix & Perm (Thermo Fisher Scientific), then stained with monoclonal antibodies against Ki67 (clone B56, peridinin chlorophyll protein (PerCP)-Cy5.5) and Bcl6 (clone K112-91, PE-CF594).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bcl6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary mouse anti-SARS-CoV-nucleoprotein antibody (Sinobiological; 40143-MM05) at 1:1000, was applied for 60 min, followed by mouse Mach-2 HRP-Polymer (Biocare) for 30 min and then counterstained with hematoxylin followed by bluing using 0.25% ammonia water.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-nucleoprotein</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This challenge stock was generated in VeroE6-TMPRSS2 cells and had a titer of 2.3×109 TCID50/ml and 2.5×107 PFU/ml in VeroE6-TMPRSS2 cells and was fully sequenced (EPI_ISL_7171744; Mehul Suthar, Emory University).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co-transfected into HEK293T cells (ATCC CRL_3216) with lipofectamine 2000 (ThermoFisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# CRL-3216, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine the neutralization activity of human serum, HEK293T-hACE2 cells were seeded in 96-well tissue culture plates at a density of 2.0 × 104 cells per well overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-hACE2</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co-transfected into HEK293T cells (ATCC CRL_3216) with lipofectamine 2000 (ThermoFisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>pLenti-CMV Puro-Luc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pcDNA3.1-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The gene fragment was subsequently cloned into a pcDNA3.1+ expression plasmid using restriction site cloning (Integrated DNA Technologies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1+</div><div>suggested: RRID:Addgene_117272)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fixed cells were transferred to 96-well round bottom plate and analyzed by BD FACSymphony™ system.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD FACSymphony™</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequent analyses were performed using FlowJo software (BD Bioscience, v.9.9.6).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Descriptive statistics and logistic regression were performed using GraphPad Prism 8.4.3, (GraphPad Software, San Diego, California).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.04.479171: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Experiments with SARS-CoV-2 involving ferrets and dwarf hamsters were approved by the Georgia State Institutional Animal Care and Use Committee under protocol A20031 and A21019, respectively.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Lonza Bioscience, cat# CC-2540S, lot# 0000646466, passage 3, donor “M4”) from a 38-year-old male were expanded in PneumaCult-Ex Plus (Stemcell Technologies cat# 05040) and differentiated in PneumaCult-ALI (Stemcell Technologies cat# 05001) for 8 weeks in following the manufacturer’s instructions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">After a minimal resting period of 2 weeks after arrival, animals were randomly assigned to groups for individual studies, transferred into an ABSL-3 facility immediately prior to study start, and housed singly in ventilated negative-pressure cages during the studies.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cells were authenticated and checked for mycoplasma prior to use.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies: SARS-CoV-2 N and goblet cells were co-stained using rabbit anti-SARS-CoV-2</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nucleocapsid monoclonal antibody (HL453) (Invitrogen, cat# MA5-36272) (1:100 dilution) and mouse anti-MUC5AC (ThermoFisher, cat# MA5-12175) (1:200 dilution) as primary antibodies, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HL453</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-36272, RRID:AB_2890568)</div></div><div style="margin-bottom:8px"><div>anti-MUC5AC</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-12175, RRID:AB_10983421)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Donkey anti-goat (Alexa Fluor® 568 (ThermoFisher Scientific, cat# A-11057)) and rabbit anti-mouse IgG (H+L) cross-adsorbed secondary antibody (Alexa Fluor® 488 (ThermoFisher Scientific, cat# A-11059)) were used at a 1:500 dilution as secondary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: (Molecular Probes Cat# A-11057, RRID:AB_142581)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For staining of SARS-CoV-2 S, mouse anti SARS-CoV-1 and 2 Spike protein clone [1A9] monoclonal (Abcam, cat# ab273433) (1:200 dilution) and goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody (Alexa Fluor® 488; 1:500 dilution (Invitrogen, cat# A-11029)), were used as primary and secondary antibodies, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti SARS-CoV-1 and 2 Spike protein</div><div>suggested: (Abcam Cat# ab273433, RRID:AB_2891068)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Molecular Probes Cat# A-11029, RRID:AB_2534088)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For staining of ciliated cells, rabbit anti-beta IV tubulin recombinant antibody conjugated with Alexa Fluor® 647 [EPR16775] (Abcam, cat# ab204034) was used at a 1:100 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>rabbit anti-beta IV tubulin recombinant antibody</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-beta IV tubulin</div><div>suggested: (Abcam Cat# ab179509, RRID:AB_2716759)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells: African green monkey kidney cells VeroE6 (ATCC CRL-1586™),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VOC delta (lineage B.1.617.2, clinical isolate #2333067) and VOC omicron (lineage B.1.1.529, WA-UW-21120120771) were obtained from the Northwestern Reference laboratory and amplified on Calu-3 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For hamsters infected with VOC gamma, delta, and omicron, plaque assays were performed with VeroE6-TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Log viral titers were normalized using the average top plateau of viral titers to define 100% and were analyzed with a non-linear regression with variable slope to determine EC50 (Prism; GraphPad)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image captures were performed with a Zeiss Axio Observer Z.1 and an LSM 800 confocal microscope with AiryScan, controlled with the Zeiss Zen 3.1 Blue software package (Windows 10).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zen</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics and reproducibility: The Microsoft Excel (versions 16.52) and Numbers (version 10.1) software packages were used for most data collection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div><div style="margin-bottom:8px"><div>Numbers</div><div>suggested: (BioNumbers, RRID:SCR_002782)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The GraphPad Prism (version 9.1.0) software package was used for data analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figures were assembled using Adobe Illustrator (version CS6).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Adobe Illustrator</div><div>suggested: (Adobe Illustrator, RRID:SCR_010279)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.05.22270494: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Using only samples collected in the summer period potentially helps to overcome issues that could arise from the transient antibody boosts due to both infection and vaccination23.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>vaccination23</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All four viruses were propagated on Madin-Darby Canine Kidney (MDCK) cells in infection medium, which consisted of MEM-Eagle Medium /EBSS (Lonza, Geleen, The Netherlands) supplemented with MEM Non-Essential Amino Acids (Gibco, ThermoFischer Scientific, Amsterdam, The Netherlands), penicillin (100 U/mL), streptomycin (100 g/mL), L-Glutamine (Lonza), HEPES (Lonza), and TPCKtrypsin (Sigma-Aldrich/Merck, Darmstadt, Germany).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MDCK</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.03.479037: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Rhesus macaque model and immunizations: All experiments conducted according to NIH regulations and standards on the humane care and use of laboratory animals as well as the Animal Care and Use Committees of the NIH Vaccine Research Center and BIOQUAL, Inc. (Rockville, Maryland).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Subgenomic RNA quantification: sgRNA was isolated and quantified by researchers blinded to vaccine history as previously described (Corbett et al., 2021c), except for the use of a new probe noted below.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, total IgG antigen-specific antibodies to variant SARS-CoV-2 S- and RBD-derived antigens were determined in a multiplex serology assay by MSD V-Plex SARS-CoV-2 Panel 23 for S and MSD V-Plex SARS-CoV-2 Panel 22 for RBD) according to manufacturer’s instructions, except 25μl of sample and detection antibody were used per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>total IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were incubated with an anti-SARS-CoV S primary antibody directly conjugated to Alexaflour-647 (CR3022-AF647) overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, ELISA against S-2P was performed in the absence or presence of sodium thiocyanate (NaSCN) and developed with HRP-conjugated goat anti-monkey IgG (H+L) secondary antibody (Invitrogen) and SureBlue 3,3′,5,5′-tetramethylbenzidine (TMB) microwell peroxidase substrate (1-Component; SeraCare) and quenched with 1 N H2SO4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-monkey IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-histidine antibody was immobilized on Series S Sensor Chip CM5 (Cytiva) allowing for the capture of his-tagged SARS-CoV-2 S-2P on active sensor surface.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-histidine</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human IgG monoclonal antibodies (mAbs) used for these analyses include: RBD-specific mAbs B1-182, A19-46.1, A20-29.1, A19-61.1, S309, A23-97.1 and A23-80.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A19-61.1</div><div>suggested: (ABclonal Cat# A19611, RRID:AB_2862699)</div></div><div style="margin-bottom:8px"><div>A23-80.1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following monoclonal antibodies were used: CD3 APC-Cy7 (clone SP34-2, BD Biosciences), CD4 PE-Cy5.5 (clone S3.5, Invitrogen), CD8 BV570 (clone RPA-T8, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD4</div><div>suggested: (BioLegend Cat# 100541, RRID:AB_10897943)</div></div><div style="margin-bottom:8px"><div>CD8</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, seven to nine days following Omicron challenge animals were euthanized and lung tissue was processed and stained with hematoxylin and eosin for pathological analysis or with a rabbit polyclonal anti-SARS-CoV-2 anti-nucleocapsid antibody (GeneTex, GTX135357) at a dilution of 1:2000 for IHC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 anti-nucleocapsid antibody (GeneTex, GTX135357</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Method details: Cells and viruses: VeroE6-TMPRSS2 cells were generated at the Vaccine Research Center, NIH, Bethesda, MD.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral pseudovirus neutralization: Neutralizing antibodies in serum or plasma were measured in a validated pseudovirus-based assay as a function of reductions in luciferase reporter gene expression after a single round of infection with SARS-CoV-2 spike-pseudotyped viruses in 293T/ACE2 cells (293T cell line stably overexpressing the human ACE2 cell surface receptor protein, obtained from Drs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/ACE2</div><div>suggested: RRID:CVCL_YZ65)</div></div><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 S-pseudotyped virus was prepared by transfection in 293T/17 cells (human embryonic kidney cells in origin; obtained from American Type Culture Collection, #CRL-11268) using a lentivirus backbone vector, a spike-expression plasmid encoding S protein from Wuhan-Hu-1 strain (GenBank no. NC_045512) with a p.Asp614Gly mutation, a TMPRSS2 expression plasmid and a firefly Luc reporter plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Vero-TMPRSS2 cells were plated and incubated overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The FRNT-50 titers were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 9.2.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were acquired on an BD FACSymphony cytometer and analyzed using FlowJo version 10.7.2 (BD, Ashland, OR)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Limitations of the study: There are several limitations to this study. First, NHP models may not fully recapitulate clinical data in humans regarding the extent of viral replication necessary for the enhanced transmission of Omicron compared to prior variants. Even if a significant component of Omicron’s growth advantage is due to immune escape, the role of viral replication kinetics cannot be ruled out. Here, viral titers were low in the lungs and low to undetectable in the upper airway. Second, neutralizing antibody titers in NHP are 5-to 10-fold greater than in humans that received the same dose and regimen of mRNA-1273 with a boost (Edara et al., 2021a; Pajon et al., 2022). Third, a second dose of mRNA-Omicron may elicit a population of B cells specific only for Omicron. Finally, since we sought to compare two different mRNA boosts, we did not have an unboosted group to determine whether the boost enhanced protection. As all the boosted NHP were completely protected in the lungs, we were unable to determine an immune threshold for protection.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.03.479007: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AlexaFluor-647-conjugated goat anti-human IgG (H+L) Ab (Invitrogen) and AlexaFluor-conjugated donkey anti-goat IgG (H+L) Ab (Invitrogen) was used as secondary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>AlexaFluor-conjugated donkey anti-goat IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An anti-mouse SARS-CoV-2 nucleocapsid protein (Clone 1C7, Bioss Antibodies)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse SARS-CoV-2 nucleocapsid protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following extensive washing (3×) with PBS, an anti-mouse IgG HRP secondary antibody solution was formulated in PBS + 1% non-fat milk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 293T-ACE2 cell line was previously reported (Prevost et al., 2020)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected by the calcium phosphate method with the lentiviral vector pNL4.3 R-E-Luc (NIH AIDS Reagent Program) and a plasmid encoding for SARS-CoV-2 Spike at a ratio of 5:4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All virus-compounds supernatant was removed from wells without disrupting the Vero E6 monolayer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell viability test: To measure the cytotoxicity of VE607 and its stereoisomers on 293T-ACE2 or Vero-E6 cells, a cell viability assay using CellTiter-Glo® One Solution Assay (Promega) was performed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The codon-optimized RBD sequence (encoding residues 319-541) fused to a C-terminal hexahistidine tag was cloned into the pcDNA3.1(+) expression vector and was reported elsewhere (Beaudoin-Bussieres et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1(+)</div><div>suggested: RRID:Addgene_129020)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid encoding the Delta (B.1.617.2) and Omicron (B.1.1.529) Spikes were generated by overlapping PCR using a codon-optimized wild-type SARS-CoV-2 Spike gene (GeneArt, ThermoFisher) that was synthesized (Biobasic) and cloned in pCAGGS as a template (Chatterjee et al., 2021; Gong et al., 2021b; Tauzin et al., 2022).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The vesicular stomatitis virus G (VSV-G)-encoding plasmid (pSVCMV-IN-VSV-G) was previously described (Emi et al., 1991).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VSV-G)-encoding</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSVCMV-IN-VSV-G</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected by the calcium phosphate method with the lentiviral vector pNL4.3 R-E-Luc (NIH AIDS Reagent Program) and a plasmid encoding for SARS-CoV-2 Spike at a ratio of 5:4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4.3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell surface staining and flow cytometry analysis: Using the standard calcium phosphate method, 10 μg of Spike expressor and 2.5 μg of a green fluorescent protein (GFP) expressor (pIRES-GFP) were transfected into 2 × 106 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pIRES-GFP</div><div>suggested: RRID:Addgene_78264)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VE607 compound was structurally preprocessed using LigPrep (Schrödinger, 2020) to generate multiple states for stereoisomers, tautomers, ring conformations, and protonation states at a selected pH range.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LigPrep</div><div>suggested: (Ligprep, RRID:SCR_016746)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were acquired on a LSRII cytometer (BD Biosciences, Mississauga, ON, Canada) and data analysis was performed using FlowJo vX.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Densitometry data were acquired with a Typhoon Trio Variable Mode Imager (Amersham Biosciences) in storage phosphor acquisition mode and analyzed using ImageQuant 5.2 (Molecular Dynamics).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageQuant</div><div>suggested: (ImageQuant, RRID:SCR_014246)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification and statistical analysis: Statistics were analyzed using GraphPad Prism version 8.0.2 (GraphPad, San Diego, CA, (USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.thelancet.com www.thelancet.com
-
Wong, S.-C., Au, A. K.-W., Chen, H., Yuen, L. L.-H., Li, X., Lung, D. C., Chu, A. W.-H., Ip, J. D., Chan, W.-M., Tsoi, H.-W., To, K. K.-W., Yuen, K.-Y., & Cheng, V. C.-C. (2022). Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: A challenge of elimination strategy of COVID-19. The Lancet Regional Health – Western Pacific, 18. https://doi.org/10.1016/j.lanwpc.2021.100360
-
With the global evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), for almost 2 years, various control strategies have been utilized around the world. While most of the western countries gradually lifted the border control and quarantine measures, elimination strategy aiming at “zero COVID-19” remains in place in Western Pacific Region such as mainland China and Hong Kong, where inbound travelers are required to undergo quarantine in designated quarantine hotels (DQHs) for up to 21 days. However, not designed for the purpose of quarantine, especially for infectious diseases with potential airborne spread, DQHs may be potential venues for COVID-19 transmission.1Dinoi A Feltracco M Chirizzi D Trabucco S Conte M Gregoris E et al.A review on measurements of SARS-CoV-2 genetic material in air in outdoor and indoor environments: Implication for airborne transmission.Sci Total Environ. 2021; 151137Crossref PubMed Scopus (1) Google Scholar We recently reported an incident of community outbreak of imported SARS-CoV-2 beta variant due to possible intra-hotel transmission in a DQH.2Cheng VC Siu GK Wong SC Au AK Ng CS Chen H et al.Complementation of contact tracing by mass testing for successful containment of beta COVID-19 variant (SARS-CoV-2 VOC B.1.351) epidemic in Hong Kong.Lancet Reg Health West Pac. 2021; 17100281Summary Full Text Full Text PDF PubMed Google Scholar Smoke tests in DQHs demonstrated that aerosols could leak out from guest rooms to the corridors, and guests in neighboring rooms may inhale the infectious aerosols when the doors were opened.3Wong SC Chen H Lung DC Ho PL Yuen KY Cheng VC. To prevent SARS-CoV-2 transmission in designated quarantine hotel for travelers: Is the ventilation system a concern?.Indoor Air. 2021; 31: 1295-1297Crossref PubMed Scopus (2) Google Scholar We also conducted a serological survey of the hotel staff members in the implicated DQHs, which showed no serological evidence of guest-to-staff-to-guest transmission of COVID-19.4Li X Chen H Lu L Chen LL Chan BP Wong SC et al.High compliance to infection control measures prevented guest-to-staff transmission in COVID-19 quarantine hotels.J Infect. 2021; (S0163-4453(21)00533-8)Summary Full Text Full Text PDF Google Scholar This provides reassurance that our infection control training of hotel staff members, which was similar to the training of healthcare workers in hospitals and community treatment facilities, was effective at preventing intra-hotel transmission to staff.5Wong SC Leung M Tong DW Lee LL Leung WL Chan FW et al.Infection control challenges in setting up community isolation and treatment facilities for patients with coronavirus disease 2019 (COVID-19): Implementation of directly observed environmental disinfection.Infect Control Hosp Epidemiol. 2021; 42: 1037-1045Crossref PubMed Scopus (6) Google Scholar After this incident, portable air purifiers with high-efficiency particulate air filters were installed in the corridors of DQHs. Residents are required to wear surgical mask for the purpose of mutual protection while opening the doors.Despite these additional measures, another incident of SARS-CoV-2 transmission inside a DQH was reported.6Gu H Krishnan P Ng DYM Chang LDJ Liu GYZ Cheng SSM et al.Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021.Emerg Infect Dis. 2021 Dec 3; 28https://doi.org/10.3201/eid2802.212422Crossref PubMed Google Scholar The asymptomatic index case (M/36), who had completed two doses of BNT162b2 mRNA COVID-19 vaccine (BioNTech) in June 2021, had anti-spike protein receptor-binding domain (anti-RBD) of 1142 AU/ml (14 November 2021). The secondary case (M/62) also completed two doses of BioNTech in May 2021. He developed respiratory symptoms on day 8 after arrival and clinically stable after hospitalization, with anti-RBD of 250 AU/ml (19 November 2021). Both cases had no chronic illness. Whole genome sequences of specimens collected from the two cases were different by only 1 nucleotide and belonged to the Omicron variant (B.1.1.529 lineage).6
-
-
www.biorxiv.org www.biorxiv.org
-
Joint Public Review:
A highly robust result when investigating how neural population activity is impacted by performance in a task is that the trial to trial correlations (noise correlations) between neurons is reduced as performance increases. However the theoretical and experimental literature so far has failed to account for this robust link since reduced noise correlations do not systematically contribute to improved availability or transmission of information (often measured using decoding of stimulus identity). This paper sets out to address this discrepancy by proposing that the key to linking noise correlations to decoding and thus bridging the gap with performance is to rethink the decoders we use : instead of decoders optimized to the specific task imposed on the animal on any given trial (A vs B / B vs C / A vs C), they hypothesize that we should favor a decoder optimized for a general readout of stimulus properties (A vs B vs C).
To test this hypothesis, the authors use a combination of quantitative data analysis and mechanistic network modeling. Data were recorded from neuronal populations in area V4 of two monkeys trained to perform an orientation change detection task, where the magnitude of orientation change could vary across trials, and the change could happen at cued (attended) or uncued (unattended) locations in the visual field. The model, which extends previous work by the authors, reproduces many basic features of the data, and both the model and data offer support for the hypothesis.
The reviewers agreed that this is a potentially important contribution, that addresses a widely observed, but puzzling, relation between perceptual performance and noise correlations. The clarity of the hypothesis, and the combination of data analysis and computational modelling are two essential strengths of the paper.
Overall this paper exhibits a new factor to be taken into account when analysing neural data : the choice of decoder and in particular how general or specific the decoder is. The fact that the generality of the decoder sheds light on the much debated question of noise correlations underscores its importance. The paper therefore opens multiple avenues for future research to probe this new idea, in particular for tasks with multiple stimuli dimensions.
Nonetheless, as detailed below, the reviewers believe the manuscript clarity could be further improved in several points, and some additional analysis of the data would provide more straightforward test of the hypothesis.
1. It would be important to verify that the model reproduces the correlation between noise and signal correlations since this is really a key argument leading to the author's hypothesis.
2. Testing the hypothesis of the general decoder:<br /> 2.1 In the data, the authors compare mainly the specific (stimulus) decoder and the monkey's choice decoder. The general stimulus decoder is only considered in fig. 3f, because data across multiple orientations are available only for the cued condition, and therefore the general and specific decoders cannot be compared for changes between cued and uncued. However, the hypothesized relation between mean correlations and performance should also be true within a fixed attention condition (cued), comparing sessions with larger vs. smaller correlation. In other words, if the hypothesis is correct, you should find that performance of the "most general" decoder (as in fig. 3f) correlates negatively with average noise correlations, across sessions, more so than the "most specific" decoder.
2.2 In figure 3f, a more straightforward and precise comparison is to use the stimulus decoders to predict the choice, and test whether the more specific or the more general can predict choices more accurately.
3. The main goal of the manuscript is to determine the impact of noise correlations on various decoding schemes. The figures however only show how decoding co-varies with correlations, but a direct, more causal analysis of the effect of correlations on decoding seems to be missing. Such an analysis can be obtained by comparing decoding on simultaneously recorded activity with decoding on trial-shuffled activity, in which noise-correlations are removed.
4. How different are the four different decoders (specific/monkey, cued/uncued)? It would be interesting to see how much they overlap. More generally, the authors should discuss the alternative that attention modulates also the readout/decoding weights, rather than or in addition to modulating V4 activity.
5. Quantifying the link between model and data :<br /> 5.1 the text providing motivation for the model could be improved. The motivation used in the manuscript is, essentially, that the model allows to extrapolate beyond the data (more stimuli, more repetitions, more neurons). The dangers of extrapolation beyond the range of the data are however well known. A model that extrapolates beyond existing data is useful to design new experiments and test predictions, but this is not done here. Because the manuscript is about information and decoding, a better motivation is the fact that this model takes an actual image as input, and produces tuning and covariance compatible with each other because they are constrained by an actual network that processes the input (as opposed to parametric models where tuning and covariance can be manipulated independently).
5.2 The ring structure, and the orientation of correlations (Fig 2b) seem to be key ingredients of the model, but are they based on data, or ad-hoc assumptions?
5.3 In the model, the specific decoder is quite strongly linked to correlated variability and the improvement of the general decoder is clear but incremental (0.66 vs 0.83) whereas in the data there really is no correlation at all (Fig 3c). This is a bit problematic because the author's begin by stating that specific decoders cannot explain the link between noise correlations and accuracy but their specific decoder clearly shows a link.
6. General decoder: Some parts of the text (eg. Line 60, Line 413) refer to a decoder that accounts for discrimination along different stimulus dimensions (eg. different values of orientation, or different color of the visual input). But the results of the manuscripts are about a general decoder for multiple values along a single stimulus dimension. The disconnect should be discussed, and the relation between these two scenarios explained.
7. Some statements in the discussion such as l 354 "the relationship between behavior and mean correlated variability is explained by the hypothesis that observers use a general strategy" should be qualified : the authors clearly show that the general decoder amplifies the relationship but in their own data the relationship exists already with a specific decoder.
8. Low-Dimensionality, beginning of Introduction and end of Discussion: experimentally, cortical activity is low-dimensional, and the proposed model captures that. But some of the reviewers did not understand the argument offered for why this matters, for the relation between average correlations and performance. It seems that the dimensionality of the population covariance is not relevant: The point instead is that a change in amplitude of fluctuations along the f'f' direction necessarily impact performance of a "specific" decoder, whereas changes in all other dimensions can be accounted for by the appropriate weights of the "specific" decoder. On the other hand, changes in fluctuation strength along multiple directions may impact the performance of the "general" decoder.
-
-
academic.oup.com academic.oup.com
-
References Andonov A., Rauh J. D. (2020): The return expectations of institutional investors. Working Paper.Barberis N., Greenwood R., Jin L., Shleifer A. (2015): X-capm: an extrapolative capital asset pricing model, Journal of Financial Economics 115, 1–24.Google ScholarCrossrefSearch ADS Find in my library WorldCat Barberis N., Greenwood R., Jin L., Shleifer A. (2016): Extrapolation and bubbles. Technical report, National Bureau of Economic Research, Cambridge, Massachusetts.Bear M., Connors B., Paradiso M. (2020): Neuroscience: Exploring the Brain, Enhanced Edition. Jones & Bartlett Learning, LLC, Burlington, Massachusetts.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Bianchi F., Ludvigson S. C., Ma S. (2020): Belief distortions and macroeconomic fluctuations. Technical report, National Bureau of Economic Research, Cambridge, Massachusetts.Bissiri P. G., Holmes C. C., Walker S. G. (2016): A general framework for updating belief distributions, Journal of the Royal Statistical Society Series B, Statistical Methodology 78, 1103.Google ScholarCrossrefSearch ADS Find in my library PubMedWorldCat Bliss T. V., Lømo T. (1973): Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path, The Journal of Physiology 232, 331–356.Google ScholarCrossrefSearch ADS Find in my library PubMedWorldCat Bordalo P., Gennaioli N., Porta R. L., Shleifer A. (2019): Diagnostic expectations and stock returns, The Journal of Finance 74, 2839–2874.Google ScholarCrossrefSearch ADS Find in my library WorldCat Bordalo P., Gennaioli N., Shleifer A. (2020): Memory, attention, and choice, Quarterly Journal of Economics 135, 1399–1442.Google ScholarCrossrefSearch ADS Find in my library WorldCat Botsch M. J., Malmendier U. (2020): The long shadows of the great inflation: evidence from residential mortgages. Working Paper.Botzen W. W., van den Bergh J. C. (2012): Risk attitudes to low-probability climate change risks: wtp for flood insurance, Journal of Economic Behavior & Organization 82, 151–166.Google ScholarCrossrefSearch ADS Find in my library WorldCat Broner F., Didier T., Erce A., Schmukler S. L. (2013): Gross capital flows: dynamics and crises, Journal of Monetary Economics 60, 113–133.Google ScholarCrossrefSearch ADS Find in my library WorldCat Caballero R. J., Simsek A. (2018): A model of fickle capital flows and retrenchment. Technical report, National Bureau of Economic Research, Cambridge, Massachusetts.Choi J. J., Laibson D., Madrian B. C., Metrick A. (2009): Reinforcement learning and savings behavior, The Journal of Finance 64, 2515–2534.Collin-Dufresne P., Johannes M., Lochstoer L. A. (2017): Asset pricing when ‘this time is different’, The Review of Financial Studies 30, 505–535.Google ScholarCrossrefSearch ADS Find in my library WorldCat Cooper I. A., Kaplanis E. (1986): Costs to crossborder investment and international equity market equilibrium, Recent Developments in Corporate Finance, Cambridge University Press, Cambridge, pp. 209–240.Google ScholarCrossrefSearch ADS Find in my library Google PreviewWorldCatCOPAC Doidge N. (2007): The Brain That Changes Itself: Stories of Personal Triumph from the Frontiers of Brain Science. Penguin, London.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Duchin R., Simutin M., Sosyura D. (2021): The origins and real effects of the gender gap: evidence from ceos’ formative years, The Review of Financial Studies 34, 700–762.Google ScholarCrossrefSearch ADS Find in my library WorldCat Ehling P., Graniero A., Heyerdahl-Larsen C. (2018): Asset prices and portfolio choice with learning from experience, The Review of Economic Studies 85, 1752–1780.Google ScholarCrossrefSearch ADS Find in my library WorldCat Forbes K. J., Warnock F. E. (2012): Capital flow waves: surges, stops, flight, and retrenchment, Journal of International Economics 88, 235–251.Google ScholarCrossrefSearch ADS Find in my library WorldCat French K. R., Poterba J. M. (1991): Investor diversification and international equity markets, The American Economic Review 81, 222–226.Google ScholarFind in my libraryWorldCat Frey U., Morris R. G. (1997): Synaptic tagging and long-term potentiation, Nature 385, 533–536.Google ScholarCrossrefSearch ADS Find in my library PubMedWorldCat Froot K. A., O’Connell G. (2007): The Pricing of US Catastrophe Reinsurance. University of Chicago Press, Chicago, Illinois.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Froot K. A., O’Connell P. G. (2008): On the pricing of intermediated risks: theory and application to catastrophe reinsurance, Journal of Banking & Finance 32, 69–85.Google ScholarCrossrefSearch ADS Find in my library WorldCat Fuster A., Laibson D., Mendel B. (2010): Natural expectations and macroeconomic fluctuations, Journal of Economic Perspectives 24, 67–84.Google ScholarCrossrefSearch ADS Find in my library PubMedWorldCat Fuster A., Hebert B., Laibson D. (2011): Natural expectations, macroeconomic dynamics and asset pricing, in: Acemoglu D. and Woodford M. (eds), NBER Macroeconomics Annual, University of Chicago Press, Chicago, Illinois. pp. 1–48.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Gilboa I., Schmeidler D. (1995): Case-based decision theory, The Quarterly Journal of Economics 110, 605–639.Google ScholarCrossrefSearch ADS Find in my library WorldCat Graham J. R., Narasimhan K. (2004): Corporate survival and managerial experiences during the great depression, Experimental & Empirical Studies eJournalGoogle ScholarFind in my libraryWorldCat Greenwood R., Nagel S. (2009): Inexperienced investors and bubbles, Journal of Financial Economics 93, 239–258.Google ScholarCrossrefSearch ADS Find in my library WorldCat Huang X. (2019): Mark twain’s cat: industry investment experience, categorical thinking and stock selection, The Journal of Finance Economics 131, 404–432.Google ScholarCrossrefSearch ADS Find in my library WorldCat Karmiloff-Smith A. (2015): An alternative to domain-general or domain-specific frameworks for theorizing about human evolution and ontogenesis, AIMS Neuroscience 2, 91–104.Google ScholarCrossrefSearch ADS Find in my library PubMedWorldCat Kaustia M., Knüpfer S. (2008): Do investors overweight personal experience? evidence from ipo subscriptions, The Journal of Finance 63, 2679–2702.Google ScholarCrossrefSearch ADS Find in my library WorldCat Kozlowski J., Veldkamp L., Venkateswaran V. (2020): The tail that wags the economy: beliefs and persistent stagnation, Journal of Political Economy 128, 2839–2879.Google ScholarCrossrefSearch ADS Find in my library WorldCat Kraus A., Sick G. A. (1980): Distinguishing beliefs and preferences in equilibrium prices, The Journal of Finance 35, 335–344.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U. (2018): Behavioral corporate finance, in: Bernheim D., DellaVigna S., Laibson D. (eds.), Handbook of Behavioral Economics, Vol. 1, Elsevier North-Holland, Amsterdam, Netherlands. pp. 277–379.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Malmendier U. (2021): Exposure, experience, and expertise: why personal histories matter in economics. Working Paper.Malmendier U., Nagel S. (2011): Depression babies: do macroeconomic experiences affect risk taking, The Quarterly Journal of Economics 126, 373–416.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U., Nagel S. (2016): Learning from inflation experiences, The Quarterly Journal of Economics 131, 53–87.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U., Shen L. S. (2018): Scarred consumption. Technical report, National Bureau of Economic Research, Cambridge, Massachusetts.Malmendier U., Tate G. (2005): Ceo overconfidence and corporate investment, The Journal of Finance 60, 2661–2700.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U., Wachter J. (2021): Memory of past experiences and economic decisions. Working Paper.Malmendier U., Tate G., Yan J. (2011): Overconfidence and early-life experiences: the effect of managerial traits on corporate financial policies, The Journal of Finance 66, 1687–1733.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U., Pouzo D., Vanasco V. (2020a): Investor experiences and international capital flows, Journal of International Economics 124, 103302.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U., Pouzo D., Vanasco V. (2020b): Investor experiences and financial market dynamics, Journal of Financial Economics 136, 597–622.Google ScholarCrossrefSearch ADS Find in my library WorldCat Malmendier U., Nagel S., Yan Z. (2021): The making of hawks and doves, Journal of Monetary Economics 117, 19–42.Google ScholarCrossrefSearch ADS Find in my library WorldCat Rabin M. (1998): Psychology and economics, Journal of Economic Literature 36, 11–46.Google ScholarFind in my libraryWorldCat Savage L. J. (1954): The Foundations of Statistics, Wiley, New York, NY.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Schoar A., Zuo L. (2017): Shaped by booms and busts: how the economy impacts CEO careers and management styles, The Review of Financial Studies 30, 1425–1456.Google ScholarCrossrefSearch ADS Find in my library WorldCat Shiller R. J. (2005): Irrational Exuberance, 2nd ed., Princeton, NJ: Princeton University Press.Google ScholarGoogle PreviewFind in my libraryWorldCatCOPAC Spunt R. P., Adolphs R. (2017): A new look at domain specificity: insights from social neuroscience, Nature Reviews Neuroscience 18, 559–567.Google ScholarCrossrefSearch ADS Find in my library PubMedWorldCat Tversky A., Kahneman D. (1974): Judgment under uncertainty: heuristics and biases, Science 4157, 1124–1131.Google ScholarFind in my libraryWorldCat Vissing-Jorgensen A. (2003): Perspectives on behavioral finance: does “irrationality” disappear with wealth? Evidence from expectations and actions, NBER Macroeconomics Annual 18, 139–194.Google ScholarCrossrefSearch ADS Find in my library WorldCat Wachter J. A., Kahana M. J. (2019): A retrieved-context theory of financial decisions. Technical report, National Bureau of Economic Research, Cambridge, Massachusetts.Wachter J. A., Kahana M. J. (2020): Associative learning and representativeness. SSRN 3602327. Working Paper.Weber E. U., Böckenholt U., Hilton D. J., Wallace B. (1993): Determinants of diagnostic hypothesis generation: effects of information, base rates, and experience, Journal of Experimental Psychology: Learning, Memory, and Cognition 19, 1151.Google ScholarPubMedFind in my libraryWorldCat Weber E. U., Blais A. R., Betz N. E. (2002): A domain-specific risk-attitude scale: measuring risk perceptions and risk behaviors, Journal of Behavioral Decision Making 15, 263–290.Google ScholarCrossrefSearch ADS Find in my library WorldCat Whitlock J. R., Heynen A. J., Shuler M. G., Bear M. F. (2006): Learning induces long-term potentiation in the hippocampus, Science 313, 1093–1097.Google ScholarCrossrefSearch ADS Find in my library PubMed
sources
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.02.22270254: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: 2.4 Ethics Statement: Animal experiments were conducted in an AAALAC International-accredited facility and approved by the Rocky Mountain Laboratories Institutional Care and Use Committee following the guidelines put forth in the Guide for the Care and Use of Laboratory Animals 8th edition, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on the Humane Care and Use of Laboratory Animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: At regular intervals, mycoplasma testing was performed.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus propagation was performed in VeroE6 cells in DMEM supplemented with 2% fetal bovine serum, 1 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin (DMEM2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
math.libretexts.org math.libretexts.org
-
This is very cumbersome because it depends on seven variables. Also, it is likely that without much care, a change in the units such as going from meters to feet would result in an incorrect value for 𝑙ll. The way to get around this problem is to look for 𝑙ll as a function of dimensionless variables multiplied by something which has units of force. It is helpful because first of all, you will likely have fewer independent variables and secondly, you could expect the formula to hold independent of the way of specifying length, mass and so forth.
Cubersome meaning: difficult to read, difficult to use. What I understood from this text is that one shouldn't rely soley on "𝑙=𝑓(𝐴,𝐵,𝜃,𝑉,𝑉0,𝜌,𝜇)". We should also take notice of 'dimensionless variables'. This is my first time hearing (technically reading) this term. So, what are dimensionless variables? Apparently, it is a, "...unitless value produced by (maybe repeatedly) multiplying and dividing combinations of physical variables, parameters, and constants." Though, I am having trouble relating this to the problem in solving.
-
-
underactuated.mit.edu underactuated.mit.edu
-
Identify a desired closed-loop dynamic
In this case, "identify desired closed-loop dynamics" asking us to choose the physical constants of the system, m, l, w, h, such that it behaves how we want it to behave? Or is it asking for us to identify a u? I'm a little confused about the difference between what part a and b are asking if it's asking to come up with a control policy.
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.03.22269612: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Subject Recruitment: All study activities were approved by the Rutgers Institutional Review Board (Pro2020000655).<br>Consent: Informed consent was obtained from the patient in her 50’s (51-55 age range, Caucasian, female) and a relative in their 46-50 age range (Caucasian, male).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Informed consent was obtained from the patient in her 50’s (51-55 age range, Caucasian, female) and a relative in their 46-50 age range (Caucasian, male).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HRP-conjugated mouse anti-human IgG1, IgG2, IgG3, and IgG4 (Southern Biotech, Birmingham, AL, USA) secondary antibodies were used at 1:2,000 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2, IgG3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To monitor depletion of antigen-specific antibodies prior to use in neutralization assays, antigen-specific IgG titers of untreated and absorbed samples were determined as described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen-specific</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antigen-specific IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Vero E6 were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA); HeLa cells stably expressing ACE2 (HeLa-ACE2) were obtained from Dennis Burton at the Scripps Research Institute 57.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Propagation of viral stocks was performed with Vero E6 cells using DMEM supplemented with 2% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 neutralization assay: HeLa-Ace2 cells were seeded in 96-well black optical-bottom plates at a density of 1 × 104 cells/well in FluoroBrite DMEM (Thermo Fisher Scientific, Waltham, MA, USA) containing 4% FBS (Seradigm, Radnor, PA, USA), 2mM L-glutamine, and 1% penicillin/streptomycin (Corning, NY, USA), and incubated overnight at 37°C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa-Ace2</div><div>suggested: JCRB Cat# JCRB1845, RRID:CVCL_B3LW)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Human Premixed Multi-Analyte Kits were used to detect 48 cytokine/chemokines (CD40L, EGF, Eotaxin, FGF-2, LT-3L, Fractalkine, G-CSF, GROa, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL3, IL-4, IL-5, IL-6, IL-7, IL8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL17A, IL-17E, IL-17F, IL-18, IL-22, IL-27, IP-10, MCP-1, MCP3, M-CSF, MDC, MIG, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB, RANTES, TGFα, TNFα, TNFβ, VEGF-A) according to the manufacturer’s recommendations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MCP-1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Proteomics: Proteomic analysis was performed by the Rutgers Biological Mass Spectrometry Facility.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Rutgers Biological</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Peak lists were generated using Proteome Discoverer 2.2 and data were searched using a local implementation of the Global Proteome Machine 62.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Proteome Discoverer</div><div>suggested: (Proteome Discoverer, RRID:SCR_014477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hierarchical clustering analysis and principal component analysis were performed in MATLAB on the standardized cytokine and protein expression measurements using custom scripts.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MATLAB</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MAST package (version 1.8.2) 67 were to identify differential expressing genes across different cell populations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAST</div><div>suggested: (MAST, RRID:SCR_016340)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Our case study has limitations. One is the study of a single patient. The particular characteristics of the case patient, including the underlying immune dysfunction, undoubtedly played a role in both the clinical outcome of the convalescent plasma donation and the ways in which disease resolution occurred. However, most of our findings are corroborated by the rapidly evolving knowledge of the pathways associated with COVID-19 disease and its severity. Thus, we are reasonably confident that our findings are applicable beyond the particular patient under study. Moreover, our report of COVID-19 resolution in a patient unable to generate humoral responses to SARS-CoV-2 infection, together with a previous report of convalescent plasma-associated resolution of COVID-19 in a patient with humoral immunodeficiency 18, strongly supports the use of well-characterized convalescent plasma for therapeutic use in COVID-19 patients who are immunocompromised due to underlying defects or immunosuppressive therapies. A second limitation of our work lies in our inability -- despite multiple attempts -- to access the plasma obtained from the first, anonymous donor, which had no beneficial effect on the recipient’s disease. A comparison between the two sets of convalescent plasma samples might have shed light on key therapeutic properties of convalescent plasma for COVID-19. Thirdly, we do not know which organ/cell(s) the viral transcripts we detected in plasma are derived from. Care of the patie...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04391309</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">COVID-19 and Anti-CD14 Treatment Trial</td></tr></table>
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.02.22270337: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethical considerations and data availability: Research was conducted under Johns Hopkins institutional review board protocol IRB00300364 with a waiver of consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">WGS was performed on the Oxford Nanopore GridION using either the V3 primer ARTIC SARS-CoV-2 sequencing protocol or the NEBNext® ARTIC SARS-CoV-2 Companion Kit (VarSkip Short SARS-CoV-2 # E7660-L).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>WGS</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
Study limitations include reliance on community prevalence to infer SARS-CoV-2 lineage for most patients. However, surveillance was performed locally with 96% concordance of inferred to confirmed variant. Model estimates from sensitivity analyses limited to confirmed variants were similar to primary analyses. Co-circulation of the comparatively severe Delta variant at low levels during Omicron-dominant transmission may overrepresent Delta among hospitalized patients, especially the severely ill. Although inferred-confirmed variant concordance decreased to 87% during Omicron-dominant transmission, this misclassification biases against finding a severity difference between Omicron and Delta. Differences in patient characteristics and care patterns may limit the generalizability of estimates of severe disease risk. Reliance on vital sign abnormalities likely includes patients whose hospitalization may be due to exacerbation of chronic medical conditions temporally related to a positive SARS-CoV-2 test and misses others with more subtle COVID-19 symptoms. Study strengths include strict, objective inclusion criteria for symptomatic COVID-19, detailed clinical information from the EMR, extensive WGS results, and robust causal inference methods. Our findings show that for vaccinated patients who are hospitalized with COVID-19, their risk of severe disease or death is low–reduced by half compared to unvaccinated patients - and equally low for both Omicron and Delta infections. Despit...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.02.03.21265607: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: The patients/participants provided their written informed consent to participate in this study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Dual-antigen testing ELISA assay: The signal of anti-RBD and anti-N IgG antibodies in the samples was analyzed using the dual-antigen VirIntel assay (20).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-N IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 3 washes with 300 μL of PBS-T, 100 μL of anti-human IgG HRP-conjugated secondary antibody (A01854, GenScript, USA) diluted 1:3000 in PBS-T+1% casein was added to the wells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A01854</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.01.478701: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The protocol was approved by the Human Subject Research Ethics, Academia Sinica (AS-IRB-BM-20025)<br>IACUC: All the animal experiments followed the protocol approved by the Institutional Animal Care and Use Committee (IACUC) at AS core (protocol ID 20-10-1521).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies for immunofluorescence staining are as followings: rabbit anti-citrullinated histone H3 (#NB100-57135; Novus), goat anti-human/mouse myeloperoxidase polyclonal antibody (# AF3667, R&D system).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-citrullinated histone H3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies for immunohistochemical (IHC) staining are: rabbit anti-citrullinated histone H3 (#NB100-57135; Novus), goat anti-human/mouse myeloperoxidase polyclonal antibody (#AF3667, R&D system)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human/mouse</div><div>suggested: (R and D Systems Cat# AF3667, RRID:AB_2250866)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-CD11b antibody (#ab13357, Abcam), anti-CD64 antibody (#MA5-29704, Invitrogen)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD11b</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD64</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-29704, RRID:AB_2785528)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-Siglec-F antibody (#PA5-11675, Invitrogen), anti-F4/80 antibody (#ab74383, Abcam)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Siglec-F</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-F4/80</div><div>suggested: (Abcam Cat# ab74383, RRID:AB_1860121)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-CCR2 antibody (#NBP-35334, Novus Biologicals), anti-Ly6C antibody (#SC-23080, Santa Cruz).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CCR2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Ly6C</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies: donkey anti-mouse IgG (H+L) Alexa 488-conjugated antibody (#715-545-151, Jackson ImmunoResearch),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 715-545-151, RRID:AB_2341099)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">donkey anti-goat IgG (H+L) Alexa 647-conjugated antibody (#705-605-147, Jackson ImmunoResearch),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 705-605-147, RRID:AB_2340437)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">donkey anti-Human IgG (H+L) HRP-conjugated antibody (#709-035-149, Jackson ImmunoResearch),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 709-035-149, RRID:AB_2340495)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Visualization and quantification of NET structure: Cells were immersed in fixation buffer (containing 4 % paraformaldehyde) overnight, followed by permeabilization using 0.5 % Triton X100 in PBS, then incubated with anti-MPO antibody (1:100)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-MPO</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-citrullinated histone antibody (1:100), and Hoechst 33342 (1:100000).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-citrullinated histone antibody ( 1:100)</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 propagation: SARS-CoV-2 Taiwan/4/2020 was propagated in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral titer was determined by observation of the cytopathic effect (CPE) in Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, HEK-293T cells were transiently transfected with pLAS2w.Fluc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse model for SARS-CoV-2 infection: Virus preparation and inoculation of SARS-CoV-2 into C57BL/6 and clec5a-/-tlr2-/- mice were as described [31].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>clec5a-/-tlr2-/-</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, HEK-293T cells were transiently transfected with pLAS2w.Fluc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLAS2w</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Ppuro, pcDNA3.1-2019-nCoV-S, and pCMV-Δ R8.91 using TransITR-LT1 transfection reagent (Mirus)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1-2019-nCoV-S</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCMV-Δ R8.91</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The level of NETs was calculated using the histone image captured by a Leica confocal microscope with white light laser system (TCS SP8 X-FALCON), and analyzed by MetaMorphTM software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MetaMorphTM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were further analyzed by the Ingenuity Pathways Analysis (IPA) software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathways Analysis</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.02.478775: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: 2.1 Cell lines and virus strains: Cell lines: African green monkey kidney cells (Vero E6 cells) were obtained from ATCC (CRL-1586) (Manassas, VA, USA) as mycoplasma-free stocks and were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific (TFS), Merelbeke, Belgium) supplemented with 10 % fetal bovine serum (FBS), 2 mM L-glutamine (TFS) and 0.075 % sodium-bicarbonate (TFS).</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">goat anti-Rabbit IgG monoclonal antibody was from Cell Signaling Technologies (MA, USA; Cat. n° 4414).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>goat anti-Rabbit IgG monoclonal antibody</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Rabbit IgG</div><div>suggested: (Cell Signaling Technology Cat# 4414, RRID:AB_10693544)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were washed twice with Perm/Wash buffer before the addition of the primary (anti-Nucleocapsid) antibody (0.3 μg per sample).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Nucleocapsid </div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine replication efficiency, the different SARS-CoV-2 strains were added to Vero E6 cells at an MOI of 0.02, as determined by end-point dilution titration on Vero E6 cells and calculated by the tissue culture infectious dose 50 (TCID50) method of Reed and Muench (5).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Acquisition of all samples was done on a BD FACSCelesta flow cytometer (BD Biosciences) with BD FACSDiva v8.0.1 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometric data were analyzed in FlowJo v10.1 (Tree Star).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.31.478507: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">34 Female Balb/cJ (5-10 weeks old, Jackson Labs) were euthanized with CO2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">The second emulsion was sonicated at 65% power for 5 min at RT.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A secondary biotinylated anti-mouse IgA, total IgG, IgG1, or IgG2a antibody (SouthernBiotech) was diluted 5,000-fold in 5-fold diluted PBSTBA and was added to plates for 2 h at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A secondary biotinylated anti-mouse IgA, total IgG, IgG1, or IgG2a antibody (SouthernBiotech)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgA, total IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2a</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To isolate T cells, spleens from female Balb/cJ mice were dissociated in 2 mg/mL Collagenase D (Sigma-Aldrich, Cat# 11088882001) in Opti-MEM media (Gibco, Cat# 11058021) and filtered through a 40 μm cell strainer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Balb/cJ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Female BALB/c mice were intramuscularly injected with adjuvant-loaded NPs (4 mg/mouse) and variable doses of stabilized SARS-CoV-2 spike glycoprotein (BEI Resources, Cat# NR-52397) into the left and right anterior tibialis anterior muscles (50 μL NPs in saline per injection) on day 0 (prime) and day 28 (boost).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MPLA loading estimation via GC-MS, LC-MS, and surrogate fluorometry has been previously described.28 PUUC and CpG loading was quantified by supernatant measurement of unbound RNA or DNA, respectively, with the Nucleic Acid Quantification workflow on a Synergy HT plate reader (BioTek) with Gen5 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gen5</div><div>suggested: (Gen5, RRID:SCR_017317)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FlowJo Software (BD) was used to generate t-distributed stochastic neighbor embedding (t-SNE) plots.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed with GraphPad Prism 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For antibody quantification with ELISA, area under the curve (AUC) across fold dilutions was computed with the AUC function on GraphPad as previously reported.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
psychclassics.yorku.ca psychclassics.yorku.ca
-
Footnotes
What I got from this article a sequence was used [S1-R1] = 0. [2]occurs as a change in [So-Ro] can be an increase (positive condition) (a) and also a decrease (negative condition) (b). [p.67] Type l and type ll reflexes correlates with pseudo type.Under different circumstance food and saliva was used as scientific examples to further explain the relationship and reaction between the two types of conditions. Type ll should be formulated as pseudo reflex condition. The condition itself is in question due to it being unsatisfactory but still has to be pursued.pseudo type is undetermined the data is hard to get rid of an is seen as false but is very similar to type ll. Both types plays different roles inside the economy of structure. These reflex conditions relate to Skinner human behavior concept. **References psychclassics.yorku.ca/Skinner/Twotypes/twotypes.htm
- Pavlov, I.P. Conditioned reflexes (Trans. & ed. by G.V.Anrep) London: Oxford Univ. Press, 1927.Pp xvi + 430.
- Skinner, B.F. Drive and reflex strength: I .J. Gen. Psychol., 1932, 6, 22-37. 3.----------. The rate of establishment of a discrimination. J. Gen. Psychol., 1933, 9, 302-350.
- -----------. The generic nature of the concepts of stimulus and response.J. Gen. Psychol., 1935, 12, 40-65. Harvard University Cambridge, Massachusetts
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.31.478460: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.
Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blots were incubated either with anti-His antibody (6x-His Tag Monoclonal Antibody (HIS.H8), Alexa Fluor 488; ThermoFisher Scientific-MA1-21315-A488; 1:5000) or with anti-Strep-tag mouse monoclonal antibody (anti-Strep-tag mouse monoclonal, C23.21; PROGEN-910STR; 1:5000) overnight at 4°C in dilution buffer (TBS-T containing 5% bovine serum albumin (BSA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-His</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Strep-tag</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK 293T cells were seeded onto 96-well white plates before 24 h of transfection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For this, fragments BstXI-mNG-Mpro-Nter-auto-NLuc-XhoI and BstXI-mNG-Mpro-Nter-auto-L-NLuc-XhoI were synthesized (Integrated DNA Technologies, IDT; Iowa, USA) and inserted into pIDTSmart (Kan) vectors to generate the plasmid constructs pIDT-mNG-Mpro-Nter-auto-NLuc and pIDT-mNG-Mpro-Nter-auto-L-NLuc, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pIDT-mNG-Mpro-Nter-auto-NLuc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pIDT-mNG-Mpro-Nter-auto-L-NLuc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Restriction enzymes BstX-I and XhoI were used to excise the two DNA fragments of interests from entry clones pIDT-mNG-Mpro-Nter-auto-NLuc and pIDT-mNG-Mpro-Nter-auto-L-NLuc and ligated into similarly digested destination plasmid pmNeonGreen-DEVD-NLuc [Addgene: 98287]49 and further confirmed by Sanger sequencing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pmNeonGreen-DEVD-NLuc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For bacterial expression and purification of the Mpro sensor, the mNG-Mpro-Nter-auto-NLuc plasmid construct was digested with HindIII and XhoI and the mNG-Mpro-Nter-auto-NLuc fragment was subcloned into similarly digested pET-28b(+) plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>mNG-Mpro-Nter-auto-NLuc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET-28b(+ )</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live cell, BRET-based Mpro proteolytic cleavage activity assays: Live cell Mpro proteolytic cleavage activity assays were performed by co-transfecting HEK 293T cells with either the pmNG-Mpro-Nter-auto-NLuc or the pmNG-Mpro-Nter-auto-L-NLuc Mpro sensor plasmid constructs along with either pLVX-EF1alpha-SARS-CoV-2-nsp5-2xStrep-IRES-Puro (Mpro WT) (a gift from Nevan Krogan (Addgene plasmid # 141370; http://n2t.net/addgene:141370 ; RRID:Addgene_141370)85or pLVX-EF1alpha-SARS-CoV-2-nsp5-C145A-2xStrep-IRES-Puro (C145A mutant Mpro) plasmid (a gift from Nevan Krogan (Addgene plasmid # 141371 ; http://n2t.net/addgene:141371 ; RRID:Addgene_141371)85 in 96-well white flat bottom plates (Nunc; 136101).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pmNG-Mpro-Nter-auto-L-NLuc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_141370)</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_141371)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For dose-response experiments, the filler plasmid (a pcDNA3.1-based plasmid) is also co-transfected.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1-based</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live cell Mpro proteolytic cleavage inhibitor assay: HEK 293T cells were co-transfected with either pmNG-Mpro-Nter-auto-NLuc or pmNG-Mpro-Nter-auto-L-NLuc plasmid along with either pLVX-EF1alpha-SARS-CoV-2-nsp5-2xStrep-IRES-Puro (Mpro WT) (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pmNG-Mpro-Nter-auto-NLuc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live cell, FlipGFP-based Mpro proteolytic assay: For live cell FlipGFP-based Mpro proteolytic activity assays, HEK 293T cells were seeded onto 24-well plates and co-transfected with the FlipGFP sensor plasmid (pcDNA3 FlipGFP(Mpro)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3</div><div>suggested: RRID:Addgene_15475)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mpro N-terminal autocleavage sequence analysis: A total of 1984 sequences for the SARS-CoV-2 pp1a polyprotein available at the NCBI Virus database (https://www.ncbi.nlm.nih.gov/genome/viruses/) were downloaded and aligned using MAFFT server (https://mafft.cbrc.jp/alignment/server/)63, 64.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>https://www.ncbi.nlm.nih.gov/genome/viruses/</div><div>suggested: (NCBI Viral Genomes, RRID:SCR_013789)</div></div><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Models were generated using MODELLER (10.1 release, Mar. 18, 2021)66.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MODELLER</div><div>suggested: (MODELLER, RRID:SCR_008395)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The NAMD output structure was then used as an input for Gaussian accelerated molecular dynamics (GaMD) simulation utilizing the integrated GaMD module in NAMD and its default parameters73, 74 which included 2 ns of conventional molecular dynamics (cMD) equilibration run in GaMD, to collect potential statistics required for calculating the GaMD acceleration parameters, and another 50 ns equilibration run in GaMD after adding the boost potential74, 75, and finally GaMD production runs for 1000 ns.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NAMD</div><div>suggested: (NAMD, RRID:SCR_014894)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Restriction enzymes BstX-I and XhoI were used to excise the two DNA fragments of interests from entry clones pIDT-mNG-Mpro-Nter-auto-NLuc and pIDT-mNG-Mpro-Nter-auto-L-NLuc and ligated into similarly digested destination plasmid pmNeonGreen-DEVD-NLuc [Addgene: 98287]49 and further confirmed by Sanger sequencing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Addgene</div><div>suggested: (Addgene, RRID:SCR_002037)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The ImageJ macro script used for the analysis is provided in the Supporting Text.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis and figure preparation: GraphPad Prism (version 9 for macOS, GraphPad Software, La Jolla California USA; www.graphpad.com), in combination with Microsoft Excel, was used for data analysis and graph preparation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figures were assembled using Adobe Illustrator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Adobe Illustrator</div><div>suggested: (Adobe Illustrator, RRID:SCR_010279)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.01.478504: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Neutralization assays: All SARS-CoV-2 manipulations were conducted at the Biosafety Level-3 facility with the approval from the Institutional Biosafety Committee at the University of Texas Medical Branch.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Female BALB/c mice aged 10-12 weeks (n = 10) were infected intranasally (IN) with 104 PFU of mouse-adapted SARS-CoV-2 CMA4 strain50 or the Beta and Gamma variants23 in 50 μl of PBS.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Seven-week-old female BALB/c (Jackson lab, USA) were randomly divided into three groups (5 mice/group) and were injected by i.p with 10 mg/kg of antibody.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The blocking percentages at each concentrations were calculated as: (normalized ACE2 response of isotype antibody-normalized ACE2 response of tested antibody)/ normalized ACE2 response of isotype antibody *100.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-normalized ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The anti-human IgG Fab2 HRP-conjugated antibody was diluted 1:5000 and added at a volume of 100 μl per well for incubation at 37°C for 1h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The HRP-conjugated goat anti-human IgG-F(ab’)2 was used as the secondary antibody and incubated at room temperature for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-F(ab’)2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero (ATCC® CCL-81) and Vero E6 cells (ATCC, CRL-1586) were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 1 h incubation at 37 °C, the antibody-virus mixtures were inoculated onto a monolayer of Vero E6 cells pre-seeded on 6-well plates on the previous day.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For mouse study with the Delta variant, the 8-10-week-old female K18-hACE2 mice were ordered from The Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Seven-week-old female BALB/c (Jackson lab, USA) were randomly divided into three groups (5 mice/group) and were injected by i.p with 10 mg/kg of antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ForteBio’s data analysis software was used to export data, and the binding profile was processed by GraphPad prism 8 Software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The initial model for the complex between 14-H-06 with four RBD molecules (one RBD bound for each of the four paratopes of IgG-scFv bsAb 14-H-06) was subjected to MD simulations using NAMD 2.1246.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NAMD</div><div>suggested: (NAMD, RRID:SCR_014894)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structure analysis and image production were made using PyMOL (https://pymol.org, Schrödinger Inc.) and COOT49.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.02.01.478695: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants provided written informed consent before participation in the study, and the study was conducted in accordance with Good Clinical Practice.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Cell Lines: 293T cells (Homo sapiens; sex: female, embryonic kidney) obtained from the ATCC (CRL-3216) and HT1080Ace2 cl14 cells (parental HT1080: homo sapiens; sex: male, fibrosarcoma) (Schmidt et al., 2020) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C and 5% CO2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines have been tested negative for contamination with mycoplasma.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 6 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody-virus-mix was then directly applied to each well (n = 3 per dilution) and incubated for 24 h at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-virus-mix</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A rabbit polyclonal anti-SARS-CoV-2 nucleocapsid antibody (GeneTex, catalog no. GTX135357) was added to the cells at 1:1,000 dilution in blocking solution and incubated overnight at 4 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, goat anti-rabbit AlexaFluor 594 (Life Technologies, catalog no. A-11012) was used as a secondary antibody at a dilution of 1:2,000 and incubated overnight at 4 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human</div><div>suggested: (GenWay Biotech Inc. Cat# 18-202-335793-0.1 mg, RRID:AB_1981874)</div></div><div style="margin-bottom:8px"><div>anti-CD20-PECy7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD3-APC-eFluro 780</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Lines: 293T cells (Homo sapiens; sex: female, embryonic kidney) obtained from the ATCC (CRL-3216) and HT1080Ace2 cl14 cells (parental HT1080: homo sapiens; sex: male, fibrosarcoma) (Schmidt et al., 2020) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HT1080Ace2 cl14</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6 cells (Chlorocebus sabaeus; sex: female, kidney epithelial) obtained from the ATCC (CRL-1586™) and from Ralph Baric (University of North Carolina at Chapel Hill), and Caco-2 cells (Homo sapiens; sex: male, colon epithelial) obtained from the ATCC (HTB-37™) were cultured in DMEM supplemented with 1% nonessential amino acids (NEAA) and 10% FBS at 37 °C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The original WT virus was amplified in Caco-2 cells, which were infected at a multiplicity of infection (MOI) of 0.05 plaque forming units (PFU)/cell and incubated for 6 days at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6TMPRSS2 cells were infected at a MOI = 0.1 PFU/cell and incubated for 4 days at 33 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The infectious dose for each virus was pre-determined on VeroE6UNC cells to yield 50-60% antigen-positive cells upon this incubation period (USA-WA1/2020: 1,250 PFU/well and B.1.351: 175 PFU/well).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6UNC</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(R683G) and pSARS-CoV-SΔ19 expressing C-terminally truncated SARS-CoV-2 and SARS-CoV spike proteins and the polymutant PMS20 spike were as described before (Schmidt et al., 2021c).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSARS-CoV-SΔ19</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A panel of plasmids expressing spike proteins from SARS-CoV-2 variants were based on pSARS-CoV-2-SΔ19(R683G) and contain the following substitutions/deletions: Alpha (B.1.1.7): ΔH69/V70, ΔY144, N501Y, A470D, D614G, P681H, T761I, S982A,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSARS-CoV-2-SΔ19</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pNL4-3ΔEnv-nanoluc(Robbiani et al., 2020; Schmidt et al., 2020) and either spike plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3ΔEnv-nanoluc(Robbiani</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The average of its signal was used for normalization of all of the other values on the same plate with Excel software before calculating the area under the curve using Prism V9.1(GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Excel</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression (GraphPad Prism V9.1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analyses were done using Prism 8 software (Graphpad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NTD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence analysis was performed using MacVector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MacVector</div><div>suggested: (MacVector, RRID:SCR_015700)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cryo-EM data collection and processing: Single-particle cryo-EM data were collected on a Titan Krios transmission electron microscope (Thermo Fisher) equipped with a Gatan K3 direct detector, operating at 300 kV and controlled using SerialEM automated data collection software(Mastronarde, 2005).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A subset of 4x-downsampled particles were used to generate ab initio models, which were then used for heterogeneous refinement of the entire dataset in cryoSPARC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">3D classifications (k=6, tau_fudge=4) were carried out using Relion v3.1.1(Fernandez-Leiro and Scheres, 2017) without imposing symmetry and a soft mask.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Relion</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence-updated models were built manually in Coot(Emsley et al., 2010) and then refined using iterative rounds of refinement in Coot and Phenix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenix</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Glycans were modeled at potential N-linked glycosylation sites (PNGSs) in Coot.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.31.478406: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics statement: All mouse works were conducted in accordance with the “Guideline for the Care and Use of Laboratory Animals” as defined by the Council of Agriculture, Taiwan and was approved by the Institutional Animal Care and Use Committee of Academia Sinica (protocol ID: 20-05-1471).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, the cells were incubated with anti-RBD polyclonal antibody (1μg/tube) at 4°C for 30 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were then washed two times, followed by 30-minute incubation with PE-goat-anti-mouse IgG (H+L) antibody (Jackson ImmunoResearch, PA, USA) at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PE-goat-anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RBD expression and binding assay: The variant-specific RBD mRNA was transfected into 293T cells via lipofectamine (Invitrogen, MA, USA) and the variant-specific RBD-LNP was transfected by directly added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To test the ability of RBD binding to human ACE2 or mouse ACE2, 293T-hACE2 or 3T3-mACE2 cells were harvested and aliquoted into FACS tubes at 5×105 cells/tube.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>3T3-mACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixtures were then added to pre-seeded 293T-hACE2 cells and incubated for 3 days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals: BALB/c mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan) and maintained in a specific pathogen-free environment in the animal facilities of the Institute of Biomedical Sciences, Academia Sinica.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were washed twice and resuspended in 300 μl of staining buffer containing 7-AAD (Biolegend, CA, USA) for flow cytometry analysis (Thermo Fisher Attune NxT - 14 color analyzer, Thermo Fisher Attune NxT software v2.2, FlowJo 10.6.1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Attune NxT</div><div>suggested: (Attune Nxt Nxt, RRID:SCR_019590)</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 50% neutralization titer (NT50) was calculated by nonlinear regression using Prism software version 8.1.0 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GraphPad Software Inc.)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 14. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:
- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.25.477616: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fifty μL of 1:3000 diluted mouse anti-SARS-CoV-2 Spike Protein S1 monoclonal antibody (GT623, Invitrogen) in 1% BSA-PBS blocking buffer was added and incubated at room temperature for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>GT623</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells, tissues, and viruses: Vero E6 and A549 cells were purchased from ATCC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were maintained as previously described (Stasko et al., 2021b).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical significance for viral titers and cell cytotoxicity were determined using the Mann-Whitney ranked sum test using GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.30.478305: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Memory B-cell staining, sorting and antibody cloning: CD19+IgA–IgD–IgM-primary B cells were sorted out from peripheral blood mononuclear cells (PBMC) of recovered patients of COVID-19 and expanded in vitro in MEM medium with 10% FBS in the presence of irradiated 3T3-msCD40L feeder cells, IL-2 and IL-21 as previously described 18.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IL-21</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 3 washing steps with PBS 0.05% Tween 20 (PBS-T), 1:2500 diluted HRP-conjugated goat anti-human IgG antibody (Jackson Immuno Research Laboratories, USA) was added for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After permeabilized with 0.2% Triton X-100 for 20 min at room temperature, the plates were sequentially stained with cross-reactive rabbit anti-SARS-CoV-2 N IgG (Cat. No.: 40143-T62, Sino Biological Inc) as the primary antibody and HRP-conjugated goat anti-rabbit IgG(H+L) (No.: 109-035-088, Jackson ImmunoResearch) as the secondary antibody in 37°C for 1 hour respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 N IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG(H+L</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines, proteins, viruses and plasmids: The human primary embryonic kidney cell lines (HEK293T) and 293T-hACE2 cells were cultured in DMEM medium with 10% fetal bovine serum (FBS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">African green monkey kidney-derived Vero E6 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudoviruses were generated by co-transfection of 293T cells with an env-deficient HIV backbone pNL4-3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">104 293T-hACE2 cells were then added to the mixture and cultured for 48 h at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">From the wells with SARS-CoV-2 neutralization activities, the variable regions of the antibody (VH and VL) genes were amplified by RT–PCR. mAbs were expressed as human IgG1 by HEK293F cells and purified using a protein G column (Smart-Lifesciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293F</div><div>suggested: RRID:CVCL_6642)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">3. 293F cells were transiently transfected with bispecific Abs plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alpha (containing 69–70 and 144 deletions and N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H substitutions), Beta (containing D80A, D215G, 241-243 deletions and K417N, E484K, N501Y, D614G and A701V substitutions), Gamma (containing L18F,T20N,P26S,D138Y, R190S,K417T, E484K,N501Y, D614G.H655Y,T1027I, and V1176F substitutions), Delta (containing T19R, 157-158 deletions and L452R, T478K, D614G, P681R and D950N substitutions), and Omicron (containing A67V, 69-70del, T95I, G142D, 143-145del, N211I, 212del, ins215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F substitutions), SARS-CoV, bat SARSr-CoVs (WIV1 and Rs3367) were synthesized by BGI and constructed in pcDNA3.1 vector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudoviruses were generated by co-transfection of 293T cells with an env-deficient HIV backbone pNL4-3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The IC50s of NAbs were calculated using the GraphPad Prism 7.04 software (La Jolla, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Automated data acquisition was carried out with SerialEM software21 through beam-image shift method22.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A total of 4,363 movie stacks was binned 2 × 2, dose weighted, and motion corrected using MotionCor2 25 within RELION.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MotionCor2</div><div>suggested: (MotionCor2, RRID:SCR_016499)</div></div><div style="margin-bottom:8px"><div>RELION</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Remaining 3,817 good images were imported into cryoSPARC for further patched CTF-estimating, blob-picking and 2D classification.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Model building and refinement: For model building of SARS-CoV-2 Omicron S FD01 complex, the SARS-CoV-2 Omicron S trimer model and the antibody model generated by swiss-model 31 were fitted into the map using UCSF Chimera and then manually adjusted with COOT 32.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 20. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
psyarxiv.com psyarxiv.com
-
Andersen, D. B., Petersen, M. B., Midtgaard, S. F., Højlund, A.-S. G., Lippert-Rasmussen, K., & Pedersen, V. M. L. (2021). Collective paternalism and vaccination programmes. PsyArXiv. https://doi.org/10.31234/osf.io/5hvqc
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.29.22270066: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The ethics committee of the Saxonian medical chamber approved the study (registry number EK-allg-37/10–1) and informed consent was obtained from all volunteers.<br>Consent: The ethics committee of the Saxonian medical chamber approved the study (registry number EK-allg-37/10–1) and informed consent was obtained from all volunteers.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Another 11 study participants (63.6 % females, median age 31 [IQR 26-37]) received a heterologous ChAdOx1-S vector based prime (EMA fact sheet [10]) and BNT162b2 boost vaccination (AZ/BNT).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Commercial assays for the detection of antibodies against S1 and Nucleocapsid: All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥0.8).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2-QuantiVac-ELISA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, baseline sera were screened for IgG antibodies against SARS-CoV-2 nucleocapsid (Virotech, Rüsselsheim, Germany; cut-off ≥11 VE/ml)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 nucleocapsid (Virotech,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sera (diluted 1:100) were incubated for 1.5 h at room temperature and binding antibodies were detected using a HRP-conjugated secondary goat anti human IgG antibody (Dianova, 1:20,000) or goat anti human IgG+IgM+IgA H&L antibody (Abcam, 1:10,000) for 1 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti human IgG+IgM+IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 focus forming units were stained using a monoclonal rabbit anti-S1 antibody (CR3022, abcam, 1:1,000) and a secondary goat anti-rabbit IgG HRP-conjugated antibody (Dianova, 1:1,000).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CR3022</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After another wash step, beads were resuspended in 500 µl of BD sheath fluid and analyzed using a BD FACS Lyric flow cytometer (BD Biosciences, San Jose, CA, U.S.) with PMT voltage settings adapted to discriminate beads specific for Spike S1- and Spike RBD-specific IgA antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Therefore, we compared FRNT-suggested nAb titers in matched serum samples with calculated concentrations of neutralizing surrogate antibodies in DBS and found a high degree of correlation (S3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RBD protein (AA residues 329-538 of spike protein, strain Wuhan-Hu-1) was expressed in Drosophila S2 cells and purified from cell culture supernatants with tandem immobilized metal affinity and size exclusion chromatography using the ÄKTA pure 25 l chromatography system (GeHealthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 neutralization assay: Focus reduction neutralization assays (FRNT) were performed according to Rockstroh et. al. 2021.[3] Briefly, heat-inactivated human serum samples were serially diluted in DMEM without FCS from 1:2.5 to 1:5120 and incubated with 50-150 focus forming units of SARS-CoV-2 wt, B.1.1.7 or B.1.351 for 1 h at 37°C before addition to confluent Vero E6 monolayers in 96-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 viral stocks: SARS-CoV-2 wildtype virus (wt) (isolate BetaCoV/Germany/BavPat1/2020, obtained from the European Virus Archive Global, EVAg)[11], SARS-CoV-2 B.1.1.7 (isolate MUC1-IMB1-CB, kindly provided by Klaus Überla from the Institute of Clinical and Molecular Virology, University of Erlangen-Nürnberg) and SARS-CoV-2 B.1.351 (SARS-CoV-2/human/Germany/LE-B14HXA2/2021 kindly provided by Corinna Pietsch from the Institute of Virology, University Hospital Leipzig) were propagated in VeroE6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: SPSS version 21 (IBM, Armonk, NY, USA) and GraphPad PRISM version 6 (GraphPad Software, San Diego, CA, USA) were used for statistical calculations and generation of figures.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div><div style="margin-bottom:8px"><div>GraphPad PRISM</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.26.477915: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animals and immunizations: The study protocol and all veterinarian procedures were approved by the Bioqual IACUC per a memorandum of understanding with the Duke IACUC, and were performed based on standard operating procedures.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Male and female macaques per group were balanced when availability permitted.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Samples were scored by a board-certified veterinary pathologist in a blinded manner.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cells were tested monthly for mycoplasma.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2 and neutralizing antibody blocking assay: ELISA plates were coated as stated above with 2 μg/mL recombinant ACE-2 protein or neutralizing antibodies, then washed and blocked with 3% BSA in 1x PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A peroxide block (Leica) was applied for 5 min to quench endogenous peroxidase activity prior to applying the SARS-CoV-2 antibody (1:2000, GeneTex, GTX135357).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: (Leinco Technologies Cat# LT2000, RRID:AB_2893936)</div></div><div style="margin-bottom:8px"><div>GTX135357</div><div>suggested: (GeneTex Cat# GTX135357, RRID:AB_2868464)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2-Fc was expressed by transient transfection of Freestyle 293-F cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293-F</div><div>suggested: RRID:CVCL_6642)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions were produced in HEK 293T/17 cells (ATCC cat. no. CRL-11268) by transfection using Fugene 6 (Promega, Catalog #E2692).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions were produced by co-transfection of Lenti-X 293T cells with psPAX2(gag/pol),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The supernatants were collected at 48 h after transfection and filtered through 0.45-μm membranes and titrated using HEK293T cells that express ACE2 and TMPRSS2 protein (293T-ACE2-TMPRSS2 cells).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the neutralization assay, 50 μl of SARS-CoV-2 spike pseudovirions were pre-incubated with an equal volume of medium containing serum at varying dilutions at room temperature for 1 h, then virus-antibody mixtures were added to 293T-ACE2-TMPRSS2 cells in a 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, target cells were either Vero E6 cells after a 2 day-infection with SARS-CoV-2 USA-WA1/2020 or 293T cells 2-days post transfection with a SARS-CoV-2 S protein (D614) expression plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_A7UJ)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse immunization and challenge: Eleven-month-old female BALB/c mice were purchased from Envigo (#047) and were used for the SARS-CoV, SARS-CoV-2 WA-1, SARS-CoV-2 B.1.351, and RsSHC014-CoV protection experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions for 293T/ACE2 infection were produced by co-transfection with a lentiviral backbone (pCMV ΔR8.2) and firefly luciferase reporter gene (pHR’ CMV Luc) (Naldini et al., 1996)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV ΔR8.2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions were produced by co-transfection of Lenti-X 293T cells with psPAX2(gag/pol),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The recombinant pcDNA3.1 plasmid was linearized, transcribed using MEGAscript T7 Transcription Kit (ThermoFisher, catalog # AM1334), and purified with MEGAclear Transcription Clean-Up Kit (ThermoFisher, catalog # AM1908).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All mutations were confirmed by full-length spike gene sequencing by Sanger Sequencing, using Sequencher and SnapGene for sequence analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sequencher</div><div>suggested: (Sequencher, RRID:SCR_001528)</div></div><div style="margin-bottom:8px"><div>SnapGene</div><div>suggested: (SnapGene, RRID:SCR_015052)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis was performed using FlowJo 10 software (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were analyzed by 2D class averages using standard protocols with Relion 3.0 (Zivanov et al., 2018).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Relion</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics Analysis: Data were plotted using Prism GraphPad 8.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wilcoxon rank sum exact test was performed to compare differences between groups with p-value < 0.05 considered significant using SAS 9.4 (SAS Institute, Cary, NC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAS Institute</div><div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. First, our study did not evaluate the durability of vaccine-induced immune responses and protection against SARS-CoV-2 variants. Second, we did not set up longer time intervals between the second and the third booster vaccination, to mimic 4-6 month boosting interval in humans. Lastly, we challenged the animals with WA-1 strain, the Beta variant and the Delta variant; future in vivo protection studies will be required upon availability of viral stocks of other SARS-CoV-2 variants such as the Omicron variant. Thus, our study demonstrates that scNP vaccines with SARS-CoV-2 spike or spike subunits confer potent protection in NHPs against WA-1, Beta and Delta variants, and that they induce neutralizing antibodies to all SARS-CoV-2 variants tested in vitro. These findings have important implications for development of the next generation of COVID-19 vaccines.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04915768</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Evaluating the Safety and Immunogenicity of Stabilized CH505…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04177355</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSI…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
RESPONSE TO REVIEWER #1:
We wish to express our appreciation to Reviewer #1 for his or her insightful comments, which will significantly improve this paper. We thank the reviewers for giving us the opportunity to improve the manuscript. We have responded to all the comments pointed out. The revised sections are highlighted in red characters and yellow backgrounds in the preliminary revised manuscript.
Reviewer #1 (Evidence, reproducibility and clarity (Required)): This manuscript "Histidine-rich protein 2: a new pathogenic 1 factor of Plasmodium falciparum malaria" by Iwasaki, et al. reports effects of recombinant HRP2 protein on various mammalian cell lines. The MS clearly demonstrates that recombinant HRP2 enters into HT1080 cells, causes inhibition of autolysosome fusion, increases lysosomal Ca ion concentration and reduces general autophagic degradation. The authors also show that the presence of FBS or metal chelators like EDTA and EGTA mitigate toxicity of HRP2, as the former traps HRP2 and the latter compete with HRP2 for Ca binding. The experiments are appropriately carried out with suitable controls in most of the cases. There are some concerns as listed below:
**Major concerns:** 1.HRP2 has been shown to be associated with virulence and causes vascular leakage, particularly cerebral malaria (references 37 and 38 ). Plasmodium falciparum histidine-rich protein II has been demonstrated to exacerbate experimental cerebral malaria in mice, which has been proposed to be associated with vascular leakage, activation of inflammasome and cytokine production (references 37, 38 and PMID: 31858717). This study complements the previous findings of the effect of HRP2 on mammalian cells. However, this study reveals another mechanism by which HRP2 might cause toxicity, which is inhibition of general autophagy and increase in lysosomal Ca concentration. However, whether these in vitro effects would translate in vivo needs to be shown.
Response: We sincerely appreciate the reviewer's effort to evaluate our work. As the reviewer pointed out, this is an in vitro study, so further in vivo validation is essential in the future. However, it is also true that we discovered new findings that have been overlooked because we conducted an artificial and simple in vitro experiment. In the future, it is necessary to demonstrate the cytotoxicity, autophagy inhibition, and lysosomal calcium concentration variation of PfHRP2 by in vivo studies using model animals. Concretely, we need to confirm whether PfHRP2 behaves as a similar virulence factor in vivo by animal experiments using PfHRP2-administrated or PfHRP2-overexpressing/deficient P. falciparum-infected mouse models. These future tasks have been added to the Discussion (page 9, lines 294–297 and 309–310; page 10, lines 339–342). We have also added the study (PMID: 31858717) reporting PfHRP2 elicits pro-inflammatory effect and induces vascular permeability as reference 40.
Furthermore, the title of the original paper was vague and gave the impression that it included in vivo experiments. Therefore, to avoid misunderstanding, we modified the paper's title to be more concrete, "Plasmodium falciparum histidine-rich protein II exhibits cell penetration and cytotoxicity with autophagy dysfunction".
Reference
P. Dinarvand, L. Yang, I. Biswas, H. Giri, A. R. Rezaie, Plasmodium falciparum histidine rich protein HRPII inhibits the anti-inflammatory function of antithrombin. J. Thromb. Haemost. 18, 1473–1483 (2020).
2.All the experiments are done with recombinant HRP2 and BSA as a control. The authors should show if similar effects happen with infected parasites.
Response: As the reviewer pointed out, it is required to perform in vivo experiments, i.e., to clarify whether the same phenomenon observed in the present study occurs in PfHRP2-administrated or P. falciparum-infected mouse models. However, in vivo studies are not possible immediately because we do not have the research facilities to carry out in vivo experiments. Therefore, we have added statements (page 9, lines 294–297 and 309–310; page 10, lines 339–342) to emphasize that the present findings are limited to in vitro and that further in vivo studies described above will be required in the future.
3.HRP2 is released in circulation, making it accessible to endothelial cells and immune cells. How would it reach to the equivalents of these cells in the human body?
Response: Since PfHRP2 induces vascular permeability as described in References 37–40, we propose that PfHRP2 can reach and contact cells in the human body after causing vascular leakage. I have added this possibility of contact between PfHRP2 and cells in the human body to Discussion (page 9, lines 287–290).
**Minor concerns** 1.p62 is an appropriate marker to assess autophagy cargo degradation. If possible, it would be good to support this with LC3 processing as well.
Response: Following the reviewer's advice, we will use LC3 as an autophagy marker as well as p62 to evaluate the autophagy inhibition of PfHRP2. Concretely, we plan to treat HT1080 cells with PfHRP2 (1 μM) for 12–60 hours and quantify the amount of LC3 protein by Western blotting. The results of this experiment will be added to Fig. 5 in the main manuscript.
2.HRP2 might affect general lysosomal degradation process. The authors can also check whether HPR2 affects degradation of a lysosomal substrate.
Response: Following the reviewer's advice, we will determine the effect of PfHRP2 on lysosomal degradation activity using the plasmid-based lysosomal-METRIQ (MEasurement of protein Transporting integrity by RatIo Quantification) probe, reported in a previous study (https://doi.org/10.1038/s41598-019-48131-2), to quantify lysosomal activity. The results of this experiment will be added to Fig. 5 in the main manuscript.
Reviewer #1 (Significance (Required)): This study compelements previous findings (references 37, 38 and PMID: 31858717). It identifies a new mechanism by which HRP2 might cause toxicity. However, it is completely an in vitro study, and the previous studies (references 37 and 38) have used in vivo models as well.
Response: We wish to thank the reviewer for this comment. As the reviewer pointed out, this study is completely in vitro, and further in vivo studies are essential in the future. Therefore, we have added statements (page 9, lines 294–297 and 309–310; page 10, lines 339–342) to emphasize that the present findings are limited to in vitro and that further in vivo studies are required in the future. We have also added the study (PMID: 31858717) reporting PfHRP2 elicits pro-inflammatory effect and induces vascular permeability as reference 40.
Furthermore, the title of the original paper was vague and gave the impression that it included in vivo experiments. Therefore, to avoid misunderstanding, we modified the paper's title to be more concrete.
Reference
P. Dinarvand, L. Yang, I. Biswas, H. Giri, A. R. Rezaie, Plasmodium falciparum histidine rich protein HRPII inhibits the anti-inflammatory function of antithrombin. J. Thromb. Haemost. 18, 1473–1483 (2020).
We thank you again for giving us the opportunity to improve our paper, and we hope that the changes are satisfactory.
RESPONSE TO REVIEWER #2:
We wish to express our appreciation to Reviewer #2 for his or her insightful comments, which will significantly improve this paper. We thank the reviewers for giving us the opportunity to improve the manuscript. We have responded to all the comments pointed out. The revised sections are highlighted in red characters and yellow backgrounds in the preliminary revised manuscript.
Reviewer #2 (Evidence, reproducibility and clarity (Required)): This paper showed that recombinant Plasmodium falciparum HRPII generated in E. coli is internalized by human tumor derived cells lines and at high concentrations, induces calcium-dependent cell death. The authors propose that HRPII inhibits autolysosome formation and autophagy. Of major concern is the use of E. coli generated HRP2 without addressing the inherent confounders of copurified bacterial components, namely endotoxin LPS. It is crucial for validation of their conclusions that the authors address steps taken to remove endotoxin which is known to bind poly-histidine and HRPII, the quantification of endotoxin bound to purified protein, and the LPS sensitivity of model cell lines. Even small quantities of LPS have been shown to potentially inhibit endosome maturation (https://doi.org/10.1074/jbc.M114.611442). Would recommend caution with conclusions regarding cytotoxicity and autophagy inhibition without addressing this issue.
Response: We sincerely appreciate the reviewer's effort to evaluate our work. The reviewer points out that the endotoxin LPS may also affect the cytotoxicity and autophagy inhibition of PfHRP2 in this study. The reviewer's point is crucial, and we agree with the reviewer. In our study, recombinant PfHRP2 was captured by anti-FLAG antibody-immobilized affinity gel (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) and washed with 20-bed volumes of washing buffer (20 mM Tris-HCl pH7.4, 500 mM NaCl, 0.1% Triton X-100) to remove contaminants including endotoxin LPS according to the manufacturer's protocol (https://ruo.mbl.co.jp/bio/dtl/dtlfiles/3328R-ver4.0.pdf). After washing, affinity gel was equilibrated with 10-bed volumes of washing buffer without Triton X-100, and recombinant PfHRP2 was eluted by 10-bed volumes of elution buffer (20 mM Tris-HCl pH7.4, 500 mM NaCl, 0.1 mg/mL FLAG peptide: DYKDDDDK). However, we did not determine the residual endotoxin LPS bound to purified PfHRP2. To address the reviewer's concern, we will follow the reviewer's suggestion and quantify the residual endotoxin LPS in the purified PfHRP2 using the LAL Endotoxin Assay Kit. We also plan to test whether the same amount of endotoxin LPS alone as the residual endotoxin LPS affects cytotoxicity and autophagy inhibition. The results of additional experiments on endotoxin LPS will be added to Supplementary Information as Fig. S2. Furthermore, we have added additional information on the purification and washing of PfHRP2 to the Materials and methods section (page 11, lines 356–362).
Additional concerns for specific experiments are as follows: Figure 2A. There is an increase in BSA penetration at lower pH as well which suggests nonspecific increased cell permeability.
Response: As pointed out by the reviewer, the cell membrane permeability of BSA was enhanced at low pH (pH less than 5.8), and this result implies an increase in nonspecific cell permeability. Since we have reported in another study (https://doi.org/10.1093/bbb/zbab221) that BSA shows cell penetration to human gastric cancer cell lines at pH 5.0, the cell membrane permeability of BSA at low pH in this study is satisfactory. However, comparing pH 7.4 and pH 5.6, the net charge of BSA increased by 21.9 from -14.0 (pH7.4) to +7.9 (pH5.6), and the cell penetration increased by 34%. On the other hand, the net charge of PfHRP2 increased by 79.4 from -19.2 (pH7.4) to +60.2 (pH5.6), and the cell penetration increased by 246%. This suggests that the increase in cell membrane permeability of PfHRP2 under low pH conditions is due to the increase in net charge, not to the non-specific increase in cell permeability as seen in BSA. The above explanation has been added to lines 97–103.
Figure 3A, 3B, and 4C. There is inconsistency between the cell viability data. For example, in panel A, 1 μM of HRPII for 24 h showed 84% cell viability whereas in panel B, the cell viability is 61% for 1 μM HRP2 by 24 hours. Figure 3A and 4C (full length) differ at cell viability for 5 μM HRP2.
Response: We thank the reviewer for the critical remarks. There was an error in the time condition described in the graph of Fig. 3A. Correctly, Fig. 3A is the result of cell viability treated with 1 μM PfHRP2 for 3 hours, so we have corrected the time condition described in Fig. 3A. Namely, Fig. 3A and 3B show that a 3-hour treatment with 1 μM PfHRP2 results in 84% cell viability, but a 24-hour treatment with 1 μM PfHRP2 decreases cell viability to 61%. These results are correctly described in lines 119–120, highlighted in yellow.
On the other hand, as the reviewer points out, in Fig. 3A and Fig. 4C (full-length PfHRP2), the cell viability treated with 5 μM PfHRP2 for 24 hours was 5% and 26%, respectively. We believe that the discrepancy in these values is an experimental error. However, both Fig. 3A and Fig. 4C (full-length PfHRP2) agree that 5 μM PfHRP2 is statistically and significantly cytotoxic, which should not affect the claims of this study.
Figure 5C. It would be more informative if the cell viability data at 1 μM of HRP at timepoints beyond 60 hours and for bafilomycin treatment is also presented.
Response: We thank the reviewer for their suggestions. However, the purpose of the experiment in Figure 5C is to prove that PfHRP2 induces autolysosomal dysfunction. Since we confirmed that treatment of cells with 1 µM PfHRP2 for 60 hours resulted in accumulation of p62 in the same amount as the positive control, Bafilomycin A1, we believe that no further additional experiments are necessary.
Figure 3D. (Minor) Consider additional experimental detail regarding maintenance of cell cultures for 5 day. Are there interval media changes or supplement additions?
Response: We apologize for the insufficient information in the description of the experimental procedure in Fig. 3D. In the experiment in Fig. 3D, cell culture was maintained for 5 days by changing a fresh medium containing each concentration of proteins every day. We have added this information to the legends of Figure 3 (page 23, lines 653–655) and Figure S2 (page 4, lines 28–29).
Reviewer #2 (Significance (Required)): The authors present the novel finding of HRP2 permeability into human cells. The significance of these findings is limited given the major confounder with endotoxin and also since the experiments were conducted in tumor-derived cells lines with supraphysiologic concentrations of HRPII. Although the authors showed cell viability effects with lower concentrations over 3 and 5 days, the bulk of the experiments were at more than 10-fold mean physiological concentrations. Also, since these are early findings in tumor-derived cell lines, it is difficult to extrapolate the physiological relevance of these findings and use of calcium chelators as therapeutics. Several studies have proposed a pathogenic role for HRP2 including those cited in the paper regarding blood-brain barrier disruption (references 37 and 38), coagulation disruption (DOI: 10.1182/blood-2010-12-326876), and pro-inflammatory signaling (DOI: 10.1111/jth.14713). The challenge with all these studies is establishing the clinical relevance of the multitude of HRPII effects. If the issue of endotoxin is addressed, this paper could establish an interesting mechanism for further study in more clinically representative systems. Our lab has studied the many functions of HRPII including catalysis of heme polymerization, inhibition of antithrombin, brain endothelial disruption using tissue culture and mouse models.
Response: As pointed out by the reviewer, this study must clear up the effect of endotoxin LPS. In this regard, as mentioned above, we plan to quantify the residual endotoxin LPS in the purified PfHRP2 using the LAL Endotoxin Assay Kit. We will also check the effect of the endotoxin LPS itself on cytotoxicity and autophagy inhibition.
Furthermore, as the reviewer pointed out, this is an in vitro study using high concentrations of PfHRP2 and a tumor-derived cell line, so further in vivo validation is essential in the future. However, it is also true that we discovered new findings that have been overlooked because we conducted an artificial and simple in vitro experiment. In the future, it is necessary to demonstrate the cytotoxicity and autophagy inhibition of PfHRP2 by in vivo studies using model animals. Concretely, we need to confirm whether PfHRP2 behaves as a similar virulence factor in vivo by animal experiments using PfHRP2-administrated or PfHRP2-overexpressing/deficient P. falciparum-infected mouse models. We also need to demonstrate that calcium chelators such as EDTA have an in vivo therapeutic effect. These future tasks have been added to the Discussion (page 9, lines 294–297 and 309–310). We have also added the studies (DOI: 10.1182/blood-2010-12-326876, DOI: 10.1111/jth.14713) reporting PfHRP2 elicits pro-inflammatory effect and induces vascular permeability as reference 37 and 40.
Furthermore, the title of the original paper was vague and gave the impression that it included in vivo experiments. Therefore, to avoid misunderstanding, we modified the paper's title to be more concrete, "Plasmodium falciparum histidine-rich protein II exhibits cell penetration and cytotoxicity with autophagy dysfunction".
References
M. Ndonwi, et al., Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II. Blood 117, 6347–6354 (2011). P. Dinarvand, L. Yang, I. Biswas, H. Giri, A. R. Rezaie, Plasmodium falciparum histidine rich protein HRPII inhibits the anti-inflammatory function of antithrombin. J. Thromb. Haemost. 18, 1473–1483 (2020).
We thank you again for giving us the opportunity to improve our paper, and we hope that the changes are satisfactory.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this paper, Harterink and colleagues investigate the establishment of minus-end-out microtubule polarity in the anterior dendrite of C. elegans PVD neurons. These neurons offer an excellent model system due to their simplicity and well-defined microtubule polarity. The authors investigate the role of two proteins in particular, the well-studied Patronin protein and a newly identified homologue of Ninein (Noca-2). They show that these proteins are redundantly required for correct minus-end-out polarity. Absence of one of these proteins results in a low penetrant phenotype, but absence of both results in a strongly penetrant phenotype. Interestingly, in all cases the neurons display either almost fully retrograde or almost fully anterograde microtubule polarity, and not a mix of retrograde and anterograde microtubules. This is probably linked to the fact that the authors show that endosomes at the distal tip of the dendrite (that are known to mediate retrograde microtubule nucleation events) are either present or absent in these mutants (to differing degrees that reflect the polarity phenotypes of each mutant type). The authors further show that Noca-2, but not Patronin, is required for proper localisation of γ-tubulin to the distal endosomes, suggesting that the proteins influence microtubule polarity in different ways. They provide some evidence that Patronin clusters, while not colocalized to the distal endosomes, are somehow connected. The paper and figures are clear and the work should be reproducible.
Most conclusions are supported by the data, except for when the authors say: "Taken together, these results show that PTRN-1 (CAMSAP) and NOCA-2 (NINEIN) act in parallel in the PVD neuron during early development to establish minus-end out microtubule organization, and that this organization is important for proper dendritic morphogenesis." But the authors show that removal of Patr results in some neurons having a complete anterograde phenotype in the anterior genotype, but that no Patr neurons have a severe morphology defect (Fig 2). This would suggest that the severe morphology defects in Patr/Noca-2 double mutants are not simply due to the reversal of polarity in the anterior dendrite. This should be discussed.
The paper could be strengthened with some biochemistry showing that Noca-2 can associate with γ-TuRCs i.e. do purified fragments of Noca-2 pull out γ-TuRCs from a cell extract (not necessarily a neuron cell extract)? This should be possible within 1 month.
Minor comments
- "However, in polarized cells such as neurons, most microtubules are organized in a non-centrosomal manner (Nguyen et al., 2011)." Need more up to date reference here, such as a recent review from Jens Lüders.
- "and also in Drosophila Patronin was found important for dendritic microtubule polarity (Feng et al., 2019)." Also Wang et al., 2019 in eLife.
- "In the non-ciliated PHC neuron or the ciliated URX neuron we did not observe microtubule organization defects in the ptrn-1 mutant (Supplemental figure 1A-B), which suggests that these neurons do less or do not dependent on PTRN-1." End of sentence needs re-phasing
Significance
Overall, the paper adds some interesting information to the field but does not make a conceptual advance that would make it attractive to a wide audience. It will, however, be of interest to those studying mt regulation in neurons. It is a shame that the molecular mechanism that allow Noca-2, and particularly Patronin, to establish microtubule polarity remain to be determined. Figuring out these mechanisms would significantly strengthen the paper.
-
- Jan 2022
-
Local file Local fileuntitled1
-
B l e n d i n g D i s c u s s i o n , D i a l o g u e , a n d C o n v e r s a t i o n
.h3
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.25.476850: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Human serum samples: Human serum specimens were collected at Peking Union Medical College Hospital, Beijing Ditan Hospital, 309 Hospital of the Chinese People’s Liberation Army, Fangzhuang Community Health Service Center, and the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS).<br>IRB: This study was conducted in strict accordance with the recommendations in the “Guide for the Care and Use of Laboratory Animals” issued by the Ethics Committee of IMCAS.<br>Consent: Informed consent was obtained from all of the participants.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Specific-pathogen-free (SPF) BALB/c 6-8-week-old female mice were purchased from Beijing Vital River Animal Technology Co.,</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The HRP-labeled anti-mouse Fc secondary antibody (Yeasen) was added after washing the microplates three times.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression and purification: The objective recombinant protein sequences carried on the pCAGGS vector were expressed via HEK293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation at 37°C for one hour, 2 × 104 Vero E6 per cell were added to each well to make a final volume of 200 μl, which was incubated for 24 hours in a 37°C, 5% CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animal experiments: For immunization, 6-8-week-old female BALB/c mice were primarily vaccinated with 4 μg S-encoding mRNA vaccine candidate via intramuscular (i.m.) route.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression and purification: The objective recombinant protein sequences carried on the pCAGGS vector were expressed via HEK293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All of the graphs were generated with GraphPad Prism version 7.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.26.477790: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Field protocols followed guidelines for safe and humane handling of bats from the American Society of Mammalogists (Sikes and Gannon, 2011) and were approved by the Institutional Animal Care and Use Committee of the American Museum of Natural History (AMNHIACUC-20190129).<br>Field Sample Permit: Serum specimens used for proteomic analysis were approved by the National Institute of Standards and Technology Animal Care and Use Coordinator under approval MML-AR19-0018.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Using the original sample randomization gave a randomized sample order, and injection volumes were determined for 0.5 μg loading (0.21–0.44 μL sample).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Resulting sequences were aligned using Geneious (Biomatters; (Kearse et al., 2012), followed by analysis using NCBI BLAST (Altschul et al., 1990)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI BLAST</div><div>suggested: (NCBI BLAST, RRID:SCR_004870)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PhyML 3.0 was used to build a maximum-likelihood phylogeny of these and additional CoV sequences (Guindon et al., 2010).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PhyML</div><div>suggested: (PhyML, RRID:SCR_014629)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The method file (85min_DIA_40×21mz.meth) and mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD031075.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PRIDE</div><div>suggested: (Pride-asap, RRID:SCR_012052)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To search the bat samples, we used the NCBI RefSeq Desmodus rotundus Release 100 GCF_002940915.1_ASM294091v2 FASTA (29,845 sequences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RefSeq</div><div>suggested: (RefSeq, RRID:SCR_003496)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To additionally search for CoV proteins (Neely et al., 2020), we performed a secondary search using the same settings and the addition of a Coronaviridae FASTA (117709 sequences) retrieved from UniProtKB (2021_03 release) using taxon identifier 1118 with all SwissProt and TrEMBL entries.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UniProtKB</div><div>suggested: (UniProtKB, RRID:SCR_004426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Our identified bat proteins were then mapped to human orthologs using BLAST+ (Camacho et al., 2009) and a series of python scripts described previously (Neely et al., 2020) to facilitate downstream analysis using human-centric databases (see Supplemental Material for full details).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These ratios were used in a moderated t-test with the limma package in R to evaluate protein changes within sera samples before and after heat treatment (Ritchie et al., 2015), followed by Benjamini–Hochberg (BH) correction (Benjamini and Hochberg, 1995).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>limma</div><div>suggested: (LIMMA, RRID:SCR_010943)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We then used a permutation multivariate analysis of variance (PERMANOVA) with the vegan package to test for differences in protein composition between uninfected and infected bats (Dixon, 2003).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>vegan</div><div>suggested: (vegan, RRID:SCR_011950)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used a modified function (https://github.com/dnafinder/roc) in MATLAB to generate the area under the ROC curve (AuROC) as a measure of classifier performance with 95% confidence intervals, which we calculated with standard error, α = 0.05, and a putative optimum threshold closest to 100% sensitivity and specificity (Hanley and McNeil, 1982; Pepe, 2003).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MATLAB</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We also visualized the matrix of all candidate serum biomarkers with the pheatmap package, using log2-transformed protein abundances (scaled and centered around zero) and Ward’s hierarchical clustering method (Murtagh and Legendre, 2014; Kolde and Kolde, 2015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pheatmap</div><div>suggested: (pheatmap, RRID:SCR_016418)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, we used the gprofiler2 package as an interface to the g:Profiler tool g:GOSt for functional enrichment tests (Raudvere et al., 2019; Kolberg et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>g:Profiler</div><div>suggested: (G:Profiler, RRID:SCR_006809)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We restricted our data sources to GO biological processes, the Kyoto Encyclopedia of Genes and Genomes (KEGG), and WikiPathways (WP).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>WikiPathways</div><div>suggested: (WikiPathways, RRID:SCR_002134)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Additionally, our ability to detect viral proteins may have been further restricted by ongoing limitations in applying proteomics to wild species. In humans, over 3000 serum proteins can be detected by mass spectrometry after depletion of the most abundant proteins (Uhlén et al., 2019). However, using antibody-based depletion techniques is not an effective strategy in non-human mammals (Neely et al., 2014), such that undepleted serum proteomics in bats will be limited to the top 300–600 proteins, with false negatives for low abundance proteins such as those of viruses (Anderson and Anderson, 2002). Alternatively, lack of detection of CoV proteins in sera despite detection of CoV RNA in oral and rectal swabs could indicate tropism, as CoVs have been more readily detected in bat feces and saliva than in blood (Smith et al., 2016). Using our novel α-CoVs, we then tested for differential composition and abundance of serum proteins between uninfected and infected vampire bats. In both cases, we found negligible overall differences in serum proteomes with CoV infection. However, such null results should be qualified by the challenges posed to differential abundance tests by sample imbalance, given the small number of infected relative to uninfected bats (Yang et al., 2006). To partly address this imbalance, we used ROC curve analyses to identify proteins with strict (AuROC ≥ 0.9; n = 7) and less conservative (AuROC ≥ 0.8; n = 25) classifier ability for infection (Arthur et al., 201...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.25.22269808: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: These studies were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-20-03374,IRB-16-00791).<br>Consent: All participants signed written consent forms prior to sample and data collection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with PBS-T, 50 μl/well of the pre-diluted secondary anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in goat; Sigma-Aldrich) diluted 1:3,000 in PBS-T containing 1% milk powder were added and plates were incubated for one hour incubation at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>the pre-diluted secondary anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The biotinylated mAb 1C7C7, a mouse anti-SARS nucleoprotein monoclonal antibody generated at the Center for Therapeutic Antibody Development at the Icahn School of Medicine at Mount Sinai ISMMS (Millipore Sigma), was used for NP staining at a concentration of 1μg/ml in PBS, 1% BSA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were incubated with an anti-SARS-CoV spike primary antibody directly conjugated to Alexafluor-647 (CR3022-AF647) for up to 4 hours at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following this, 50 μL per well of 1X MSD SULFO-TAG Anti-Human IgG detection antibodies were added and incubated for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, residues 1-1208 of the spike protein (Wuhan-1 strain numbering) were codon optimized with proline substitutions at residues 986 and 987, the furin cleavage site modified to “GSAS”, and a T4 fibritin trimerization motif and a 8X HIS tag were added on the C-terminus and the construct was cloned into pCDNA3.4. 293F cells were transfected with plasmid using PEIMax in FreeStyle 293 Expression Medium (Fisher) and cultured for three days at 32°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero.E6 cells were seeded in 96-well high binding cell culture plates (Costar) at a density of 20,000 cells/well in complete Dulbecco’s modified Eagle medium (cDMEM) a day before infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero.E6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody-virus mixture was then added to Vero.E6-TMPRSS2 cells and incubated at 37°C for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero.E6-TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sequences for the proteins were cloned into a mammalian expression vector, pCAGGS, as previously described and proteins were purified after transient transfections with each respective plasmid (23, 26).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_127347)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, residues 1-1208 of the spike protein (Wuhan-1 strain numbering) were codon optimized with proline substitutions at residues 986 and 987, the furin cleavage site modified to “GSAS”, and a T4 fibritin trimerization motif and a 8X HIS tag were added on the C-terminus and the construct was cloned into pCDNA3.4. 293F cells were transfected with plasmid using PEIMax in FreeStyle 293 Expression Medium (Fisher) and cultured for three days at 32°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDNA3.4</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Area under the curve (AUC) values were calculated and plotted using Prism 9 software (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using GraphPad Prism 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All the analyses were performed using Prism 7 software (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. We include a limited number of samples, and our dataset comes from a comparison of imperfectly matched groups from a clinical trial in Thailand and an observational cohort study in New York City. Strengths of the study include the use of authentic SARS-CoV-2 for neutralization assays and that the findings could be replicated with different methods in a different, blinded, and independent laboratory. In summary, we show that a vaccine candidate which can be produced locally in LMICs at low cost induces neutralizing antibody titers to SARS-CoV-2 comparable to those observed in cohorts having received mRNA-based COVID-19 vaccines. The NDV-HXP-S vaccine candidate induces a strong RBD focused immune response resulting in a high proportion of neutralizing antibodies, which are associated with protection from infection and severe disease (20, 24, 25).
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04871737</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Study of a Live rNDV Based Vaccine Against COVID-19</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT05181709</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Live Recombinant Newcastle Disease Virus-vectored COVID-19…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04830800</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vacc…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04764422</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04993209</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactiv…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.17.22269278: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: They all acknowledged that they had understood the study protocol and signed the informed consent.<br>IRB: The protocol was approved by the ethics committee (full name: comité d’éthique hospitalo-facultaire universitaire de Liège) of Liège University Hospital (approval number 2021-54).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Assessment of total anti-spike IgGs: The DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay (DiaSorin, Stillwater, USA), a chemiluminescent immunoassay using magnetic particles coated with recombinant trimeric SARS-CoV-2 spike protein, was used for quantitative determination of IgG antibodies in human serum samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike IgGs</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Separating individuals with neutralizing versus non-neutralizing antibodies by anti-S IgG: Logistic regression of neutralizing status at the last time point (T4 at 6 months post-vaccine, 1st dose) on the log of anti-Spike IgG was used to determine the threshold immunoglobulin value that provides the best separation of the classes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Spike IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus isolation, expansion, titration and SNT analysis were all performed using nonadherent sub-confluent Vero E6 cells (ATCC® CRL-1586) grown in DMEM supplemented with 2% FBS and penicillin-streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation, 100 μl of a Vero cells suspension were added so that 20,000 cells were deposited in each well (19).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04796896</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Study to Evaluate Safety and Effectiveness of mRNA-1273 CO…</td></tr></table>
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.24.477505: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: This project was approved by the KU Leuven ethical committee (P015-2020), following institutional guidelines approved by the Federation of European Laboratory Animal Science Associations (FELASA).<br>Euthanasia Agents: Hamsters were euthanized by intraperitoneal administration of 500 μL (hamsters) Dolethal (200 mg/mL sodium pentobarbital, Vétoquinol SA).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Biodistribution: WT hamsters (6-8 weeks old, female) were inoculated intraperitoneally with 104 PFU/mL dose of YF17D (n = 6) or YF-S0 (n = 6).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Original YF17D vaccine (Stamaril, Sanofi-Pasteur; lot number G5400) was purchased via the pharmacy of the University Hospital Leuven and passaged twice in Vero E6 cells prior to use.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All virus stocks were titrated by plaque assay on BHK21 cells [17].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK21</div><div>suggested: ATCC Cat# CRL-6282, RRID:CVCL_1914)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animal experiment: Hamsters: Wild-type (WT) outbred specific pathogen-free Syrian hamsters (Mesocricetus auratus) were purchased from Janvier Laboratories, France.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Janvier Laboratories</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Half-maximal serum neutralizing titers (SNT50) were determined by curve fitting in GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.25.477789: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The mouse and hamster studies were carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals under the approval of the Institutional Animal Care and Use Committee of Xiamen University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Rhesus monkey immunizations: Ten rhesus monkeys were allocated randomly into two groups (three females and two males per group).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Rhesus monkey immunizations: Ten rhesus monkeys were allocated randomly into two groups (three females and two males per group).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Microscopic evaluation of pathological lung lesions was performed blindly by pathologists following a semiquantitative scoring system with the inclusion of three indicators (49): (i) alveolar septum thickening and consolidation; (ii) hemorrhage, exudation, pulmonary edema, and mucous; and (iii) recruitment and infiltration of inflammatory immune cells.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Two weeks after boosting, serum samples were collected for antibody analyses, including measurement of anti-spike IgG, anti-RBD IgG, pseudovirus neutralizing antibody, and authentic neutralizing antibody titers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RBD IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, single-cell suspensions were obtained from mouse spleen (106 cells per well) through grinding in 70 μm cell strainers and were seeded in anti-mouse IFN-γ antibody precoated ELISpot plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IFN-γ</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixtures (150 μL per well) were added to a monolayer of Vero cells in a 96-well plate and incubated at 37 °C supplying with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Experimental animals: BALB/c and C57BL/6 mice were purchased from Shanghai SLAC Laboratory Animal Co.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse immunizations: Six to eight-week-old BALB/c mice (n=6 per group) were immunized with STFK vaccines at 0.01, 0.1, 1, or 10 μg per dose in 150 μL through intramuscular injection following a two-dose schedule at weeks 0 and 3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The tag-free STFK and STFK variants were constructed into a pGS01b vector, modified from the pCGS3 vector containing glutamine synthetase (GS) selection marker (Sigma Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGS01b</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCGS3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using the SerialEM software on an FEI Tecnai F30 transmission electron microscope (ThermoFisher Scientific) operated at 300 kV and equipped with a Gatan K3 direct detector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image processing and 3D reconstruction: Drift and beam-induced motion correction were performed with MotionCor2 (38) to produce a micrograph from each movie.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MotionCor2</div><div>suggested: (MotionCor2, RRID:SCR_016499)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We initially fitted the templates into the corresponding final cryo-EM maps using Chimera (43), and further corrected and adjusted them manually by real-space refinement in Coot (44).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting models were then refined with phenix.real_space_refine in PHENIX (45).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PHENIX</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The final atomic models were validated with Molprobity (46, 47).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Molprobity</div><div>suggested: (MolProbity, RRID:SCR_014226)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analyses were conducted in GraphPad Prism 8 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.26.477856: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation for 1h at room temperature and washing, the ACE-2 mFc Tag was revealed using a peroxidase-conjugated anti-mouse secondary antibody (1:1000 dilution).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 clinical isolates (D614G variant; GenBank accession number MW322968) , Alpha (GenBank accession number MW633280) , Beta (GenBank accession number MW580244) , Gamma (Gene accession number pending), Delta (Gene accession number pending) and Omicron (Gene accession number pending) were isolated from SARS-CoV-2 RT-PCR confirmed patients by inoculating Vero cells with sputum sample or nasopharyngeal swabs in the biosafety level-3 (BSL-3) facility of the Pitié-Salpêtrière University Hospital.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hundred μl of a Vero E6 cell suspension (3 × 105 cells/ml) were then added to the mixture and incubated at 37°C under an atmosphere containing 5% CO2 until microscopy examination on day 4 to assess cytopathogenic effect (CPE), as previously described (Vanhove et al</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50s were analyzed by nonlinear regression using a four-parameter dosage-response variable slope model with the GraphPad Prism 8.0.2 software (GraphPad Software, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr style="background-color:#FF0000"><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT0492830</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Trial number did not resolve on clinicaltrials.gov. Is the number correct?</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NA</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.25.477784: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Assays were run in two formats i.e., antibodies/ACE2 coated, or spike coated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibodies/ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies were incubated at room temperature for 1 hour, washed and binding detected with goat anti-human-HRP (Jackson ImmunoResearch Laboratories, PA) and TMB substrate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse anti-monkey IgG-HRP (Southern Biotech, CAT# 4700-05) and Goat anti-human IgG-HRP (Jackson ImmunoResearch Laboratories, CAT# 109-035-098) secondary antibodies were used to detect antibody bound to the spike proteins.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-monkey IgG-HRP</div><div>suggested: (SouthernBiotech Cat# 4700-05, RRID:AB_2796069)</div></div><div style="margin-bottom:8px"><div>anti-human IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All spike ectodomains were cloned into the mammalian expression vector pαH and have been deposited to Addgene (10) (https://www.addgene.org).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>https://www.addgene.org</div><div>suggested: (Addgene, RRID:SCR_002037)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sensogram data were analyzed using the BiaEvaluation software (Cytiva, MA) Negative-stain electron microscopy: Fab-spike complex of DH1044 was generated by mixing 5.9 μg of spike with 6.2 μg of Fab in ~25 μl of HEPES-buffered saline (HBS) containing 20 mM HEPES and 150 mM NaCl, pH 7.4, and incubating at 37 °C for 1 hr and using sample directly for negative stain without further purification.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BiaEvaluation</div><div>suggested: (BIAevaluation Software, RRID:SCR_015936)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were analyzed and 3D reconstructions generated using standard protocols with Relion 3.0 (28).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Relion</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cryoSPARC (29) software was used for data processing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phenix (30, 31), Coot (32)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Pymol (33), Chimera (34), ChimeraX (35) and Isolde (36) were used for model building and refinement.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pymol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Difference distance matrices (DDM): DDM were generated using the Bio3D package (39) implemented in R (R Core Team (2014).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio3D</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The collected diffraction images were indexed, integrated, and scaled using HKL2000 (40) Initial phases were calculated by molecular replacement using Phenix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenix</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 34 and 27. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.25.22269794: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Remnant samples were biobanked and retrospective medical chart reviews for relevant demographic and clinical metadata were performed under a waiver of consent and according to protocols approved by the UCSF Institutional Review Board (protocol numbers 10-01116 and 11-05519).<br>IRB: Remnant samples were biobanked and retrospective medical chart reviews for relevant demographic and clinical metadata were performed under a waiver of consent and according to protocols approved by the UCSF Institutional Review Board (protocol numbers 10-01116 and 11-05519).<br>Field Sample Permit: Second, plasma samples were also collected through the UMPIRE (UCSF EMPloyee and community member Immune REsponse) study, a longitudinal COVID-19 research study focused on collection of prospective whole blood and plasma samples from enrolled subjects to evaluate the immune response to vaccination, with and without boosting, and/or vaccine breakthrough infection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transfection mixture was incubated for 20 minutes at room temperature and then added dropwise to 293T cells in 2 mL of DMEM containing fetal bovine serum and penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Each heat inactivated serum sample was serially diluted from 1:20 to 1:20480 dilution in complete DMEM media prior to incubation (1hr at 37°C) with 40μL VLPs with total volume of 50μL, then plated onto receiver cells (50000 293T ACE2-TMPRSS2 cells).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS CoV-2 isolation in cell cultures: Vero E6-TMPRSS2-T2A-ACE2 and Vero-81 were cultured with MEM supplemented with 1x penicillin-streptomycin (Gibco), glutamine (Gibco) and 10% Fetal calf serum (Hyclone).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6-TMPRSS2-T2A-ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Vero-81</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live virus neutralization assay: CPE endpoint neutralization assays were done following the limiting dilution model using p0 stock of Omicron and p1 stock of Delta in Vero E6-TMPRSS2-T2A-ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>p1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Scripting code used for the data analysis and visualization, a table showing deidentified clinical and demographic metadata, and consensus genome FASTA files are available in a Zenodo data repository pending</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zenodo</div><div>suggested: (ZENODO, RRID:SCR_004129)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genome Assembly and Variant Identification: Raw sequencing data were simultaneously demultiplexed and converted to FASTQ files and screened for SARS-CoV-2 sequences using BLASTn (BLAST+ package 2.9.0)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BLASTn</div><div>suggested: (BLASTN, RRID:SCR_001598)</div></div><div style="margin-bottom:8px"><div>BLAST+</div><div>suggested: (Japan Bioinformatics, RRID:SCR_012250)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads containing adapters, the ARTIC and/or VarSkip primer sequences, and low-quality reads were filtered using BBDuk (version 38.87) and then mapped to the Wuhan-Hu-1 SARS-CoV-2 reference genome (National Center for Biotechnology Information (NCBI) GenBank accession number NC_045512.2) using BBMap (version 38.87).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BBMap</div><div>suggested: (BBmap, RRID:SCR_016965)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analyses and Data Visualization: Statistical analyses and data visualization were performed using R (version 4.0.3) and Python (version 3.7.10).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plots were generated using ggplot2 (version 3.3.5) in R and seaborn package (version 0.11.0) in Python.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of the current study is the lack of both acute and convalescent samples from patients with Delta or Omicron breakthrough infections. Indeed, we found a significant difference in the median days between symptom onset or PCR positivity and sample collection (Table 1, 17 versus 8.5 days, p=0.008). However, when we analyzed a more comparable subset of samples collected ≤15 days following PCR positivity and sample collection, the difference in neutralization titers between Omicron and Delta was still significant (p=0.037). To confirm these findings, collection and analysis of samples from patients with Omicron breakthrough infections at later time points is ongoing. Other studies have looked at the effect of boosting on neutralization of Omicron and the role cross-variant immunity plays in Omicron breakthrough infections. A study from Laurie, et al. (2022) reported a 4 to 8-fold reduction in neutralization titer in sera from boosted individuals using a pseudovirus assay, comparable to the 7.4-fold reduction that we observed using a VLP assay. Similar to our findings, the study by Khan, et al. (2021) found that sera from patients with Omicron breakthrough infections can enhance Delta virus neutralization to a limited extent (4.4-fold), but that immunity elicited against the specific infecting variant (Omicron) is higher (17.4-fold). Our findings have implications with regard to the likelihood of Omicron infections providing mass immunization on the population level aga...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.25.22269670: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants gave written informed consent.<br>IRB: The study protocol used was approved by the Institutional Review Board of Stanford University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Clinical cohort and samples: The samples used were from 109 participants enrolled in a Phase 2, single-blind, randomized placebo-controlled trial evaluating the efficacy of Peginterferon Lambda-1a in SARS-CoV-2 infected outpatients (Jagannathan et al., 2021).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This is followed by adding 25 μL of 1:5000 diluted horse radish peroxidase (HRP) conjugated anti-Human IgG secondary antibodies (Southern Biotech) and incubated for 1 hour at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Prior to infection, Vero cells were washed twice with 1X PBS and then 50 μL of the incubated pseudo-typed particles and patient plasma mixture was transferred onto the Vero cells, followed by a 24 hour incubation at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used Prot_M and Prot_N, consisting of complete sequences of the membrane ‘M’ glycoprotein (GenBank MN908947.3,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prot_M</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All samples were analyzed on an Attune NXT flow cytometer and analyzed with FlowJo X (Tree Star) software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A non-linear curve and the half-maximal neutralization titer (NT50) were generated using GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All statistical analyses were performed using Prism 6.0 (GraphPad)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">STATA version 16 (College Station),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STATA</div><div>suggested: (Stata, RRID:SCR_012763)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses of global cytokine profiles (pie charts) were performed by partial permutation tests using SPICE.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPICE</div><div>suggested: (SPICE, RRID:SCR_016603)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study had some limitations. Half of the study participants in this trial received an investigational Type III IFN at the time of infection. However, in this study, this agent neither shortened the duration of viral shedding nor symptoms (Jagannathan et al., 2021), nor did we observe any significant impact on either innate (Hu et al., 2021) or adaptive (Chakraborty et al., 2021) immune responses between arms, allowing us to utilize data from both arms to improve statistical power. In addition, stratified analyses, and multivariate models adjusted for treatment arm as a covariate, confirmed pooled results. Although we would have liked to have assessed for correlations with protection against reinfection, only one participant had evidence of reinfection during follow-up. Future larger cohorts, and/or case/control designs, will be required to address this question. Finally, we only utilized data assessing responses to the original consensus strain, and do not present data on responses to variants. However, others have recently reported that infection-induced SARS-CoV-2 T cell responses have broad reactivity against viral variant proteins (Keeton et al., 2021; Tarke et al., 2021). By providing insight into the shifting quality of the SARS-CoV-2-specific CD4+ T cell response following infection, how this is impacted by vaccination, and which features most strongly correlate with immune effector mechanisms, our study adds to our growing understanding of the memory T cell respon...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04331899</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Single-Blind Study of a Single Dose of Peginterferon Lambda-…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 48. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2021.02.11.21251553: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study protocol was approved by the ethics committee of Hospital Germans Trias i Pujol (Badalona, Spain).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">All Ag-RDT determinations were performed in parallel by two blinded technicians, who used approximately 100 μL of 1:2 mix of each kit buffer and the sample previously homogenized.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Outcomes and statistical analysis: We calculated that a sample size of at least 73 positive specimens and 165 negative specimens would give 80% power to estimate overall sensitivity and specificity of Ag-RDT assays in our study.</td></tr></table>Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several strengths and limitations. We used the same fresh set of samples for assessing five different Ag-RDTs and the sample size met the FIND recommendation for retrospective assessments of the clinical performance of these tests. Furthermore, to our knowledge, this is the first head-to-head comparison of Ag-RDT in asymptomatic screenings, an intended use proposed by various authors.4,9,16,22 On the other hand, our study was limited by the small number of specimens with Ct <30, a threshold deemed of interest for the use of Ag-RDT in screenings of the general population. In our sample, specimens below this threshold accounted for 30%; however, other authors have reported proportions of nearly 60% in random screenings of the general population.22 Of note, we used specimens in transport medium. This approach is convenient for mass screening strategies in which individuals with positive Ag-RDT results may need further diagnostic confirmation by PCR. However, only one manufacturer (i.e., the Roche assay) provided instructions on how to process samples collected in virus transport medium. The consistency of our results across assays, particularly regarding negative results, suggests that the use of this media had a little or negligible impact on test performance. Finally, it is worth mentioning that all nasopharyngeal swabs in our analysis were collected by trained healthcare professionals. According to a recent report of lateral flow viral antigen detection devices,...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.24.477502: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wells were then washed with 200 μl of PBS buffer three times followed by incubation with 100 μl of anti-his antibody prepared in 1X PBST buffer at 1:5,000 dilution and incubated at 37 °C for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-his</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.14.22269235: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Informed consent was obtained from parents and assent from children over 7 years of age.<br>Field Sample Permit: Blood specimens were immediately added to acid citrate dextrose tubes upon collection which were then spun down to separate out the red blood cell fraction.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-N IgG index values were assessed; higher index values reflected higher antibody levels.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-N IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To perform neutralization assays, 1.25x104 HEK-293T-ACE2 cells (39) (BEI resources NR-52511) are added in 50ul per well of a 96-well poly-L-lysine coated plate (Greiner; no. 655936).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NT50 values were calculated using the neutcurve python package version 0.5.3 available here: https://github.com/jbloomlab/neutcurve which fit a Hill curve to our data to determine the 50% inhibitory concentration (IC50).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 IgG assay: The SARS-CoV-2 IgG assay, an FDA Emergency Use Authorized immunoassay, which utilizes a chemiluminescent test to assess immunoglobulin G (IgG) binding to nucleocapsid (N) protein, was performed according to manufacturer specifications (Abbott)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of our study include small sample size, a limited number of children with follow-up at 52-weeks, and differences in the sex distribution between the pediatric and adult cohorts. Follow-up is ongoing with children who had not yet reached 52-weeks post-symptom onset at the time of this analysis. Furthermore, blood volume obtained from younger children is limited and therefore the number of assays utilized was also limited. The adult comparative specimens were obtained from the same geographic location and analyzed in the same laboratory, although not necessarily collected from the same families or at the same time. The adult specimens were also plasma, whereas the pediatric specimens were serum, and the differences in collection and storage of these could possibly result in slight differences in antibody concentrations. Additionally, the adults in this study were a convenience sample of a broader study, and approximately half were older adults, over 65 years of age, meaning that the data presented here may not be representative of all adults across wider age ranges. Likewise, our pediatric cohort was also a convenience sample and may also not be representative of the broader population. Furthermore, unlike the pediatric cohort, adults were only enrolled following RT-PCR confirmed infection without enrollment based on household RT-PCR positive contacts. Of note, both children and adult cohorts were enrolled prior to the widespread introduction of the SARS-CoV-2 Delta...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.defenseurdesdroits.fr www.defenseurdesdroits.fr
-
B · L e d r o i t à l’ é d u c at i o n d e s e n fa n t s d’o r i g i n e R o m : l a p e r s i s t a n c e d e r e f u s d e s c o l a r i s at i o n d i s c r i m i n at o i r e s
-
-
32poems.com 32poems.com
-
refracted ocean light
I often connect refracted ocean light to summer days at the beach. My body immediately relaxes and that feeling of "nothing to do, nothing to complete" sets in.
Tags
Annotators
URL
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.24.22269768: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: The exclusion criteria were defined as diarrhea resulting in dehydration; pregnancy or lactation; metastatic cancer or immunosuppressive chemotherapy and inability to understand the consent form (Lopes et al., 2021).<br>IRB: The study was approved by the National Ethics Committee, Brazil (CONEP, CAAE: 30248420.9.0000.5440).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Eight-week-old male K18-hACE2 mice were infected with 2×104 PFU of SARS-CoV-2 (in 40 μL) by the intranasal route as previously described (Oladunni et al, 2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: The dataset generated by authors is publicly available at https://covid19-balf.cells.ucsc.edu/.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The slides were overnight stained with the following antibodies: a) Mouse anti-myeloperoxidase (MPO, 2C7, Abcam, cat. ab25989, 1:500); B) Rabbit anti-GSDMD-NT (Abcam, cat. ab215203).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-myeloperoxidase ( MPO</div><div>suggested: (Antibodies-Online Cat# ABIN235893, RRID:AB_10764910)</div></div><div style="margin-bottom:8px"><div>anti-GSDMD-NT</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, the samples were incubated with alpaca anti-mouse IgG Alexa Fluor 488 (Jackson ImmunoResearch, cat. 615-545-214, 1:1000) or alpaca anti-rabbit IgG Alexa Fluor 594 (Jackson ImmunoResearch, cat. 611-585-215, 1:1000) secondary antibodies for 30 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 615-545-214, RRID:AB_2721889)</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 611-585-215, RRID:AB_2721875)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">tenofovir disoproxil fumarate) – CAS 202138-50-9 - (10 μM); neutralizing anti-hACE2 antibody - αACE2 - RheaBiotech; Cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membranes were incubated overnight at 4°C under mild agitation in 5% nonfat dry milk in 1X TBS-T buffer containing the following primary antibodies: mouse anti-Caspase-1 (p20) (mAb (Bally-1); Adipogen; AG-20B-0048-C100; 1:1000), mouse anti-Caspase-4 (MBL cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Caspase-1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Caspase-4</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-E6 cells were cultured in DMEM high glucose supplemented with 10% fetal bovine serum (FBS; HyClone, Logan,Utah) and 100 U/mL penicillin, and 1% μg/mL streptomycin (P/S Corning; cat. 30-002-CI), 1% glutamine (Corning; cat. 15718008), 1% hepes (Corning; cat.25-060-CI), and 1% fungizone (Gibco; cat. 15290-018) at 37°C in the 5% CO2 atmosphere.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plaque Reduction Neutralization Test using disulfiram against SARS-CoV-2: A PRNT (Plaque Reduction Neutralization Test) was performed in VERO E6 cells on a cell-monolayer in 24-well plates to evaluate the effect of disulfiram on SARS-CoV-2 infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VERO E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cytopathic effect of SARS-CoV-2 infected neutrophils on A549 and HUVECcell lines by flow cytometry: Neutrophils were isolated from healthy controls (1×106) incubated or not with disulfiram (10 μM) for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse infection and treatment: To evaluate the effects of Disulfiram in vivo, we infected the K18-hACE2 humanized mice (B6.Cg-Tg(K18-ACE2)2Prlmn/J) (McCray et al., 2007; Oladunni et al., 2020; Bao et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Eight-week-old male K18-hACE2 mice were infected with 2×104 PFU of SARS-CoV-2 (in 40 μL) by the intranasal route as previously described (Oladunni et al, 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The blood cells were then resuspended in Hank’s balanced salt solution (Corning; cat. 21-022-CV), and the neutrophil population was isolated by Percoll (GE Healthcare; cat. 17-5445-01) density gradient (72%, 63%, 54%, and 45%).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GE Healthcare</div><div>suggested: (GE Healthcare, RRID:SCR_000004)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This fluid was mixed 1:1 with 0.1 M dithiothreitol (Thermo Fisher Scientific; cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Scientific</div><div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All images acquired were analyzed using Fiji by ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The acquisition of the cells was performed in a flow cytometer (FACS Verse) and the analyses were made using the FlowJo software (FlowCytometry Analysis Software v10).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses and graph plots were performed with GraphPad Prism 8.4.2 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 33, 24, 26, 27, 29 and 30. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.20.477164: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics statement: All animal experiments were approved by the Institutional Animal Care and Use Committee of Rocky Mountain Laboratories, NIH and carried out in an Association for Assessment and Accreditation of Laboratory Animal Care (AALAC</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The animals used in the infection study consisted of 9 females and two males; intake female body weight range 1.04 kg – 1.47 kg, mean = 1.18 kg, male weights were 2.06 kg and 2.73.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Mycoplasma testing was performed at regular intervals and no mycoplasma was detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Upon arrival whole blood from all mink were screened for antibodies against SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibody was the Vector Laboratories ImPress VR anti-rabbit IgG polymer (cat# MP-6401).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To detect ACE-2, ACE-2 Antibody R&D Systems (catalog #AF933) was used at a 1:100 dilution with Vector Laboratories ImPress anti-goat IgG polymer (Cat #MP-7405) as a secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat IgG</div><div>suggested: (Vector Laboratories Cat# MP-7405, RRID:AB_2336526)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, plates pre-coated with poly-L-lysine (Sigma-Aldrich, St. Louis, MO, USA) were seeded with 293T cells and transfected the following day with 1,200 ng of empty plasmid and 400 ng of plasmid encoding coronavirus spike or no-spike plasmid control (green fluorescent protein (GFP)).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BHK cells were seeded in black 96-well plates and transfected the next day with 100 ng plasmid DNA encoding human or mink ACE2, using polyethylenimine (Polysciences, Inc., Warrington, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After a 1-hour incubation at 37°C and 5% CO2, the virus-serum mixture was added to VeroE6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These spike sequences were synthesized and cloned into pcDNA3.1+ (GenScript Biotech, Piscataway, NJ, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1+</div><div>suggested: RRID:Addgene_117272)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BHK cells previously transfected with ACE2 plasmid of interest were inoculated with equivalent volumes of pseudotype stocks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: RRID:Addgene_164219)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads were de novo assembled using SPAdes v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPAdes</div><div>suggested: (SPAdes, RRID:SCR_000131)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The percent identity between the ACE2 sequences was calculated by Clustal Omega (39)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Clustal Omega</div><div>suggested: (Clustal Omega, RRID:SCR_001591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutagenesis to show residues that differ in mink ACE2, and the alpha and delta variant RBD, was performed in COOT (40).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The figures were generated using The Pymol Molecular Graphics System (https://www.schrodinger.com/pymol).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pymol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ARTIC primers and Illumina adapters were trimmed, low quality bases and duplicate reads were filtered out, and mapping and variant calling were completed as described in the iVar and PrimalSeq pipeline described by Grubaugh et al.(47).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PrimalSeq</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analysis was performed using GraphPad Version 8.4.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.22.477073: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The experimental procedures in animals were approved by the National animal welfare and ethics committee (permit no. 124/2021) and were performed in compliance with the Directive 2010/63/EU as adopted in the national legislation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">In total, 24 naïve 9-10 weeks old specific pathogen free (SPF) male Golden Syrian hamsters (strain HsdHan®:Aura) were purchased from Envigo (US) and after introduction they were single-housed in individually ventilated cages GR900 (Tecniplast, Italy), HEPA-ventilated by SmartFlow air handling unit (Tecniplast, Italy) at 75 air changes per hour in a negative pressure mode.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Tissue sections (7 μm) were stained with hematoxylin and eosin stains and analyzed blindly for lung damage by a certified pathologist.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Vero E6 cells (African green monkey kidney, ATCC CRL-1586) and Calu3 (human lung adenocarcinoma cells, ATCC HTB-55) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% bicarbonate (all from Gibco).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infection of cells with SARS-CoV-2 and treatment with Larifan: Calu3 and HSAEC cells were grown to a monolayer in 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HSAEC</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Absolute quantifications of virus RNA copies were estimated by modelling a Poisson distribution using QuantaSoft™ analysis software version 1.7 (Bio-Rad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>QuantaSoft™ analysis</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: GraphPad Prism (GraphPad Software, Inc.) was used to perform statistical analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.21.477274: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of monoclonal antibodies against CHI3L1 (FRG): The murine monoclonal anti-CHI3L1 antibody (FRG) was generated using peptide antigen (amino acid 223-234 of human CHI3L1) as immunogen through Abmart Inc (Berkeley Heights, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CHI3L1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then the cells on the slides were fixed, permeabilized, and treated with blocking buffer then incubated with anti-ACE2 antibody (R&D, AF933) for overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The photographs of cellular immunofluorescence of GFP (+) pseudovirus and Cy-5 (+) ACE2 expression was taken with fluorescent microscopes Western blotting (Immunoblotting): 25 µg lung or cell lysates were subjected to immunoblot analysis using antibodies against phosphorylated (p) ERK (pERK), total ERK(ERK), Phosphorylated(p) AKT (pAKT), total AKT(AKT) (Cell Signaling Tech, MA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antibodies against phosphorylated (p) ERK</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Phosphorylated(p) AKT (pAKT), total AKT(AKT) (Cell Signaling Tech, MA</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and primary cells in culture: Calu-3 (HTB-55) lung epithelial cells were purchased from American Tissue Type Collection (ATCC) and maintained at 37°C in Dulbecco’s modified eagle medium (DMEM) supplemented with high glucose, L-Glutamine, minimal essential media (MEM) non-essential amino acids, penicillin/streptomycin and 10% fetal bovine serum (FBS) until used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293T cells were transfected with the FRG construct using Lipofectamine™ 3000 (Invitrogen, # L3000015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry analysis of GFP (+) cells was carried out 48 h after infection on a BD LSRII flow cytometer and analyzed with the FlowJo software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification and Statistical analysis: Statistical evaluations were undertaken with GraphPad Prism software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 29. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.23.22269723: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study protocol was approved by the Yokohama City University Hospital institutional review board (B200700100).<br>Consent: The requirement for informed consent was waived due to the observational nature of the study.<br>IACUC: Animal experiments: All animal experimental protocols were approved by Yokohama City University Animal Research Committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Male specific-pathogen-free C57/BL6J mice aged 8–10 weeks were used.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Twelve animals were randomly allocated to one of the following three groups (n = 4 per group): control, mild COVID-19, and severe COVID-19.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To evaluate effects of anti-HMGB-1 neutralizing antibodies in severe COVID-19 animal model, six animals were randomly placed in either anti-HMGB-1 antibody or isotype control groups (n = 3 for each).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-HMGB-1 neutralizing</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-HMGB-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, 100 μg anti-HMGB-1 neutralizing or isotype control antibodies dissolved in 100 μL PBS were intravenously administered via the tail vein 4 h after intratracheal instillation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>isotype control antibodies dissolved in 100 μL PBS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lung tissue sections were stained with anti-phospho-MLKL and anti- GSDMD n-terminal antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-phospho-MLKL</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti- GSDMD</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Male specific-pathogen-free C57/BL6J mice aged 8–10 weeks were used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57/BL6J</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses: Statistical analyses were performed using Prism 9 (GraphPad Software, La Jolla, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has some limitations. First, only patients admitted to a single center were included in the analysis due to the limited availability of clinical samples. Further studies that use samples from multiple centers several countries are warranted. Second, our animal model was created by exposing mice to components of SARS-CoV-2, and not an infectious strain of SARS-CoV-2. Despite this, the observation of a COVID-19- like pathology supports the use of our animal model. Importantly, use of a non- infectious model is convenient for laboratories that do not specialize in infectious disease research. Third, the efficacy of inhibiting a single DAMP, HMGB-1, was evaluated. Several DAMPs are released from necrotic cells; therefore, future studies that investigate whether other DAMP are promising therapeutic targets for COVID-19 are warranted.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.pnas.org www.pnas.org
-
Kuchipudi, S. V., Surendran-Nair, M., Ruden, R. M., Yon, M., Nissly, R. H., Vandegrift, K. J., Nelli, R. K., Li, L., Jayarao, B. M., Maranas, C. D., Levine, N., Willgert, K., Conlan, A. J. K., Olsen, R. J., Davis, J. J., Musser, J. M., Hudson, P. J., & Kapur, V. (2022). Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer. Proceedings of the National Academy of Sciences, 119(6). https://doi.org/10.1073/pnas.2121644119
-
-
www.biorxiv.org www.biorxiv.org
-
Leaf shape among
Reviewer 2. Tim Dickinson.
Review of GIGA-D-16-00069, "Morphometric analysis of Passiflora leaves I: the relationship between landmarks of the vasculature and elliptical Fourier descriptors of the blade" by D.H. Chitwood and W.C. Otoni.
This is a valuable contribution, both in terms of (a) the data collected (leaf outlines and landmarks from a large sample of Passiflora species exhibiting a wide range of leaf shapes), and (b) the well thought out analyses undertaken with care and, for the most part, attention to detail. The paper also showcases, at least for me, the range of tools now available for comparative biologists and others who seek to analyze patterns of morphological variation and ontogenetic change. Until relatively recently it appeared that there was no real replacement for MorphoSys (Meacham, 1993) and the ability of this MS-DOS based system for outline capture and measurement. In many ways there still isn't, leaving workers to pick through an assortment of programs with more limited scopes or (better), to learn to use the imageJ toolbox effectively (Schneider, Rasband, and Eliceiri, 2012). Or SHAPE (Iwata and Ukai, 2002), if only outline data are needed. And in the meantime, adepts from the morphometrics world have embraced R (R Core Team, 2016) as a data analysis and graphics environment, resulting in packages like shapes (Dryden, 2016) and Momocs (Bonhomme et al., 2014). Others (e.g. Jensen, Ciofani, and Miramontes, 2002), myself included, have compared results from different analytical methods based, variously, on landmark and outline data from a common sample of study objects.
The authors' correlation analysis (Fig. 7) is especially valuable (and as far as I know entirely original) for the way it enables the authors to infer connections between particular landmarks (their x or y coordinates) and particular elliptic Fourier coefficients (A, B, C, or D) for a given harmonic. Although they tend to contrast their landmark data as reflecting leaf vasculature features (because these provide the locations of several of their landmarks), as against overall shape features provided by their outline data, the authors also emphasize the complementarity of these two aspects of their study objects (p. 5). In their subsequent ms (GIGA-D-16-00070) the authors are more adroit in emphasizing this complementarity. Here, they occasionally sound as if they think these associations are somehow intrinsic in these data sources, as if the would obtain even in objects other than leaves (pp. 2, 3, 6). It may be that what's at issue here is just unnecessarily bringing forward interpretations of their results (as if they described the results) before those results have been fully presented. I have three concerns about this ms. First, the authors have been variously careless about details of spelling ("fratal," "heteroblatsy") and the agreement between verb and noun ("data" is a plural noun) and somewhat cavalier about explaining terms when first introduced ("eigenleaf"; "amplification factor," in the caption to Fig. 1).
Second, basic details of the authors' sampling are unclear, probably because they are so abundantly obvious to them. What is the actual sample size for their study? They refer (pp. 2, 4, 5, 10) to having analyzed more than 3,300 leaves, and (on p. 5) to making available a dataset comprising "...555 scans of leaves from 40 different species of Passiflora..." Presumably, the data released represent a subset of the total sample, but it would help to make this, and their overall sampling strategy, explicit by tabulating how many vines (with what numbers of leaves) were studied for each of the 40 species. These details are important in order to dispel any idea that their discriminant analyses are overfitted because of the large numbers of descriptors (30, 80, or 110) and binary-valued dummy variables for species and leaf position (39, 10); Gittins 'monograph on canonical analysis (Gittins, 1985) references simulation studies suggesting that upwards of 20 times as many study objects as descriptors (measured, plus those designating groups) are needed in order for an analysis to be anything other than a deterministic description of a particular dataset. One of the exciting aspects of this study is the refreshingly large sample size that appears to have been used.
The third, related, concern is that the way in which leaf position on individual vines was recorded is unclear, given that nothing seems to be said about whether the same number of leaves was produced on all vines of all species during the period during which the study material was grown. Numbering leaves from the youngest leaf at the tip of the shoot, to the base, suggests that the youngest leaf would be numbered 1, the next 2, and so on to N, the most basal leaf on the vine. If the total number of leaves varies from vine to vine then there won't be an exact homology between leaf positions. Figures 5 and 6 suggest that leaf position 1 (basal-most, left-most, respectively) is in fact the most basal leaf. Would this position in fact correspond to the cotyledons, or to the first post-cotyledonary leaf? Clarification would be helpful. I also wonder about the continued reference to "node position" and "heteroblastic node position" as well as, in one case, "shoot position." I suggest that a more transparent usage would be to refer throughout to leaf position (numbered from the most basal leaf), or to the position of a leaf on a shoot. Reference to "heteroblastic node position" seems completely unnecessary, since heteroblasty is an emergent property of some or all of the shoots studied, as seen from the way in which leaves vary over the course of shoot development in shape (or some other property) from the most basal to the most apical.
BONHOMME, V., S. PICQ, C. GAUCHEREL & J. CLAUDE. 2014. Momocs: Outline Analysis Using R. Journal of Statistical Software 56: 1-24. DRYDEN, I. L. 2016. shapes package, version 1.1-13. website: https://www.maths.nottingham.ac.uk/personal/ild/shapes/index.html. GITTINS, R. 1985. Canonical Analysis. Springer-Verlag, Berlin. IWATA, H. & Y. UKAI. 2002. SHAPE: A computer program package for quantitative evaluation of biological shapes based on elliptic Fourier descriptors. Journal of Heredity 93: 384-385. JENSEN, R. J., K. M. CIOFANI & L. C. MIRAMONTES. 2002. Lines, outlines, and landmarks: morphometric analyses of leaves of Acer rubrum, Acer saccharinum (Aceraceae) and their hybrid. Taxon 51: 475-492. MEACHAM, C. A. 1993. MorphoSys An interactive machine vision program for acquisition of morphometric data. In R. Fortuner [ed.], Advances in computer methods for systematic biology: Artificial intelligence, databases, computer vision, 393-402. R CORE TEAM. 2016. R: A language and environment for statistical computing. website: http://www.R-project.org. SCHNEIDER, C. A., W. S. RASBAND & K. W. ELICEIRI. 2012. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9: 671-675.
Re-review; The authors have responded to my comments, and for the most part have satisfied my concerns. In this regard, the copy of the original ms marked up to show the changes the authors have made is extremely helpful. The material on github consists of the data files and R code used to produce the figures, and does not appear provide direct access to the original leaf spectra that would show the variation observed in outline and landmark position. For the publication, I trust that the journal will require that the raw data referenced as "44. Giga DB reference" will consist of a series of files, e.g. one for each species, comprising complete leaf spectra, with the leaves labeled acropetally, i.e. in the heteroblastic sequence from base to tip, for each plant referenced in Figure S1A. If these are provided as vector files (outlines plus landmarks) this data repository should not be excessively large. The vector format will also make it possible for the interested reader to zoom in and out without loss of resolution in order to examine the patterns of variation at different scales.
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.20.477107: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: EXPERIMENTAL MODEL AND SUBJECT DETAILS: Blood, PBMCs and HLA typing: Whole blood from COVID-19 convalescent donors, healthy donors, or vaccine recipients was collected under protocol approved by the UMass Chan Medical School Institutional Review Board of the University of Massachusetts and informed consent was obtained from all subjects.<br>Consent: EXPERIMENTAL MODEL AND SUBJECT DETAILS: Blood, PBMCs and HLA typing: Whole blood from COVID-19 convalescent donors, healthy donors, or vaccine recipients was collected under protocol approved by the UMass Chan Medical School Institutional Review Board of the University of Massachusetts and informed consent was obtained from all subjects.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For blocking of antigen-stimulation assays, in-house produced antibodies to HLA-DR (LB3.1), HLA-DQ (SPVL-3), HLA-DP (B7/21), or HLA-ABC (w6/32), were added at a final concentration of 10 μg/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HLA-DR</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HLA-DP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HLA-ABC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were collected, washed, and stained using a standard protocol which included: staining for dead cells with Live/Dead Fixable Aqua Dead Cell Stain Kit™ (Life Technologies, Thermo Fisher Scientific, Waltham, MA); blocking of Fc receptors with human Ig (Sigma-Aldrich, St. Louis, MO); staining with the mix of DP4-PE and APC tetramers (final concentration of 2-4 μg/mL each) at 37°C for 2 hours; surface staining antibodies CD3-APC-H7, CD4-PerCP-Cy5.5, CD8-APC-R700, CD14-BV510, CD19-BV510, CD56-BV510 were added for the last 20 minutes of incubation, followed by washes and resuspension in buffer for data acquisition.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD19-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD56-BV510</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Partially-match HLA cell lines: EBV-transformed LG2 cell line (10984, IPD-IMGT/HLA), 9068 cell line (BM9, IHWG), and mouse DP4-transfected MN605 cell line (M12C3-DPA1*0103/DPB1*0401; (Williams et al., 2018); kindly provided by Dr. S. Kent, UMMS), were maintained in RPMI 1640 medium supplemented with L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 μg/mL) and 10% FBS at 37°C/5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MN605</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 6 hours incubation, cells were collected, washed, and stained using a standard protocol, which included: staining for dead cells with Live/Dead Fixable Aqua Dead Cell Stain Kit™ (Life Technologies, Thermo Fisher Scientific, Waltham, MA); blocking of Fc receptors with human Ig (Sigma-Aldrich, St. Louis, MO); surface staining with mouse anti-human CD3-APC-H7 (SK7), CD4-PerCPCy5.5 (RPA-T4), CD8-APC-R700 (RPA-T8), CD14-BV510 (MϕP9), CD19-BV510 (SJ25C1), CD56-BV510 (NCAM16.2); fixation and permeabilization using BD Cytofix/Cytoperm™; and intracellular staining with mouse anti-human IFN-γ-V450 (B27), TNF-α-PE-Cy7 (MAb11), IL-2-BV650 (5344.111), (all from BD Biosciences, San Jose, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Cytofix/Cytoperm™</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using a BD LRSII flow cytometer equipped with BD FACSDiva software (BD Biosciences, San Jose, CA) and analyzed using FlowJo v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Polyfunctional analysis was performed in FlowJo, defining Boolean combinatorial gates for all the markers in the CD3+/CD4+/CD8-population.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These results were visualized in SPICE software v6.0 (Roederer et al., 2011). t-SNE analysis was done in concatenated samples (control, SARS-CoV-2, peptide 163 and peptide 164) from 3 donors using the available plugin in FlowJo.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPICE</div><div>suggested: (SPICE, RRID:SCR_016603)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All primers sequences shown in STAR Methods.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These files were processed using MIGEC v1.2.9 pipeline: Checkout-batch for de-multiplexing and UMI tag extraction, Histogram for MIG (molecular identifier groups) statistics, and Assemble-batch to perform UMI-guided assembly (Shugay et al., 2014); followed by MiXCR v3.0.13: analyze amplicon pipeline, to align, assemble and export clonotypes (Bolotin et al., 2015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MIGEC</div><div>suggested: (migec, RRID:SCR_016337)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HLA-peptide binding prediction was performed with NetMHCIIpan v4.0 server (Reynisson et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NetMHCIIpan</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are several limitations of our study. We mapped the specificity of the cross-reactive response by following IFN-γ-secreting cells, but non-IFN-γ-secreting populations could also contribute to the response. In expanded T cell lines we observed higher frequencies of T cells staining with DP4-163/164 tetramer than responding to the same peptide in IFN-γ ELISPot essays, indicating that some T cells can recognize the epitope but not secrete IFN-γ. We observed the cross-reactive T cell response to involve mostly CD4+ T cells. This might be due to in vitro culture conditions that favor CD4+ over CD8+ T cell populations, or an intrinsic bias of cross-reactive T cells because of the different patterns of pMHC-TCR interaction for MHC-I and MHC-II proteins. We studied a relatively small group of 27 individuals exposed to SARS-CoV-2 antigens by infection or vaccination, mostly over 40 years of age. Younger individuals with more frequent previous exposures to HCoVs might show a different pattern of response. Our initial screen for immunodominant epitopes involved only three donors, all of whom recognized 163/164, but other immudominant cross-reactive epitopes might have escaped our attention, including those recognized by other MHC proteins. For all of the donors, previous HCoV infection was inferred but not observed, and we did not attempt to determine which donors were exposed previously to which of the HCoVs. In conclusion, we identified a pan-coronavirus epitope that dominates t...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 32 and 36. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.17.475291: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2-Fc and Antibodies: The sequence of ACE2-Fc the same as the sequence of mACE2-Ig [2] (catalytic activity reduced variant) was synthesized and cloned into pcDNA3.4 to express in ExpiCHO™ Expression System (ThermoFisher).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-Fc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, after washing and blocking, S1 protein (Sino Biological) biotin-labeled using EZ-Link™ Sulfo-NHS-LC-LC-Biotin (ThermoFisher) was mixed with 50 μg/mL competitor antibodies before adding into the coated plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sulfo-NHS-LC-LC-Biotin</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, lentivirus bearing ACE2 gene was transduced to 293T cells to attain ACE2-293T cell pool, which was subsequently sorted out the 1% highest ACE2 expression cells with FACS Aria III instrument (BD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>ACE2-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 48 h post-transfection, culture supernatants were collected and filtered through 0.22 μ m filter into fresh BHK21 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK21</div><div>suggested: ATCC Cat# CRL-6282, RRID:CVCL_1914)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">If typical cytopathic effect (CPE) was observed 2 - 3 days after VSV infection, BHK-21 cells were transfected with pCAGGS-VSV-G plasmid to assist in creating passage 1 (P1), supernatants were collected and viruses were plaque-purified in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21</div><div>suggested: ATCC Cat# CRL-6281, RRID:CVCL_1914)</div></div><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The VL and VH sequences of antibodies were synthesized and cloned into pcDNA3.4 to express in ExpiCHO™ Expression System.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: RRID:Addgene_131198)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This plasmid together with psPAX2 and pLVX-Luc2 were transfected into 293T cells using Lipofectamine 3000 Reagent (ThermoFisher) according to the manufacture’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>pLVX-Luc2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The package plasmids of escape mutants from literatures were constructed by site-directed mutagenesis based on pMD2.G encoding WT spike.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2.G</div><div>suggested: RRID:Addgene_12259)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Recovery of Replication-Competent VSV-SARS-CoV-2-S: Briefly, co-transfection of VSV constructs (pVSVΔMT-ΔG-SpikeΔ21) with helper plasmids, pBS-N, P, L and G, was performed into BHK21 cells infected with a recombinant vaccinia virus (vTF7-3) expressing T7 RNA polymerase.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pVSVΔMT-ΔG-SpikeΔ21</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pBS-N</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">If typical cytopathic effect (CPE) was observed 2 - 3 days after VSV infection, BHK-21 cells were transfected with pCAGGS-VSV-G plasmid to assist in creating passage 1 (P1), supernatants were collected and viruses were plaque-purified in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-VSV-G</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 were determined by four-parameter nonlinear regression using GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Escape Mutants Data Analysis: Escape mutants data were downloaded from COG-UK Mutation Explorer (COG-UK-ME).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Mutation Explorer</div><div>suggested: None</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, there is a limitation that the neutralization ability of ACE2-Fc was not efficient enough. APN01, a recombinant human ACE2 drug, has failed to show significant protection in COVID-19 patients in a phase II clinical trial (NCT04335136), probably because of its lack of Fc fusion to enhance pharmacokinetics and low affinity with RBD [28,29]. So it is necessary to engineer the ACE2 decoy receptors to improve their affinity with RBD in the meantime maintaining their broad neutralization spectrum. In previous studies, scientists have mutated and screened out ACE2 decoy receptors with higher affinity with RBD, which were evaluated by co-incubation with authentic SARS-CoV-2 and observed no emergence of escape variants [9]. In other work, S19W, T27W and N330Y mutations were included in ACE2 to enhance its affinity with RBD and demonstrate neutralization against antibody-resistant viruses [11]. Scientists also used molecular dynamics simulation to predict and design ACE2 decoy with T27Y/H34A mutations and confirmed its enhanced affinity against both WT and mutated RBD [30]. Structure-based approaches were used to engineer ACE2, resulting in enhanced neutralization against authentic SARS-CoV-2 [7]. Other investigators demonstrated that an engineered decoy receptor broadly binds spike variants in spike mutant libraries with saturation mutagenesis of RBD [10]. So these engineered ACE2 decoy receptors are promising partners for SARS-CoV-2 neutralizing antibodies and whether their ...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04335136</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) a…</td></tr></table>
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
psyarxiv.com psyarxiv.com
-
Budak, C., Soroka, S., Singh, L., Bailey, M., Bode, L., Chawla, N., Davis-Kean, P., Choudhury, M. D., Veaux, R. D., Hahn, U., Jensen, B., Ladd, J., Mneimneh, Z., Pasek, J., Raghunathan, T., Ryan, R., Smith, N. A., Stohr, K., & Traugott, M. (2021). Modeling Considerations for Quantitative Social Science Research Using Social Media Data. PsyArXiv. https://doi.org/10.31234/osf.io/3e2ux
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.19.476998: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Following sera binding and neutralization analysis, two mice were selected for hybridoma fusion and received two final boosts consisting of 50-100 μg of the RBD protein at - 5 and -2 days before being euthanized by IACUC approved methods with spleens harvested and a final bleeding collected for sera analysis (“fusion sera”).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Biodistribution Study: Female CD-1-IGS (strain code #022) were obtained from Charles River at 6-8 weeks of age.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Binding was detected using an anti-rat IgG-APC detection antibody and samples were run on a high-throughput flow cytometer (Intellicyte High Throughput Flow Cytometer [Intellicyte Corp., Albuquerque, NM].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rat IgG-APC</div><div>suggested: (SouthernBiotech Cat# 0108-11, RRID:AB_2793937)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For antibody binding to the cells expressing the Spike proteins, the cells were dispensed into wells of a 96-well V bottom plate (40 µL per well), and an equal volume of 2x final concentration of serially-diluted anti-S1 antibody solution was added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of bound antibody was carried out by staining the cells with 50 µL of 1:500 diluted APC AffiniPure F(ab’)₂ Fragment (Goat Anti-Human IgG (H+L).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, pseudotyped VSV was incubated with anti-spike (concentration as indicated) and anti-VSV-G (1 µg/mL) antibodies for 30 minutes at room temperature and added to the HEK-Blue 293 hACE2-TMPRSS2 cells in triplicate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-VSV-G (1 µg/mL)</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-30138, RRID:AB_1961360)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-human fragment crystallizable region (Fc region) antibody was immobilized on a CM5 sensor chip to approximately 8,000 resonance units (RU) using standard N-hydroxysuccinimide/N-Ethyl-N′-(3- dimethylaminopropyl) carbodiimide hydrochloride (NHS/EDC) coupling methodology.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-human fragment crystallizable region (Fc region)</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For neutralization, VsV-SARS-spike GFP-expressing reporter virus was pre-incubated with mouse sera (1:100-1,200), hybridoma supernatants (1:10-1:10,000), or purified human monoclonal antibodies (0.1 ng/ml-1 μg/ml) and incubated at 4 °C for 1 hr before the inoculum was added to HEK-293 cells expressing human ACE2 and Transmembrane Serine Protease-2 overnight at 37 °C, 5% CO2 27.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells were transfected using FuGeneHD transfection reagent according to manufacturer’s protocol (Promega, Cat # E2311).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BHK21/WI-2 cells (Kerafast #EH1011) were maintained in DMEM (Thermo Fisher #11965092) supplemented with 5% fetal bovine serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293-ACE2 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 200 µg/mL G418 (Invivogen #ant-gn-2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293-ACE2</div><div>suggested: RRID:CVCL_DR94)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lambda: G75V, T76I, R246N, Δ247-253, L452Q, F490S, D614G, and T859N. B.1.1.318: T95I, ΔY144, E484K, D614G, P681H, and D796H. Mu: T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, and D950N. Omicron: A67V, del69-70, T95I, G142D, del143-145, N211D, del212, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T457K, D614G, H665Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F VSV-Spike pseudotype generation: To generate each Spike pseudotyped VSV, 1.2E6 BHK21 cells were nucleofected with 2 µg of Spike plasmid using an Amaxa Nucleofector II with cell line kit L (Lonza #VCA-1005) and program A-031.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK21</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">medium was removed, and serial dilution of homogenized lungs were added to Vero cells and subsequently incubated for 1 h at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture media was removed from cells and sera/virus premix was added to VeroE6 cells at 100 μL/well and incubated for 1 h at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunizations were done on eight-to twelve-week-old H2L2 mice interperitoneally with 50-100 μg of a recombinant SARS-CoV2 Spike RBD319-591-Fc fusion protein generated from sequence from the original Wuhan seafood market pneumonia virus isolate (GenBank Accession# MN908947) and cloned in-frame into pcDNA vectors containing human IgG1 and mouse IgG2a Fc tags (GenScript USA Inc., Piscataway, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>H2L2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pharmacokinetic Study: Female CD-1-IGS (strain code #022) were obtained from Charles River Laboratories at 6-8 weeks of age.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD-1-IGS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">khACE2 mouse model of COVID-19 infection: K18-hACE2 transgenic mice were purchased from Jackson laboratory and maintained in pathogen-free conditions and handling conforms to the requirements of the National Institutes of Health and the Scripps Research Institute Animal Research Committee.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunizations were done on eight-to twelve-week-old H2L2 mice interperitoneally with 50-100 μg of a recombinant SARS-CoV2 Spike RBD319-591-Fc fusion protein generated from sequence from the original Wuhan seafood market pneumonia virus isolate (GenBank Accession# MN908947) and cloned in-frame into pcDNA vectors containing human IgG1 and mouse IgG2a Fc tags (GenScript USA Inc., Piscataway, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA</div><div>suggested: RRID:Addgene_66792)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Unique clones were chosen from each clonal family, and DNA was synthesized and cloned in-framed into pcDNA-based vectors containing a human IgG1 constant region and a human kappa light chain constant region (GenScript USA Inc., Piscataway, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA-based</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids: All SARS-CoV-2 Spike constructs for pseudotype generation were expressed from plasmid pCDNA3.1 (ThermoFisher #V79020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells with a high mean fluorescence intensity (MFI) were identified using FlowJo software (Tree Star, Inc.) and graphed using GraphPad Prism to create a heat map based on mean fluorescence intensity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Purified PCR product was then submitted for Sanger sequencing using 3’ constant gene primers (GeneWiz, South Plainfield, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GeneWiz</div><div>suggested: (GENEWIZ, RRID:SCR_003177)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pharmacokinetic analysis of the collected ELISA data was performed with the Phoenix WiNnonlin suite of software (version 6.4, Certara) using a non-compartmental approach consistent with an IN-bolus route of administration.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phoenix</div><div>suggested: (Phoenix, RRID:SCR_003163)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
nixos.org nixos.org
-
Specifying dependencies
Annotations prehonor Just now Public
L C, [2022/1/24 下午3:57] [ 图片 ]
L C, [2022/1/24 下午3:57] A dependency is said to be propagated when some of its other-transitive (non-immediate) downstream dependencies also need it as an immediate dependency. [3]
这里的 "依赖的传递性" 具体怎么理解呀?
L C, [2022/1/24 下午3:59] 就是, 如果 a 依赖 b , c , 然后 b 也依赖 c , 这时候说 a 依赖 c 是 propagated 的?
dram🎀, [2022/1/24 下午3:59] a 依赖 b,b propagated 依赖 c,那么 a 把 b 作为依赖的时候也会把 c 拉进来
L C, [2022/1/24 下午4:00] [回复 dram🎀] soga, 这个有点类似运行时依赖
L C, [2022/1/24 下午4:02] [回复 dram🎀] 我感觉这句话不好理解主要是 downstream 这个词的意思拿不准 🤣
L C, [2022/1/24 下午4:05] 还有, 这个表我看不懂咋办 🙈
dram🎀, [2022/1/24 下午4:05] [回复 L C] ?
dram🎀, [2022/1/24 下午4:05] 怎么说呢
dram🎀, [2022/1/24 下午4:06] 比如 git 依赖 openssh
𝚅𝚒𝚝𝚊𝚕𝚢𝚁, [2022/1/24 下午4:06] [回复 Harry Ying] tectonic的路线是把xetex逐步氧化
dram🎀, [2022/1/24 下午4:06] 你把 git 加到 nativeBuildInputs 里
𝚅𝚒𝚝𝚊𝚕𝚢𝚁, [2022/1/24 下午4:06] 它自己就是latex引擎
dram🎀, [2022/1/24 下午4:06] [回复 dram🎀] 然后 git 会跑到你构建环境的 path 里但是 ssh 不会被加到 path 里
dram🎀, [2022/1/24 下午4:07] 但是如果 git 是 propagatedBuildInputs 有 openssh
dram🎀, [2022/1/24 下午4:07] [回复 dram🎀] 那你这样的话 ssh 也会被加到 path 里
L C, [2022/1/24 下午4:07] 好像有点懂了
L C, [2022/1/24 下午4:07] It is important to note that dependencies are not necessarily propagated as the same sort of dependency that they were before, but rather as the corresponding sort so that the platform rules still line up. To determine the exact rules for dependency propagation, we start by assigning to each dependency a couple of ternary numbers
L C, [2022/1/24 下午4:08] "so that the platform rules still line up" , 这是啥意思? "line up"
L C, [2022/1/24 下午4:10] [回复 L C] 这个表里的 build ,host, target 是啥?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:11] 就是platform
L C, [2022/1/24 下午4:13] 可不可以认为是: 每个依赖是一条有向边, 比如 a -> b , 然后我们是在这条边上赋予了一个属性 (上文说的 ternary number), 这个属性的取值是 build ,host, target 三者之一?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:14] 是个offset
Nick Cao | 想吃狐狐, [2022/1/24 下午4:14] offset to current derivation's host platform
L C, [2022/1/24 下午4:15] we start by assigning to each dependency a couple of ternary numbers (-1 for build, 0 for host, and 1 for target), representing how respectively its host and target platforms are “offset” from the depending derivation’s platforms.
所以我还是这句没看懂 😭
Nick Cao | 想吃狐狐, [2022/1/24 下午4:15] 你现在理解为啥是a couple
Nick Cao | 想吃狐狐, [2022/1/24 下午4:15] 不是triple了吗 !/usr/bin/env cat, [2022/1/24 下午4:15]
整几张图看比较好 !/usr/bin/env cat, [2022/1/24 下午4:15]
看 nix 这些洋洋洒洒半篇章 !/usr/bin/env cat, [2022/1/24 下午4:16]
还是弄不明白
L C, [2022/1/24 下午4:16] assigning to each dependency a couple of ternary numbers (-1 for build, 0 for host, and 1 for target)
意思是, 每个依赖是一条有向边, 然后每条边上, 赋予一个 (TernaryNumber, TernaryNumber) 属性?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:16] [回复 L C] 这个是说
Nick Cao | 想吃狐狐, [2022/1/24 下午4:16] depsXY
Nick Cao | 想吃狐狐, [2022/1/24 下午4:16] (X, Y) -> (0, 1)
Nick Cao | 想吃狐狐, [2022/1/24 下午4:16] 这种
Mika Akizuki 秋月🏳️⚧️, [2022/1/24 下午4:17] [回复 𝚅𝚒𝚝𝚊𝚕𝚢𝚁] 氧……化?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:17] [回复 Mika Akizuki 秋月🏳️⚧️] riir
Mika Akizuki 秋月🏳️⚧️, [2022/1/24 下午4:17] [回复 Nick Cao | 想吃狐狐] 呃,不懂
Mika Akizuki 秋月🏳️⚧️, [2022/1/24 下午4:18] 啊,看懂了
Xosdy 🐕, [2022/1/24 下午4:18] rewrite it in rust !/usr/bin/env cat, [2022/1/24 下午4:18]
用 Rust 重新实现
Mika Akizuki 秋月🏳️⚧️, [2022/1/24 下午4:18] rust -> Fe2O3 -> Oxidize
Mika Akizuki 秋月🏳️⚧️, [2022/1/24 下午4:18] 是这样吗?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:18] 是
L C, [2022/1/24 下午4:20] [回复 Nick Cao | 想吃狐狐] 意思是, 每个依赖是一条有向边, 然后每条边上, 赋予一个 (TernaryNumber, TernaryNumber) 属性?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:21] [回复 L C] 对
Nick Cao | 想吃狐狐, [2022/1/24 下午4:21] 你不要纠结这个啊
Nick Cao | 想吃狐狐, [2022/1/24 下午4:21] 你想想这个数字是干嘛用的
L C, [2022/1/24 下午4:22] -1 for build, 0 for host, and 1 for target
L C, [2022/1/24 下午4:22] 这个没懂
Nick Cao | 想吃狐狐, [2022/1/24 下午4:23] depsBuildBuild -> (-1, -1)
Nick Cao | 想吃狐狐, [2022/1/24 下午4:23] depsHostTarget -> (0, 1)
L C, [2022/1/24 下午4:24] 为什么这个 pair 的 fst 一定 小于或等于 snd 呢?
Nick Cao | 想吃狐狐, [2022/1/24 下午4:25] 你想一个需要大于的使用场景呢
L C, [2022/1/24 下午4:25] 主要我不知道它的意思,,,, (所以自然不知道为什么有这种约束
Nick Cao | 想吃狐狐, [2022/1/24 下午4:26] 其实这里的问题是
Nick Cao | 想吃狐狐, [2022/1/24 下午4:26] build host target这三个词
Nick Cao | 想吃狐狐, [2022/1/24 下午4:26] 被用作两种不同的意思
Nick Cao | 想吃狐狐, [2022/1/24 下午4:26] 所以不好理解
Nick Cao | 想吃狐狐, [2022/1/24 下午4:26] 首先是对于一个特定的derivation来说
Nick Cao | 想吃狐狐, [2022/1/24 下午4:27] 他有自己的drv->build,drv->host,drv->target
Nick Cao | 想吃狐狐, [2022/1/24 下午4:27] [回复 L C] 也就是这表里面的第一行
L C, [2022/1/24 下午4:27] [回复 Nick Cao | 想吃狐狐] 这个没懂
Nick Cao | 想吃狐狐, [2022/1/24 下午4:27] 就是比如你有一个gcc
Nick Cao | 想吃狐狐, [2022/1/24 下午4:28] 他是在x86上面编译出来的
Nick Cao | 想吃狐狐, [2022/1/24 下午4:28] 能跑在aarch64上
Nick Cao | 想吃狐狐, [2022/1/24 下午4:28] 支持编译出riscv64的代码
Nick Cao | 想吃狐狐, [2022/1/24 下午4:28] 那 gcc->build 就是 x86
Nick Cao | 想吃狐狐, [2022/1/24 下午4:28] gcc->host 就是 aarch64
Nick Cao | 想吃狐狐, [2022/1/24 下午4:29] gcc->target 就是 riscv64
Nick Cao | 想吃狐狐, [2022/1/24 下午4:29] 所以说是对于gcc这个derivation而言的
Nick Cao | 想吃狐狐, [2022/1/24 下午4:29] 三个platform
L C, [2022/1/24 下午4:29] ok
Nick Cao | 想吃狐狐, [2022/1/24 下午4:29] 好那这里有三个platform
Nick Cao | 想吃狐狐, [2022/1/24 下午4:29] 我们注意到
Nick Cao | 想吃狐狐, [2022/1/24 下午4:30] gcc->build其实是不关键的
Nick Cao | 想吃狐狐, [2022/1/24 下午4:30] 如果我们已经编译好了这个gcc
Nick Cao | 想吃狐狐, [2022/1/24 下午4:30] 那它不管被如何使用
Nick Cao | 想吃狐狐, [2022/1/24 下午4:30] 都不会被这个build platform影响
L C, [2022/1/24 下午4:30] 对的
Nick Cao | 想吃狐狐, [2022/1/24 下午4:30] 所以关键是host和target
Nick Cao | 想吃狐狐, [2022/1/24 下午4:31] [回复 Nick Cao | 想吃狐狐] 那这个使用
Nick Cao | 想吃狐狐, [2022/1/24 下午4:31] 其实在这里就是指被作为依赖
Nick Cao | 想吃狐狐, [2022/1/24 下午4:31] 那我们将这个gcc作为依赖
Nick Cao | 想吃狐狐, [2022/1/24 下午4:31] 去编译一个hello
Nick Cao | 想吃狐狐, [2022/1/24 下午4:31] 对于这个hello而言
Nick Cao | 想吃狐狐, [2022/1/24 下午4:31] 他也有三个platform吧
L C, [2022/1/24 下午4:31] 这就是是你说的 "为啥是a couple 不是triple"
Nick Cao | 想吃狐狐, [2022/1/24 下午4:32] [回复 L C] 对
Nick Cao | 想吃狐狐, [2022/1/24 下午4:32] [回复 Nick Cao | 想吃狐狐] 同时又因为他还没有被build出来
Nick Cao | 想吃狐狐, [2022/1/24 下午4:32] 所以它的build platform是不可以忽视的
Nick Cao | 想吃狐狐, [2022/1/24 下午4:32] 现在为了这个hello
Nick Cao | 想吃狐狐, [2022/1/24 下午4:32] 我们需要找一个合适的gcc
Nick Cao | 想吃狐狐, [2022/1/24 下午4:33] 第一个要求
Nick Cao | 想吃狐狐, [2022/1/24 下午4:33] 这个gcc需要能在hello->build上跑
Nick Cao | 想吃狐狐, [2022/1/24 下午4:33] 第二个要求
Nick Cao | 想吃狐狐, [2022/1/24 下午4:33] gcc产生的代码
nicball, [2022/1/24 下午5:00] nix💊里写过propagated(其实是造了一个贫民版stdenv(唠叨
nicball, [2022/1/24 下午5:00] (但是没讲platform
Nick Cao | 想吃狐狐, [2022/1/24 下午5:00] 这个应该写在交叉编译导论里 prehonor Public
Annotations can be freely reused by anyone for any purpose.
-
-
www.biorxiv.org www.biorxiv.org
-
Author Response:
Reviewer #1 (Public Review):
The paper clearly indicates that by using parallel fMRI and ECoG experiments, the authors are able to detail the hierarchy of predictive coding in the cortical and higher subcortical areas of the auditory pathway. The methodology is well detailed and I didn't spot any major concerns.
The scientific methodology detailed in this paper appears to be sound. Further, the main conclusions appear to be well argued.
We thank the reviewer for the positive comments.
The statistical analysis, however, is not reported clearly in the main text. For instance, I'm unsure how multiple comparison correction was addressed. A more detailed primer on the statistical methods used in the results section is warranted.
In the fMRI analysis, to assess the novelty responses as a function of the different number of sequence types, we performed a within-subject one-way ANOVA design in SPM, where the single-session contrast images corresponding to trial types were introduced as within-subject factor. To directly compare the responses of different novelties, we defined each type of contrast using the pair-wise t-test. We initially observed the results with a threshold of uncorrected p < 0.001 at the voxel level, and then considered the results as significant at p < 0.05 with false discovery rate (FDR) corrected for multiple comparisons across the brain (Cacciaglia et al., 2019; Uhrig et al., 2014). If no voxel survived FDR correction, then a threshold of uncorrected p < 0.001 was used. In the ECoG analysis, we performed the independent-sample t-test for each comparison in TFRs. The multiple comparison problem originates from the fact that ECoG data are multidimensional. For ECoG data from a single electrode, the signals are sampled at multiple frequencies and multiple time points. Therefore, we used a nonparametric cluster-based permutation test for multiple comparisons over frequency and time (Chao et al., 2018; El Karoui et al., 2015). To report the statistical analysis more clearly, we have added the details about statistical methods of fMRI and ECoG analyses, and multiple comparison correction, in the results of the main text. Please see the section of 1 st -level (local) novelty (xY sequences).
My largest concerns are to do with communication, and language overreach. At one point the term "lower auditory pathways" is used, but the lowest portion investigated in this study is the IC, and this usage was in reference to the thalamus. There's a lot of brain between the IC and cochlea, to say nothing of the thalamus. There are also concerns about both the temporal and spatial resolution of fMRI and ECoG - the text at times implies that the resolution for these techniques is far greater than it is. However, these are communication issues that should be easily addressed.
We are grateful for the reviewer’s suggestions. The temporal and spatial terms we used in the last version were based on our paradigm and recording methods. With 9.4 T fMRI, the lowest area of the auditory pathway that we can assess is the midbrain. Thus, we limited the observed range of the auditory pathway from midbrain to frontal cortex (as shown in Figure 1C). In the design of our paradigm, the local auditory information focus on the millisecond timescale, and the global auditory information refer to the second timescale. Therefore, we defined the temporal range from millisecond to second. However, we have realized that the temporal and spatial terms we used were not rigorous and may cause ambiguity. Throughout the revised manuscript, we have rewritten them as lower- and higher-level areas, shorter- and longer-time scales.
Reviewer #2 (Public Review):
In this study, Jiang et al. combined whole-brain 9.4 T functional magnetic resonance imaging and large-scale electrocorticography to study brain wide activation patterns in response to different pattern violations in marmosets. The authors confirm previous results of a cortical hierarchy for auditory predictive processing and expand on these results by quantifying subcortical responses in MGB and IC as well as using omission to confirm previous results obtained with mismatches. The results highlight the existence of the two levels of auditory prediction signals in the marmoset brain that can be interpreted in a hierarchical predictive processing framework.
The paradigm used to assess the hierarchical depth of predictive auditory sequences for processing predictions errors and prediction updates at two distinct timescales is well designed, and presumably based on one of the authors earlier studies (Chao et al., 2018). Unfortunately, the current study fails to highlight the novelty of this work (as far as we can tell, mainly the omission responses) and give adequate credit to previous work on the topic. However, this can be easily fixed by rephrasing the relevant passages of the manuscript.
We thank the reviewer for the positive comments. We have now revised the Results and Discussion to provide more details about the omission responses and discuss the contribution and novelty of omission sequences in the hierarchical predictive coding. Please also see the reply to Q1 of the Main concerns.
Main concerns:
1) It would be good to clarify what the novelty of the present manuscript is (omission responses) in comparison to the previous work (Chao et al., (2018)). The authors do argue that their higher resolution fMRI, allows them to also study subcortical response - which is correct - but the authors make no use of them in any meaningful way in the manuscript. The emphasis on novelty is likely better placed on the omission responses.
We thank the reviewer for the constructive suggestion. In the revised Discussion, in comparison to the previous work (Chao et al., 2018), we have specifically emphasized the novelties of the present study.
-First, the model described the 1st - and 2nd - levels of violations (prediction and error) in the present study is novel and more straightforward. Instead of using the partial- or full-global predictions in the Chao et al. model, which is challenging to interpret, we first introduce the sequences with xx and xY as separate internal templates. Similarly, as we mentioned in the discussion, although the local-global paradigm has been intensively studied in humans and macaque monkeys (Chao et al., 2018; Uhrig et al., 2014; Wacongne et al., 2011), most studies tested the global violation by combining xx|xY and xY|xx novelties, which, in fact, contain two different types of predictions. Our study is the first to separate the two novelties and search for their neural representations, respectively. This is important because xx|xY novelty was only involved in the 2nd-level signal with the xY sequence as the internal sequence template, and the xY|xx novelty was involved in both 1st - and 2nd -level signals (the 1st-level novelty triggers the 2nd-level novelty), where the xx sequence was the internal template (see Discussion).
-Second, this is the first study to construct the hierarchy of predictive auditory sequences in the marmoset brain using fMRI. Our results extended the hierarchical organization of predictive coding from the cortex to the subcortical regions. To emphasize the importance of this animal model, we have added a section of Marmosets as an animal model for auditory sequences in the Discussion.
-Third, most importantly, as suggested by the referee, the omission responses is indeed novel. To highlight it, we have expanded the results of omission and provided more discussion of its contribution to the hierarchical predictive coding.
2) Figure 3C (and all similar figures). We fear this figure is not interpretable without a substantially improved explanation. Both what the arrows mean (i.e. how they are computed), and what the values indicate that are listed next to the arrows is not explained (arrows appear randomly bi- or unidirectional and the legend at the bottom of the figure is not very helpful).
We apologize for the missing details in Figure 3C. The color dots in the brain diagrams indicate the electrodes with significant responses found in corresponding comparisons, which were subsequently used in the functional correlation test (see Materials and Methods). Lines represent significant functional correlations between signals from the paired brain diagrams. Labeled values close to lines provide the Pearson correlation coefficient (p-value) of the corresponding correlations. Unidirectional arrows indicate relative temporal orders at which the signals appear, while bidirectional arrows indicate uncertain temporal orders of the signals. Figure 3D, 5C and D, Figure 3-figure supplement 1C and D, Figure 5-figure supplement 1C and D have the same format as Figure 3C. Accordingly, we have revised the legend of Figures 3C and D, 5C and D and added more explanations in the Results.
References:
Cacciaglia, R., Costa-Faidella, J., Zarnowiec, K., Grimm, S., & Escera, C. (2019, Feb 1). Auditory predictions shape the neural responses to stimulus repetition and sensory change. Neuroimage, 186, 200-210. https://doi.org/10.1016/j.neuroimage.2018.11.007
Chao, Z. C., Takaura, K., Wang, L., Fujii, N., & Dehaene, S. (2018, Dec 5). Large-Scale Cortical Networks for Hierarchical Prediction and Prediction Error in the Primate Brain. Neuron, 100(5), 1252-1266.e1253. https://doi.org/10.1016/j.neuron.2018.10.004
El Karoui, I., King, J. R., Sitt, J., Meyniel, F., Van Gaal, S., Hasboun, D., Adam, C., Navarro, V., Baulac, M., Dehaene, S., Cohen, L., & Naccache, L. (2015, Nov). Event-Related Potential, Timefrequency, and Functional Connectivity Facets of Local and Global Auditory Novelty Processing: An Intracranial Study in Humans. Cereb Cortex, 25(11), 4203-4212. https://doi.org/10.1093/cercor/bhu143
Uhrig, L., Dehaene, S., & Jarraya, B. (2014, Jan 22). A hierarchy of responses to auditory regularities in the macaque brain. J Neurosci, 34(4), 1127-1132. https://doi.org/10.1523/jneurosci.3165- 13.2014
Wacongne, C., Labyt, E., van Wassenhove, V., Bekinschtein, T., Naccache, L., & Dehaene, S. (2011, Dec 20). Evidence for a hierarchy of predictions and prediction errors in human cortex. Proc Natl Acad Sci U S A, 108(51), 20754-20759. https://doi.org/10.1073/pnas.1117807108
-
-
www.biorxiv.org www.biorxiv.org
-
Now published in GigaScience doi: 10.1093/gigascience/giaa051 Amanda Warr 1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteNabeel Affara 2Department of Pathology, University of Cambridge, Cambridge CB2 1QP, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteBronwen Aken 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteH. Beiki 4Department of Animal Science, Iowa State University, Ames, Iowa, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteDerek M. Bickhart 5Dairy Forage Research Center, USDA-ARS, Madison, Wisconsin, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteKonstantinos Billis 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteWilliam Chow 6Wellcome Sanger Institute, Cambridge, CB10 1SA, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteLel Eory 1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteHeather A. Finlayson 1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this sitePaul Flicek 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteCarlos G. Girón 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteDarren K. Griffin 7School of Biosciences, University of Kent, Canterbury CT2 7AF, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteRichard Hall 8Pacific Biosciences, Menlo Park, California, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteGreg Hannum 9Denovium Inc., San Diego, California, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteThibaut Hourlier 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteKerstin Howe 6Wellcome Sanger Institute, Cambridge, CB10 1SA, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteDavid A. Hume 1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteOsagie Izuogu 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteKristi Kim 8Pacific Biosciences, Menlo Park, California, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteSergey Koren 10Genome Informatics Section, Computational and Statistical Genomics Branch, National Human Genome Research Institute, Bethesda, Maryland, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteHaibou Liu 4Department of Animal Science, Iowa State University, Ames, Iowa, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteNancy Manchanda 11Bioinformatics and Computational Biology Program, Iowa State University, Ames, Iowa, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteFergal J. Martin 3European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteDan J. Nonneman 12USDA-ARS U.S. Meat Animal Research Center, Clay Center, Nebraska 68933, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteRebecca E. O’Connor 7School of Biosciences, University of Kent, Canterbury CT2 7AF, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteAdam M. Phillippy 10Genome Informatics Section, Computational and Statistical Genomics Branch, National Human Genome Research Institute, Bethesda, Maryland, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteGary A. Rohrer 12USDA-ARS U.S. Meat Animal Research Center, Clay Center, Nebraska 68933, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteBenjamin D. Rosen 13Animal Genomics and Improvement Laboratory, USDA-ARS, Beltsville, Maryland, U.S.AFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteLaurie A. Rund 14Department of Animal Sciences, University of Illinois, Urbana, Illinois, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteCarole A. Sargent 2Department of Pathology, University of Cambridge, Cambridge CB2 1QP, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteLawrence B. Schook 14Department of Animal Sciences, University of Illinois, Urbana, Illinois, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteSteven G. Schroeder 13Animal Genomics and Improvement Laboratory, USDA-ARS, Beltsville, Maryland, U.S.AFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteAriel S. Schwartz 9Denovium Inc., San Diego, California, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteBen M. Skinner 2Department of Pathology, University of Cambridge, Cambridge CB2 1QP, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteRichard Talbot 15Edinburgh Genomics, University of Edinburgh, Edinburgh EH9 3FL, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteElizabeth Tseng 8Pacific Biosciences, Menlo Park, California, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteChristopher K. Tuggle 4Department of Animal Science, Iowa State University, Ames, Iowa, U.S.A.11Bioinformatics and Computational Biology Program, Iowa State University, Ames, Iowa, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteMick Watson 1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteFor correspondence: alan.archibald@roslin.ed.ac.uk tim.smith@ARS.USDA.GOV mick.watson@roslin.ed.ac.ukTimothy P. L. Smith 12USDA-ARS U.S. Meat Animal Research Center, Clay Center, Nebraska 68933, U.S.A.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteFor correspondence: alan.archibald@roslin.ed.ac.uk tim.smith@ARS.USDA.GOV mick.watson@roslin.ed.ac.ukAlan L. Archibald 1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, U.K.Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Alan L. ArchibaldFor correspondence: alan.archibald@roslin.ed.ac.uk tim.smith@ARS.USDA.GOV mick.watson@roslin.ed.ac.uk
A version of this preprint has been published in the Open Access journal GigaScience (see paper https://doi.org/10.1093/gigascience/giaa051 ), where the paper and peer reviews are published openly under a CC-BY 4.0 license.
These peer reviews were as follows:
Reviewer 1: http://dx.doi.org/10.5524/REVIEW.102287 Reviewer 2: http://dx.doi.org/10.5524/REVIEW.102288
-
-
www.biorxiv.org www.biorxiv.org
-
Now published in GigaScience doi: 10.1093/gigascience/giaa044 Benjamin B. Chu 1Department of Computational Medicine, UCLA, Los Angeles, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Benjamin B. ChuKevin L. Keys 2Department of Medicine, University of California, San Francisco, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Kevin L. KeysChristopher A. German 3Department of Biostatistics, Fielding School of Public Health at UCLA, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteHua Zhou 3Department of Biostatistics, Fielding School of Public Health at UCLA, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Hua ZhouJin J. Zhou 4Division of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ 85724, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteEric Sobel 1Department of Computational Medicine, UCLA, Los Angeles, USA5Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteJanet S. Sinsheimer 1Department of Computational Medicine, UCLA, Los Angeles, USA5Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Janet S. SinsheimerFor correspondence: jsinshei@ucla.eduKenneth Lange 1Department of Computational Medicine, UCLA, Los Angeles, USA5Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Kenneth LangeFor correspondence: klange@ucla.edu
A version of this preprint has been published in the Open Access journal GigaScience (see paper https://doi.org/10.1093/gigascience/giaa044 ), where the paper and peer reviews are published openly under a CC-BY 4.0 license.
These peer reviews were as follows:
Reviewer 1: http://dx.doi.org/10.5524/REVIEW.102262 Reviewer 2: http://dx.doi.org/10.5524/REVIEW.102263
-
-
www.biorxiv.org www.biorxiv.org
-
Now published in GigaScience doi: 10.1093/gigascience/giaa050 Annarita Marrano 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteFor correspondence: amarrano@ucdavis.eduMonica Britton 2Bioinformatics Core Facility, Genome Center, University of California Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this sitePaulo A. Zaini 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteAleksey V. Zimin 3Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteRachael E. Workman 3Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteDaniela Puiu 4Center for Computational Biology, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21205, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteLuca Bianco 5Research and Innovation Center, Department of Genomics and Biology of Fruit Crops, Fondazione E Mach, San Michele all’ Adige (TN) 38010, ItalyFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Luca BiancoErica Adele Di Pierro 5Research and Innovation Center, Department of Genomics and Biology of Fruit Crops, Fondazione E Mach, San Michele all’ Adige (TN) 38010, ItalyFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteBrian J. Allen 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteSandeep Chakraborty 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteMichela Troggio 5Research and Innovation Center, Department of Genomics and Biology of Fruit Crops, Fondazione E Mach, San Michele all’ Adige (TN) 38010, ItalyFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteCharles A. Leslie 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteWinston Timp 3Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteORCID record for Winston TimpAbhaya Dandekar 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteSteven L. Salzberg 3Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USA4Center for Computational Biology, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21205, USA6Departments of Computer Science and Biostatistics, Johns Hopkins University, Baltimore, MD 21218Find this author on Google ScholarFind this author on PubMedSearch for this author on this siteDavid B. Neale 1Department of Plant Sciences, University of California, Davis, CA 95616, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this site
A version of this preprint has been published in the Open Access journal GigaScience (see paper https://doi.org/10.1093/gigascience/giaa050 ), where the paper and peer reviews are published openly under a CC-BY 4.0 license.
These peer reviews were as follows:
Reviewer 1: http://dx.doi.org/10.5524/REVIEW.102235 Reviewer 2: http://dx.doi.org/10.5524/REVIEW.102236
-
-
Local file Local file
-
1.2 Binomial distribution
$$ \begin{aligned} X & \sim f_{b}(x ; n, p) \\ \operatorname{Pr}(X=k) &=\left\{\begin{array}{lll} \left(\begin{array}{l} n \\ k \end{array}\right) p^{k}(1-p)^{n-k} & \forall & k \in\{0, \ldots, n\} \\ 0 & \forall & k \notin\{0, \ldots, n\} \end{array}\right. \end{aligned} $$
where $$\left(\begin{array}{l}n \ k\end{array}\right)=\frac{n !}{k !(n-k) !}$$ and with $$\mathrm{E}[X]=n p$$ and $$\operatorname{var}(X)=n p(1-p) $$ The Bernoulli distribution is a binomial distribution with $$n=1$$.
-
-
www.biorxiv.org www.biorxiv.org
-
Now published in GigaScience doi: 10.1093/gigascience/giz030 Matthew A. Conte 1Department of Biology, University of Maryland, College Park, MD 20742, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteRajesh Joshi 2Centre for Integrative Genetics (CIGENE), Department of Animal and Aquacultural Sciences, Faculty of Biosciences, Norwegian University of Life Sciences, Ås, NorwayFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteEmily C. Moore 3Department of Biological Sciences and W. M. Keck Center for Behavioral Biology, North Carolina State University, Raleigh, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteSri Pratima Nandamuri 1Department of Biology, University of Maryland, College Park, MD 20742, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteWilliam J. Gammerdinger 1Department of Biology, University of Maryland, College Park, MD 20742, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteReade B. Roberts 3Department of Biological Sciences and W. M. Keck Center for Behavioral Biology, North Carolina State University, Raleigh, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteKaren L. Carleton 1Department of Biology, University of Maryland, College Park, MD 20742, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteSigbjørn Lien 2Centre for Integrative Genetics (CIGENE), Department of Animal and Aquacultural Sciences, Faculty of Biosciences, Norwegian University of Life Sciences, Ås, NorwayFind this author on Google ScholarFind this author on PubMedSearch for this author on this siteThomas D. Kocher 1Department of Biology, University of Maryland, College Park, MD 20742, USAFind this author on Google ScholarFind this author on PubMedSearch for this author on this site
A version of this preprint has been published in the Open Access journal GigaScience (see paper https://doi.org/10.1093/gigascience/giz030 ), where the paper and peer reviews are published openly under a CC-BY 4.0 license.
These peer reviews were as follows:
Reviewer 1: http://dx.doi.org/10.5524/REVIEW.101604 Reviewer 2: http://dx.doi.org/10.5524/REVIEW.101605
-
-
figshare.com figshare.com
-
2017-11-19 22:25:14;;;isa@alphabet.com Adam Marshall Dobrin;;;... and they will see his face, and his name will be on their foreheads ... rev 22;4;;;79;;;8550;;;11152 2017-11-22 07:03:13;;;a@alphabet.com CANDLEMAS DADIVAN;;;Queso er ahh? and... and... and... whare's the Pi-wer?;;;80;;;4465;;;5755 2017-11-22 23:20:52;;;rigel@amhaga.ga ROCK OF SEGA;;;"Words" from the Creator of Earth, proof and purpose encoded into (all) our languages.;;;81;;;13336;;;18902 2017-11-23 19:41:37;;;rigel@alphabet.com Adam Marshall Dobrin;;;DA ... LET IT BE TEQUILA?;;;82;;;3032;;;4170 2017-11-26 18:34:03;;;northword@reseacsheisme.cf MECARUS LETTERSON;;;http://IStheOME.GA ... is Earth Picasso's ear?;;;83;;;18807;;;25180 2017-11-28 18:22:46;;;adam@reseacsheisme.ga cl'ADAM;;;Friends, Romans, Family... lend me your ears and I will turn our Earth to the heart of Heaven.;;;84;;;3487;;;5900 2017-11-30 09:03:34;;;left@laslanet.ga MECARI "RIG EL WOW?!" WRITONSKY;;;Hocus Focus; OPTOME to ONCOL... timestamp Nov 29 2017 23:41:15;;;85;;;6703;;;9639 2017-12-01 15:47:52;;;arealjcl@countable.us ADAM MARCHALK DOBRIN;;;THE DAY THE MATRIX STOOD STILL. I MEAN STOPPED GLITCHING.... AND NOVEMBER RAIN, THE OLD MAN, HE'S AWAKE...;;;86;;;8090;;;13115 2017-12-02 18:27:03;;;amd@reseacsheisme.cf LITTLE BOY BLUE;;;CAN I HAVE YOUR AT TEN T I O N PLEASE? IR MAX ... "ON MINNOWS AND HAMSTERS.";;;87;;;8962;;;12463 2017-12-03 17:48:36;;;ELIBEARTHANKU@EFF.ORG RED ARK TIC Y AN;;;THE DAY BEFORE YESTERDAM.;;;88;;;7668;;;10486 2017-12-03 19:45:55;;;arealjcl@countable.us.me C Si AM LE D SEE UCLA;;;YOU'RE MAUI ARE HERE TO CHANGE THE WORLD.. AT TEN NOIT.;;;89;;;56;;;78 2017-12-04 05:49:50;;;man.chow.na@nanana.nananana.heyzeus.tweet.me ADAM AN2PEVADER;;;DR. A$THOR Y. R. PEND
2017-11-19 22:25:14;;;isa@alphabet.com Adam Marshall Dobrin;;;... and they will see his face, and his name will be on their foreheads ... rev 22;4;;;79;;;8550;;;11152 2017-11-22 07:03:13;;;a@alphabet.com CANDLEMAS DADIVAN;;;Queso er ahh? and... and... and... whare's the Pi-wer?;;;80;;;4465;;;5755 2017-11-22 23:20:52;;;rigel@amhaga.ga ROCK OF SEGA;;;"Words" from the Creator of Earth, proof and purpose encoded into (all) our languages.;;;81;;;13336;;;18902 2017-11-23 19:41:37;;;rigel@alphabet.com Adam Marshall Dobrin;;;DA ... LET IT BE TEQUILA?;;;82;;;3032;;;4170 2017-11-26 18:34:03;;;northword@reseacsheisme.cf MECARUS LETTERSON;;;http://IStheOME.GA ... is Earth Picasso's ear?;;;83;;;18807;;;25180 2017-11-28 18:22:46;;;adam@reseacsheisme.ga cl'ADAM;;;Friends, Romans, Family... lend me your ears and I will turn our Earth to the heart of Heaven.;;;84;;;3487;;;5900 2017-11-30 09:03:34;;;left@laslanet.ga MECARI "RIG EL WOW?!" WRITONSKY;;;Hocus Focus; OPTOME to ONCOL... timestamp Nov 29 2017 23:41:15;;;85;;;6703;;;9639 2017-12-01 15:47:52;;;arealjcl@countable.us ADAM MARCHALK DOBRIN;;;THE DAY THE MATRIX STOOD STILL. I MEAN STOPPED GLITCHING.... AND NOVEMBER RAIN, THE OLD MAN, HE'S AWAKE...;;;86;;;8090;;;13115 2017-12-02 18:27:03;;;amd@reseacsheisme.cf LITTLE BOY BLUE;;;CAN I HAVE YOUR AT TEN T I O N PLEASE? IR MAX ... "ON MINNOWS AND HAMSTERS.";;;87;;;8962;;;12463 2017-12-03 17:48:36;;;ELIBEARTHANKU@EFF.ORG RED ARK TIC Y AN;;;THE DAY BEFORE YESTERDAM.;;;88;;;7668;;;10486 2017-12-03 19:45:55;;;arealjcl@countable.us.me C Si AM LE D SEE UCLA;;;YOU'RE MAUI ARE HERE TO CHANGE THE WORLD.. AT TEN NOIT.;;;89;;;56;;;78 2017-12-04 05:49:50;;;man.chow.na@nanana.nananana.heyzeus.tweet.me ADAM AN2PEVADER;;;DR. A$THOR Y. R. PENDRIPPY AT YOUR SERVIC;;;90;;;21392;;;29480 2017-12-05 00:03:22;;;arealjcl@countable.us LET ELIBEARTHANKU@EFF.ORG RING;;;G;;;91;;;1032;;;1511 2017-12-05 17:32:23;;;prevader@caltech.edu PROVOST;;;RED: Y on D;;;92;;;24;;;36 2017-12-06 11:31:30;;;gilate@september2016.com LITTLE BOY CrYAN;;;hashemesh: holy name fire.;;;93;;;3091;;;5208 2017-12-07 15:32:28;;;ancsa2kin@china.jim.and.ha.yon.is.me ADAM MAR S H ALL DOBRIN;;;Approaching the Day of the Immaculate Conception of Mary.. Happy Birthday, dear Adam.;;;94;;;1388;;;2632 2017-12-07 20:18:40;;;SPANKHERLIPS@abRIGHTflaSH.GQ;;;MACK MY ZELDA! DIS EARLY, USIMS. ;;;95;;;8061;;;12207 2017-12-08 15:01:56;;;adam5@reallyhim.com HEAVEN'S COLGATE;;;ISKAREEOUAC'S SEA, USANG DREIDEL?;;;96;;;5508;;;7784 2017-12-09 00:14:59;;;upstairs@sunsentinel.com UPS SRI IT EL RV AN CH TE;;;NOW;;;97;;;15092;;;22856 2017-12-10 03:06:22;;;upstairs@sunsentinel.com UPS SRI IT EL RV AN CH TE;;;UPS SRI. Per Ezekiel, Keflex alone wasn't good enough for Camelot ... s/cancer/kungfu, and give us all sight of David's goddess of Dawn.;;;98;;;3717;;;6032 2017-12-10 18:24:25;;;who@atho.cf ADAMAS EL YO, N!;;;S p o o n.;;;99;;;4305;;;6789 2017-12-10 19:05:50;;;itwins@adw.org AD IS EL "YO, N!";;;EX OR CIZE THE NOLIST;;;100;;;16818;;;19321 2017-12-12 06:32:38;;;anbam@d.arkho.me JOAN D' ADAM;;;Mazer Rakham's run.;;;101;;;13947;;;17353 2017-12-12 14:22:16;;;float@d.arkho.us JEAN LUC D'ADAM;;;Any questions?;;;102;;;108;;;160 2017-12-12 22:12:58;;;siiamez@intel.com YggDRasiROD? 1. SILVER 2. GIGI 3. U;;;ON THE FAM CHAN THIS MORN, ZORO ASTER BRUCE WAYNE; AND WISHING UPON ENDER WILGAMESH.;;;103;;;11368;;;16284 2017-12-13 14:34:32;;;tapestry@wowascii.GQ R GQ FH MC AD IF ER RA NA SI AG;;;BLOBACK;;;104;;;4715;;;6617 2017-12-13 21:29:26;;;adt@clisbed.arkho.me ADAM CSHAYSi DO B? K, B. ;;;In the beginning God said... "blow on it" ;;;;105;;;15755;;;21859 2017-12-14 16:03:00;;;risk@natiweb.com HA CROSSING OF THE C's .. are wett?;;;AT THE GREAT WALTERNATI-ON... LETS PLAY ROCK, CASPER, and "the ward" to DRAW OU? HO, ANDER! ## ISPENDEX;;;106;;;7500;;;9666 2017-12-14 21:57:44;;;theadam@bbonear.com THIS SEA WILL PART;;;Re: AT THE GREAT WALTERNATI-ON... LETS PLAY ROCK, CASPER, and "the ward" to DRAW OU? HO, ANDER! ## ISPENDEX;;;107;;;4397;;;6321 2017-12-15 05:01:04;;;theadam@aaa.org AB, RA, and HA;;;xeROX thAT, HOuston.;;;108;;;604;;;854 2017-12-15 16:17:59;;;meis@arkho.me STICKS AND STONE. HAS WORD, HAM, AND DICK ;;;ON BEHLKF OF THE GENERATOR MASCHIACH ## ((WISDOMINAD));;;109;;;10198;;;13470 2017-12-17 00:06:23;;;rigel@xerox.com AMDentonite!!!;;;Rigel, and the gate.;;;110;;;3874;;;6484 2017-12-17 14:48:38;;;alephb4u@aftertheome.ga;;;Fwd: walking on water;;;111;;;2312;;;3394 2017-12-17 15:18:25;;;adam@happ.us DA Y;;;Re: walking on water;;;112;;;1744;;;3291 2017-12-17 15:53:26;;;piller@microsoft.com EL PILKER OF HÆÆL SHA-1 AES ;;;Re: fwd: walking on water;;;113;;;679;;;806 2017-12-17 20:52:52;;;itsexisit@clisdabed.arkho.us TR IN IT Y I NEED AN AS... DEUTERON OH MY CIRCKE;;;Hello, Eos. To help you decode "topics" for discussion, "EULA" means End User Licensing Agreement.;;;114;;;7520;;;11159 2017-12-18 04:08:17;;;zomg@veradna.cn HA'SHEKHINAD;;;I ' M C A K L I N G H E R S H I C I T Y O Pl Æ;;;115;;;3118;;;4795 2017-12-18 19:35:33;;;arealjcl@countable.us ADAM DEEMEMBERK DOBRIN ;;;Chapter 22: MYLIFE.md;;;116;;;4270;;;6245 2017-12-20 16:09:47;;;gipilate.setibex@oferaxxel.cf HAS'DAM SEA'OAT HA'ARETZ;;;there's a (c) reasen (ation) for the seesan & "an"'s search for po$itive energy.;;;117;;;14497;;;18384 2017-12-21 06:43:38;;;proof@rigetheft.cf !!!!@@@PROOF#$*&@! you are now enlightened by this eggdrop;;;"I don't need no proof, I look at my daughter and I believe." -Heaven, by Live;;;118;;;7494;;;10002 2017-12-21 18:54:14;;;ha@xeROX.com HOSEA HORUS ET HOMER;;;Does the sign say "mi lazy" or "I'm only one Perun" ... ? ## /etc/init.d/postfix restart;;;119;;;16001;;;21282 2017-12-24 08:49:08;;;intelk@amd.com ADAM VENTING;;;GREETINGS SEASONING!!! TAKE ME TO YOUR APPETIZERS?;;;120;;;18112;;;23182 2017-12-24 22:40:49;;;red@xerox.com knees buckled, he dove into the red sea searching for a sickel and it parted;;;#Confuseus say if you are in a cave surrounded by monsters, and you try to blend in the next innocent will be that much more frightened. TS 2/24/2017AD 1441 PST;;;121;;;1709;;;2195 2017-12-25 15:14:37;;;noletson@magdalane.rm;;;there is a first time for everything.;;;122;;;169;;;243 2017-12-25 21:04:54;;;eyecaramd@pyreic.cf BYU KNOX OURA NO_BR@ WO/HAMU PLASTER;;;#Confuseus say "Kansas crawls on thinking #stycks to cross the #frostbitex over the abyss; and #stones make waves and turn tides" butt if you do not act now, you've lost "Internet";;;123;;;5784;;;8257 2017-12-27 17:39:03;;;wario@nintendo.com ADCASINO PETROVERCAL;;;VIETNAM IS EVERY TOWN, TONNES NORTH BY NINTENDO.;;;124;;;10257;;;13897 2017-12-28 05:01:28;;;ad2a@dork.cum.la.la.la;;;abra ... see a.d. "a" with dork magick.... "ho ho ho";;;125;;;1804;;;2461 2017-12-28 15:01:34;;;uxi@arm.y.la SAINT HUXLEY;;;WHO KISS THE Y?;;;126;;;1050;;;1301 2017-12-28 22:04:42;;;thegreatdiv@iad.illiad.windows.me HONESTLY THO? WHAT DID YOU WANT?;;;there is no place to go, there is no place to go, there is no place to go... and to ra: "toe";;;127;;;17019;;;23497 2017-12-29 16:18:56;;;high.coupie@seaga.me SHORT (FUSE'd) AD ON E;;;Oh, Canada? Yes we can, "eh";;;129;;;13354;;;18189 2017-12-30 20:09:09;;;ckimush@seussville.com DOB OTA CHR NOC WER RIN;;;Presence, presents... and CLIMAX.;;;130;;;9247;;;13618 2018-01-01 03:52:35;;;adam@genius.com BROVARD ET ET URADEN;;;TADAI.;;;131;;;12018;;;18941 2018-01-06 23:30:42;;;rear@apparinessir.ml ha, "r: ear";;;AN on "Why do I keep seeing this dick?";;;132;;;16486;;;20140 2018-01-07 17:21:19;;;vertical@apparinessir.ga LAUDERAKE ADSORELEASY;;;op·si·math: a person who begins to learn or study only late in life.;;;133;;;8148;;;11621 2018-01-09 03:07:27;;;m@tearshapedr.ga CLOROX THAT, LOST AT SALT SEA;;;I looked inside your heart shaped box.;;;134;;;7515;;;9847 2018-01-11 00:57:08;;;adam@amhori.cf HO THROWS ROX, ZING;;; AKE ... con... naked? Conscience, I said "sea of n.... science?";;;135;;;17913;;;22124 2018-01-12 16:17:45;;;oheo@oheresho.ml xeROX thAT HOuston "a problem";;;TENNESSEE | MINNESOTA | NINTENDO | MICROSOFT;;;136;;;8099;;;10065 2018-01-13 20:32:16;;;rwaoh@oheresho.ml Noshisuach to the Hyperisees;;;The real Dryad Pirate Roberts is actually left handed.;;;137;;;10483;;;14957 2018-01-14 15:47:11;;;melize@appearansays.cf ME-L GEE (whiz), I BE SON?;;;Not to point out the obvious... but "FOREVER YOUNG?" I mean... "!";;;138;;;318;;;555 2018-01-15 04:32:22;;;waypaper@northeastby1.cf rockkng the... C as P AH;;;B IN KY ... and The Coven's ant.;;;139;;;12878;;;17333 2018-01-17 02:44:36;;;nasex@northbynes.cf S 2 N x NE Stronger than stone;;;Get ready for the Frank Rothstein show ... "Ace is high!";;;140;;;18232;;;23368 2018-01-19 05:24:52;;;guacamole@nxnes.ga HEY TAY, MELUX?;;;"Now I am become Osiris, the re-animator of cartoons" -K. Borat Appenweiner;;;141;;;7672;;;11176 2018-01-25 06:34:36;;;yitsheyzeus.ser@onin.twitter.com Why it's "Hey, Suez!!";;;You have what you need.;;;142;;;3639;;;5605 2018-01-26 01:03:17;;;drome@m-w.com DOCTOR OWE ME;;;I am a blinking, flashing square... what am I?;;;143;;;12498;;;19611 2018-01-27 08:59:46;;;adam@xerox.com Copy that, USA -- you da m :);;;Reddit? I really need you tonight... forever's gonna start, tonight.;;;144;;;7782;;;11118 2018-01-27 18:21:59;;;slick@marorbystand.cf Seriously, you are gazing at "IT";;;Splashing around.;;;145;;;9793;;;15323 2018-02-01 02:05:30;;;theoa@crashoverride.ga THE OA;;;Per se us, you're shield?;;;146;;;11479;;;17691 2018-02-03 19:08:35;;;rsq@dozeldapink.ga Ding... Ace's High.;;;I call it a serenade. Dancing with Medusa; last of the Godorgones.;;;147;;;19842;;;25113 2018-02-09 18:51:16;;;cleineik@gozelda.ml TRIBEKA of URKEL;;;ding... dong... #CLANG!;;;150;;;10806;;;17144 2018-02-10 05:28:11;;;narloladonavy@gozelda.cf MAXx THE DOGg;;;Anions craftily pairing with cats, and in formation ... a vorkable solution.;;;152;;;8051;;;12123 2018-02-11 04:09:28;;;laboraty@gozeldarath.cf RE: P TO EARTH, NORH ;;;Verifiable proof we live in The Matrix, woven through it a map to building Heaven of it.. and of an insane global conspiracy to hide this proof that literally is in every word.;;;153;;;12922;;;18639 2018-02-12 18:34:02;;;IVRANI@dozeldapink.cf ADAM, the ONE and ONLI...;;;Monday "art" ... when Jesus tells Heave
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.19.476898: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The Medical Ethical Committee of the Erasmus MC Rotterdam granted permission for this study (METC 2012-512)</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cell lines were tested negative for mycoplasma.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, cells were incubated in FACS buffer (2mM EDTA, 2.5% bovine serum albumin (BSA) in PBS) on ice for 5 min, stained with the AT2 marker antibody HTII-280 (1:40; Terrace Biotech) on ice for 15 min, and with goat anti-mouse IgM Alexa Fluor 488 (1:400; Invitrogen) for 5 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AT2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgM</div><div>suggested: (Bethyl Cat# A90-140P, RRID:AB_10630983)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were incubated with primary antibodies overnight at 4°C in blocking buffer, washed twice with PBS, incubated with corresponding secondary antibodies (Alexa488- and 594-conjugated anti-rabbit IgG, anti-mouse IgG, or anti-mouse IgG1 (1:500; Invitrogen)) in blocking buffer for 2 hours at room temperature, washed two times with PBS, incubated with indicated additional stains (hoechst or phalloidin), washed twice with PBS, and mounted in Prolong Antifade mounting medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Antifade mounting medium .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike was stained using mouse-anti-SARS-CoV-2 S2 (1:1000, Genetex), SARS-CoV-2 nucleoprotein was stained using rabbit-anti-SARS-CoV NP (1:1000, Sino Biological) and VSV nucleoprotein was stained using mouse-anti-VSV-N (1:1000, Absolute Antibody).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>NP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>mouse-anti-VSV-N</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Material and Methods: Cell lines: Vero and VeroE6 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS), HEPES (20 mM, Lonza), sodium pyruvate (1 mM, Gibco), penicillin (100 IU/mL), and streptomycin (100 IU/mL) at 37°C in a humidified CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">TMPRSS2, GFP11 and GFP1-10 stable cells were maintained in a medium containing hygromycin (Invitrogen), puromycin (Invivogen) and geneticin (Invitrogen), respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GFP1-10</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine the 8-hour infectious titer, virus stocks were thawed and diluted in 10-fold serial dilution in 200μl Opti-MEM I (1X) + GlutaMAX. 100μl of each dilution was added to monolayers of 1 × 105 VeroE6, VeroE6-TMPRSS2 or Calu-3 cells in a 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">30 μl of each dilution was transferred to 2 × 104 VeroE6 and VeroE6-TMPRSS2 cell monolayers or 8 × 104 Calu-3 cell monolayers in the same medium in a 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transfected HEK-293T cells were transferred in three technical replicates to GFP1-10 expressing VeroE6, VeroE6-TMPRSS2 and Calu-3 cell monolayers in a ratio of 1:80 (HEK-293T cells : GFP1-10 expressing cells).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pGAGGS-Omicron expression plasmid was kindly provided by Dr. Berend Jan Bosch.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGAGGS-Omicron</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pGAGGS-β-Actin-P2A-7xGFP11-BFP plasmid was cloned into pQCXIP and used for retrovirus production and subsequent generation of the GFP11 stable cells as previously described by Mykytyn et al. (42).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGAGGS-β-Actin-P2A-7xGFP11-BFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pQCXIP</div><div>suggested: RRID:Addgene_15714)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 1.5 μg pGAGGS-spike DNA and pGAGGS-β-Actin-P2A-7xGFP11-BFP DNA or empty vector DNA were transfected into HEK-293T cells with PEI (Polysciences) in a ratio of 1:3 (DNA: PEI)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pGAGGS-spike</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To assess the effect of camostat mesylate (Sigma) and E64D (MedChemExpress) on viral replication, 2D cultures were pretreated in the basal and apical compartment for 1 hour with 10μM of either compound or the combination of both, or DMSO in the negative control Submerged 2D monolayers of VeroE6 and Calu-3 cells were washed in 300 μl PBS and subsequent infection was performed in AdDF +++ medium. 3D AT2 cultures were incubated with TrypLE Express for 5 minutes at room temperature and washed three times with 5 ml AdDF+++ medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AdDF</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All confocal imaging was performed on a LSM700 confocal microscope using ZEN software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ZEN</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Read 2 was aligned to the CRCh38 human RefSeq transcriptome, with the addition of SARS-CoV-2 (Ref-SKU: 026V-03883; MW947280) genomes, using BWA using standard settings (67).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BWA</div><div>suggested: (BWA, RRID:SCR_010910)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential expression analysis were performed using the DESeq2 package(68).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was stitched, uploaded, shared and annotated using Omero (annotated using Omero) and PathViewer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Omero</div><div>suggested: (OMERO, RRID:SCR_002629)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed using the ImageQuant TL 8.2 image analysis software (GE Healthcare) by calculating the sum of all GFP+ pixels per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageQuant</div><div>suggested: (ImageQuant, RRID:SCR_014246)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analysis was performed with the GraphPad Prism 9 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
Author Response:
Reviewer #1 (Public Review):
The investigators' goals were to describe the epidemiology and kinetics of post-acute covid lung sequalae and to determine the risk factors predictive of persistent lung impairment. A major strength of the study is the longitudinal observation through 6 months with protocolized clinical assessments that included patient-reported outcomes, lung function tests, inflammatory marker testing, and computed tomography of the chest, in a reasonably sized cohort that reflects the spectrum of disease severity in the pre-vaccination era. We learn a great deal about the different patterns of recovery in this group of COVID-19 survivors. The primary epidemiologic finding is that 52% of survivors continued to have symptoms at 6 months, while up to 72% of those with severe COVID requiring ICU level care continued to have lung abnormalities by chest imaging. This confirms general observations of "long covid" which also encompasses non-lung effects. While lung disease is less common in those with milder disease, the proportion of patients who were never hospitalized but experienced persistent symptoms is striking (50%), with lung function impairment in 17% at 6 months. As expected, the patients who had the most severe disease-those who needed the ICU-had the highest degree of chest imaging abnormalities. The kinetics of recovery is a significant observation: Figure 3 shows that most of the post-acute recovery in structural lung abnormalities occurs in the first 3 months and slows down thereafter, particularly for the hospitalized non-ICU patients. The investigators then embarked on a sophisticated analysis to determine how to predict persistent lung abnormalities (as detected by chest CT) at 6 months. When analyzed individually, among 50 clinical characteristics or lab values, the strongest unfavorable risk factors were elevated IL-6 (an inflammatory cytokine that is the target of tocilizumab) and CRP (c-reactive protein). Other variables that were strongly associated with CT abnormalities included immunosuppressive therapy, ICU stay as well as pre-existing conditions. When machine learning techniques were applied, risk factors that correlated with each other could be grouped together, and the patients could be categorized as low, intermediate, and high risk for delayed pulmonary recovery. As expected, known factors for COVID19 infection (age, male sex, medical comorbidities) and disease severity (need for oxygen therapy, ICU care and antibiotics) were more frequent in the intermediate and high risk groups. These predictive factors at acute COVID and day 60 follow-up mostly held up when tested against part of the cohort that was not used for analysis. Interestingly lung function impairment as measured by pulmonary function tests were only weakly correlated with persistent and severe chest imaging abnormalities.
The novelty of this study lies in taking the epidemiology a step further with a machine learning analysis to determine which clinical characteristics and chest imaging features at the onset of acute COVID-19 are predictive of later persistent disease. One limitation of this study, however, is that it was conducted on patients in the early part of the pandemic, prior to the widespread use of remdesivir and corticosteroids/anti-cytokine therapies, that are now considered standard of care. Based on these findings, we can now hypothesize that current treatments are likely to reduce the impact of long-covid.
We would like to thank the reviewer for careful study of the manuscript and appreciation of our work. We agree, that our longitudinal cohort and its hospitalized, severe COVID-19 subset in particular encompasses the patients, for whom the therapeutic armamentarium was limited and far from the therapeutic options available now. Whether novel anti-viral and anti-inflammatory medication as well as, in case of the vaccinated patients, the immunization status may accelerate the recovery or reduce the pulmonary damage is a matter of current research also in our center. We address this issue in the Discussion section to support a clear interpretation of the data by the interested reader.
Machine learning (artificial intelligence, AI) is now being increasingly used to answer clinical questions on limited cohorts; the application of machine learning in this study contributes to our conceptual understanding of how clinical characteristics and biological factors cluster together to contribute to long-term COVID outcomes. Namely, the profound inflammation that characterizes severe acute COVID-19 pneumonia and poor early outcomes also contributes to chronic lung damage in survivors. In addition, a robust antiviral immune response (as seen with elevated anti-viral antibodies) without elevated systemic inflammatory markers were associated with less severe chest imaging patterns, also supporting the notion that an individual's immune response to the virus is responsible for the trajectory of disease. As noted, a significant proportion of non-hospitalized patients also suffered from chronic lung impairments. Taken together, the impact of prolonged convalescence on the workforce, healthcare, and individual lives should not be underestimated. These results underscore the paramount need for continued public health measures and vaccinations to prevent COVID-19, particularly for the most vulnerable individuals (older, immunocompromised, and with preexisting health problems). These observations provide additional biologic justification for the use of agents directed at reducing lung inflammation early in the course of disease, and potentially at an early post-recovery time point (i.e 2 months). Machine learning algorithms may one day help clinicians decide which patients should be targeted for additional therapies after the acute phase. With further study, implementation of AI to real world medicine may be on the horizon.
We agree with the Reviewer that machine learning algorithms can overcome limitations of ‘canonical’, ordinal and generalized regression methods in the multidimensional setting i. e. when the number of available clinical parameters approaches or exceeds the number of observations/patients. Consequently, machine learning or AI allows for serial screening of medical record data at low cost and supports diagnostic and therapeutic decisions. We discuss those two aspects in the revised manuscript in the context of acute COVID-19 course prediction and long COVID prediction and phenotyping in light of the recent literature [1–4,6].
Reviewer #2 (Public Review):
This is a potentially valuable manuscript which links early markers of inflammation with residual abnormalities on chest CT following SARS-CoV-2 infection. Surprisingly, early surveyed symptoms do not predict long term radiologic outcomes (6 months after infection) while inflammatory markers have stronger predictive value. The cohort is well designed and the selected tools for analysis are appropriate.
We thank the Reviewer for the careful study, critic and appreciation of our work.
While this finding is potentially of high importance for clinical practice, the endpoints are inconsistently defined, and certain components of the machine learning and clustering analyses are difficult to interpret as presented. It is therefore challenging to understand whether the conclusions are justified by the analysis.
We apologize for this unclarity. In the revised manuscript, we precisely define the analysis endpoints (any radiological lung findings at the 6-month follow-up, radiological lung abnormalities with CT score > 5, lung function impairment and persistent symptoms at the 6-month follow-up) of the analysis; see: Introduction and Methods/Study design. We also indicate the numbers of participants reaching those endpoints in Table 3.
Several components of the analysis are confusing and would benefit from further elucidation:
1) The authors do not clearly define "delayed pulmonary recovery". My sense is that they are using several radiologic based definitions rather than their functional definition (defined by FEV1, FEV:FVC & DLCO) of lung function but this is never explicitly stated. Are the functional outcomes and symptomatic recovery considered in any of the analyses other than correlations with radiologic findings in S1?
As described above in our previous response, the prime focus and primary endpoint of the analysis was the presence of radiological lung abnormalities at the 6-month follow-up. Our motivation to focus on radiological endpoints was to focus on the potential development of persistent structural lung abnormalities, fibrosis and interstitial lung disease following COVID-19, as observed in SARS-CoV-1 patients [7,8]. Of note, lung function parameters were only weak correlates of radiological impairment as shown in Figure 3 – figure supplement 1 – 3 and our previous work [27]. This finding is in line with numerous studies in ILD patients which demonstrate a low sensitivity of lung function testing (especially FEV1 and FVC assessment) in patients with early interstitial lung disease (ILD) [10,11]. In addition, we could not exclude a pre-existing, COVID-19-independent impairment of lung function in a subset of the study participants suffering from pulmonary diseases, obesity and/or cardiovascular diseases (Table 1). Thus, lung function parameters only partially reflect COVID-19 mediated lung injury and convalescence.
Nevertheless, we agree, that clinical and functional endpoints are of great interest for the scientific and clinical community. For this reason, we present additional results of univariable risk modeling for long-term (6-month follow-up) symptom persistence and lung function impairment (Figure 5, Appendix 1 – table 2), the results of machine learning modeling for those outcomes (Figure 9, Appendix 1 – table 5) and discuss the findings. We also present the prevalence of such long-term manifestations and lung function impairment in the Low-, Intermediate and High-Risk clusters of the study participants defined by non-CT and non-lung function clinical features (Figure 8).
2) To this end, I was surprised that the functional definition and symptomatic recovery were not used as the primary endpoints. The functional definition and resolution of symptoms seem most important for the recovering patient so seems like the more important outcome. However, in Figures 5-7, it is often not clear whether the functional outcome is being considered at all.
As mentioned above, the focus of the study was the assessment of structural lung impairment following COVID-19 and both, lung function parameters as well as symptom burden moderately correlate with structural lung damage (Figure 3 – figure supplement 1 – 3) – a phenomenon observed previously in SARS-CoV-1 [7,8]. Although the symptom burden and its resolution during follow-up are of major importance for the individual patient during post-acute recovery, these parameters are not a good marker for the potential long-term pulmonary outcome. E.g. younger patients with moderate to severe lung damage may demonstrate only mild pulmonary symptoms during post-acute recovery, but the structural damage may be associated with severe impairment at long-term follow-up due to progression of lung fibrosis or age-related decrease of functional pulmonary capacity [11]. Still, we agree with the reviewer that the follow-up on symptoms and lung function is of interest for the reader and additionally included those outcomes in the univariate and multi-parameter risk modeling. In addition, we present the frequencies of symptom persistence and lung function impairment in the low-, intermediate- and high-risk participant clusters defined solely by non-CT and non-lung function clinical parameters. See previous issue for more details.
3) For the clustering in figure 5, I am uncertain how CT severity score >5 & CT abnormalities cluster separately, when these 2 outcomes appear to logically overlap. Specifically, does the CT abnormalities outcome include patients with the high severity score outcome? In other words, are patients in the "high severity" group a subset of patients with "CT abnormality"? If not a subset, then the CT abnormality should be labeled "non-severe CT abnormality". This could all be clarified by listing the number of patients in each group and showing with a Venn diagram whether there is any overlap.
We apologize for the lacking clarity in this matter. As pointed by the reviewer, the patients with CT abnormalities scores > 5 points were a subset of the participants with any CT abnormalities. The same was true for the GGO-positive subgroup. We agree, that the overlap between the radiological outcomes obscures the message of the clustering and modeling results. To overcome this, we removed the GGO outcome variable from the analyses in the revised manuscript. In the revised manuscript, we clearly differentiate between mild (CT severity score ≤ 5) and moderate-to-severe radiological abnormalities (CT severity score > 5) in feature (Figure 6) and participant clustering (Figure 8). Frequencies of mild and moderate-tosevere CT abnormalities in the study collective stratified by the severity of acute COVID-19 are presented in Figure 3 – figure supplement 3B. Numbers of the study participants with any, mild or moderate-to-severe CT abnormalities at the subsequent follow-up visits are listed in Table 3.
4) For the same reason, figure 4 is hard to interpret. Are CT severity >5 being compared to those with normal CTs only or those with normal or mild / moderate CTs? Please provide more specific definitions of normal, "CT abnormality" and "severe CT abnormality" and provide the number of people in each category and specify the comparator groups in all analyses.
We are sorry for the confusion. In Figure 4 of the initial manuscript, any CT abnormalities, GGO-positivity and abnomalities with CT severity score > 5 were analyzed as separate outcome variables. The baseline was specific for the given explanatory variable, e. g. for the ICU stay this was the mild COVID-19 group or for the elevated IL-6, normal serum IL-6 levels. In the revised manuscript we present the modeling results in an abbreviated form for the 5 strongest co-variates of any CT abnormalities, moderate-to-severe CT abnormalities (CT severity score > 5), persistent symptoms and lung function impairment each (Figures 4 – 5). We indicate the baseline and the n number in the plots. The complete summary of univariable risk modeling with the requested information is provided in Appendix 1 – table 2.
5) Similarly, how can GGO @V3 be used a potential explanatory variable for the outcome CT abnormalities @V3 when these 2 variables are clearly non-independent. Inclusion of highly related and likely correlated variables may throw off the overall conclusions of the clustering analysis.
We agree with the editor and the reviewer that this representation was confusing. For this reason and the reasons described in Response 4, we removed the GGO variable from the revised analysis pipeline and differentiate between mild (CT severity score ≤ 5) and moderate-tosevere (CT severity score > 5) radiological lung abnormalities in modeling and machine learning classification. In addition, we define symptom and participant clusters solely with the non-CT parameters (Figure 6 – 7). To investigate the association of mild and moderate-to-severe CT abnormalities with other non-CT variables (Figure 6, Supplementary Figure S5), the CT features are assigned to the no-CT clusters by a k-NN-based label propagation algorithm, i. e. semi-supervised procedure [12,13,26] employed in our recent paper as well [6].
6) In Figure 6, the criteria for the low, medium, and high-risk subsets are unclear. Is this high risk for persistent functional abnormality, radiologic abnormality, or both? Why were 3 sub populations selected? Was this done subjectively based on the clustering algorithm?
This is an important issue. The study subject clusters were named according to the increasing frequency of any radiological lung abnormalities in the respective cluster (Figure 8A). We stress this more clearly in the revised manuscript. In addition, as suggested by the reviewer above, we show the frequency of functional lung impairment and persistent symptoms in the study participant clusters. There are multiple criteria for choice of the optimal clustering algorithm and the optimal number of clusters. In our cohort, two criteria for the choice of optimal clustering algorithm were applied:
- High fraction of the data set variance ‘explained’ by the cluster assignment (ratio of between-cluster sum-of-squares to the total sum-of-squares, Figure 6 – figure supplement 1A and Figure 7 – figure supplement 1A)
- The relatively highest cluster stability or reproducibility of the clustering structure in 20-fold cross-validation (Figure 6 – figure supplement 1B and Figure 7 – figure supplement 1B) [15] The optimal number of clusters of the study participants based on non-CT study variables was based on the algorithm (SOM + hierarchical clustering algorithm, see Reviewer 2, Issue 4) [17,18], as done usually in the unsupervised or semi-supervised setting. The prime criterion for the optimal cluster number was the bend of the curve of within-cluster sum-of-squares versus cluster number as presented in Figure 7 – figure supplement 1D. In addition, this decision was supported by a visual analysis the SOM node dendrogram (Figure 7 – figure supplement 1E) and the curve of the crossvalidated stability statistic (classification error) vs cluster number (Figure 7 – figure supplement 1F) [15].
7) The accuracy and sensitivity of the machine learning approaches shown in S5 & S6 are somewhat limited. Please comment on why such highly granular data can only provide limited prediction about degree of lung damage post infection. Are there missing data types that might make the algorithm more predictive?
This is an important issue that deserves more discussion in the revised manuscript. Each of the machine learning classifiers presented in the previous and the revised version of the manuscript was extremely sensitive and specific at predicting the outcomes in the training data encompassing the entire cohort (Supplementary Figure S11), as expected. However, their performance was way worse in repeated holdout (previous version) or 20-fold cross-validation (revision, Figure 9) used here as surrogate tools used to check the sensitivity and specificity with ‘unseen’ test data. We believe that there are two prime sources of such suboptimal performance: the size of the training set and the choice of the classifier. To address the first limitation, the following alterations to the analysis pipeline were introduced:
- We do not restrict the analysis to the subset of the CovILD study with the complete set of all variables. Instead, the non-missingness criterion is applied to each outcome variable separately (any CT abnormalities: n = 109, moderate-to-severe abnormalities: n = 109, lung function impairment: n = 111, persistent symptoms: n = 133).
- We altered the internal validation strategy. Instead of the repeated holdout approach applied to the machine learning classification, which strongly limits the size of the training data set, we switched to 20-fold cross-validation both for the cluster algorithms (Figure 6 – figure supplement 1BD and Figure 7 – figure supplement 1BF) [15] and the machine learning models (Figure 9, Appendix 1 – table 5) [19]. To address the second issue, the following changes were introduced:
- We compare the performance of a broader set of classifiers representing different classes of machine learning algorithms provided by the R package caret [19] (tree model: C5.0 [20], bagged tree model: Random Forests [21], support vector machines with radial kernel [22], shallow neural network: nnet [23], and elastic net regression: glmnet [24]) (Figure 9, Appendix 1 – table 4).
- Finally, a model ensemble representing a linear combination of the classifiers presented above developed with the elastic net regression algorithm (Figure 9, Figure 9 – figure supplement 2) and tools provided by caretEnsemble package [25]. Such model displayed better performance at predicting any CT abnormalities and persistent symptoms than single classifiers (Figure 9, Appendix 1 – table 5). Finally, we agree with the Reviewer, that the input variable set, despite its size, was still not complete. We believe that inclusion of other inflammatory markers recorded during acute COVID19 and at the 60-day follow-up may additionally improve the prediction of the radiological abnormalities at the 6-month follow-up visit. Of note, our data set missed important readouts of cellular immunity such as neutrophil levels or neutrophil: lymphocyte ratio (NLR) and blood parameters for the mild COVID-19 subset. We discuss this issue in more detail in the revised Discussion section.
8) The authors state that "the sole application of a lung function measurement at screening for subjects at risk of delayed lung recovery may bear insufficient sensitivity". I am not sure that I agree with this assessment. From the perspective of a patient, full recovery of lung function with limited or no residual symptoms, even in the presence of residual chest CT abnormalities, seems like a favorable outcome. I would suggest either changing this statement or providing citations that associate residual chest CT abnormalities (in the absence of residual functional lung dysfunction) with adverse long-term outcomes. Do the authors hypothesize that persistent radiologic abnormalities may predate organizing pneumonia which will ultimately become symptomatic?
We thank the reviewer for the interesting point of discussion. We agree with the reviewer that the functional status and symptom burden is of major importance for the individual patient in the postacute phase of COVID-19. Still, prioritizing lung function over mild structural lung abnormalities may pose two major problems. First, as previously discussed, lung function testing has a rather low sensitivity to detect early ILD [10,11], is not a good prognostic marker for long-term clinical outcomes and may not correlate well with patients' symptom burden. For instance, a patient with a normal lung function status may still be highly symptomatic (e. g. due to reduced capacity of respiratory muscle function) [7] and/or demonstrate structural lung abnormalities (e.g. it has been shown for various ILD that lung function test such as FVC and FEV1 may be normal even in pronounced disease and lung function testing is not sufficient to rule out ILD [10]). Second, to date, it is not known if persistent structural lung abnormalities following COVID-19 (even when mild) are at risk for progressing at long-term follow-up. Especially, sub-clinical structural changes may behave like incidentally detected interstitial lung abnormalities (ILAs) and develop to symptomatic progressive fibrotic interstial lung disease including IPF [11]. For this reason, we think that further pulmonary follow-up is necessary for patients with structural lung abnormalities due to COVID-19 and a sole focus on lung function is not sufficient to assess pulmonary COVID-19 outcomes [9].
9) The authors note selection bias against ordering CT and perhaps inflammatory markers early during infection as a limitation. I would suggest a sensitivity analysis to understand whether this misclassification will impact the model's predictions.
We now address this issue in a more detailed way. As shown in Figure 1, there was indeed a significant dropout of participants during the study due to missing the longitudinal visits and missingness of the longitudinal variable set. This phenomenon was indeed the most evident for the mild COVID-19 patients, who lost interest at the participation most likely because of subjective complete convalescence. This issue is discussed now as a limitation in the revised manuscript. In the revised manuscript, we investigated highly influential factors for clustering and machine learning classifiers. To determine, which variables played the most important role for the clustering of the study individuals, we applied the explanatory variable ‘noising’ procedure initially described by Breiman for the random forest algorithm [21] and compared the ‘explained’ variance (ratio of between-cluster sum-of-squares to the total sum-of-squares) of the initial clustering structure with the clustering structures generated in the datasets with noised variables. Although this algorithm is not free from shortages such as blindness to tight correlations, it may provide a coarse measure of the variable’s impact on the cluster formation (Figure 7 – figure supplement 2). For three of the machine learning algorithms tested importance statistics were extracted from the models: (1) for the C5.0 algorithm, the percentage of variable usage in the decision tree, (2) for the Random Forests algorithm, the delta of Gini index obtained by variable noising [21] and (3) for the elastic net/glmNet procedure, the absolute values of regression coefficients β [24] (Figure 9 – figure supplement 4 – 7). The technical details are provided in Methods, the cluster and model importance data are discussed in the manuscript text.
References
- Gutmann C, Takov K, Burnap SA, et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun 2021;12. doi:10.1038/S41467-021-23494-1
- Benito-León J, Castillo MD Del, Estirado A, et al. Using Unsupervised Machine Learning to Identify Age- and Sex-Independent Severity Subgroups Among Patients with COVID-19: Observational Longitudinal Study. J Med Internet Res 2021;23. doi:10.2196/25988
- Demichev V, Tober-Lau P, Lemke O, et al. A time-resolved proteomic and prognostic map of COVID-19. Cell Syst 2021;12:780. doi:10.1016/J.CELS.2021.05.005
- Estiri H, Strasser ZH, Brat GA, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med 2021;19. doi:10.1186/S12916-021-02115-0
- Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021;27. doi:10.1038/s41591-021-01292-y
- Sahanic S, Tymoszuk P, Ausserhofer D, et al. Phenotyping of acute and persistent COVID-19 features in the outpatient setting: exploratory analysis of an international cross-sectional online survey. Clin Infect Dis Published Online First: 26 November 2021. doi:10.1093/CID/CIAB978
- Hui DS, Wong KT, Ko FW, et al. The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. Chest 2005;128:2247–61. doi:10.1378/CHEST.128.4.2247
- Ng CK, Chan JWM, Kwan TL, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax 2004;59:889–91. doi:10.1136/THX.2004.023762
- Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respir. Med. 2020;8:839–42. doi:10.1016/S2213-2600(20)30349-0
- Suliman YA, Dobrota R, Huscher D, et al. Pulmonary function tests: High rate of falsenegative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015;67:3256–61. doi:10.1002/ART.39405/ABSTRACT
- Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020;8:726. doi:10.1016/S2213-2600(20)30168-5
- Leng M, Wang J, Cheng J, et al. Adaptive semi-supervised clustering algorithm with label propagation. J Softw Eng 2014;8:14–22. doi:10.3923/JSE.2014.14.22
- Lelis L, Sander J. Semi-supervised density-based clustering. Proc - IEEE Int Conf Data Mining, ICDM 2009;:842–7. doi:10.1109/ICDM.2009.143
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32. doi:10.1016/S0140- 6736(20)32656-8
- Lange T, Roth V, Braun ML, et al. Stability-Based Validation of Clustering Solutions. Neural Comput 2004;16:1299–323. doi:10.1162/089976604773717621
- Hartigan JA, Wong MA. Algorithm AS 136: A K-Means Clustering Algorithm. Appl Stat 1979;28:100. doi:10.2307/2346830
- Kohonen T. Self-Organizing Maps. Berlin, Heidelberg: : Springer Berlin Heidelberg 1995. doi:10.1007/978-3-642-97610-0
- Vesanto J, Alhoniemi E. Clustering of the self-organizing map. IEEE Trans Neural Networks 2000;11:586–600. doi:10.1109/72.846731
- Kuhn M. Building predictive models in R using the caret package. J Stat Softw 2008;28:1–26. doi:10.18637/jss.v028.i05
- Quinlan JR. C4.5: Programs for Machine Learning. San Francisco, CA, USA: : Morgan Kaufmann Publishers Inc. 1993. doi:10.5555/152181
- Breiman L. Random forests. Mach Learn 2001;45:5–32. doi:10.1023/A:1010933404324
- Weston J, Watkins C. Multi-Class Support Vector Machines. 1998.
- Ripley BD. Pattern recognition and neural networks. Cambridge University Press 2014. doi:10.1017/CBO9780511812651
- Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33:1–22. doi:10.18637/jss.v033.i01
- Deane-Mayer ZA, Knowles JE. Ensembles of Caret Models [R package caretEnsemble version 2.0.1]. 2019.https://cran.r-project.org/package=caretEnsemble (accessed 13 Dec 2021).
- Glennan T, Leckie C, Erfani SM. Improved Classification of Known and Unknown Network Traffic Flows Using Semi-supervised Machine Learning. Lect Notes Comput Sci (including Subser Lect Notes Artif Intell Lect Notes Bioinformatics) 2016;9723:493–501. doi:10.1007/978-3-319-40367-0_33
- Sonnweber T, Sahanic S, Pizzini A, et al. Cardiopulmonary recovery after COVID-19 - an observational prospective multi-center trial. Eur Respir J Published Online First: 10 December
- doi:10.1183/13993003.03481-2020
-
-
www.defenseurdesdroits.fr www.defenseurdesdroits.fr
-
I l e s t u r g e n t d e d é pa s s e r l e s l o g i q u e s d e s i l o s. L a s a n t é m e n ta l e d e s e n fa n t s, v é r i ta b l e e n j e u d e s o c i é t é p o u r n o s e n fa n t s a u j o u r d’ h u i c o m m e p o u r l e s a d u lt e s q u ’ i l s s e r o n t d e m a i n , m é r i t e m i e u x q u e d e s a p p r o c h e s f r a g m e n ta i r e s e t u n e a p p r o c h e s t r i c t e m e n t s a n i ta i r e .
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.16.476016: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal model and sample collection: All procedures involving animals and SARS-CoV-2 were approved by the Institutional Animal Care and the Use Committee (# 20232) and Institutional Biosafety Committee (# 10-262) at the University of Alabama at Birmingham (UAB).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Random effects included random intercept only.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Histological analysis: H&E stained trachea and lung slices were blinded and semiquantitatively scored by a board-certified veterinary anatomic pathologist following published criteria54.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Standard IHC process was applied with antigen retrieval by 0.01 M sodium citrate buffer (pH 6), 1:30,000 dilution of anti-acetylated tubulin (cat. # T7451 from Sigma-Aldrich) and 1:500 dilution of goat anti-mouse IgG H&L secondary antibody conjugated with HRP (Abcam ab6789).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-acetylated tubulin</div><div>suggested: (Sigma-Aldrich Cat# T7451, RRID:AB_609894)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Abcam Cat# ab6789, RRID:AB_955439)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, virus was serially diluted and added to confluent Vero E6 cells grown on 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Airway surface liquid (ASL) depth, periciliary layer (PCL) height, cilia beat frequency (CBF), mucociliary transport (MCT) rate, and ciliation coverage (CC) on epithelial surfaces of tracheas were analyzed using ImageJ (NIH, Bethesda, MD) and MATLAB software (MathWorks, Natick, MA)57–60.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">52 The CBF map was generated through a MATLAB script to visualize the location and frequency of active cilia across the epithelial cell surface and the proportion of pixels with active cilia quantified as previously described71.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MATLAB</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Data were analyzed using unpaired t-test, one-way or two-way analysis of variance (ANOVA) followed by recommended Tukey’s or Šídák’s multiple-comparison tests, descriptive statistics, and regression methods (both univariable regression and linear mixed models) in GraphPad Prism 9.2.0 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GraphPad Software, Inc., La Jolla, CA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">), SPSS Statistics (IBM, Armonk, NY), or SAS v9.4 (Cary, NC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 29. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
pyramids.hu pyramids.hu
-
6
A 6-os érték hogyan jön ki?
B = 5, l = 200 cm, akkor nem 1000-nek kellene lennie?
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.13.22268697: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: This study was approved by the Federal University of Santa Catarina Ethics Committee (CAAE:</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Briefly, complementary DNA (cDNA) was synthesized from viral RNA using 50 μM random primers and 200 U/μL Superscript IV reverse transcriptase (ThermoFisher Scientific, Waltham, MA, USA).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, low-quality bases (Q < 25) and Illumina adapters were trimmed (19), and mapped to the human reference genome (hg19 - GCF_000001405.13) to remove contaminants using BWA v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BWA</div><div>suggested: (BWA, RRID:SCR_010910)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1.3 (21) and mpileup function from samtools v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>samtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutations, deletions, and insertions were used to assess the dissimilarity of the genomes using the vegan R package v. 2.5.6 (25) with the Jaccard index method.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>vegan</div><div>suggested: (vegan, RRID:SCR_011950)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The multidimensional scaling (MDS) and the distribution of variants in SC were plotted using the ggplot2 R package v. 3.3.0 (26)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">7.310 (27) with default parameters and were manually curated using AliView v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AliView</div><div>suggested: (AliView, RRID:SCR_002780)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A ML tree was constructed using the alignment, with GTR+F+I as the substitution model predicted by ModelFinder (29), 1,000 bootstrap runs using UFBoot tree optimization (30) and SH-like approximate likelihood ratio test (SH-aLRT) (31), using IQ-TREE v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IQ-TREE</div><div>suggested: (IQ-TREE, RRID:SCR_017254)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike (S) gene sequence polymorphism and protein structure analysis: For structural analysis of S protein of VOC Gamma, 57 presented full-length S protein coverage of VOC Gamma sequenced in this study with 722 retrieved from GISAID (December 3rd, 2021), including the reference sequence (NC_045512.2) were aligned using MAFFT (27).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mutations were highlighted and colored according to observed frequencies and built with PyMOL version 2.3.3 software (35).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.12.22269095: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: COVID MED (NCT04340557) was approved by the Institutional Review Boards of Bassett Medical Center (Cooperstown, NY [April 3, 2020] [#1581969]), Goshen Health (Goshen, IN) and Reid Health (Richmond, IN).<br>Consent: Target recruitment was maximized by daily assessment of positive SARS-CoV-2 swab tests from Bassett’s laboratory in hospitalized patients with review of inclusion/exclusion criteria for all such patients by the study’s enrollment nurse and offering enrollment to all interested in participating after a comprehensive informed consent process (see Supplementary material for Informed Consent Form [ICF]).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Post-consent, patients were randomly assigned by an unblinded enrollment research nurse in a 2:2:2:1 ratio in blocks to one of four groups using a computer-generated randomization schedule provided by the study’s statistician (without stratification): hydroxychloroquine, lopinavir/ritonavir, losartan, or placebo; this ratio was selected because early in the pandemic patients declined participation in trials with low likelihood of receiving ‘active’ drug.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">If crushed drug or drug in solution had to be administered (nasogastric/gastric tube), eye shields were used to maintain blinding.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data from CRFs and AE/SAE reports were entered into REDCap using secure login/password entry; data were deidentified in working documents which were available only to study investigators; all study identifying data will be destroyed/deleted upon publication to allow wider sharing if requested.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Study limitations included single-arm, nonrandomized, open-label design with external historical controls, and between-group imbalance. 34 of 347 screened patients were enrolled (10%). The second, an open-label RCT compared the ARB telmisartan and SOC vs. SOC alone in two hospitalized COVID-19 patients in Argentina up to 4 days post symptoms onset (earlier than our trial) [14]. The primary outcome was CRP at days 5 and 8. In an interim analysis, 40 telmisartan/SOC vs. 38 SOC were compared. Mean CRP was significantly lower in telmisartan/SOC vs. SOC groups at days 5 (24.2 vs. 51.1 mg/L [p<0.05]) and 8 (9.0 vs. 41.6 mg/L [p<0.05]). Median time to discharge was shorter with telmisartan, 9 vs. 15 days (p=0.01) and 30-day mortality trend favored telmisartan (5.26 vs. 11.76%, p=0.41); there were no differences for ICU admission, mechanical ventilation, and a composite of ICU admission, mechanical ventilation, and death; fewer patients receiving telmisartan needed oxygen at day 15 (2/4 vs. 13/14, p<0.05). No telmisartan related AEs occurred and BP was similar. 82 of 185 screened patients were enrolled (56% [higher than our trial]). The third, an open-label RCT compared the ARB losartan and SOC vs. SOC alone in 31 SHARP (San Diego) hospitalized patients with COVID-19 with mild hypoxia (requiring </= 3 L oxygen) [15]. The primary measurement was a composite of mechanical ventilation/death. No significant primary or secondary differences were found: the composite endpoint occurred in 1...</blockquote>
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04340557</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Do Angiotensin Receptor Blockers Mitigate Progression to Acu…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04328012</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">COVID MED Trial - Comparison Of Therapeutics for Hospitalize…</td></tr></table>
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.12.22269133: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study, according to the National COVID-19 procedures, was approved by the Italian Regulatory Agency (AIFA) and by the Ethics Committee of IRCCS L.<br>Consent: A written consent was obtained by the study participant.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Laboratory Procedures: Anti-Spike SARS-CoV-2 antibodies and T-cell response were monitored at 5 time points (Figure 1): the day of first dose administration (T0), the day of second dose administration (T1); between 5 and 7 weeks after T0 for patients receiving Pfizer/BioNTech vaccine and between 6 and 8 weeks after T0 for patients receiving Moderna vaccine (T2); the day of the booster dose (T pre-3D) and 3 or 4 weeks after (T post-3D).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Spike SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Finally, secondary endpoints included evaluation of neutralization activity of vaccine-induced anti-Spike antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The humoral (anti-Nucleoprotein-IgG and the anti-RBD-IgG, neutralizing antibody) and cell mediated immune response was performed as previously described [22] and detailed in the Supplementary materials.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Nucleoprotein-IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RBD-IgG, neutralizing antibody</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IBM SPSS vers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of our study is the lack of measurement of neutralization titers against the emerging Omicron variant. However, in this context it has to be taken into account that in healthy subjects a significant increase in the neutralizing response against this variant has been observed after the third dose[37,38]. In conclusion, we demonstrated a lower prevalence of seroconversion among immunosuppressed patients compared to HCW. The lowest humoral response was reported among patients treated with anti-B-cell therapies. However, T-cell response results showed more encouraging data, suggesting a possible benefit of the vaccination due to cellular immunity, particularly in light of the observation that T-cell epitopes are shared among wild type and Omicron variant[39]. Finally, data on the third dose indicate a potential immunological benefit and highlights HM as the major fragile group.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.12.476120: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study was approved by the Institutional Review Board of Vanderbilt University Medical Center and specimens were obtained after written informed consent.<br>Consent: The study was approved by the Institutional Review Board of Vanderbilt University Medical Center and specimens were obtained after written informed consent.<br>IACUC: The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381–01).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Eight to nine week-old mice of both sexes were inoculated with 103 PFU of SARS-CoV-2 by an intranasal route.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Mycoplasma testing of Expi293F and ExpiCHO cultures was performed monthly using a PCR- based mycoplasma detection kit (ATCC, 30-1012K).</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, synthesized antibody-encoding DNA (∼2 μg per transfection) was added to OptiPro serum free medium (OptiPro SFM), incubated with ExpiFectamine CHO Reagent and added to 800 µL of ExpiCHO cell cultures into 96-deep-well blocks using a ViaFlo 384 liquid handler (Integra Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-encoding DNA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody binding was detected with anti-IgG Alexa-Fluor-647-labelled secondary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IgG Alexa-Fluor-647-labelled secondary antibodies .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were incubated sequentially with 1 μg/mL of rCR3022 anti-S antibody or a murine anti-SARS-CoV-2 mAb, SARS2-16 (hybridoma supernatant diluted 1:6,000 to a final concentration of ∼20 ng/mL) and then HRP-conjugated goat anti-human IgG (Sigma-Aldrich, A6029) in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% BSA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (Sigma-Aldrich Cat# A6029, RRID:AB_258272)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum antibody competition binding ELISAs with biotinylated reference mAbs: mAb COV2-3434 was biotinylated using NHS-PEG4-biotin (Thermo Fisher Scientific, cat# A39259) according to manufacturer protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NHS-PEG4-biotin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Competition ELISA of mAbs, related to Figure 4 Competition ELISA of mAbs with previously mapped antibodies COV2-2130, COV2-2196, COV2-2676, COV2-2489, r4A8 or rCR3022.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COV2-2489</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Vero (ATCC, CCL-81), HEK293 (ATCC, CRL-1573) and HEK293T (ATCC, CRL-3216) cells were maintained at 37°C in 5% CO2 in Dulbecco’s minimal essential medium (DMEM) containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 1× non-essential amino acids and 100 U/mL of penicillin–streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero-furin cells were obtained from T. Pierson (NIAID, NIH) and have been described previously (45) Vero-hACE2-TMPRSS2 cells were a gift of A. Creanga and B. Graham (Vaccine Research Center, NIH)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-hACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody-virus complexes were added to Vero E6 cell-culture monolayers in 96-well plates for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A suspension of 18,000 Vero-E6 cells in 50 μL of cell culture medium was seeded in each well, and the plate was placed on the analyzer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Triplicate wells containing virus only (maximal CPE in the absence of mAb) and wells containing only Vero cells in medium (no-CPE wells) were included as controls.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice (8 to 9 weeks old) were inoculated with 1 × 104 focus forming units of SARS-CoV-2 (viral titer was determined on Vero-TMPRSS2-ACE2 cells) via the intranasal route.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-TMPRSS2-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A plasmid encoding cDNA for each spike protein mutant was transfected into HEK-293T cells and allowed to express for 22 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, lung homogenates were serially diluted and added to Vero+TMPRSS2+hACE2 cell monolayers in 12-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero+TMPRSS2+hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">B. Neutralization of VSV-S by COV2-3434 was measured in the absence or presence of 25 μM biliverdin in Vero-CCL81 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-CCL81</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Heterozygous K18-hACE c57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were obtained from Jackson Laboratory (034860).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE c57BL/6J</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Female heterozygous K18-hACE C57BL/6J mice were housed in groups of up to 5 mice per cage at 18 to 24°C ambient temperatures and 40 to 60% humidity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Eight-week-old female K18-hACE2 transgenic mice were inoculated by the intranasal route with 104 FFU of SARS-CoV-2 (WA1/2020 D614G).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">) sequencing core laboratory at an appropriate target concentration for 10X Genomics library preparation and subsequent sequence analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Genomics</div><div>suggested: (UTHSCSA Genomics Core, RRID:SCR_012239)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Half maximal inhibitory concentration (IC50) values were determined by nonlinear regression analysis (with a variable slope) using Prism software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 50 μL of cell culture medium (DMEM supplemented with 2% FBS) was added to each well of a 96-well E-plate using a ViaFlo384 liquid handler (Integra Biosciences) to obtain background reading.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Integra Biosciences</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expressed protein was incubate with BioLock (IBA Lifesciences) and then isolated by Strep affinity chromatography on StrepTrap HP columns (GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioLock</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image processing was performed using the cryoSPARC (Punjani et al., 2017) software package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For each plate, background signal (signal from wells that were not coated with antigen) was subtracted and values were normalized to no-competition controls (signal from wells that had no competing serum or mAb) Four-parameter dose-response/inhibition curves were fit to the normalized data using Prism software (GraphPad) v8.1.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.13.22269213: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Donors signed informed consent forms.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">KLRG1 Monoclonal Antibody (13F12F2), eBioscience,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KLRG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Peptide stimulation was performed in the presence of costimulatory antibodies against CD28 and CD49d (BD Biosciences) and Brefeldin-A (10 μg/mL, Millipore Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibodies against CD28</div><div>suggested: (Novus Cat# NB100-93558, RRID:AB_1236789)</div></div><div style="margin-bottom:8px"><div>CD49d</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody staining panel setup: Purified CD19 (Biolegend), TCRVα7.2, CD160 and KLRG1 (R&D Systems) antibodies lacking carrier proteins (100 μg/antibody) were conjugated to DN3 MAXPAR chelating polymers loaded with heavy metal isotopes following the recommended labelling procedure (Fluidigm).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD19</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>TCRVα7.2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD160</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">174Yb anti-PD anti-1/CD279</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>174Yb</div><div>suggested: (Fluidigm Cat# 3143013, RRID:AB_2661810)</div></div><div style="margin-bottom:8px"><div>anti-PD</div><div>suggested: (Abcam Cat# ab120611, RRID:AB_11157298)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed, and each well was then stained with 100 μL of a unique double metal–labelled (Y89, Cd-106, Cd-110, Cd-112, Cd-116 and Cd-196) anti-CD45 antibody mix to further barcode the cells of individual donor.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD45</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All Antibodies were purchased from BD biosciences except towards Blimp-1 and IRF4 (Thermofischer) and IgM, CD71 and HLA-DR (Biolegend).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IRF4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgM , CD71</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HLA-DR</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One Million cells per donor samples, healthy donor PBMCs and VeriCells were seeded in 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeriCells</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All participants had received both doses of SARS-CoV-2 vaccines (either BNT162 or mRNA-1273) according to the Norwegian National Vaccination Program.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Norwegian National Vaccination Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis was performed using CYTOGRAPHER® (ImmunoScape cloud based analytical software), custom R-scripts, GraphPad Prism (GraphPad Software) and FlowJo v10 software (BD Life Sciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Delta breakthrough samples were in addition stimulated with mutated Spike peptides (PepTivator</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PepTivator</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The rest of the following mAbs were directly purchased from Fluidigm: y89 anti-CD45, 106Cd anti-CD45, 110Cd anti-CD45</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fluidigm</div><div>suggested: (Fluidigm CyTOF, RRID:SCR_021055)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Each sample was manually de-barcoded followed by gating on live CXCR5+CD4+ T cells for TFH analysis (CD45+ DNA+ cisplatin− CD3+ cells) after gating out residual antigen-presenting cells (HLA-DR+CD3- such as monocytes (CD14) and B cells (CD19) using FlowJo (Tree Star) software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A correlation matrix was calculated comparing phenotypic and serological marker variables in a pairwise fashion, using the corr.test function from the psych CRAN package; the corrplot package was subsequently used to graphically display the correlation matrix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CRAN</div><div>suggested: (CRAN, RRID:SCR_003005)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.12.476031: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethical approvals: The animal experiments were approved by the Institutional Review Board of The University of Hong Kong Committee on the Use of Live Animals in Teaching and Research (CULATR) and the use of clinical specimens was approved by the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Briefly, male and female hamsters, aged 8-10 weeks old, were obtained from the Chinese University of Hong Kong Laboratory Animal Service Centre through the HKU Centre for Comparative Medicine Research.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Gender- and age-matched hamsters were randomized into different experimental groups.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">titers, cytokine/chemokine gene copies, body weights and clinical scores, no blinding procedures were applied to the experimentalists involved.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">The group sizes were chosen based on statistical power analysis and our prior experience in examining virus burdens and cytokine/chemokine profiles in hamsters.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were then washed 6 times, rabbit anti-hamster horseradish peroxidase antibody (100 μL/well) at the dilution of 1:2000 was added and incubated for 30 min at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hamster</div><div>suggested: (LSBio (LifeSpan Cat# LS-C61251-2000, RRID:AB_1512928)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 and VeroE6-TMPRSS2 cells were maintained in DMEM culture medium supplemented with 10% heat-inactivated FBS, 50 U/ml penicillin and 50 μg/ml streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Equal PFUs of two variants (1:1 ratio) were inoculated onto Calu-3 cells at a final MOI of 0.10 for each variant.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell cytopathic effects (CPE) were monitored to validate complete inactivation using Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All data were analysed with GraphPad Prism software (GraphPad Software, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Illustrations: The hamster illustrations and schematic figures were created with BioRender software (https://biorender.com/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr></table>Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study had limitations. The transmission rate of SARS-CoV-2 may vary according to different durations of exposure. In this study, we selected 6 hours of non-contact transmission to simulate the scenarios of staying with an infected index patient within the same facility for a routine business day and on medium-haul flights. It would be worthwhile to further compare the transmissibility of the Omicron and other variants after different durations of exposure in future studies. It would also be important to investigate the pathogenicity and transmissibility of the Omicron variant in additional animal models such as the hACE2-transgenic mouse and non-human primate models, as each of these animal models have their advantages and disadvantages in recapitulating human disease. In summary, the present study shows that despite comparatively lower pathogenicity than the Delta variant, the Omicron variant undoubtedly still causes obvious clinical effects, increased viral burdens and pro-inflammatory cytokines/chemokines, as well as histopathological damages in infected hosts. Taking into consideration the Omicron variant’s higher transmissibility than the already-highly transmissible Delta variant, our findings highlight the urgent need to find next-generation COVID-19 vaccines and broad-spectrum therapeutics, as well as to tighten non-pharmaceutical measures to reduce acute and chronic disease burden (long COVID) on the public and healthcare facilities.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.metallacycle.com www.metallacycle.com
-
N A T U R A L A T O M I C O R B I T A L A N D N A T U R A L B O N D O R B I T A L A N A L Y S I S
Welcome to the NBO results for propargyl silane! Atom numbering in the molecule is as shown below. Silicon is atom 1; that's tough to see. Most important is that carbons 3 and 4 are triply bonded and carbon 3 is the internal carbon.

-
-
www.metallacycle.com www.metallacycle.com
-
N A T U R A L A T O M I C O R B I T A L A N D N A T U R A L B O N D O R B I T A L A N A L Y S I S
Welcome to the NBO results for propargyl silane! Atom numbering in the molecule is as shown below. Silicon is atom 1; that's tough to see. Most important is that carbons 3 and 4 are triply bonded and carbon 3 is the internal carbon.

-
-
thelatinlibrary.com thelatinlibrary.com
-
Hennensium
Of the people of Henna (modern Enna)
-
-
www.medrxiv.org www.medrxiv.org
-
SciScore for 10.1101/2022.01.12.22269192: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All studies are approved by the University of Washington Human Subjects Division Institutional Review Board.<br>Consent: Informed consent was obtained from all enrolled participants.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(HAARVI) study (STUDY00000959), Healthy Adult Specimen Repository study (STUDY00002929) or COVID-19/SARS-CoV-2 Prevalence and Antibody Therapy Development study (Gale Lab, STUDY00009810).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STUDY00000959</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>STUDY00002929</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>STUDY00009810</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were diluted in dilution buffer as follows: anti-human IgG-HRP (Jackson ImmunoResearch) at 1:3000, anti-human IgM-HRP (Southern Biotech) at 1:3000, or anti-human IgA-HRP (Southern Biotech) at 1:1500.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgM-HRP</div><div>suggested: (MyBioSource Cat# MBS673990, RRID:AB_10891687)</div></div><div style="margin-bottom:8px"><div>anti-human IgA-HRP</div><div>suggested: (SouthernBiotech Cat# 2050-05, RRID:AB_2687526)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For surface phenotyping, cells were washed and barcoded using four different fluorescently labeled CD45 antibodies to create eight unique barcodes as previously described (Becht et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD45</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For intracellular cytokine staining, cells were first incubated with anti-CXCR5 antibody at room temperature for 40 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CXCR5</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 1 hour incubation at 37°C, the plasma/virus mixtures were added to 96-well poly-L-lysine-coated plates seeded with human ACE2-expressing 293T cells (BEI Resources: NR-52511) 20 hours prior.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 30 min of incubation at 37°C, the plasma/virus mixtures were added to 12 well plates of Vero cells and incubated for 1 h at 37°C, rocking every 15 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Percent neutralization was calculated as (1 – (sample+293T-ACE2+virus RLU - 293T+virus RLU)/(293T-ACE2+virus RLU - 293T+virus RLU) x 100.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RLU - 293T+virus RLU)/ ( 293T-ACE2+virus RLU - 293T+virus RLU</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GFP vector plasmid (BEI Resources; NR52516), a second generation helper plasmid pMD2.g (gift from Didier Trono; Addgene #12260), and either: the SARS-CoV-2(o) pseudotyping plasmid above, or a plasmid encoding the SARS-CoV-2(Δ) variant spike (Invivogen, San Diego, CA,USA; pLV-Spike-V8, B.1.617.2, delta).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GFP</div><div>suggested: RRID:Addgene_126657)</div></div><div style="margin-bottom:8px"><div>pMD2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed in Prism (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">High-dimensional analysis of cytometry data: AIM-positive (CD154+CD69+) cells from all data files were concatenated with keywords and subjected to Phenograph clustering algorithm using k=40 nearest neighbors (Levine et al., 2015) and UMAP dimensionality reduction plugins using parameters IL-2, IFN-γ, IL-10, IL-4, IL-21, CD127, CD25, and CXCR5 in FlowJo 10 (Becton Dickinson).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenograph</div><div>suggested: (Phenograph, RRID:SCR_016919)</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-
-
www.biorxiv.org www.biorxiv.org
-
SciScore for 10.1101/2022.01.11.475922: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
<table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>Table 2: Resources
<table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western blot: Western blot was performed using an anti-SARS-COV-2 S antibody following a protocol described previously (56).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-COV-2 S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alkaline phosphatase conjugated anti-Rabbit IgG (1:5000) (Sigma-Aldrich, St. Louis, MO) was used as a secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To measure binding of a full-length S protein to monoclonal antibodies, the antibody was immobilized to anti-human IgG Fc Capture (AHC) biosensor (ForteBio, Fremont, CA) following a protocol recommended by the manufacturer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Control sensors with no ACE2 or antibody were also dipped in the S protein solutions and the running buffer as references.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Expi293F cells transfected with monomeric ACE2 or dimeric ACE2 expression construct and the supernatant of the cell culture was collected.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, to produce S-expressing cells, HEK293T cells were transfected by polyethylenimine (PEI; 80 μg) with either 5 or 10 μg of the full-length SARS-CoV2 (G614</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To prepare for infection, 7.5×103 of HEK 293 cells, stably transfected with a full-length human ACE2 expression construct, in 15 μl culture medium were plated into a 384-well white-clear plate coated with poly-D-Lysine to enhance the cell attachment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudotyped virus particles were produced in 293T/17 cells (ATCC) by co-transfection of plasmids encoding codon-optimized SARS-CoV-2 full-length S constructs, packaging plasmid pCMV DR8.2, and luciferase reporter plasmid pHR’ CMV-Luc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 293T cell line stably overexpressing the human ACE2 cell surface receptor protein was kindly provided by Drs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The S gene was fused with a C-terminal twin Strep tag (SGGGSAWSHPQFEKGGGSGGGSGGSSAWSHPQFEK) and cloned into a mammalian cell expression vector pCMV-IRES-puro (Codex BioSolutions, Inc, Gaithersburg, MD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV-IRES-puro</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudotyped virus particles were produced in 293T/17 cells (ATCC) by co-transfection of plasmids encoding codon-optimized SARS-CoV-2 full-length S constructs, packaging plasmid pCMV DR8.2, and luciferase reporter plasmid pHR’ CMV-Luc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV DR8.2, and luciferase reporter</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pHR’</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Automated data collection was carried out using SerialEM version 3.8.6 (59) at a nominal magnification of 105,000× and the K3 detector in counting mode (calibrated pixel size, 0.83 Å) at an exposure rate of 13.362 electrons per pixel per second.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image processing and 3D reconstructions: Drift correction for cryo-EM images was performed using MotionCor2 (60), and contrast transfer function (CTF) was estimated by Gctf (61) using motion-corrected sums without dose-weighting.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MotionCor2</div><div>suggested: (MotionCor2, RRID:SCR_016499)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Density maps were corrected from the modulation transfer function of the K3 detector and sharpened by applying a temperature factor that was estimated using post-processing in RELION.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RELION</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Several rounds of manual building were performed in Coot (64).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr></table>Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 32, 26, 28 and 30. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
<footer>About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
</footer>
-